Circulating Tumour DNA in Localised Urological Cancers by Patel, Keval Mahendra
Circulating Tumour DNA in Localised 
Urological Cancers
 
THIS DISSERTATION IS SUBMITTED FOR THE DEGREE OF 
DOCTOR OF PHILOSOPHY BY
DR. KEVAL MAHENDRA PATEL
SUPERVISED BY: DR. NITZAN ROSENFELD
 
 
 
HOMERTON COLLEGE
MARCH 2017
 
 II of 233 
ABSTRACT 
There is a need for informative biomarkers in localised urological cancers. At present, no 
method can accurately distinguish between indolent and aggressive prostate cancers, and 
men often require repeated biopsies. Patients with muscle invasive bladder cancer (MIBC) 
undergo neo-adjuvant chemotherapy (NAC) to improve survival. However, many do not 
respond to NAC unnecessarily delaying definitive treatment. Cell-free mutant DNA 
(mutDNA) analysis represents an opportunity for non-invasive monitoring of cancer 
through tumour genome analysis. MutDNA derived from plasma can monitor tumour 
burden. There is emerging evidence that mutDNA can identify mutations from multiple 
clones and is abundant in adjacent body fluids. This work explores the utility of plasma and 
urinary mutDNA in localised prostate and bladder cancers. 
This thesis describes the optimisation of urinary mutDNA analysis by assessing urinary 
DNA processing and extraction methods using healthy volunteer and bladder cancer 
patient urine samples. Primer panels were designed and validated to target frequently 
mutated regions in prostate and bladder cancers, as well as for analysis of patient-specific 
mutations. Sequencing-based methods and digital Polymerase Chain Reaction (dPCR) 
were employed to analyse clinical samples including plasma and urine, to detect and 
quantify mutDNA. Molecular and clinical data were integrated to explore potential areas of 
application of mutDNA analysis.  
For bladder cancer, mutDNA was analysed from liquid-biopsy samples including plasma, 
cell pellets from urine (UCP) and urine supernatant (USN) from multiple time-points of 17 
MIBC patients undergoing NAC. I showed that mutDNA was more frequently detected and 
was present at higher AFs in urine compared to plasma samples. Of potential clinical 
relevance, I showed that the presence of mutDNA after starting NAC was associated with 
disease recurrence. This original contribution to knowledge could offer patients an 
opportunity to expedite surgical resection in a timely manner, if corroborated in large-scale 
trials. 
For prostate cancer, a TP53 specific panel was applied to men with metastatic disease, to 
demonstrate that clones containing TP53 mutations, which are dominant in at the 
metastatic stage were present in historical prostatectomy samples taken when then patient 
was believed to have localised disease only. Furthermore, I showed that these TP53 
mutations could be detected at the localised stage of disease. To investigate the ability of 
mutDNA detection private clonal mutations I developed a method for higher sensitivity 
 III 
analysis (MRD-Seq). This was applied to a clinical cohort of 2 men with multi-focal 
localised prostate cancer to demonstrate the though the overall levels of mutDNA is low, 
private clonal mutations may be detectable. Taken together, these original contributions to 
knowledge could allow for less invasive surveillance of men with low risk prostate cancer 
and warrants further investigation.  
In this thesis, I used a range of molecular methods were applied to small cohorts of clinical 
samples from patients with urological malignancies, in an exploratory analysis. The 
molecular data was analysed in conjunction with clinical information to draw hypotheses 
on the biology and natural history of these cancer, and to suggest possible utility of 
mutDNA analysis in their clinical management. Some of the findings suggest areas of 
potential utility, which merit further validation or investigation in larger cohorts or clinical 
studies. 
 IV of 233 
 
ACKNOWLEDGEMENTS 
I would firstly like to thank my supervisor, Dr. Nitzan Rosenfeld, and my post-doctoral 
supervisors, Dr. Tim Forshew, Dr. Dana Tsui, Dr. Charlie Massie, Dr. Florent Mouliere and 
Dr. Chris Smith for their invaluable advice and support. I would also like to thank all 
members of Rosenfeld research group and collaborating research groups who took time 
out of their busy schedules to guide and help me. Without their help, these investigations 
would not have been possible. 
I am very grateful for the generous support of my sponsors, the Royal College of Surgeons 
of England, the Addenbrooke’s Charitable Trust and Cancer Research UK Cambridge 
Centre.  
Finally, I would like to thank my wife and family without whose support, I would not have 
been able to complete this work. 
 
 
STATEMENT OF ORIGINALITY 
I declare that the following ideas and work is my own, except where referenced otherwise. 
Any collaborative work is specifically declared in relevant text.  
This work has not been submitted for a degree or diploma at the University of Cambridge 
or any other institution before and is not concurrently being submitted for any such degree.  
This doctoral thesis does not exceed the prescribed work limit of 60,000 words set by the 
Clinical Medicine and Clinical Veterinary Medicine Degree Committee. 
 V 
 
TABLE OF CONTENTS 
Abstract II	
Acknowledgements IV	
Statement of Originality IV	
Table of contents V	
Figures XI	
Tables XVII	
Abbreviations 20	
CHAPTER 1: INTRODUCTION 23	
1.1	 Circulating Tumour DNA 23	
1.1.1	 Monitoring Tumour Evolution With ctDNA 24	
1.1.2	 Detecting ctDNA in Low Volume Disease 25	
1.1.3	 cfDNA in other bodily fluids 26	
1.1.4	 Urinary Processing 28	
1.1.5	 Size of Urinary cfDNA 29	
1.2	 Prostate Cancer 29	
1.2.1	 Prostate Cancer Epidemiology 30	
1.2.2	 Prostate Cancer Diagnosis 31	
1.2.2.1	 Biopsy approach 31	
1.2.2.2	 Histological classification 32	
1.2.3	 Risk stratification following prostate cancer biopsy 33	
1.2.4	 Prostate Cancer Mutational Profile 35	
 VI of 233 
1.2.5	 Prostate heterogeneity obfuscates accurate stratification in localised disease
 36	
1.2.6	 Biomarkers using genetic analysis 37	
1.3	 Bladder Cancer 37	
1.3.1	 Bladder Cancer Epidemiology 38	
1.3.2	 Aggressive & Non-Muscle Invasive Bladder Cancer 39	
1.3.3	 Treatment Options For Muscle Invasive Bladder Cancer 41	
1.3.3.1	 Radical Radiotherapy 41	
1.3.3.2	 Radical Cystectomy 41	
1.3.4	 Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer 42	
CHAPTER 2: URINARY CELL-FREE DNA 45	
2.1	 Synopsis 45	
2.2	 Publications arising from this work 46	
2.3	 Aims 47	
2.4	 Methods 48	
2.4.1	 Urinary processing protocols 48	
2.4.2	 Extracted DNA quantification through digital PCR 49	
2.4.3	 TAm-Seq Panel Design 51	
2.4.3.1	 CTNNB1 primer design 52	
2.4.3.2	 FGFR3 primer design 53	
2.4.3.3	 NFE2L2 primer design 55	
2.4.3.4	 TERT primer design 56	
2.4.4	 Primer Validation 57	
2.4.5	 Identifying mutDNA through TAm-Seq 58	
 VII 
2.5	 Results 60	
2.5.1	 Urine DNA extraction 60	
2.5.2	 Urinary DNA Processing 62	
2.5.3	 Urinary DNA Size 66	
2.5.4	 Primer Validation 68	
2.5.4.1.1	 TERT re-design 70	
2.5.5	 Mutant DNA analysis from urine 72	
2.6	 Original Contributions to Knowledge 73	
CHAPTER 3: MUTANT DNA ANALYSIS IN MIBC 75	
3.1	 Synopsis 75	
3.2	 Publications arising from this work 76	
3.3	 Aims 77	
3.4	 Methods 78	
3.4.1	 Sample Collection: 78	
3.4.2	 TAm-Seq: 78	
3.4.3	 Shallow Whole Genome Sequencing 79	
3.4.4	 Mutation Calling Criteria 79	
3.5	 Statistical Inferences: 81	
3.6	 Results 82	
3.6.1	 Patient recruitment for longitudinal analysis of mutDNA kinetics 82	
3.6.2	 cfDNA yield and mutDNA levels are comparable when extracting with QIAmp 
Circulating Nucleic Acid kit and QIAsymphony (Qiagen) 85	
3.6.3	 Detection of DNA alterations in TUR samples from MIBC patients undergoing 
NAC 88	
 VIII of 233 
3.6.4	 Comparison of genomic profiles in tumour and pre-NAC peripheral samples 93	
3.6.5	 Presence of mutDNA in pre-NAC peripheral samples has poor correlation to 
outcome. 95	
3.6.6	 Presence of mutDNA during NAC is associated with recurrence 97	
3.6.7	 Comparison of peripheral sample types reveals that UCP and USN are 
enriched in mutDNA as compared to plasma 101	
3.6.8	 Comparison of CNA and SNV detection 103	
3.6.9	 Longitudinal analysis of mutDNA in peripheral samples of patients with MIBC
 104	
3.6.10	 Urinary mutDNA demonstrates tumour evolution during therapy 111	
3.6.11	 SNP analysis suggests sample crossover during the experiment is unlikely
 116	
3.6.12	 MutDNA analysis can be valuable in multiple disease settings of urothelial 
cancer 118	
3.7	 Original Contributions to Knowledge 121	
CHAPTER 4: ctDNA DETECTION IN LOCALISED PROSTATE CANCER 123	
4.1	 Synopsis 123	
4.2	 Publications arising from this work 124	
4.3	 Aims 125	
4.4	 Methods 126	
4.4.1	 Proof of Principle Analysis 126	
4.4.1.1	 Initial Primer Panel 127	
4.4.1.2	 Prostate Specific Primer Panel 127	
4.4.2	 Exploring the utility of ctDNA analysis in aggressive Prostate Cancer 130	
4.4.3	 Accounting for prostate heterogeneity in localised disease 131	
 IX 
 
4.5	 Results 133	
4.5.1	 Few mutations are detectable in localised prostate cancer using a standard 
gene panel 133	
4.5.2	 Using multiple targets to improve detection in localised prostate cancer 135	
4.5.2.1	 Prostate Specific Panel validation 135	
4.5.3	 Localised prostate tumour tissue contains few mutations detected by prostate 
specific TAm-Seq 137	
4.5.4	 Clones that dominate in metastatic castrate resistant prostate cancer are 
present at a localised stage 140	
4.5.5	 TP53 SNVs in tissue samples are unlikely to accurately predict biochemical 
recurrence 144	
4.5.6	 Investigating prostate heterogeneity in localised disease 148	
4.5.6.1	 Heterogeneity in localised prostate cancer is not well represented in 
plasma ctDNA using standard TAm-Seq 152	
4.5.7	 Development of a Multiplexed Replicate Dilution Sequencing approach (MRD-
Seq) 156	
4.5.7.1	 MRD-Seq optimisation with high fidelity enzymes 157	
4.5.7.1.1	 Optimising PCR reactions for MRD-Seq 162	
4.5.7.1.2	 Optimisation of PCR cycling conditions for high-fidelity enzyme 166	
4.5.7.1.3	 Removal of primer dimer to improve proportion of aligned reads for 
MRD-Seq 170	
4.5.7.2	 Characterisation of MRD-Seq detection limit 171	
4.5.7.3	 Utilising MRD-Seq to detect ctDNA AFs in heterogeneous localised 
prostate cancer 175	
4.6	 Original Contributions to Knowledge 182	
CHAPTER 5: DISCUSSION 183	
 X of 233 
5.1	 Urinary DNA extraction 183	
5.1.1	 Urinary processing protocols 184	
5.1.2	 Urinary DNA size 185	
5.1.3	 Detection of mutDNA for urine processing study 187	
5.2	 MutDNA in MIBC 187	
5.3	 ctDNA in Localised Prostate cancer 192	
5.3.1	 TP53 as a marker of aggressive disease 192	
5.3.2	 Accounting for prostate heterogeneity 193	
5.4	 Future Work 196	
References 197	
Appendices 211	
A-1	 Amplifiable GE copies/ml of urine in cfDNA extracted from urine 
supernatant samples taken from healthy volunteers 211	
A-2	 Amplifiable GE copies per ml of urine in cfDNA extracted from urine 
supernatant samples taken from healthy volunteers 213	
A-3	 Pilot Bladder Primer Panel 215	
A-4	 Amplifiable GE copies in cfDNA extracted from urine supernatant 
samples taken from patients with metastatic bladder cancer 217	
A-5	 Proof of Principle Primer Panel 218	
A-6	 TP53 Primer Panel 220	
A-7	 Prostate Specific Primer Panel 221	
A-8	 Summary of TP53 mutant allele fractions determined using TAm-seq 227	
A-9	 Multifocal Prostate Cancer Case 7 Primer Panel. 229	
A-10	 Multifocal Prostate Cancer Case 8 Primer Panel. 232	
 XI 
 
FIGURES 
Figure 2.1: COSMIC gene-browser overview of mutational burden in CTNNB1 ................ 53	
Figure 2.2: CTNNB1 region spanning chr3:41265875-41266356. ..................................... 53	
Figure 2.3: Distribution of somatic mutations of FGFR3 (Forbes et al.) ............................. 54	
Figure 2.4: DNA Sequence for Exon 6 of FGFR3. .............................................................. 54	
Figure 2.5: DNA Sequence for Exon 8 of FGFR3. .............................................................. 54	
Figure 2.6: DNA Sequence for Exon 13 of FGFR3. ............................................................ 55	
Figure 2.7: Distribution of somatic mutations of NFE2L2 (Forbes et al.) ............................ 55	
Figure 2.8: DNA sequence for NFE2L2 exon on chr2:178098679-178160622. ................. 56	
Figure 2.9: Distribution of somatic mutations for TERT (Forbes et al.). .............................. 56	
Figure 2.10: DNA sequence for TERT promoter regions on chr5:1294977-1296504. ....... 57	
Figure 2.11: Flow diagram for patient samples used to evaluate urinary DNA. .................. 60	
Figure 2.12: Box plots suggesting that urine DNA extraction with QIagen Circulating 
Nucleic Acid and Norgen slurry kits achieved the highest yield of DNA. ..................... 62	
Figure 2.13: Cell-free DNA levels are higher in urine samples processed without a 
centrifugation step. ...................................................................................................... 63	
Figure 2.14: 10mMol EDTA may improve cell-free DNA yield ............................................ 64	
Figure 2.15:  Reduced time to processing of fresh urine improved cfDNA yield. ............... 65	
Figure 2.16: GE 360bp (and larger) copies/ml for samples of urine that were centrifuged 
(n=9) and those that were not (n=12). ......................................................................... 66	
Figure 2.17: Comparison of GE copies/ml for urine cfDNA amplicons of 65bp, 97bp and 
360bp lengths from 7 replicate urine aliquots from 2 patients. .................................... 67	
Figure 2.18: Comparison of GE copies/ml for urine cfDNA amplicons of 65bp and 97bp 
from 15 replicate aliquots from 2 patients. ................................................................... 68	
Figure 2.19: Bioanalyser trace of PCR products with 3 FGFR3 primer pairs. .................... 68	
 XII of 233 
Figure 2.20: Bioanalyser trace of PCR products with 3 TERT primer pairs. ....................... 69	
Figure 2.21: Bioanalyser trace of PCR products with 3 NFE2L2, 1 CTNNB1 and 2 re-
designed TERT primer pairs. ....................................................................................... 70	
Figure 2.22: Alternative strategy to design primer pairs for TERT promoter region. .......... 70	
Figure 2.23: Bioanalyser trace of PCR products with re-designed TERT primer pairs. ...... 71	
Figure 2.24: Basic statistics for pooled library submission to MiSeq (Illumina) NGS. ........ 72	
Figure 3.1: Flow diagram of patient samples used to investigate mutDNA. ....................... 82	
Figure 3.2: Amount of DNA (genome equivalent copies/ml) extracted from peripheral 
samples. ...................................................................................................................... 85	
Figure 3.3: Scatter plot of total amplifiable copies detected from replicate aliquots 
extracted by QIAsymphony and Circulating Nucleic Acid kits. .................................... 87	
Figure 3.4: Scatter plot of mAFs detected from replicate aliquots extracted by 
QIAsymphony and Circulating Nucleic Acid kits. ......................................................... 88	
Figure 3.5: Analysis of Longitudinal mutDNA kinetics in MIBC. A. Study design. .............. 90	
Figure 3.6: sWGS data for TUR and peripheral fluids taken prior to NAC for 17 MIBC 
patients. ....................................................................................................................... 94	
Figure 3.7: AUC plots showing the trade off between sensitivity and specificity for mutDNA 
to predict recurrence at various threshold cut-offs. ..................................................... 95	
Figure 3.8: Buffy coat AFs at TAm-Seq called locations with technical threshold plotted as 
0.5%. ........................................................................................................................... 96	
Figure 3.9: Empirical Cumulative Distribution Function plot of SNV AFs for all samples at 
each time-point from patients who recurred (red) and those who did not (black). ....... 98	
Figure 3.10: Presence of mutDNA at the 2nd cycle of NAC predicts early recurrence in 
MIBC. ......................................................................................................................... 100	
Figure 3.11: Kaplan-Meier curve depicting time to recurrence from initial TUR in a subset 
of 9 patients who had TP53 SNVs detected in their tumour sample. ........................ 101	
 XIII 
Figure 3.12: Venn diagrams demonstrating that more SNVs (A) and CNVs (B) were 
detected in the urine, as compared to the plasma samples for time-points where all 
three sample types were collected. ........................................................................... 102	
Figure 3.13: Allele fractions of paired plasma and urinary samples taken from patients with 
MIBC undergoing NAC. ............................................................................................. 103	
Figure 3.14: Waterfall plot depicting the relationship between CNAs and SNV AF. ......... 104	
Figure 3.15: SNV mutDNA kinetics for each peripheral sample type across the 6 patients 
who recurred early. .................................................................................................... 106	
Figure 3.16: SNV mutDNA kinetics for each peripheral sample type across the 6 patients 
who were free from early recurrence. ........................................................................ 107	
Figure 3.17: SNV mutDNA kinetics for each peripheral sample type of patient 11, who died 
shortly after surgery from surgical complication. ....................................................... 108	
Figure 3.18: Summary of longitudinal dynamics of patient specific SNVs and CNAs. A. 
Patient specific SNV kinetics across PLS, UCP and USN samples. ......................... 109	
Figure 3.19: Maximum mutDNA AF during NAC demonstrates differing kinetics in PLS, 
UCP and USN. .......................................................................................................... 110	
Figure 3.20: MutDNA kinetics of patient 12 reveal tumour evolution on therapy. ............. 112	
Figure 3.21: mutDNA demonstrates on therapy tumour evolution. ................................... 114	
Figure 3.22: Patient 15 CNA profiles of all three peripheral samples taken pre-NAC (T1), 
prior to Radical Cystectomy and lymph node dissection (T6) and from the radical 
cystectomy specimen. ............................................................................................... 115	
Figure 3.23: Median coverage for all samples included in SNP analysis. ........................ 116	
Figure 3.24: SNP analysis demonstrating concordance of SNP genotypes for samples 
taken from the same patient. ..................................................................................... 117	
Figure 3.25: mutDNA kinetics for patients with a broader spectrum of urothelial cancers.
 ................................................................................................................................... 120	
Figure 4.1: Multiplexed primer pair 96 well template. ....................................................... 129	
 XIV of 233 
Figure 4.2: Prostate samples sent for genome wide sequencing as part of ICGC prostate 
cancer project. ........................................................................................................... 131	
Figure 4.3: Flow diagram of patient material used to investigate ctDNA in localised 
prostate cancer. ......................................................................................................... 133	
Figure 4.4: Agarose eGel (Invitrogen) image following PCR amplification of 65 newly 
designed primers for the prostate cancer panel. ....................................................... 136	
Figure 4.5: Agarose eGel (Invitrogen) image analysis following PCR amplification of 
duplicate results of 3 re-designed primer pairs with positive (lane 1-6) and negative 
(lane 10) controls. ...................................................................................................... 136	
Figure 4.6: Median amplicon coverage for TAm-Seq using the prostate primer panel. .... 139	
Figure 4.7: TP53 mutations identified via TAm-Seq. (a) ................................................... 142	
Figure 4.8: TP53 mutations identified via TAm-seq. ......................................................... 143	
Figure 4.9: Median coverage for amplicons in the TP53 panel, showing each amplicon (x 
axis) vs. the median depth of sequencing coverage (y axis) for all samples. ............ 147	
Figure 4.10: Image of e-Gel PCR product analysis for primers designed to target case 7 
clones. ....................................................................................................................... 148	
Figure 4.11: Multiplex planning for Case 7 primer pairs. .................................................. 150	
Figure 4.12: Median coverage (y axis) per amplicon (x axis) for Case 7 (a) and Case 8 (b).
 ................................................................................................................................... 151	
Figure 4.13: Median coverage (y axis) per amplicon (x axis) with overall median coverage 
in dotted black for primer pairs targeting case 7 (a) and case 8(b), indicating that 
sequencing coverage was not even across the amplicons. ...................................... 153	
Figure 4.14: Concordance of AFs between TAm-Seq and WGS determined AFs for Case 7 
(a) and Case 8 (b). .................................................................................................... 154	
Figure 4.15: Heatmap depicting AFs for each genomic location (y axis) in libraries 
prepared from spatially separate tumour foci and from plasma (x axis) in case 7 (a) 
and case 8(b) ............................................................................................................. 155	
 XV 
Figure 4.16: Density plot of expected amplicon sizes with additional amplicon tags for the 
case 7 primer panel. .................................................................................................. 159	
Figure 4.17: DNA1000 Bioanalyser traces showing size distribution of PCR products 
created with high-fidelity enzymes using case 7 primer panel and template DNA 
extracted from healthy plasma. ................................................................................. 161	
Figure 4.18: MiSeq reads resulting from investigation of high-fidelity enzymes. .............. 162	
Figure 4.19: Distribution of reads allocated to samples. ................................................... 164	
Figure 4.20: ECDF plots of each group of samples undergoing PCR with a specified each 
enzyme type (coloured). ............................................................................................ 165	
Figure 4.21: Barchart showing the frequency of bases (y axis) having a non-reference AF 
(x axis) for MRD-Seq using healthy volunteer plasma. ............................................. 166	
Figure 4.22: Distribution of reads for the PCR condition optimisation experiment. .......... 167	
Figure 4.23: ECDF plots of sequencing target depth for varying annealing time (a), 
polymerase concentration (b), magnesium concentration (c) and PCR annealing and 
extension temperatures (d). ....................................................................................... 168	
Figure 4.24: Box plots comparing the background noise distributions from experiments 
comparing different Magnesium concentrations (a), annealing times (b), the 
polymerase enzyme concentrations (c) and PCR annealing and extension 
temperatures (d). ....................................................................................................... 169	
Figure 4.25: Distribution of reads following library size selection. .................................... 171	
Figure 4.26: Heatmap demonstrating the number of molecules detected during 
characterisation of MRD-Seq sensitivity. ................................................................... 173	
Figure 4.27: ECDF plot demonstrating cumulative AF distribution for each dilution to 
determine the limit of detection for MRD-seq. ........................................................... 174	
Figure 4.28: Median amplicon coverage for MRD-Seq from healthy volunteer plasma 
(HVP) samples with man 7 assays (a), pre-operative plasma from man 7(c), HVP 
samples and man 8 assays (b) and pre-operative plasma from man 8(d). ............... 176	
Figure 4.29: ECDF plot showing the distribution of AFs in the plasma (red) and HVP 
(black) replicates of man 7 (a) and man 8 (b). ........................................................... 177	
 XVI of 233 
Figure 4.30: Heatmaps showing the distribution of mutations detected in MRD-Seq 
experiments. .............................................................................................................. 179	
Figure 4.31: Waterfall plot showing the ordered Allele Fractions (y axis) for patient (red) 
and healthy control (black) plasma replicates (x-axis) at four example genomic 
locations. ................................................................................................................... 180	
Figure 5.1: DNA fragment size distribution for healthy urine. ........................................... 186	
Figure 5.2: Fragment size distribution showing the differing sizes of urinary cfDNA with 
detectable CNAs, urinary cfDNA without detectable CNAs and from healthy 
volunteers. ................................................................................................................. 186	
Figure 5.3: MutDNA analysis may help stratify patients with MIBC in the future. ............. 190	
 
 
XVII of 233 
TABLES 
Table 1.1: Bladder cancer histological subtypes, modified from (Sexton et al., 2010) and 
(Boustead et al., 2014) ................................................................................................ 39	
Table 2.1: Urinary DNA sample processing variables tested. ............................................ 48	
Table 2.2: Genomic regions interrogated by TAm-Seq for SNV analysis. .......................... 51	
Table 2.3: The criteria for designing and selecting primers for targeting mutDNA ............. 52	
Table 2.4: Primer testing PCR master mix concentrations ................................................. 57	
Table 2.5: PCR thermocycling conditions for primer testing. .............................................. 58	
Table 2.6: Alternative designs for TERT promoter region primer pairs. ............................. 71	
Table 3.1: Genomic regions interrogated by TAm-Seq for SNV analysis. .......................... 79	
Table 3.2: Demographics of 17 MIBC patients: .................................................................. 84	
Table 3.3: Grid depicting total GE copies inputted per reaction across all patients and time-
points. .......................................................................................................................... 91	
Table 3.4: Grid depicting mutDNA AFs across all patients and time-points. ...................... 92	
Table 3.5: Sensitivity and specificity for mutDNA detection to predict response to NAC. .. 96	
Table 3.6: Sensitivity and specificity for mutDNA detection in pre-NAC samples. ............. 97	
Table 3.7: Patient demographics for additional patients are shown in a similar format to 
Table 3.2. ................................................................................................................... 118	
Table 4.1: Genomic regions interrogated by the initial panel and their mutation frequency 
in localised prostate cancer. ...................................................................................... 127	
Table 4.2: Genomic regions interrogated by multiplex prostate specific panel in localised 
prostate cancer. ......................................................................................................... 130	
Table 4.3: Clinical characteristics of samples used in the proof-of-principle cohort. ........ 134	
Table 4.4: Qubit fluorometer DNA quantification of DNA extracted from FFPE embedded 
tissue for the pilot prostate TAm-Seq analysis. ......................................................... 135	
 XVIII of 233 
Table 4.5: Single Nucleotide variants in two samples from patients with localised prostate 
cancer. ....................................................................................................................... 135	
Table 4.6: Clinical details of 11 men with localised prostate cancer subjected to TAm-Seq 
analysis using the prostate specific primer panel. ..................................................... 137	
Table 4.7: Qubit fluorometer DNA quantification of DNA extracted from prostate FFPE 
embedded tissue of 11 men and matched normal tissue (where applicable). ........... 138	
Table 4.8: Single Nucleotide variant detected in one patient with Tam-Seq using the 
extended prostate panel. ........................................................................................... 139	
Table 4.9: DNA yield of samples obtained from men with metastatic prostate cancer. .... 141	
Table 4.10: Clinical characteristics of men with localised prostate cancer used to 
determine the prognostic utility of TP53 mutation analysis. ...................................... 145	
Table 4.11: DNA yield from FFPE prostatectomy slides in 16 men treated for Gleason 7 
localised prostate cancer. .......................................................................................... 146	
Table 4.12: TP53 SNVs detected in prostatectomy samples in men with Gleason 7 
prostate cancer. ......................................................................................................... 148	
Table 4.13: Table of DNA amounts from multiregional patients with prostate cancer  before 
and after whole genome amplification (REPLI-G, Qiagen). ....................................... 149	
Table 4.14: Amplifiable GE copies in cfDNA extracted from plasma of men with 
heterogenous localised prostate cancer. ................................................................... 156	
Table 4.15: Comparison of high fidelity enzyme error rates, hot start and exonuclease 
activity. ....................................................................................................................... 158	
Table 4.16: PCR cycling conditions used for assessing high-fidelity enzymes. ............... 159	
Table 4.17: List of temperatures and high-fidelity enzymes input into microfluidic multiple 
singleplex PCR. ......................................................................................................... 162	
Table 4.18: Number of reactions (Nr) per dilution factor used to determine the detection 
limit of MRD-Seq. ...................................................................................................... 172	
Table 4.19: Characterisation of the MRD-Seq detection limit. .......................................... 173	
XIX of 233 
Table 4.20: Input amounts GE copies, assays targeted, number of replicates, mutant 
molecules and sensitivity estimates for each patient. ................................................ 177	
Table 4.21: MRD-Seq results showing mutation position, gene, effect, clonal origin and 
AFs for mutant molecules above Dt. .......................................................................... 178	
 
 20 of 233 
ABBREVIATIONS 
AF   Allele Fraction 
BC   Bladder Cancer 
BCG   Bacillus Calmettee Guerin 
BLAT   BLAST like Alignment Tool 
bp   base pair 
BR   Biochemical Recurrence 
BUF   Buffy coat 
BWA   Burrows-Wheeler Alignment 
CA15-3  Cancer Antigen 15-3  
CAPRA  Cancer of the Prostate Risk Assessment 
cfDNA  Cell-Free DeoxyriboNucleic Acids 
CI   Confidence Interval 
CIS   Carcinoma In-Situ 
CNAs   Copy Number Aberrations 
COSMIC  Catalogue Of Somatic Mutations In Cancer 
CR    Chemoradiotherapy 
CRPC   Castrate Resistant Prostate Cancer 
CTCs    Circulating Tumour Cells  
ctDNA  Circulating Tumour DeoxyriboNucleic Acids 
DNA   DeoxyriboNucleic Acids 
dPCR   Digital Polymerase Chain Reaction 
ECDF   Empirical Cumulative Distribution Function 
EDTA   Ethylenediaminetetraacetic acid  
EORTC  European Organization for Research & Treatment of Cancer 
FFPE   Formalin Fixed Paraffin Embedded 
GC content  guanine-cytosine content 
GE copies  Genomic Equivalent copies 
HVP   Healthy Volunteer Plasma 
ICGC   International Cancer Genome Consortium 
Indel   Insertions or Deletions 
ISUP    International Society of Urological Pathology 
LND    Lymph Node Dissection 
mAF   Mutant Allele Fraction 
MCDNA  Male Genomic (Control) DNA from healthy volunteers 
MIBC   Muscle Invasive Bladder Cancer 
MRD-Seq  Multiple Replicate Dilution Sequencing 
MRI   Magnetic Resonance Imaging 
mutDNA Mutant DNA in body fluids including plasma and urine (so called 
as we analysed both cell-free DNA and cellular DNA)  
NA   Nucleic Acid 
NAC   Neo-Adjuvant Chemotherapy 
NCCN   National Comprehensive Cancer Network 
NGS   Next Generation Sequencing 
 21 of 233 
NICE   National Institute for Health and Care Excellence 
NKI   National Cancer Institute 
NMIBC  Non-Muscle Invasive Bladder Cancer 
OS   Overall Survival 
PC   Prostate Cancer 
pCR   pathological complete response 
PCR   Polymerase Chain Reaction 
PCSM   Prostate Cancer Specific Mortality 
PIN   Prostatic Intra-epithelial Neoplasia 
PLS   Plasma 
pPD   pathological progressive disease 
pPR   pathological partial response 
PSA   Prostate Specific Antigen 
pSD   pathological stable disease 
qPCR   Quantitative PCR 
Rad   Radiotherapy 
RC    Radical Cystectomy 
RNA   RiboNucleic Acid 
SCC    Squamous Cell Carcinoma  
SNP   Single Nucleotide Polymorphism 
SNV   Single Nucleotide Variant  
SOP   Standard Operating Procedure 
sWGS  Shallow Whole Genome Sequencing 
TAm-Seq   Tagged Amplicon deep Sequencing  
TRUS   TransRectal Ultrasound Biopsy 
TUR   Tumour  
U.K.   United Kingdom 
UCC   Urothelial Cell Carcinoma 
UCP    Urine Cell Pellet 
UCSC   University of California, Santa Cruz 
USA   United State of America 
USN   Urine Supernatant 
WGA   Whole Genome Amplified 
WGS   Whole Genome Sequencing 
 

  
CHAPTER 1: INTRODUCTION 
The ideas presented in this chapter were first described in my first year report and parts 
were published in Clinical Biochemistry and Journal of Clinical Urology. The text is 
therefore to a large extent excerpted from my first year report and the related publication, 
but has been updated to incorporate novel ideas, findings and up-to-date references. 
K.M. Patel, D.W.Y. Tsui. The translational potential of circulating tumour DNA in 
oncology. Clinical Biochemistry. October 2015. 48:15, 957-961. ISSN 0009-9120, 
http://dx.doi.org/10.1016/j.clinbiochem.2015.04.005. 
K.M. Patel, V.J. Gnanapragasam, Novel concepts for risk stratification in prostate 
cancer. Journal of Clinical Urology. December 2016. 9(2), 18-23, 
doi:10.1177/2051415816673502. 
1.1 Circulating Tumour DNA 
In 1948, Mandel et al. were the first to describe cell free nucleic acids circulating freely in 
the blood (Mandel and Metais, 1948). It was not until 1977, when Leon et al. compared 
serum DNA levels (later termed circulating free DNA or cfDNA) of 173 cancer patients and 
55 healthy volunteers, did the realisation that circulating DNA could be an important 
marker of disease burden occur (Leon et al., 1977).  
Unfortunately, measurement of cfDNA alone has a great overlap between healthy 
volunteers and cancer patients and is therefore not sensitive (Jung et al., 2010; Zhang et 
al., 2010; Gonzalez-Masia et al., 2013; van der Vaart and Pretorius, 2010). It is also non-
specific, being raised in numerous conditions ranging from pregnancy, autoimmune 
conditions, trauma, pancreatitis, cancer and myocardial infarction (Bartoloni et al., 2011; 
Chen et al., 2011; Antonatos et al., 2006; Ha et al., 2011; Lui and Dennis, 2002).  
However, all tumours contain genetic alterations and, rare DNA fragments in blood contain 
tumour-specific mutations (circulating Tumour DNA or ctDNA). By designing PCR assays 
for known mutation hotspots in pancreatic cancer, Sorenson et al. were able to 
demonstrate the presence of ctDNA in blood almost twenty years ago (Sorenson et al., 
1994). A more personalised approach was utilised by Diehl et al. who used Sanger 
sequencing to identify point mutations in the tumour of each patient, then by designing 
mutation specific fluorescent probes, were able to detect mutant copies of DNA in the 
plasma of colorectal patients (Diehl et al., 2005). In a subsequent study evaluating 162 
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plasma samples from 18 patients, Diehl et al. demonstrated that levels of ctDNA correlate 
well with tumour burden and was more sensitive than serum measurements of Carcino-
Embryonic Antigen, the current standard biomarker, for monitoring disease burden (Diehl 
et al., 2008).  
Several groups demonstrated the presence of tumour specific point and rearrangement 
mutations in the plasma of patients with different cancer types. In each case, the initial 
step would be to determine the mutational profile of the tumour tissue or to use known 
mutation locations to then design tumour specific assays to track ctDNA levels in the blood 
(Leary et al., 2010; McBride et al., 2010; Chen et al., 1999; Yung et al., 2009; Otsuka et 
al., 2004; Diaz et al., 2012; Dawson et al., 2013).  
1.1.1 Monitoring Tumour Evolution With ctDNA 
The above techniques rely on having prior knowledge of the mutational profile of the 
tumour. This is achieved as either; there are few known tumour-specific mutations to target 
or, through tumour re-sequencing of patient derived tissue. However in 2012, Forshew et 
al. demonstrated that novel mutations can be detected directly through plasma re-
sequencing (Forshew et al., 2012). For a woman with ovarian cancer, re-sequencing of 
tumour tissue from right oophorectomy specimen, taken at the time of de-bulking surgery, 
had shown TP53 mutation. ctDNA levels of TP53 were tracked using TAm-Seq. As the 
patient progressed, TAm-Seq of plasma samples showed the presence of an EGFR 
mutation, not initially found in the oophorectomy specimen. On further investigation, the 
same EGFR mutation was present at low frequency in samples taken from the Omentum 
at the time of de-bulking surgery. It is likely that this clone became more dominant as 
chemotherapy regimes contained other clones.  
In 2013, the Rosenfeld group, in collaboration with the group of Professor Carlos Caldas, 
investigated 30 women with metastatic breast cancer. Tumour tissue mutations were 
identified using next generation re-sequencing and subsequently, TAm-Seq was used to 
successfully detect ctDNA in 29 out of the 30 women. Computerised Tomograms were 
compared with levels of ctDNA, Cancer Antigen 15-3 (CA15-3) and Circulating Tumour 
Cells (CTCs) taken with from serial samples. Overall, ctDNA was able to detect changes in 
tumour burden faster and with greater sensitivity than either the standard biomarker 
(CA15-3) or CTCs (Dawson et al., 2013).  
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By following 6 patients with metastatic tumours, Murtaza et al. were able to demonstrate 
that direct sequencing of the plasma can be used to track tumour evolution in response to 
therapy and to detect novel mutations. This was achieved by selecting 6 patients that had 
high fractions of mutant:wild type alleles in their plasma circulating DNA. Further analysis 
was conducted by generating barcoded and pooled libraries using the commercially 
ThruPLEX-FD kit (Rubicon genomics), followed by library enrichment using the TruSeq 
Exome Enrichment Kit (Illumina). Subsequent re-sequencing and variant analysis revealed 
that plasma ctDNA may harbour additional mutations, when compared to biopsy material. 
These additional mutations are likely to come from tumour clones underrepresented in the 
original biopsy (Murtaza et al., 2013).  
1.1.2 Detecting ctDNA in Low Volume Disease 
Several approaches have been used to detect ctDNA, each with differing analytical 
sensitivities and associated costs. On the one extreme, dPCR can be used to target 
known mutations or mutation hotspots, however the number of genomic locations 
targetable are low due to the inability to significantly multiplex reactions. However, the 
analytical sensitivity is high, reported at 1 in 13,000 mutant:wild-types (Milbury et al., 2014) 
and the cost per sample, relatively low. On the other extreme are WGS approaches, which 
prepare sequencing libraries directly from cfDNA. WGS approaches are therefore 
unbiased, assessing all genomic locations, and can detect previously unknown mutations. 
However, the cost is high due to the sequencing needed to attain even modest coverage. 
Subsequently, the analytical sensitivity is limited to 5-10 in 100 mutant:wild-types 
molecules (Heitzer et al.). Amplicon based and capture based sequencing form the 2 
intermediate approaches used and accommodate reduced breadth of genomic 
interrogation for increased sequencing reduced sequencing cost and improved coverage. 
Importantly, as the cost of sequencing continues to drop, the feasibility of attaining higher 
coverage increases and hence improve analytical sensitivity. 
As the sensitivity of ctDNA analysis improves, the unbiased detection of ctDNA at lower 
levels will become more feasible. Currently many cancer patients still present too late for 
curative therapies and our best chance of improving cancer mortality rates lie in the early 
detection of cancer (Vogelstein et al., 2013). However, at present published studies have 
largely focused on ctDNA analysis in the advanced cancer setting, where levels of 
mutant:wild type allele fractions is around 10-50% (Murtaza et al., 2013; Forshew et al., 
2012; Diehl et al., 2005). For earlier stages, the mutant:wild type allele fractions are likely 
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to be lower. Despite the challenges at the onset of my investigations, several studies used 
dPCR or amplicon sequencing strategies to detect ctDNA in several, non-urological, 
cancers from the plasma of patients at an early stage of disease.  
In Diehl et al.’s seminal work, mutant:wild type allele frequencies ranging from 0.001-
0.12% were detected in patients with localised colorectal cancer. Of note, ctDNA was also 
detected from plasma samples in their control group of patients with adenoma, with 
mutant:wild type allele frequencies of 0.001–0.02% (Diehl et al., 2005). The ability to 
detect ctDNA in patients with adenomatous colorectal polyps has important implications. 
Colorectal adenomas are precursors to adenocarcinoma and as such, often require further 
treatment. That ctDNA was detected at this pre-cancerous stage suggests a potential role 
of ctDNA in early diagnosis or even for population screening. 
In more recent work, Bettegowda et al. reported a range of 0 (not-detected) to 135,000 
mutant fragments/5ml of blood in 223 patients with 12 tumour types, all with localised 
disease (Bettegowda et al., 2014). By detecting mutations in tumour tissue and 
subsequently searching for these in matched plasma samples, they detected ctDNA in 
55% (122/223) of patients (Bettegowda et al., 2014). Furthermore, by using a digital 
droplet PCR (Taly et al., 2012) assay, Beaver et al. were able to detect PIK3CA mutations 
in the pre-operative plasma samples of 14/15 patients with low volume breast cancer and 
who had PIK3CA mutations detected in their tumour samples (Beaver et al., 2014). For 10 
patients, blood samples were collected post-operatively and 5 had persistently detectable 
ctDNA. Indeed, one of these patients went on to have cancer recurrence. The ability of 
ctDNA to detect and track tumour heterogeneity, coupled with the ability to detect low 
volume disease could be of vital importance in urological cancers where currently tumour 
heterogeneity leads to much clinical uncertainty  (as outlined below in section 1.2.3). 
1.1.3 cfDNA in other bodily fluids 
Much ctDNA research to-date focuses on plasma and serum derived samples. However, 
frequent blood sampling in patients who are already prone to anaemia of chronic disease 
is not ideal. Indeed, ethical committees often limit the amount of blood that can be drawn 
for study purposes. Interestingly, tumour-specific nucleic acids have been detected in 
other bodily fluids, including stool (Vogelstein and Kinzler, 1999), urine (Millholland, 2012), 
saliva (Li et al., 2004), cerebrospinal fluid (Pan et al., 2015) and pleural fluid (Soh et al., 
2006). To refer to mutant DNA extracted from bodily fluids, including plasma and urine, I 
use the term mutDNA, as the DNA of interest arises from circulating and non-circulating 
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fluids and can be cellular or cell-free. Particular fluids may concentrate mutDNA from 
regional drainage and may facilitate low volume disease mutDNA detection. For example, 
mutated DNA fragments from localised oral cancers are hypothesized to be more 
concentrated in saliva than in the circulation. Additionally, many bodily fluids are freely 
available and found in abundance, particularly urine. This may allow more frequent and 
more voluminous sampling aiding low volume disease detection.  
In likeness to ctDNA found in plasma, the presence of mutDNA in the urine has long been 
established (Sidransky et al., 1991). However, the DNA detected by Sidransky et al. was 
cellular in origin. For bladder cancer, cellular diagnostic approaches (urinary cytology) are 
widely used clinically for monitoring. Despite this, abnormal cells can be absent in more 
than 50% of cases, particularly for low-grade urothelial cancers (Simon et al., 2003; Babjuk 
et al., 2014).  
In 1999, Zhang et al. demonstrated the presence of SRY gene (found on the Y 
chromosome) in the urine supernatant of female recipients of male donor renal transplants 
(Zhang et al., 1999). By 2000, Botezatu et al. demonstrated that some genomic DNA 
escaped into the urine through renal filtration (Botezatu et al., 2000). They demonstrated 
this by subcutaneously injecting mice with radiolabelled human DNA and collecting urine 
over the next 3 days. Collected urine was determined to contain human cfDNA through its 
radioactivity and PCR amplification of human specific Alu repeat sequences Subsequently, 
by performing nested PCR to detect highly repetitive regions located on the Y 
chromosome, Botezatu et al. demonstrated the presence of male DNA in the urine of 
pregnant women carrying male foetuses (Botezatu et al., 2000).  
In 2004, Su et al. demonstrated the presence of mutated DNA in the urine of colorectal 
carcinoma patients. Using Restriction Enriched PCR with 46 base primer pairs targeting a 
known mutation in KRAS codon 12, they were able to selectively amplify mutated DNA in 
the fractionated urine of colorectal cancer patients.  
At the onset of my investigations, next generation sequencing (NGS) approaches had 
been used to detect mutDNA derived from the urine of cancer patients. In 2012, 
Millholland et al. targeted the known hotspots in FGFR3 exons 7, 10 and 15 and detected 
FGFR3 mutations in urinary DNA (Millholland, 2012). They reported a concordance of 91% 
by detecting mutant urinary cfDNA in 10 out of 11 patients with FGFR3 mutations in their 
primary tumours. In a separate group, the investigators assessed the urine of 43 known 
patients with bladder cancer  and found mutated FGFR3 in 24 of 43 cases (Millholland, 
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2012). As the mutation status of the primary tumour was not reported, no comment can be 
made on the concordance of their urinary assay with tumour mutations, though it appears 
proportional to the prevalence of FGFR3 mutations in bladder cancer populations detected 
in other studies (Lamy et al., 2006; Sjodahl et al., 2011).  
Similar findings were also presented in previous studies relying on molecular assays to 
analyse FGFR3 mutations (van Kessel et al., 2012; Zuiverloon et al., 2010). The ability of 
the assays to detect bladder cancer mutations as a whole was, however, low due to the 
sole focus on FGFR3, despite some studies selecting patients who had FGFR3 
aberrations in their initial tumour sample.  
The findings of Botezatu and Su demonstrate that renally filtered cfDNA is available for 
mutational analysis in urine, a bodily fluid that is readily available and abundant. However, 
quantification of peripheral fluid mutDNA may prove difficult to interpret, with additional 
factors such as the hydration state, renal disease and presence of bladder outflow 
obstruction in the case of urine, potentially affecting mutDNA levels. The fact that urine is 
freely available in large volumes, would make it of particular interest for analysis using a 
broader targeted sequencing approach. In addition, urinary DNA is likely to be of 
importance in urological cancers, especially bladder cancer, where the tumours may shed 
large quantities of DNA directly into the urine.  
1.1.4 Urinary Processing 
There is no consensus on urine processing for optimal urinary cfDNA yield. It is likely that 
the first morning urine sample will have poor DNA yield due to the prolonged exposure to 
urinary DNAses. Therefore, all urine samples were provided after the first morning 
micturition. However, 3 urine processing factors were investigated further. Firstly the 
influence of time between processing samples and urinary cfDNA yield was investigated. 
In plasma, cfDNA yields have been shown to increase when processed after from 4-25 
hours after collection (Xue et al., 2009). This is likely due to cell lysis, most probably 
leucocytes, releasing wild-type DNA into the sample. Therefore delayed plasma 
processing would obscure mutDNA analysis where detection of rare mutant molecules is 
already challenging. The effect of delayed processing on urinary cfDNA yield has not yet 
been investigated.  
Secondly, the addition of Ethylenediaminetetraacetic acid (EDTA) has also been shown to 
improve the cfDNA yield from plasma for ctDNA analysis (Lam et al., 2004), due to EDTA 
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mediated ion chelation and hence DNAse activity inhibition (Barra et al., 2015). For urine 
samples the effect of EDTA on cfDNA remains to be investigated however, previous 
studies have added EDTA in concentrations ranging from 10mmol/L (Su et al., 2004; Tsui 
et al., 2012) to 25mM final concentration (Millholland, 2012). 
Thirdly, the effect of centrifugation on urine was chosen for investigation. For plasma, 
centrifugation of samples have been suggested to improve the quality of cfDNA for rare 
mutant molecule analysis (Lam et al., 2004). In urine, there are likely to be less leucocyte 
to contaminate samples. However, lysis of shed urothelial cells could contaminate mutant 
molecule analysis, though may improve mutant molecule analysis in bladder cancer. 
Previous urinary cfDNA reports have often used a low speed, single centrifugation step for 
10mins (Su et al., 2004; Tsui et al., 2012). 
1.1.5 Size of Urinary cfDNA 
Plasma cfDNA has a 166bp peak size with further peaks periodically every 10bp (Lo et al., 
2010), thought to correspond with a turn of the DNA helix around a histone core (Mouliere 
and Rosenfeld, 2015). At the start of my investigations, there were few reports 
investigating urinary cfDNA size. Of note, Su et al. performed size analysis on urinary DNA 
using polyacrylamide gels and found two main bands of DNA (Su et al., 2004). The first a 
band approximately 150 – 250 nucleotides long, which they hypothesised derived from the 
circulation through renal filtration, the second a much larger band representing DNA 
>1kilobase long, which they hypothesised derived from the lining of the urinary tract (Su et 
al., 2004). In a subsequent study by Tsui et al., greater resolution NGS approaches were 
used to assess the size of DNA present in the urine of pregnant women. They found that 
maternal urinary cfDNA was had a predominant peak at 29bp and the majority of maternal 
cfDNA was below 100bp in length (Tsui et al., 2012). If a similar difference in mutDNA and 
cfDNA size distribution is present in urine for cancer patients, size selection (either during 
library preparation or in-silico) may help select mutDNA and aid their investigation.  
1.2 Prostate Cancer  
Prostate cancer has affected men since antiquity. Though Adams demonstrated prostate 
cancer pathology for the first time in 1853, the clinical entity of prostate cancer has been 
described since the time of the ancient Egyptians. Indeed, the first known human prostate 
cancer was detected in “M1”, an Egyptian mummy, using High Resolution Computerised 
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Tomography (Prates et al., 2011). In the 1950’s, men with prostate cancer would be 
typically diagnosed when they presented with bony metastasis (Denmeade and Isaacs, 
2002). Since then many changes, including the advent of Prostate Specific Antigen testing 
has allowed for earlier diagnosis. Despite the trend for earlier diagnosis, prostate cancer 
remains a significant cause of mortality and improvements are required in particular in our 
ability to distinguish between indolent and aggressive forms of prostate cancer.  
1.2.1 Prostate Cancer Epidemiology 
Prostate cancer is the most common male malignancy. Prostate cancer is almost always 
Prostatic adenocarcinoma (McAninch et al., 2013). Since the work of Franks in the 1950s, 
post-mortem studies of men have been the main method of inferring the true prevalence of 
prostate cancer amongst men. Of American Caucasian men who died from trauma, Sakr 
et al. demonstrated the prevalence of prostate cancer and its precursor (Prostatic Intra-
epithelial Neoplasia – PIN) to be as high as 44% for men between 51 and 60 years of age, 
rising up to 83% in men aged between 71 and 80 year old men (Sakr et al., 1993). In 2011 
there were 41,736 new diagnoses of prostate cancer (CRUK, 2014). The incidence 
increases sharply with age. The incidence per 100,000 men is 800 for those aged between 
75 to 79 compared with only 60 for men aged between 50 to 54 (CRUK, 2014). 
Furthermore, the incidence of prostate cancer is increasing (Hsing et al., 2000; CRUK, 
2014).  
Prostate cancer is now the second leading cause of cancer mortality in men and caused 
10,800 deaths in the U.K. in 2011 with the majority of deaths occurring in men aged over 
75 years (2014). 5 year survival rates have increased from 31% during 1971 - 1975 to 
68.3% during 1996 – 2000 (CRUK, 2014). For 2005 – 2009, the 5 year survival rate was 
81.4% (CRUK, 2014) and there were an estimated 10.07 deaths per 100,000 men in the 
U.K. (Haas et al., 2008).  
Prostate cancer is staged according the TNM classification system. The major “T” or 
Tumour stages are: 
• T1  tumour is too small to be felt during digital rectal examination 
• T2  tumour is confined to the prostate gland 
• T3  tumour invades prostatic capsule 
• T4  tumour invades surrounding organs  
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Historically, most men presented with late stage complications of prostate cancer and life 
expectancy from time at diagnosis was short. The recent improvement in survival rates 
has largely been due to improvement in early diagnosis of prostate cancer and treatment. 
1.2.2 Prostate Cancer Diagnosis 
The current trend for early diagnosis in prostate cancer is largely due to the increase 
utilisation of Prostate Specific Antigen (PSA) testing. PSA is a kallikrein-related serine 
protease normally found in prostatic secretions but found in blood when the normal 
prostatic architecture is disturbed (Lilja et al., 2008). Since its use as a screening tool from 
the 1980’s PSA-detected early prostate cancer has become more prevalent. However, 
recent studies suggest that early treatment of all prostate cancers may not be necessary. 
In one study of >180,000 men with prostate cancer, Schroder et al. found that 1410 men 
would need to be screened and 48 additional cases of prostate cancer would need to be 
treated to prevent one prostate cancer death (Schroder et al., 2009). Indeed, in the PIVOT 
trail, Wilt et al. report no significant difference between men treated with radical 
prostatectomy and those who underwent observation in 731 men. However, when 
categorised according to risk, men with high-risk prostate cancer had improved all-cause 
mortality following prostatectomy (Wilt et al., 2012). Therefore, the impact that PSA testing 
and subsequent treatment of localised disease has had on prostate cancer specific 
mortality (PCSM) is questionable (Schroder and Zappa, 2012; Andriole et al., 2012) and 
there is therefore a drive to manage men with less invasive therapies or active surveillance 
(a PSA & biopsy based protocol) alone. Indeed, several international guidelines suggest 
the use of active surveillance for prostate cancer at low risk of causing PCSM (Heidenreich 
et al., 2014; NICE).  
1.2.2.1 Biopsy approach 
The diagnosis of localised prostate cancer relies on the histological analysis of prostate 
biopsy tissue samples. The original random sextant systematic prostate biopsy involved a 
6-core biopsy taken trans-rectally with the help of ultrasound guidance (Hodge et al.). In 
2004, King et al. demonstrated that a 10-core transrectal biopsy, with an additional 2 
lateral-mid and 2 lateral base biopsies had final pathological upgrading rates of 13% 
compared with 25% of men undergoing sextant biopsy when compared to surgical 
pathology in 78 men. Interestingly however, there was no statistical difference between the 
rates of men who had correctly identified grading status (62% for sextant and 63% for 10-
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core biopsy) (King et al.). More recently however, there has been the inclusion of ever 
more cores (Moore et al.) and saturation (>20 cores) rectal or transperineal biopsies have 
been advocated to increase the rate of clinically significant prostate cancer detection 
(Guichard et al.; de la Taille et al.) and by proxy therefore to reduce the upgrading rate 
from final pathology. However, in a systematic review, Eichler et al. demonstrated that the 
addition of further cores (18 to 24) did not detect significantly more cancers and may have 
had a poorer side-effect profile, though reporting for reviewed studies was poor (Eichler et 
al.). Currently therefore, 10-12 core TRUS biopsy is standard practice in the initial biopsy 
setting, despite having been shown to miss around 30-45% of prostate cancers (Scattoni 
et al., 2007; Lecornet et al., 2012). Indeed, a recent survey of Urologists in the U.K. 
revealed that saturation biopsy is infrequently used in the initial biopsy setting, only when 
transrectal biopsies are contraindicated or if the prostate volume is >70cc (NICE, 2014).  
Biopsy techniques continue to evolve and transperineal template biopsy strategies, 
coupled with multi-parametric MRI guidance (MRI-B) are increasingly being adopted. Pinto 
et al. used fusion MRI-B to demonstrate an improved efficiency of diagnosis (fewer 
number of cores needed to detect prostate cancer). However, they were unable to 
demonstrate a change in the rate of detection (Pinto et al.). In 2013, Moore et al. 
conducted a systematic review of MRI-B and standard TRUS biopsy and similarly revealed 
no difference in the detection of clinically significant cancer whilst confirming the ability of 
MRI-B to detect cancer with fewer cores (Moore et al., 2013). These initial results are 
exciting however, studies determining the value of MRI-B compared with TRUS biopsy in 
relation to long-term outcomes are needed.  
1.2.2.2 Histological classification 
Since 1966, the Gleason Grading has summed the two most common grade patterns, 
each scored from 1-5 according to glandular architecture, to produce a Gleason score. In 
2005 the International Society of Urological Pathology (ISUP) updated the Gleason scoring 
system (Epstein et al., 2005). The 2005 ISUP changes were broadly aimed at limiting the 
scope of glandular architecture pattern 3 whilst widening the scope of pattern 4 (Montironi 
et al., 2010; Epstein et al., 2005). Therefore cancers that were previously graded 3 were 
subsequently graded as 4. Indeed, Greenburg et al. demonstrated that adoption of 2005 
ISUP scoring led to an increased incidence of intermediate and high-risk prostate cancer 
whilst low-risk prostate cancer incidence remained stable in the U.K. In 2014, the ISUP 
committee updated guidelines to grade prostate cancer, largely to overcome the fear that 
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patients had when assigned a cancer diagnosis but with a Gleason score of 6 (Epstein et 
al., 2016a). The novel Grade Groups assigns a prognostic score of 1-5 according to 
glandular pattern (see Table 1). The lead author showed these groups to be a more 
accurate predictor of BR in American men undergoing radical treatment (Epstein et al., 
2016b). Most recently, a new risk stratification system incorporating this new prognostic 
grouping system has been shown to significantly improve prediction of PCSM in a new 
diagnosis cohort of U.K. men (Gnanapragasam et al., 2016).  
1.2.3 Risk stratification following prostate cancer biopsy 
Risk stratification tools have repeatedly been shown to outperform clinicians at identifying 
the men at low risk of PCSM and in whom more conservative management strategies 
should be pursued (Shariat et al., 2009). Men with localised prostate cancer are currently 
risk-stratified according to their PSA at diagnosis, clinical stage and Gleason grade at 
biopsy. In the U.K., the National Institute for Clinical Excellence (NICE) has published a 
scoring system that groups men according to the risk of prostate cancer recurrence 
following treatment. In brief, there are three groups: low-risk, for men with a PSA 
<10ng/ml, Gleason score ≤6, and clinical stage T1-T2a, the intermediate-risk group for 
men with a PSA 10–20ng/ml, or Gleason score 7, or clinical stage T2b and a high-risk 
group for men with a PSA >20ng/ml, or Gleason score 8-10, or clinical stage ≥T2c. 
However, these guidelines draw on studies that have never been assessed against PCSM. 
Indeed, the PSA cut-off points are replicated from D’Amico’s work in 1998, using 
biochemical recurrence (BR) as a surrogate for aggression which, does not always predict 
PCSM (Freedland et al., 2005; Pound et al., 1999). Another early attempt at allocating risk, 
the Kattan nomograms predicted the presence of indolent cancers based on a study of 
clinical stage, Gleason grade, PSA and cancer volume in biopsy specimens (Kattan et al., 
1998). However, the majority of patients in this study underwent radical prostatectomy and 
again outcomes were measured against BR. Furthermore, clinical staging has not 
consistently been shown to associate with PCSM in the U.K. For example, although Reese 
et al. demonstrated that clinical staging predicted BR after radical prostatectomy in 
American men (Reese et al., 2012), Selvadurai et al. showed that clinical staging could not 
predict adverse histology on repeat biopsy for U.K. men undergoing active surveillance 
(Selvadurai et al., 2013). There have been no U.K. based studies to show that the above 
criteria can predict PCSM.  
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Despite this, with some relatively minor changes, the above clinical parameters are 
incorporated in over 20 risk stratification tools (Rodrigues et al., 2012). Many of these tools 
are validated in populations of men outside the U.K., who are undergoing radical 
prostatectomy and are measured against surrogate markers other than PCSM.  
In 2005 Cooperberg et al. described the Cancer of the Prostate Risk Assessment 
(CAPRA) score. The score indicates risk on a 1-10 scale by using; age and PSA at 
diagnosis, percentage of biopsy cores which contain cancer, Gleason score at biopsy and 
clinical stage, to assign points. Although the score was initially validated against predicting 
BR following radical prostatectomy, it has subsequently been shown to predict risk of bone 
metastases and PCSM in over 10,000 American men with localised cancer considering all 
treatment options. Cooperberg et al. showed that for each increase in CAPRA score, there 
was a statistically significant increased risk of prostate cancer specific morbidity or 
mortality (Cooperberg et al., 2009). However, only 6% of men undertook active 
surveillance / watchful waiting in their cohort, despite 49% of patients having a CAPRA 
score of 2 or less.  
National and International consortia have also acted on evidence to suggest that 
increasing the number of risk categories can improve pre-treatment risk stratification. The 
National Comprehensive Cancer Network (NCCN) have recently updated their risk 
stratification guidelines to incorporate the amount of disease present in prostate biopsy 
cores and include a new very-low risk group. The purpose of the very low risk group being 
to highlight patients who are suitable for surveillance strategies rather than aggressive 
treatment. The drive for creation of the new group came from studies such as that 
conducted by Miller et al., showing that approximately 40% of cancers diagnosed in USA 
were over-treated (Miller et al., 2006). Furthermore, in 2008 Beasley et al. showed that 
splitting the intermediate group into low-intermediate and high-intermediate groups also 
improved pre-treatment risk stratification. However, these conclusions were due to the 
high-intermediate group having reduced BR rates when given adjuvant androgen 
deprivation therapy whilst the low-intermediate group received no benefit (Beasley et al., 
2008; Rodrigues et al., 2012).  
NICE therefore, highlights that clinical risk stratification tools may not be representative of 
outcomes in U.K., not least because of the differences between PSA screened populations 
and ours, and differences in the way men are treated (NICE, 2014). A recent study from 
our institution has addressed this and tested the NICE risk groups and a new model in a 
large U.K. population. This study demonstrated poor concordance for the NICE groups in 
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predicting PCSM but a significantly improved performance by using a more refined risk 
stratification system (Gnanapragasam et al., 2016).  
But, there are multiple methods to stratify risk in prostate cancer, including nomograms, 
UCSF-CAPRA Score and D’amico classification. In brief these scoring methods take 
several factors such as Gleason score, PSA level, and clinical stage to calculate risk. Of 
these the D’amico classification, first described in 1988, is the most commonly used in 
practice (D'Amico et al., 1998). Despite extensive use, many men with seemingly low risk 
prostate cancer can still die of their disease. In a series of 458 men with low risk prostate 
cancer being treated with active surveillance, Klotz et al. found that 30% of men had a 
PSA doubling time of <3yrs (another contentious marker of high risk cancer) or had 
upgrading on repeat biopsy and were therefore offered definitive treatment (Klotz et al., 
2010).  
Concurrently, there is a real risk of being under staged during standard TransRectal 
Ultrasound Guided prostate biopsy. During analysis of 499 radical prostatectomy patients, 
Steinberg et al. found that only 58% of their academic hospital patients and 34% of 
patients from community hospitals had the same Gleason score when compared to their 
initial needle biopsy grade (Steinberg et al., 1997). However, a more recent study 
suggests that concordance is now around 75%, likely due to the increased number of 
cores taken (Rajinikanth et al., 2008). The non-invasive analysis of prostate cancer 
genomes through mutDNA analysis may aid in accurately differentiating between indolent 
and aggressive prostate cancer if it represents mutations from multiple (or the most 
significant) clone(s).  
1.2.4 Prostate Cancer Mutational Profile 
WGS and WES studies have demonstrated that prostate cancer has few mutations. 
Indeed, the mutation rate in localised disease is <0.9 mutations/Mb (Berger et al., 2011) 
and 2 mutations /Mb for CRPC (castrate resistant prostate cancer) (Grasso et al., 2012). 
By contrast, the mutation rate of other solid cancer such as malignant melanoma can be 
as high as 15 mutations /Mb (Hodis et al., 2012).   
Of the mutations that are present in localised disease, few are recurrent except the 
TMPRSS:ETS re-arrangement, which is present in >50% of all patients (Tomlins et al., 
2005; Berger et al., 2011). Unfortunately the intergenic location of the breakpoint for this 
re-arrangement is not recurrent and therefore non-invasive biomarkers targeting this 
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recurrent fusion in circulating nucleic acids have been limited to mRNA testing. Though 
fused mRNA fragments can be detected in the urine of men with prostate cancer (Laxman 
et al., 2006) and initial lab based tests were encouraging, sensitivity in the clinic was low 
(Hessels et al., 2007), possibly due to the fact that only 50% have this re-arrangement and 
due to the inherent instability of single stranded nucleic acids. For SNV’s, the most 
common mutations are TP53, SPOP, PTEN and FOXA1 which are only found in 14%, 8%, 
7% and 5% of men respectively (Forbes et al.). Furthermore, the prevalence of these 
mutations are significantly affected by the disease setting, with clones harbouring SPOP 
SNV’s often lacking TMPRSS:ETS re-arrangements  (Barbieri et al., 2012). The low 
mutation rate will make unbiased amplicon sequencing methods to detect ctDNA 
challenging and may require broader sequencing strategies.  
1.2.5 Prostate heterogeneity obfuscates accurate stratification in localised disease 
Vogelstein et al. summarised the mutational profile of multiple tumour types to define four 
categories of tumour heterogeneity (Vogelstein et al., 2013):  
1. Intra-tumoural: heterogeneity among the cells of one tumour.  
2. Inter-metastatic: heterogeneity among different metastatic lesions in the same 
patient. 
3. Intra-metastatic: heterogeneity among the cells of an individual metastasis. 
4. Inter-patient: heterogeneity among the tumors of different patients. 
Prostate cancers represent an extremely heterogeneous tumour in all four regards. 
Indeed, Haffner et al. performed tumour re-sequencing on multiple tumour clones in a 
single prostate cancer patient to find 9 distinct lesions. Of notable interest, by performing 
tumour re-sequencing of metastatic sites following rapid autopsy, Haffner et al. 
demonstrated that the metastatic clone hailed from a small tumour with Gleason 3+3 
grading as opposed to the surrounding higher Gleason tumour clones (Haffner et al., 
2013). More recently, Cooper et al. have corroborated that localised PC can be multi-focal 
by using multi-regional WGS to assess regions 6-8 regions of prostatectomy specimens 
from 3 men (Cooper et al., 2015). Of interest, they found that many cancer regions 
contained distinct clones each with independent genetic phylogenies.  
Improvements in risk stratification are urgently needed and are likely to be borne of the 
heterogeneous nature of localised prostate cancers. These factors translate to real 
uncertainty in clinical practice and current methods to overcome heterogeneity include 
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increasing the numbers of biopsy cores being taken (Boyd et al., 2012). There is therefore 
a need for a biomarker than can monitor tumour heterogeneity and progression non-
invasively. 
1.2.6 Biomarkers using genetic analysis 
There has been an increase in the use of genetic analysis to predict outcomes in prostate 
cancer. However, the majority of these studies have used prostatectomy samples, where 
the amount of tissue available makes genetic analysis easier. Through advances in PCR 
methods and genetic analysis, there is now the real ability to detect variants from the small 
amounts of genetic material found in bodily fluid or biopsy specimens. For biopsy 
specimens, several diagnostic aids are available e.g. Oncotype Dx (Knezevic et al., 2013), 
Prolaris (Cuzick et al., 2012), Dechipher (Klein et al.), etc. However, many of these assays 
assess the likelihood of aggressive cancer by analysing the expression of genes from 
isolated RNA, which can be unstable in bodily fluids.  
The presence of ctDNA has previously been reported by Bettegowda et al., who detected 
ctDNA in 2/5 patients with metastatic prostate cancer (Bettegowda et al., 2014) and by 
Heitzer et al., who described Plasma-Seq, a sWGS (shallow whole genome sequencing) 
approach to detect CNAs (copy number aberrations) in plasma of patients with CRPC 
(Heitzer et al., 2013). Heitzer et al. performed Plasma-Seq on 13 plasma samples to 
detect CNAs in 80% of patients when the AF is >10%. More recently, Carreira et al. 
demonstrated the use of deep amplicon sequencing and WGS to track SNVs and CNAs in 
sequential plasma samples from 16 ERG positive CRPC patients (Carreira et al., 2014). 
Despite this, there are no reports of ctDNA analysis in localised PC, where ctDNA levels 
are likely to be much less, potentially rendering WGS type approaches less useful. 
Furthermore, if the ability of ctDNA to monitor clonal evolution in metastatic disease can be 
applied to localised PC, a ctDNA based test could lead to profound clinical benefit. 
1.3 Bladder Cancer  
The earliest descriptions of bladder cancer can also be found from scriptures dating back 
to ancient times. The first documented European report of bladder cancer was not until an 
oral account in 1895 by Ludwig Rehn (Dietrich and Dietrich, 2001). This ignited research 
into the aetiology of bladder cancer. Historically, this remained the focus of research 
efforts until recently. Despite the breadth of research currently investigating bladder 
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cancer, it accounts for 3% of all cancer deaths (CRUK, 2014) and is the most expensive 
solid cancer to treat per patient, due to its high recurrence rate leading to costly in and 
outpatient hospital admissions (Botteman et al., 2003; Yeung et al., 2014). 
1.3.1 Bladder Cancer Epidemiology 
Bladder Cancer is the most common malignancy of the urinary tract, and the 7th most 
common cancer overall in the U.K. The risk of developing bladder cancer is strongly 
affected by occupational hazards, infection and environmental factors. For example in 
Egypt, the age-standardised incidence of bladder cancer is 21.8 per 100,000 men and 5.6 
per 100,000 women, whilst in the U.K, the age-standardised incidence of bladder cancer is 
9.3 per 100,000 men and 2.8 per 100,000 women (Ferlay et al.). There were 10,339 new 
cases diagnosed in 2011 in the U.K. and incidence rates have been decreasing overall 
since the early 1990s (CRUK, 2014). The incidence in men is higher than in women by a 
ratio of 2.5 male : 1 female in 2011 (ONS, 2011). 
Primary bladder cancer has several pathological subtypes (see Table 1.1) and the 
incidence of these subtypes vary depending on geographical location. Historically, the 
prevalence of Schistosomiasis infections in Egypt was high. As chronic Schistosoma 
Haematobium infections are associated with squamous cell carcinoma (SCC) (Mostafa et 
al., 1999), during the 1980’s the dominant subtype of bladder cancer was SCC accounting 
for 78% of the disease (Fedewa et al., 2009). More recently, following public health 
initiatives and changes to the habitat of Schistosoma Haematobium, there has been a 
reduction in the prevalence of Schistosomiasis in Egypt making urothelial carcinoma more 
prevalent (Fedewa et al., 2009). In the U.K., smoking, and industrial exposure are the main 
risk factors and therefore Urothelial carcinoma is the dominant pathological subtype 
accounting for 90% of disease (Fedewa et al., 2009). For the purposes of my research I 
will therefore focus on urothelial carcinoma of the bladder and where bladder cancer is 
stated, it will describe urothelial carcinoma of the bladder. 
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Malignant Frequency in 
UK, %  
   Urothelial carcinoma (previous Transitional Cell Carcinoma) 94.72 
Urothelial carcinoma variants  
• Keratinising 0.01 
• Squamous differentiation 0.25 
• Nested <0.01 
• Carcinosarcoma  0.16 
• Sarcomatoid  0.79 
• Undifferentiated carcinoma 0.03 
• Signet ring 0.02 
• Clear cell 0.01 
• Inverted papilloma 0.04 
   Squamous cell carcinoma (SCC) 1.65 
   Adenocarcinoma  1.61 
   Mesenchymal  0.91 
   Haematopoetic / lymphoid 0.04 
   Neuroendocrine  0.24 
Secondary Malignancies 0.08 
 
Table 1.1: Bladder cancer histological subtypes, modified from (Sexton et al., 2010) and (Boustead et 
al., 2014) 
During 2005 - 2009, 56.1% of adult patients with bladder cancer in England survived their 
cancer for five years or more (ONS, 2011). The survival rate has decreased recently; the 
five year survival for English men during 1991-1995 was 64.2% and is now down to 58.2% 
(CRUK, 2014). This is partly to be due to the recoding of carcinoma in-situ and other 
lesions that were historically coded as cancerous (Shah et al., 2008). 
1.3.2 Aggressive & Non-Muscle Invasive Bladder Cancer 
Bladder cancer is staged according to the TNM classification system. The major “T” or 
Tumour stages are: 
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• Tis / Cis tumour cells remain only in the epidermal layer and have not 
breached the basement membrane  
• T1  tumour cells are found in the subepithelial connective tissue 
• T2  tumour invades muscularis propria 
• T3  tumour invades perivesical adipose tissue 
• T4  tumour invades surrounding organs  
Tis - T1 can be termed non-muscle invasive bladder cancers (NIMBC) and represent of 
80% of urothelial carcinoma at first diagnosis. The remaining 20% are muscle invasive 
bladder cancers (MIBC) and comprise of T2 - T4 (Kirkali et al., 2005).  
The World Health Organisation classifies bladder cancer into the following grade 
groupings (Kirkali et al., 2005): 
• Papilloma  Benign tumour 
• PUNLMP Papillary urothelial neoplasm of low malignant potential 
• Low grade Cells retain an orderly appearance with minimal disruption to 
structural architecture 
• High grade  Highly abnormal & disordered cells  
Most NMIBC is low grade at diagnosis, with only 4% being high grade (Sylvester et al., 
2005). Even after complete excision the recurrence risk is high for both low and high grade 
NIMBC, with low grade NMIBC recurring in 64% and high grade NMIBC recurring in 
approximately 56% of patients (Kirkali et al., 2005). NMIBC survival rates depend on the 
risk of the urothelial cancer invading the muscle layer and becoming invasive bladder 
cancer. Once urothelial cancer invades the muscle layer of the bladder, the risk of 
metastasis increases significantly and, metastatic bladder cancer has a poor 10% survival 
rate over 5 years. Therefore, the risk of NMIBC progressing drives clinical decision-
making.  
Several factors determine the risk of progression, including tumour grade. The risk of low 
grade NMIBC progressing is 10.5% whilst for high grade NMIBC the risk is 27.1% (Kirkali 
et al., 2005). Sylvester et al. used data from previous European Organization for Research 
and Treatment of Cancer (EORTC) studies retrospectively determine a scoring system 
based an analysis of 2596 patients. The system allocated scores to the features of the 
tumour including; number of tumours, tumour size, prior recurrence rate, stage, presence 
of CIS and grade to determine the risk of recurrence and progression. Using the EORTC 
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scoring, the most weighted scores for determining progression are allocated to high-grade 
tumours and those with CIS present.  
High grade and CIS tumour share a common genetic profile, with mutations in TP53 and 
RB a common feature. These tumours often go on to progress to life threatening 
metastasis (Wu, 2005). Conversely, low-grade papillary tumours are often slow to 
metastasis. These tumours are more likely to have mutations in the receptor tyrosine 
kinase–Ras pathway, particularly in DNA coding for the Fibroblast growth factor receptor 
protein FGFR3 or in HRAS (Wu, 2005). Both tumours harbour deletions in Chromosome 9 
from an early stage. 
1.3.3 Treatment Options For Muscle Invasive Bladder Cancer  
As the progression risk is high despite aggressive NMIBC being localized, doctors and 
patients face a difficult decision regarding what treatment to take to ameliorate the risk of 
progression. There are broadly speaking two commonly used treatment options.  
1.3.3.1 Radical Radiotherapy  
Ionising radiation has been used to treat cancer since the late 19th Centaury, initially with 
Radon, then cobalt x-rays. Modern radiotherapy is delivered by linear accelerators, which 
focus a beam of ionising radiotherapy to the tumour and surrounding structures. For MIBC, 
it is most often delivered in fractions of ~2Gy /day, 5 days a week to a total of 45-50Gy. 
More recently, improvements in radiotherapy planning, verification, and delivery have allow 
more targeted delivery of higher radiation doses, with less side effects (Zhang et al., 
2015). Using hypofractionated intensity-modulated radiation therapy, Turgeon et al. report 
a 71% 3 year survival (Turgeon et al., 2014).  
1.3.3.2 Radical Cystectomy 
Cystectomy has been performed since the 1800s. The initial procedure was more akin to 
what would be termed a simple cystectomy today, with no attempt to control perivesicular 
organs or regional lymph nodes (Raj and Bochner, 2007). Despite this, the procedure had 
a formidable mortality rate in excess of 30% (Raj and Bochner, 2007). In 1949, following 
their investigation into local recurrence by cadaveric dissection, Marshall and Whitmore 
described the prototypical radical cystectomy – surgical removal of the bladder, adjacent 
organs and their lymphatic drainage. Through advances in surgical technique, anaesthesia 
INTRODUCTION - Bladder Cancer 
 
42 of 233 
and perioperative care, modern radical cystectomy has a 30 day mortality rate of 2% and 
following radical cystectomy for organ confined cancer, a disease specific five year 
survival of 94% (Manoharan et al., 2009). 
1.3.4 Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer 
Bladder Cancer (BC) is the most common malignancy of the urinary tract (Ferlay et al., 
2013). Approximately 25% of BC patients have Muscle Invasive Bladder Cancer (MIBC) at 
diagnosis (Kirkali et al.). The presence of MIBC signifies aggressive disease with a 
significant risk of metastatic progression. Even after definitive treatment (e.g. radical 
cystectomy) overall survival (OS) is on average 50% over 5yrs (Stein and Skinner). Meta-
analyses show that a 3-month regimen of cisplatin-based neo-adjuvant chemotherapy 
(NAC) can improve 5-year absolute OS by 6% (Vale, 2003; Trialists, 1999; International 
Collaboration of et al., 2011). 
Despite maximum treatment with NAC and radical cystectomy, many patients do not 
respond to NAC (Lee et al.) and MIBC patients often recur within 2 years (Koie et al., 
2015). Currently biomarkers to predict outcome during NAC are lacking and the predictive 
capacity of cystoscopy or radiological examination is limited (Nishimura et al.). In patients 
not responding to NAC, definitive treatment could be expedited or other systemic 
treatments investigated in the neo-adjuvant setting. Of note, the recent success of immune 
checkpoint inhibitors (Rosenberg et al.) provides a possible alternative non-cross-resistant 
systemic treatment for these patients and trials with checkpoint inhibitors have recently 
been initiated in the peri-operative setting. 
Circulating tumour DNA (ctDNA) offers a minimally-invasive means to monitor tumour 
status. The half-life of circulating cell-free DNA is reportedly less than 2 hours (Diehl et al.; 
Fournié et al.; Thierry et al., 2010) and the allele fraction ratio of mutant:wild type DNA 
(AF) has been shown to reflect tumour burden and response (Rago et al., 2007; Thierry et 
al., 2010; Dawson et al.). The translational potential for mutDNA in body fluids could be 
even greater in bladder cancer due to the possibility of monitoring mutDNA in urine (Patel 
and Tsui, 2015), a peripheral fluid that truly can be collected ‘non-invasively’. In BC, the 
close proximity of tumour to the peripheral fluid reservoir might be expected to lead to a 
greater accumulation of tumour derived DNA.  
Recent reports have shown that mutDNA is detectable in the plasma and the urine of 
patients with BC. Using the Affymetrix Oncoscan assay, Togneri et al. demonstrated that 
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mutation profiles present in FFPE tumour specimens were mirrored in matched urinary 
samples from patients with Non-Muscle Invasive Bladder Cancer (Togneri et al.). Ward et 
al. used digital PCR (dPCR) and NGS to analyse the somatic mutation status of cell pellets 
obtained by centrifuging urine samples (UCP), and urine supernatant (USN) in 120 primary 
patients with bladder cancer  and 89 patients post transurethral resection (TUR), and 
detected mutDNA in 70% of cases (Ward et al.). Furthermore, Birkenkamp-Demtröder et 
al. detected mutDNA in plasma and urine of patients with BC by sequencing tumour 
specimens to design personalised droplet dPCR probes for use in peripheral fluids. In 4/6 
patients, personalised probes detected plasma ctDNA several months before clinical 
progression (Birkenkamp-Demtroder et al.). These studies mostly focus on non-invasive 
BC, which are often driven by different pathways than MIBC (Cancer Genome Atlas 
Research, 2014), and none compared plasma, UCP and USN sampling methods. The 
application of mutDNA in BC represents an exciting opportunity for clinical impact in MIBC 
and, despite recent efforts, remains relatively unexplored. 
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CHAPTER 2: URINARY CELL-FREE DNA 
2.1 Synopsis 
Analysis of mutant cfDNA has the potential to help predict aggressive disease, monitor 
treatment response and monitor tumour burden. For urological cancers, the added 
potential is that mutated cfDNA may be locally shed into a body fluid that is both abundant 
and truly non-invasive. Indeed, Millholland et al. demonstrated the presence of FGFR3 
hotspot mutations in urinary cfDNA, though their approach was limited by single gene 
analysis (Millholland, 2012). At the initiation of this project, there were no direct 
comparisons of urinary cfDNA processing or extraction methods and no multi-gene 
sequencing based reports of urinary mutDNA analysis.  
To help unlock the potential of urinary cfDNA as a liquid biopsy, 7 healthy volunteer urine 
samples were used to investigate urine cfDNA extraction and processing. Four urine 
specific DNA extraction kits were compared for cfDNA yield. Urine samples were 
processed with or without centrifugation, and the addition of EDTA. To investigate the 
affect of increased length of time between harvesting and processing, urine samples were 
processed at 1hour, 6hours and 48hours after collection. A further 2 patients with 
metastatic bladder cancer were recruited to assess optimal mutDNA approaches for BC 
using a novel bladder specific primer panel. 
Of the four kits that we assessed, mean urinary cfDNA across the samples was 22,810, 
14,570, 7,243 and 1,535 Genomic Equivalent (GE) copies/ml sample for QIAmp circulating 
nucleic acid, Norgen, NeoGenStar and SNOVA kits respectively). Only the SNOVA urinary 
cfDNA extraction kits had a statistically significantly lower cfDNA yield (p<0.01). We found 
that centrifugation reduced the urinary cfDNA yield (p<0.001) and hypothesise that this is 
through removal of the fraction of urinary cfDNA that would arise from cellular lysis during 
extraction. The addition of EDTA did not significantly alter the cfDNA yield, however there 
was a small effect to improve cfDNA yield with the addition (19,350 versus 15,170 mean 
GE copies/ml for samples with 10mMol EDTA compared to no EDTA). Increased length of 
time between sample collection and processing reduced the cfDNA yield (p=0.0121). 
Using the bladder-specific panel, no SNVs were detected from the metastatic BC patients, 
precluding further analysis of urinary processing for mutDNA. 
These results demonstrate the feasibility of urine processing for cfDNA analysis using a 
scalable approach. Urinary cfDNA has since been shown to be an important source of 
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mutDNA in BC (Millholland, 2012; Togneri et al., 2016), colorectal cancer (Su et al., 2004) 
and others. The optimisation of urinary cfDNA extraction will facilitate the application of 
mutDNA analysis in the Rosenfeld laboratory. 
2.2 Publications arising from this work 
Work presented in this chapter was first described in my first year report and parts were 
published in Clinical Biochemistry as well as sections of the supplementary material of a 
published in Scientific Reports. The text is therefore excerpted from my first year report 
and related publications except to display updated data and references. 
K.M. Patel, D.W.Y. Tsui. The translational potential of circulating tumour DNA in 
oncology. Clinical Biochemistry. October 2015. 48:15, 957-961. ISSN 0009-9120, 
http://dx.doi.org/10.1016/j.clinbiochem.2015.04.005. 
KM Patel , KE van der Vos , CG Smith , FC Mouliere, D Tsui, J Morris, D 
Chandrananda, F Marass, D van den Broek, DE Neal, VJ Gnanapragasam, T 
Forshew, BW van Rhijn, CE Massie, N Rosenfeld*, MS van der Heijden*. Association 
Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive 
Bladder Cancer. Scientific Reports. 2017. 7:5554. http://dx.doi.org/10.1038/s41598-
017-05623-3 
These authors contributed equally. 
* These authors are joint senior supervisors  
 
  
2.3 Aims 
My primary objective was to explore whether urinary mutant cfDNA can be isolated for 
future investigation as an informative marker for prostate & bladder cancers. To 
develop methods for urinary cfDNA analysis, I: 
1. Initiated sample collections: I collected fresh urine from healthy volunteers 
(men with raised PSA who have normal biopsy results attending the prostate 
diagnostic clinic) and from patients with metastatic bladder cancer who attended 
oncological clinics, using previously granted ethical approval (MREC:01/4/061, 
LREC:11/H0311/2 and LREC:03/018).  
2. Optimised protocols for DNA extraction from urine supernatant: I 
performed literature searches to identify then test commercially available urinary 
cfDNA extraction kits. I used dPCR to assess the genomic yields of each kit on 
urine samples. 
3. Optimised protocols for processing urinary supernatant from fresh urine: I 
collected urinary specimens with multiple processing techniques and quantified 
extracted DNA with dPCR. 
4. Test urinary mutDNA detection in pilot metastatic bladder cancer cohort: 
Using the COSMIC database (Forbes et al., 2011) and results of major 
sequencing projects (Cancer Genome Atlas Research, 2014), I compiled a list of 
commonly mutated genes in bladder cancer. I validated the primers using 
control genomic DNA and applied it to perform TAm-Seq on urinary cfDNA from 
metastatic patients to determine the optimal conditions for mutant urinary cfDNA 
detection. 
  
2.4 Methods 
2.4.1 Urinary processing protocols 
Urine samples from 7 volunteers with raised PSA but negative prostatic biopsies were 
collected to optimise urinary supernatant processing and extraction procedures. Samples 
were collected under ethical approval previously granted for the investigation of 
biomarkers in urological diseases (LREC 03/018), see . Urine samples were processed 
according to Table 2.1 for the first 6 patients (Patient A – Patient F). Samples marked 
EDTA (dipotassium Ethylenediaminetetraacetic acid) had 600µL of 0.5M K2 EDTA per 
30ml of urine added immediately to give a final concentration on 10mM. Where 
“centrifuged” is denoted, samples were centrifuged at 3,000rpm for 10 minutes and the 
supernatant kept for further analysis. Samples were processed at the indicated times post 
sample collection. Urine from the 7th patient (patient G) was stored in aliquots that had 
been processed within 1 hour and had 10mM EDTA added to the sample to provide 
multiple replicates for DNA extraction testing. 
 
 Centrifuged (ml) Uncentrifuged (ml) 
1hr Freeze + EDTA 30ml <30ml 
1hr Freeze  5ml 5ml 
6hr Freeze + EDTA 5ml 5ml 
6hr Freeze  5ml 5ml 
48hr Freeze + EDTA 5ml 5ml 
48hr Freeze  5ml 5ml 
Table 2.1: Urinary DNA sample processing variables tested. Fresh urine samples were aliquoted into 3 
processing groups according to time. Each urine sample was then processed using the combinations 
outlined above. + EDTA signifies the addition of 10mMol of dipotassium EDTA pH 8.0 (Invitrogen) to each 
urine sample. Centrifugation was for 10mins at 3000g. 
Initial investigation of urine DNA testing was performed using 3 commercially available and 
hence scalable, DNA extraction kits. Kits were chosen based on the presence of a specific 
urinary cfDNA extraction protocol, their reported DNA (size specific) yield and the amount 
of urinary input required (i.e. between 1 and 10ml). Kit identification literature and internet 
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searches were performed in early 2013. Three kits were eventually selected for further 
testing; Norgen urine slurry kit, QIAmp Circulating nucleic acid kit, SNOVA nucleic acid kit. 
2.4.2 Extracted DNA quantification through digital PCR 
Digital Polymerase Chain Reaction (dPCR) dilutes the original sample and distributes it to 
multiple PCR reactions wells. The dilution is such that ideally there would be one molecule 
of DNA every two or more wells. Therefore, each well will have 1 or less molecules of DNA 
in the target region (Vogelstein and Kinzler, 1999), with only a very small number of wells 
(or no wells) with more than one target molecule. PCR reactions occur in parallel and 
presence of a DNA molecule can be detected by using primers and a fluorescent probe 
(TaqMan assay). The fluorescent probe consists of a fluorophore and a quencher in close 
proximity, covalently bonded to an assignable DNA sequence. During PCR, primer pairs 
anneal at either side of the probe and, during DNA polymerisation, Taq polymerase 
releases the fluorophore from the quencher due to the 5´–3´ exonuclease activity. The 
number of amplifiable copies in the original sample can then be determined by factoring 
the dilution factor, the number of positive wells, the volume of original sample used and the 
total volume of the sample master mix inputted. Allele-specific quantification can also be 
achieved using sequence-specific fluorescent probes. In order to simplify the process of 
setting up digital PCR, we use Biomark microfluidic digital PCR system (Fluidigm 
Corporation). The Biomark chips are available in a 12 and 48 panel chip, with 9,180 and 
36,960 reaction chambers, respectively and both variant were used dependent on how 
many samples were being tested. 
Urinary DNA size and concentration were analysed using 65, 97 and 360bp (base pair) 
assays. To reduce the risks of preferential amplification and primer dimer formation, 
assays were not multiplexed during dPCR. Assays were designed to target a sequence in 
the highly conserved Ribonuclease P protein subunit p30 (RPP30) region of the human 
genome. Primers were designed to target the following intronic region of RPP30: 
atactggaatttggggcacggacaggaagcgccgtggaggctcggagaaggaggaggacgtgggagtgttggaacaata
ctatctagacagagagagggtaggtgggggcagaggacatacacagcggagtggaggtggaggaggaggatagcatgg
cccaaatcgaagggaagcgaaagccttgagagacgagaacctgttttaactattggagttagtcatgggttctgtattccgtag
actgtaaagtgttggaatagagagattaaaaagaatcaagaggttcgtgtagtaacatctgctcctcagagacagttttcagctc
attgtgagttctgattactgatactgttcagaggtggtgctagaaatgacaaccacttcttggcaaagtgaatcacaccactttttta
ttgttctctttatgaagtatccgtggcgaaatgactgtccctttccactgctgccactaaatgaacgttatctctgtggtacttt 
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A 65bp sequence was detected by using the following Primers and TaqMan probes: 
RPP30_65bp_F   AGATTTGGACCTGCGAGCG 
RPP30_65bp_R   GAGCGGCTGTCTCCACAAGT 
RPP30_ROX    [ROX]TTCTGACCTGAAGGCTCTGCGCG[BHQ2] 
A 97bp sequence was detected by using the following Primers and Taq-man probes: 
RPP30_F1_97bp   TCATGGGACTTCAGCATGGC 
RPP30_R1_97bp   GGTGAGCGGCTGTCTCCA 
RPP30_ROX    [ROX]TTCTGACCTGAAGGCTCTGCGCG[BHQ2] 
A 360bp sequence was detected by using the following Primers and Taq-man probes: 
RPP30_F4_360_PM_F  CTTCAGCATGGCGGTGTT 
RPP30_R4_360_PM_R  CAGCTGTAGGCCCCTATGCA 
RPP30_362bp_HEX  [HEX]CCACCCAGACCATCGGGCCAC[BHQ1] 
DNA yield was calculated by introducing foreign DNA to each urine sample, immediately 
prior to DNA extraction. Foreign DNA was from Xenopus Tropicalis and is commonly used 
in the Rosenfeld lab for plasma DNA yield analysis (Dawson et al.). In brief, PCR 
amplification is utilised to create 170bp Xenopus Tropicalis DNA amplicon, with the 
following sequence: 
GTAGGTGTCATCATGGGGAAGtccctggggcaggtggtgatcatgggatttgtagctgtttggcccatggattatc
gatggtccatggttttcaggttggttttttacatgttattctctgtttccaaggttagcttagaaaaactGTGTTAGCAAAATC
TATTGCCTGA 
The amplicons are then quantified with dPCR using the following Taq-man probes: 
XenT_Spike.TaqMan_01_F  GTGATCATGGGATTTGTAGCTGTT 
XenT_Spike.TaqMan_01_R  AAACCAACCTGAAAACCATGGA 
XenT_Spike.Probe 6FAM   [FAM]CCCATGGATTATCG[BHQ2] 
6µL of approximately 1500 GE copies/µL Xenopus Tropicalis DNA was added to each 
sample during the first step of DNA extraction. Following the elution of DNA an estimate of 
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efficiency (DNA yield) is calculated by comparing the quantity of Xenopus Tropicalis 
amplicons in the eluted DNA with an extraction control sample prepared by introducing 
6µL of Xenopus Tropicalis DNA and 44µL of elution buffer. 
GE copies were calculated based on the number of estimated target wells detected by the 
Biomark using the following calculation: 
GE copies/ml = Est. Targets x elution from extraction (µL) ÷Sample input to mastermix 
(µL) ÷vol of plasma (ml) x dead-space correction factor (6 ÷0.65 for 37K chip and 10 ÷
4.6 for 12K chip x dilution factor 
2.4.3 TAm-Seq Panel Design 
To investigate the presence of urinary mutDNA, a panel was devised to target commonly 
mutated bladder cancer genes for application in TAm-Seq. Hotspots or entire coding 
regions of 8 genes based on recent WGS studies (Cancer Genome Atlas Research) and 
the COSMIC database (Forbes et al.) were selected. Genes were selected on the basis of 
their exon size and their mutational frequency. The final candidate genes are listed in 
Table 2.2. We aimed to design 48 or less primers to match the number of input assay 
channels on the microfluidic PCR access array chip (Fluidigm). 
Gene	 Targeting	
Expected	
mutation	
rate	in	BC	
%	of	SNVs	
covered	
with	panel	
Total	No	of	
Samples	
SNVs	covered	/	
total	SNVs	
BRAF p.V600 2% 90% 469 9/10 
CTNNB1
1 
p.T41 & p.S45 2% 100% 491 9/9 
FGFR3 p.S249, p.K652 & p.y375 41% 100% 5790 2384/2388 
HRAS p.G12 7% 99% 1585 103/104 
KRAS p.G12, p.G13 & p.Q61 4% 100% 1300 58/58 
NFE2L2 p.G31 2% 100% 157 1/1 
PIK3CA p.E545, p.G545 & p.HC1047 19% 97% 1142 215/221 
TP53 all exons 42% 100% 1335 555/555 
TERT Promoter Hot Spots^ 66% 0% 1887 0/1242 
Table 2.2: Genomic regions interrogated by TAm-Seq for SNV analysis. Analysis of COSMIC data set 
was used to estimate the number of SNVs targeted by our panel and was updated on the 24th August 2016. 
Primers in red text (TERT) were not included in the final panel. 
Primers previously designed by the Rosenfeld lab for ctDNA analysis, were present for 
BRAF, HRAS, KRAS, PIK3CA and TP53, with the remainder of genes requiring primers to 
be designed to target them. CTNNB1 had partial coverage of a bladder cancer hotspot, so 
an additional primer pair was designed to improve coverage. Initially, primers were 
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designed using Primer 3 website (Untergasser et al., 2012). Francesco Marass, a PhD 
student in the Rosenfeld group, developed an automated pipeline to design then tile 
primers, part way through the primer design stage of this project. Primer design in both 
techniques relied upon selecting primers based on the criteria listed in Table 2.3. The 
important criteria being the size as the amplicons needed to be long enough to be specific 
to a region in the human genome but at the same time short enough to be able to target 
mutDNA. In brief, the automated pipeline designed multiple such primers for a region prior 
to allocating each a score based on how far the criteria of each primer deviate from the 
median and hence calculates the optimal set of primers to tile across a region. 
Criteria		 Range		
primer size  16 - 35bp 
amplicon size  60 - 100bp 
annealing temperature  55-65  
GC content  45-55% 
Table 2.3: The criteria for designing and selecting primers for targeting mutDNA 
2.4.3.1 CTNNB1 primer design 
CTNNB1 is a dual function protein, regulating the coordination of cell–cell adhesion and 
gene transcription that is mutated in ~2% of patients with bladder carcinoma (Forbes et 
al.). The previous primer pair targeting CTNNB1 only covered the p.S37 hotspot mutation. 
The p.S45 hotspot, frequently mutated in urothelial cancer, would not have been targeted, 
see Figure 2.1. Therefore a primer pair was designed to target the region spanning 
chr3:41265875-41266356 using Primer3 (Untergasser et al., 2012), Figure 2.2. The region 
of interest is contained within square brackets and the previously designed primer targets 
bases, highlighted in yellow, whilst the new primer pairs are highlighted in pink. 
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Figure 2.1: COSMIC gene-browser overview of mutational burden in CTNNB1 
 
Figure 2.2: CTNNB1 region spanning chr3:41265875-41266356. Bold letters are exonic regions. The 
region of interest is enclosed in square brackets. The primers targeting this region are highlighted in pink. 
2.4.3.2 FGFR3 primer design 
FGFR3 mutations account for 47% of patients with bladder carcinoma (urothelial 
carcinoma) curated in the COSMIC database have mutations in FGFR3 out of a sample of 
4082. 99.8% of these SNVs fall within 3 hotspot regions, Figure 2.3 and Table 2.2. 
Therefore primers were designed targeting, these regions alone, Figure 2.4-Figure 2.6.  
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Figure 2.3: Distribution of somatic mutations of FGFR3 (Forbes et al.) 
Figure 2.4: DNA Sequence for Exon 6 of FGFR3. The formatting of the figure is similar to Figure 2.2. 
hotspot SNVs are highlighted in red. 
Figure 2.5: DNA Sequence for Exon 8 of FGFR3. The formatting of the figure is similar to Figure 2.4. 
 
 
 
 
TGGACGTGCTGGGTGAGGGCCCTGGGGCGGCGCGGGGGTGGGGGCGGCAGTGGCGGTGGTGGT
GAGGGAGGGGGTGGCCCCTGAGCGTCATCTGCCCCCACAG[AGCGCTCCC]CGCACCGGCCCA
TCCTGCAGGCGGGGCTGCCGGCCAACCAGACGGCGGTGCTGGGCAGCGACGTGGAGTTCCACT
GCAAGGTGTACAGTGACGCACAGCCCCACATCCAGTGGCTCAAGCACGTGGAGGTGAAtGGCA
GCAAGGTGGGCCCGGACGGCACACCCTACGTTACCGTGCTCAAGGTGGGCCACCGTGTGCACG
TGGGTGCCGCCGCTGGGGCTCCTGGGCTGGCCCCAAGGGTGCCCCTTGGCTGcGGGTTGCGTG
AGGATTTGGGTCTAGGGGTTGGAGCTTCGGGGGCAGAAGCTGTGGGGGTGCTTGTGGGGC 
GGAGCCCCGTGGgGGGGGGGGCCAGGCCAGGCCTCAAcGCCCATGTCTTTGCAGCCGAGGAGG
AGCTGGTGGAGGCTGACGAG[GCGGGCAGTGTGTATGCAGGCATCCTCAGCTACGGGGTGGGC
TTCTTCCTGTTCATCCTGGTGGTGGCGG]CTGTGACGCTCTGCCGCCTGCGCAGCCCCCCCAA
GAAAGGCCTGGGCTCCCCCACCGTGCACAAGATCTCCCGCTTCCCGCTCAAGCGACAGGTAAC
AGAAAGTAGATACCAGGTTCTG 
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Figure 2.6: DNA Sequence for Exon 13 of FGFR3. The formatting of the figure is similar to Figure 2.4. 
2.4.3.3 NFE2L2 primer design 
Nuclear factor (erythroid-derived 2)-like 2 is a basic leucine zipper protein that is involved 
in the regulation of antioxidant expression. In 2% of patients with BC, NFE2L2 mutations 
exist. SNVs in BC, have only been reported in one region but are reported in only 2 
hotspots in all cancer types, Figure 2.7. Therefore, 3 primer pairs were designed, targeting 
both regions. 
 
Figure 2.7: Distribution of somatic mutations of NFE2L2 (Forbes et al.) 
 
  
GGCCCTGCCCTGAGATGCTGGGAGCAGCGGGGAGAGGTGGAGAGGCTTCAGCCCTGCCTCCCA
CCCCTTCCCCAGTGCATCCACAGGGACCTGGCTGCCCGCAATGTGCTGGTGACCGAGGACAAC
GTGATGAAGATCGCAGACTTCGGGCTGGCCCGGGACGTG[CACAACCTCGACTACTACAAGAA
GACgACCAAC]GTGAGCCCGGCCCTgGGGTGCgGGGGTGGGGGTCATGCCAGTAGGACGCCTG
GCGCCAACACCGCCTTCCCACA 
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Figure 2.8: DNA sequence for NFE2L2 exon on chr2:178098679-178160622. In this figure forward and 
reverse paired primers are highlighted in the same colour, whilst hotspot mutations curated by COSMIC are 
underlined. 
2.4.3.4 TERT primer design 
Approximately 70% of patients with bladder carcinoma have TERT mutations in their 
promoter region (Hurst et al.; Kinde et al.; Forbes et al.) 2 hotspots account for 77% of 
these mutations, with a further promoter region hotspot accounting for an additional 3% of 
mutations, Figure 2.9 and Table 2.2. Therefore, primer pairs for these regions were 
designed. 
 
Figure 2.9: Distribution of somatic mutations for TERT (Forbes et al.). SNVSs are found in the promoter 
region of TERT. 
CTCAGTGTTTCCTTAAACCTGCCATAACTTTCCCAAGAACTGAGTACTCTGTA
CCTGGGAGTAGTTGGCAGATCCACTGGTTTCTGACTGGATGTGCTGGGCTGGC
TGAATTGGGAG[AAATTCACCTGTCTCTTCATCTAGTTGTAACTGAGCGA]AA
AAGGCTTTCTCTTGCTCCTTTTGGAGTTGTTCTTGTCTTTCCTTTTCAAGTTT
TTTCTGTTTTTCCAGCTCATACTCTTTC[CGTCGCTGACTGAAGTCAAATACT
TCTCGACTTACTCCAAG]A[TCTATATCTTGCCTCCAAAGTATGTCAATCA]A
ATCCATGTCCTATGTTTAAGACAAAAAAAGGAAGGAGAGAGCTCATGTTTTTT
AAATGACAGATACCACATAAATTAATTCACATTATGCCACTGTTGATGGTGGG
AAGTGGGG GATTACAAATACAATCTAAATGAGAACAC 
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Figure 2.10: DNA sequence for TERT promoter regions on chr5:1294977-1296504. Major hotspot 
mutations curated by COSMIC are highlighted in read and minor hotspot regions (i.e. with a mutation rate of 
<3%) are highlighted in blue). TERT_1forward and reverse primers are highlighted in green and TERT_2 
forward and reverse primers are highlighted in pink. 
2.4.4 Primer Validation 
Primer specificity for the target region was determined by conducting BLAT (Barbieri et al.) 
and in-silico PCR using UCSC genome browser (Kent et al., 2002). Primers were further 
validated by PCR with genomic DNA extracted from the white blood cells of healthy male 
volunteers (Promega, PR-G1471). The PCR mastermix concentrations used for testing are 
listed in Table 2.4 and cycling parameters are listed in Table 2.5. Both the PCR reagent 
concentrations and the cycling conditions were designed to mimic TAm-Seq conditions as 
previously described (Forshew et al.). PCR products were checked against expected size 
using the Broad spectrum DNA kit on Bioanalyzer 2100 (Agilent G2938) or e-Gel Agarose 
Gel Electrophoresis System (Invitrogen).  
		 Per	10μL	reaction	 Final	conc.	
10X	FastStart	High	Fidelity	Reaction	Buffer	without	MgCl2	(Roche)	 1	 1X	
25	mM	MgCl2	(Roche)		 1.8	 4.5mM	
DMSO	(Roche)	 0.5	 5%	
10mM	PCR	Grade	Nucleotide	Mix	(Roche)		 0.2	 200	μM	ea	
5	U/μL	FastStart	High	Fidelity	Enzyme	Blend	(Roche)	 0.1	 0.05U/μL	
20X	Access	Array	Loading	Reagent	(Fluidigm)	 0.5	 1X	
50	ng/μL	Genomic	DNA	 1	 10ng/μL	
Primer	Pair	(250nM)	 2	 	
PCR	Certified	Water	(Teknova)	 2.9	 		
Table 2.4: Primer testing PCR master mix concentrations 
  
TCCCCGCGCTGCACCAGCCGCCAGCCCTGGGGCCCCAGGCGCCGCACGAACGTGGCCA
GCGGCAGCACCTCGCGGTAGTGGCTGCGCAGCAGGGAGCGCACGGCTCGGCAGCGGGG
AGCGCGCGGCATCGCGGGGGTGGCCGGGGCCAGGGCTTCCCACGTGCGCAGCAGG[AC
GCAGCGCTGCCTGAAACTCGCGCCGCGAGGAGAGGGCGGGGCCGCGGAAAGGAAGGGG
AGGGGCTGGGAGGGCCCGGAGGGGGCTGGGCCGGGGACCCGGGA]GGGGTCGGGACGG
GGCGGGGTCCGCGCGGAGGAGGCGGAGCTGGAAGGTGAAGGGGCAGGACGGGTGCCCG
GGTCCCCAGTCCCTCCGCCACGTGGGAAGCGCGGTCCTGGGCGTCTGTGCCC 
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PCR	Stages	
Number	 of	
cycles	
50ºC	2	minutes	 1	
70ºC	20	minutes	 1	
95ºC	10	minutes	 1	
95ºC	15	seconds	
	60ºC	30	seconds	 10	
72ºC	1	minute	
	95ºC	15	seconds	
	80ºC	30	seconds	 2	
60ºC	30	seconds	
	72ºC	1	minute	
	95ºC	15	seconds	
	60ºC	30	seconds	 8	
72º	1	minute	
	95ºC	15	seconds	
	80ºC	30	seconds	 2	
60ºC	30	seconds	
	72ºC	1	minute	
	95ºC	15	seconds	
	60ºC	30	seconds	 8	
72ºC	1	minute	
	95ºC	15	seconds	
	80ºC	30	seconds	 5	
60ºC	30	seconds	
	72ºC	1	minute	
	Table 2.5: PCR thermocycling conditions for primer testing. 
 
2.4.5 Identifying mutDNA through TAm-Seq 
TAm-Seq was performed on cfDNA extracted from urine samples from patients with 
metastatic bladder cancer. Urine samples were collected during routine oncological follow 
up and were selected based on their high burden of disease. Ethical approval for collection 
was under Diamond (LREC 03/018) and approval for 5-6 patients was granted by the 
Cambridge Urological Biobanking board. Urine samples were processed according to 
Table 2.1 with exception that only 5ml were processed for each category. 
DNA was extracted from urine supernatants using the modified Qiagen urine protocol. 
Samples were quantified using digital PCR, as described in Chapter 2.4.2, with the 97bp 
RPP30 probe and 50ng, where possible, was utilised for pre-amplification in the TAm-Seq 
work flow. 
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The TAm-Seq process was performed according to the previously published protocol 
(Forshew et al., 2012). In brief, it involved a limited cycle PCR (pre-amplification) of each 
sample. Each sample was multiplexed with a pool of all bladder panel primers. The pre-
amplified material was then cleaned using an exonuclease (EXOSAP TM) before diluting 
and undergoing target specific PCR using a microfluidic platform (Fluidigm Access Array). 
The Access array platform allows each sample to be split into 48 wells of ~35nl (Fluidigm, 
2017) where each reaction chamber can undergo singleplex PCR with a single primer pair 
from the bladder panel. The amplified PCR material in each reaction chamber is then 
pooled so that material from each sample can be harvested from the access array. 
Samples are then barcoded in a further PCR reaction before pooling and cleaning to 
create a library suitable for submission for NGS. 
NGS was performed using MiSeq (Illumina). Sequence alignment and clipping was 
performed by Mohammed Murtaza, James Morris and Francesco Marass using Samtools. 
Variant calling was performed using a custom designed calling pipeline, taking into 
account, the read depth, the number of abnormal reads and the level of background noise, 
reported presence of single nucleotide polymorphisms and presence of the same mutation 
in duplicate samples prior to calling SNVs. 
 
  
2.5 Results 
2.5.1 Urine DNA extraction 
Only 5 out of the 7 healthy volunteers produced >150ml of urine for aliquoting according to 
Table 2.1. Volunteer A produced 80ml and only had multiple aliquots of 1 hour with EDTA 
processed. Volunteer D produced 60ml of urine and had a single 5ml aliquot for each 
processing variation. Volunteer D was therefore excluded from kit testing analysis. 
Volunteer E produced >250mls of urine allowing aliquots of multiple processing methods 
and multiple replicates. During the initial phase of testing, only urine samples that were 
frozen within 1 hour and had EDTA added were analysed, see Figure 2.11. 
 
Figure 2.11: Flow diagram for patient samples used to evaluate urinary DNA. Numbers of patients 
analysed are included in purple boxes, with figures and tables listed adjacent. A. Samples collected for 
urinary cfDNA extraction optimisation. 7 healthy volunteers provided urine samples for proof of principle 
analysis to ensure results were reproducible across multiple volunteers. 2/7 volunteers were unable to 
provide enough urine samples for multiple processing affecting some analyses. *Figure 2.12 excluded urine 
from volunteer D due to lack of sample. ^Figure 2.16 excluded urine from volunteers A and D due to lack of 
sample. +Figure 2.17-8 analysed volunteers G and E replicate urine samples. B. Samples collected for 
optimisation of mutDNA analysis. Cambridge Urology Biobank approval was received to collect urine from 
7 metastatic bladder cancer patients to allow pilot panel detection of SNVs in sufficient numbers of samples. 
Only 2 patients were recruited for before preliminary analysis of MIBC patient urine samples demonstrated 
detectable SNVs, see Chapter 3.6. Therefore further recruitment was stopped. 
A.	
7	pa%ents	enrolled	
6	pa%ents	with	urine	
processed	in	mul%ple	
variables	
Figures:	2.13-5	
Tables:	2.1	
Figures:	2.12*	and	2.16^	
1	pa%ent	with	urine	
processed	with	
mul%ple	aliquots	
Figures:	2.17+-8+	
Tables:	2.1	
B.		
2	pa%ents	with	
metasta%c	urine	 Figure:	2.24	
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Part-way through this analysis, the SNOVA nucleic acid kit was withdrawn from production 
and SNOVA ceased to trade. However a new company, NeoGeneStar set up by the same 
directors released cfDNA extraction kits based on similar magnetic bead chemistry. These 
were included in analysis of DNA extraction for remaining samples. Figure 2.12 depicts the 
GE copies detected using dPCR with each of the 4 extraction kits. The urine samples used 
for this comparison were processed within 1 hour, with the addition of EDTA but were not 
centrifuged. Shapiro Wilk testing demonstrated a non-Gaussian distribution for samples 
extracted by Norgen (W= 0.8141, p= 0.0042) and Qiagen kits (W= 0.7414, p= 0.0005). 
Gaussian distributions were suggested for samples extracted by SnoMag (W= 0.9027, p= 
0.3474) and NeoGeneStar kits (W= 0.9617, p= 0.82). Due to the comparison of data sets 
with mixed distributions, non-parametric analysis was used to determine statistical 
significance of differing yields. Kruskall Wallis demonstrated statistically significant 
differences for the yield obtained by the extraction kits tested. Dunn testing demonstrated 
statistically higher yield from both Qiagen and Norgen extraction when compared with 
SnoMag (p=0.0028 and p=0.0088). Total DNA yields and cfDNA concentrations for each 
sample are listed in Appendix A-1 and indicates that of the column-based beads the 
Qiagen nucleic acid kit has a higher yield for every case apart from Volunteer E. However, 
there was no statistically significant difference between urine extraction with Norgen, 
NeoGeneStar nor Qiagen kits (p= 0.3053 for Qiagen versus Norgen, p=0.3752 from 
NeoGeneStar versus Norgen and p= 0.2516 for NeoGeneStar versus Qiagen). Of note, 
extracted DNA from volunteer E was further aliquoted into two replicates for unspun urine 
and further dPCR performed, the low amplifiable copies/ml detected imply that extraction 
is likely to have failed in this sample.   
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Figure 2.12: Box plots suggesting that urine DNA extraction with QIagen Circulating Nucleic Acid and 
Norgen slurry kits achieved the highest yield of DNA. 
2.5.2 Urinary DNA Processing 
Based on these results, the Qiagen Circulating Nucleic Acid extraction kit was selected 
and subsequently used to extract remaining aliquots of urine samples processed 
according to Table 2.1. This was due to the Qiagen kit having the highest mean cfDNA GE 
copies/ml isolated during the comparison and, it having been extensively used by the 
Rosenfeld lab to extract cfDNA from plasma samples. Use of the Qiagen extraction kits 
also facilitated further comparison of matched plasma and urine samples. DNA yields and 
cfDNA concentrations are listed in Appendix A-2. Based on this work, this kit has since 
been in use in the lab for additional projects where urine has been collected and analysed. 
At a later stage, a new method of automating the Qiagen extraction through the 
qiasymphony arose and we compared manual and automated kits in section 3.6.2. 
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Urine samples that were subjected to centrifugation had lower GE copies/ml than those 
that were not (Figure 2.13), The centrifuged urine samples had a mean of 2,050 GE 
copies/ml of DNA extracted, whilst un-centrifuged samples had a mean of 33,060 GE 
copies/ml (Kruskall-Wallis p = 1.47xe-5).  
 
Figure 2.13: Cell-free DNA levels are higher in urine samples processed without a centrifugation step. 
The addition of 10mMol EDTA to urine samples resulted in a higher concentrations of 
cfDNA when compared to samples that did not have EDTA (mean of 19,350 GE copies/ml 
versus 15,170 GE copies/ml respectively). However, this was not a statistically significant 
difference, Kruskal Wallis p = 0.0809.  
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Figure 2.14: 10mMol EDTA may improve cell-free DNA yield 
Reducing the time taken to process urine samples resulted in increased DNA yield. 
Samples processed at 1 hour had a mean GE copies/ml of 23,370 compared to 22,570 GE 
copies/ml for samples processed at 6 hours and 5,083 GE copies/ml for urine samples 
processed at 48 hours, Figure 2.15A. Figure 2.15B depicts the change in GE copies/ml 
from the matched 1 hour specimen. For samples processed at 6 hours 11/20 had lower 
DNA yield than when processed at 1 hour. For samples processed after 48 hours, 14/20 
had lower DNA yields than those processed at 1 hour suggesting that processing samples 
earlier improves the yield of DNA. This difference was statistically significant (p= 0.0121, 
Friedman test), Figure 2.15A. For urinary mutDNA to be clinically useful, longitudinal 
sampling would ideally be analysed, typically when patients are attending clinic. We 
therefore attempted to limit the time taken to process urine samples to 6 hours, so that it 
would be feasible for research nurses to collect all samples from a clinic before processing 
them. 
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Figure 2.15:  Reduced time to processing of fresh urine improved cfDNA yield. A. Total GE copies/ml 
for urine samples extracted at 1, 6 and 48 hours. Shapiro Wilk testing revealed non-Gaussian distribution 
for samples processed at 1 hour (W= 0.4004, p= 2.88xe-09) for samples processed at 6 hours (W= 0.3637, 
p= 3.39xe-09) and for samples processed at 48 hours (W= 0.2794, p = 1.18xe-09). Friedman testing revealed 
statistically significant differences between the cfDNA amounts obtained with different processing times 
(p=0.0121). B. Change in GE copies/ml (y axis) for matched samples processed at 1, 6 and 48 hours 
(x axis). GE copies/ml at 1 hour were subtracted from GE copies/ml for matched samples at 6 and 48 hours. 
Samples are coloured by patient. 
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2.5.3 Urinary DNA Size 
To investigate whether there may be longer DNA fragments in urinary cfDNA, an RRP30 
dPCR assay targeting an amplicon of 360bp was used to quantify DNA eluted from patient 
G. Centrifuged and non-centrifuged urine samples that were processed within 1 hour and 
had EDTA added were assessed. Initial results suggested a drastic reduction in 360bp 
fragments. Comparison between centrifuged and un-centrifuged samples revealed a 
respective mean of 1,058 and 3,941 GE copies/ml for amplicons ≥360bp, see Figure 2.16, 
indicating that longer urine cfDNA fragments can be found in un-centrifuged urine. Indeed, 
this would be expected as not performing centrifugation would retain cellular debris in the 
urine specimen. Subsequent lysis during the extraction protocol would increase the 
proportion of longer cellular DNA fragments. However, this finding was not statistically 
conclusive (p= 0.0633) possibly due to the small sample size (n=21). 
 
Figure 2.16: GE 360bp (and larger) copies/ml for samples of urine that were centrifuged (n=9) and 
those that were not (n=12).  
Figure 2.17 demonstrates that smaller sized primer pairs amplify more fragments of 
cfDNA. This is likely due to the smaller primer pairs amplifying both small and large 
fragments of DNA. However, even after subtraction of longer fragments, i.e. fragments the 
360bp assay detected, there are numerous additional amplifiable copies that have been 
amplified by the 65bp and 97bp assays. This implies that there are fewer long urinary 
cfDNA fragments than short fragments. Kruskal-Wallis testing confirms a statistical 
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significance in this difference with 360bp urine fragments being shown to be significantly 
lower than 65bp and 97bp fragments (p= 0.0029 and p= 0.0156 respectively). 
 
Figure 2.17: Comparison of GE copies/ml for urine cfDNA amplicons of 65bp, 97bp and 360bp 
lengths from 7 replicate urine aliquots from 2 patients. Each sample was processed with EDTA and 
frozen within 1hour. PCR reactions were carried out in singleplex, to avoid bias from preferential 
amplification of amplicons of different lengths. Kruskal-Wallis testing demonstrated a significant difference 
between the 3 sizes (p=0.0150). Post-hoc Dunn testing revealed significant differences less 360bp 
fragments when compared with 65bp and 97bp DNA fragments (p= 0.0029 and p= 0.0156). There was no 
difference between 65bp and 97bp size fragments in this small sample-set.  
Figure 2.18 demonstrates no statistically significant difference between 65bp and 97bp 
fragment sizes, though the median GE copies/ml for 65bp fragments was higher than for 
97bp fragments (28,910 versus 41,120 GE copies/ml). The small sample size and 32bp 
difference between sizes tested may have impacted on the ability to detect a difference. 
Tsui et al. demonstrate that most foetal urinary cfDNA lies between 29bp and 45bp in 
length and most maternal urinary cfDNA between 29bp and 85bp (Tsui et al., 2012). A 
considerably higher proportion of 97bp amplicons were amplified from our urine samples 
than expected based on the data of Tsui et al. alone and this is likely to be due to differing 
urine processing (urine centrifugation and filtration by Tsui et al. versus centrifugation 
alone) and DNA extraction techniques (Promega Wizard Plus by Tsui et al. versus QIAmp 
Circulating Nucleic Acid kit) used. However, both data sets emphasise the importance of 
targeting short urine cfDNA fragments and therefore, primers were designed to target 
amplicons of 60bp -100bp in size. 
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Figure 2.18: Comparison of GE copies/ml for urine cfDNA amplicons of 65bp and 97bp from 15 
replicate aliquots from 2 patients. dPCR reactions were carried out in singleplex. Kruskal-Wallis testing 
showed no difference (p= 0.1776). 
2.5.4 Primer Validation 
Bioanalyser traces revealed no PCR product bands for negative control wells and tight 
bands of PCR products at the expected amplicon size range for each of the FGFR3 primer 
pairs investigated (Figure 2.19). 
 
 
Figure 2.19: Bioanalyser trace of PCR products with 3 FGFR3 primer pairs. X-axis key for primer pairs 
tested in each lane: 1:FGFR_Ex6 region, 2: negative PCR control (FGFR_Ex6 region without DNA), 3: 
FGFR_Ex8 region, 4: negative PCR control (FGFR_Ex8 region without DNA), 5: FGFR_Ex13 region, 6: 
negative PCR control (FGFR_Ex13 region without DNA). 
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Primer pairs targeting TERT, had no or very weak PCR product bands in the expect size 
range and multiple weak bands in other size ranges (Figure 2.20), this result was 
replicated on repeat experimentation (data not shown). 
 
Figure 2.20: Bioanalyser trace of PCR products with 3 TERT primer pairs. X-axis key for primer pairs 
tested in each lane: 1:TERT1_F - TERT1_R, 2: negative PCR control (TERT region 1), 2: TERT_2_F - 
TERT_2_R, 4: negative PCR control (TERT region 2), 5: positive PCR controls (using FGFR3_Ex6 primers). 
Bioanalyser testing revealed no PCR product bands for the negative control well and a 
tight band of PCR product at the estimated size range for the positive control band. Tight 
product bands, at the expected size, were present for all 3 primer pairs targeting NFE2L2 
and the supplementary primer pair targeting CTNNB1, see Figure 2.21. 
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Figure 2.21: Bioanalyser trace of PCR products with 3 NFE2L2, 1 CTNNB1 and 2 re-designed TERT 
primer pairs. X-axis key for primer pairs tested in each lane: L: DNA ladder, 1: TERT region 1F-2R, 2: TERT 
region 2BF – 2R, 3: NFE2l2 region 1 primers, 4: NFE2l2 region 2, 5: NFE2l2 region 3, 6: CTNNB_SUPP, 7: 
negative control for PCR (CTNNB_SUPP without DNA). 
2.5.4.1.1 TERT re-design 
Due to the failure of the primer pairs to specifically bind to the TERT promoter region, 
multiple new primer pairs were designed, focusing on the most commonly mutated 
hotspot. Multiple forward primers were designed to be tested with one or two reverse 
primers, see Figure 2.22 and Table 2.6. In addition, the previously designed forward 
primer, TERT_1F was tested with the primer TERT_2R with the aim of avoiding repetitive 
regions, but creating an amplicon with ~250bp. 
 
Figure 2.22: Alternative strategy to design primer pairs for TERT promoter region. Multiple forward 
primers in the repeat region were designed to pair with one or two reverse primers in a relatively 
heterogeneous region. Testing of multiple primer pairs was performed in singleplex. 
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Name Seq Tm Len SNPs Insilico PCR 
TERT_Prom_2B_F CGGAAAGGAAGGGGAGGG 59.0 18 No OK 
TERT_Prom_2B_R CTGCCCCTTCACCTTCCAG 60 19 No OK 
TERT_Prom_2C_F GGCCGCGGAAAGGAAG 57.9 16 No OK 
TERT_Prom_2C_R CGTCCTGCCCCTTCACC  17 No OK 
TERT_Prom_2D_F CTGCCTGAAACTCGCGC  17 No OK 
TERT_Prom_2E_F CTGAAACTCGCGCCGC  16 No OK 
TERT_Prom_2F_F AGGAAGGGGAGGGGCT  16 No OK 
TERT_Prom_2G_F CTTCCCACGTGCGCAG  16 No OK 
Table 2.6: Alternative designs for TERT promoter region primer pairs. 
Figure 2.21 demonstrates that re-designed TERT primer pairs were not able to produce a 
specific PCR product within a tight expected amplicon size range despite, whilst 
appropriate negative and positive controls worked gave expected results. Similarly, Figure 
2.23 also shows poor specificity for re-designed primer pairs targeting the promoter region. 
 
Figure 2.23: Bioanalyser trace of PCR products with re-designed TERT primer pairs. X-axis key for 
primer pairs tested in each lane: 1: TERT_Prom_2C_F - TERT_Prom_2C_R, 2: TERT_Prom_2G_F - 
TERT_Prom_2B_R, 3: TERT_Prom_T2D_F - TERT_Prom_2B_R, 4:TERT_Prom_2E_F - 
TERT_Prom_2B_R, 5: FGFR3 Exon 13, 6: negative PCR control (FGFR3 Exon 13 without DNA), 7: 
TERT_Prom_T2C_F - TERT_Prom_2B_R, 8: Prom1R-T2BRv, 9: TERT_Prom_T2_F - TERT_Prom_2B_R, 
10: FGFR3 Exon 13, 11: negative PCR control (FGFR3 Exon 13 without DNA). 
A list of final primers used in the pilot bladder cancer panel is included in Appendix A-3. 
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2.5.5 Mutant DNA analysis from urine 
Only 2 patients were enrolled in this arm of the study. Both patients were able to provide 
>120ml of urine. Each urine sample was processed and aliquots were frozen according to 
Table 2.1. Digital PCR was performed, on DNA extracted from the urine supernatants.  
NGS with 150bp paired end using 2 lanes of a MiSeq (Illumina) instrument resulted in 
approximately 50 million reads with the majority of reads have a mean sequence quality 
(PHRED score) of above 30, see Figure 2.24A. Primer dimer removal, quality clipping of 
the reads followed by alignment of the reads to the human reference genome resulted in 
approximately 35 million useable reads, Figure 2.24B. 
 
Figure 2.24: Basic statistics for pooled library submission to MiSeq (Illumina) NGS. A. PHRED score 
CDF graph demonstrating the high quality scoring for most of the reads. B. Pie chart showing that most 
reads were useable. 
The median coverage was 5501 reads per base across all samples. Barcodes 
representing uniquely positioned No Template Controls (NTCs) were easily deducible by 
their low read count (median read count of <2, compared with median read count of 5823 
in samples with patient / control DNA). These matched the position NTCs were inputted, 
indicating that sample switching was unlikely during the experiment. Despite other 
experimental metrics performing well, there were no SNVs that were detected that passed 
quality filtering. For this reason, the expected optimum processing method for mutant 
cfDNA purification was used. 
Aligned
Unaligned PEDRO
Clipped
Lost
Lost Reads: 8.68M
PEDRO Reads: 1.16M
Clipped Reads: 0.86M
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2.6 Original Contributions to Knowledge 
1. Urine DNA extraction by SNOVA kits gave a statistically significant lower yield than 
the other urine DNA extraction. It is likely that QIAmp circulating nucleic acid kit 
produced the highest yield, though this was not statistically significant. 
2. Centrifugation of urine samples within 6 hours, likely with the immediate addition of 
EDTA, will likely improve cfDNA yield for mutDNA analysis. 
Results from these investigations have been incorporated to form the Rosenfeld group 
urine extraction and processing SOPs and are being shared with international 
collaborators for future projects. 
 

  
CHAPTER 3: MUTANT DNA ANALYSIS IN MIBC 
3.1 Synopsis 
(The following text has been excerpted from work published in Scientific Reports) 
Patients with Muscle Invasive Bladder Cancer (MIBC) have a poor 5-year overall survival 
(OS) rate. Though there is a 6% improvement in OS with Neo-Adjuvant Chemotherapy 
(NAC), many patients fail to respond. Analysis of mutant DNA in body fluids (mutDNA) 
could be used to allow non-invasive identification of NAC failure and tracking of clonal 
kinetics (in real-time) during systemic chemotherapy.  
We prospectively collected 248 liquid-biopsy samples including plasma, cell pellets from 
urine (UCP) and urine supernatant (USN) from multiple time-points of 17 MIBC patients 
undergoing NAC. We assessed Single Nucleotide Variants (SNVs) and Copy Number 
Alterations (CNAs) in mutDNA using Tagged-AMplicon Sequencing (TAm-Seq) and 
shallow Whole-Genome Sequencing (sWGS). 
MutDNA was detected in 35.3%, 47.1% and 52.9% of pre-NAC plasma, UCP and USN 
samples respectively. Though urine samples contained higher levels of mutDNA 
(p=<0.001), some mutations were only identified in plasma suggesting comprehensive 
analysis requires sampling multiple fluids. MutDNA was detected in 49/116 samples from 
patients who recurred, compared with 4/117 samples from non-recurrent patients 
(p<0.001) and SNVs were present at higher allele fractions (p<0.001). In 12 patients 
mutDNA was assessed 2-3 weeks after starting NAC, and persistence of mutDNA (with 
SNV allele fractions >0.5%) was associated with disease recurrence (83% sensitivity, 
100% specificity, p=0.003). Longitudinal analysis of SNVs and CNAs in mutDNA 
demonstrated tumour evolution under the selective pressures of surgery and NAC in 
several cases. In one case, urine analysis tracked two distinct cancer clones with non-
overlapping sets of TP53 mutations.  
This proof of principle study shows that mutDNA analysis may serve as an early biomarker 
for recurrence, offering MIBC patients an opportunity to switch NAC or expedite surgical 
resection in a timely manner. Furthermore, BC patients might benefit from tracking clonal 
kinetics during systemic therapy. These results warrant further evaluation of mutDNA in 
larger trials. 
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3.2 Publications arising from this work 
Work presented in this chapter is published in Scientific Reports. The text is therefore 
excerpted from this manuscript except to extend explanations, display updated data and 
provide more in-depth references. 
KM Patel , KE van der Vos , CG Smith , FC Mouliere, D Tsui, J Morris, D 
Chandrananda, F Marass, D van den Broek, DE Neal, VJ Gnanapragasam, T 
Forshew, BW van Rhijn, CE Massie, N Rosenfeld*, MS van der Heijden*. Association 
Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive 
Bladder Cancer. Scientific Reports. 2017. 7:5554. http://dx.doi.org/10.1038/s41598-
017-05623-3 
These authors contributed equally. 
* These authors are joint senior supervisors  
 
 
  
3.3 Aims 
My primary objective was to explore whether urinary mutDNA can be a clinically 
useful biomarker in bladder cancer. Through international collaborations, I collected 
plasma, urine cell pellets and urine supernatant to investigate: 
1. Which body fluid, if any, allow for mutDNA analysis in MIBC: I investigated 
mutDNA in fresh urine and plasma samples taken concurrently from MIBC 
patients undergoing NAC. These samples were used to compare both the 
number of times a mutation is detected and the AF of the mutations.  
2. The ability of mutDNA to predict response to NAC and outcome: Each 
MIBC patient had sequential samples collected prior to each cycle of NAC. 
These samples were assessed to determine whether presence of mutDNA or 
mutDNA AF changes at early time points may be utilised to predict response to 
NAC. 
3. Whether tumour evolution can be monitored using mutDNA: Use of a 
bladder panel, rather than patient specific probes may also allow monitoring of 
tumour clones. Sequential samples from MIBC patients undergoing NAC were 
used to assess whether tumour evolution occurs. 
  
3.4 Methods 
3.4.1 Sample Collection: 
Approval according to Dutch national guidelines was obtained (N13KCM/CFMPB250). All 
patients gave informed consent to participate in this study. Formalin-fixed paraffin-
embedded (FFPE) tumour blocks from the transurethral resection (TUR) samples were 
collected from referring hospitals. Slides were cut from FFPE blocks and used for 
Haematoxylin and Eosin (H&E) staining and DNA extraction. H&E stains were evaluated to 
identify areas with >50% tumour cells, from which DNA was extracted using the QIAamp 
DNA mini kit (Qiagen, Germany). Urine and blood samples were collected 1-2 hours prior 
to each chemotherapy session and were processed as follows; 10ml of peripheral blood 
was drawn into K2-EDTA haematology tubes and centrifuged at 380g for 20mins. The 
buffy coat layer was carefully transferred before the remaining plasma was aliquoted and 
spun at 20,000g for 10mins. Urine samples were processed by optimised methods 
described in section 2.5.2. In brief, urine samples were processed with the immediate 
addition of EDTA and subsequent centrifugation at 380g for 10mins before aliquoting the 
urine supernatant. The remaining UCP (Urine cell pellet) was re-suspended in 1ml of PBS. 
All peripheral fluids were processed within 6 hours and stored at -80°C.  
DNA was extracted from 3 ml of urine supernatant using the optimal extraction system as 
investigated in Chapter 2: Section 2.5.1. In brief, we used the Qiagen Circulating Nucleic 
Acid kit to extract DNA from urine supernatant. DNA from TUR, BUF, UCP and plasma 
specimens was extracted using the QIAamp FFPE Tissue, DNeasy, DNA Mini Blood Mini 
and, Circulating Nucleic Acid kits (Qiagen) respectively. DNA extracted from BUF and 
UCP samples were subjected to mechanical shearing using either a Covaris S220 or 
LE220 (Covaris, USA). TUR was also sheared using the same protocol due to improved 
FFPE preservation methods leading to longer DNA fragment sizes (Greer et al., 1991). 
Recommended parameters were used to shear fragments to an average fragment length 
of 140-180bp. Successful shearing was confirmed by running 1µl of DNA on a High-
Sensitivity Bioanalyser gel (Agilent, USA).  
3.4.2 TAm-Seq: 
Tagged-AMplicon Sequencing (TAm-Seq) primers were designed to assess the mutation 
status for hotspots or entire coding regions of 8 genes (Table 3.1). Genes were 
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incorporated into the panel based on the frequency of mutation in WGS studies of BC and 
on exon length. Primer details are listed in Appendix A-3. TAm-Seq libraries were 
prepared as previously described (Forshew et al.). Libraries were sequenced using an 
Illumina HiSeq 2500 (Illumina, USA).  
 
Table 3.1: Genomic regions interrogated by TAm-Seq for SNV analysis. ^Specificity of TERT assays 
was poor due to constraints of targeting short amplicons in the repetitive TERT promoter region. Data 
resulting from them were therefore excluded from downstream analysis. Other than TERT, 90-100% of 
mutations reported in the above listed genes were covered by the panel. Alterations in these genes would be 
expected to capture 72% of alterations reported in MIBC patients. The prevalence of the mutations shown 
here are based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov/., green 
squares represent missense mutations and black squares represent truncating mutations (Gao et al.; Cerami 
et al.).  
3.4.3 Shallow Whole Genome Sequencing 
Libraries were prepared from 10ng of plasma, USN, and TUR, BUF and UCP DNA using 
the ThruPLEX Plasma-Seq (Rubicon Genomics, USA) kit. Briefly, this involves end repair 
and ‘A-tailing’ of fragment ends. This precedes the ligation of truncated Illumina sequencer 
compatible adapters to fragment ends. Thermocycling of libraries completes the adapters 
through the addition of sample specific index sequences, and was performed as described 
in the Plasma-Seq protocol, using 8-14 (plasma, UCP and USN) or 8 (TUR and BUF) 
amplification cycles. Following amplification, libraries were cleaned with Agencourt 
AMPure XP beads (Beckman Coulter, USA) at a 1:1 (v/v) ratio and eluted in 30µl 
nuclease-free water. Successful library preparation was confirmed using a High-Sensitivity 
Bioanalyser gel and libraries were quantified using SYBR green based qPCR (Kapa 
Biosystems, USA). Libraries were pooled in an equimolar fashion and 125bp paired end 
sequencing was performed (to give a mean of 14.2 million reads per sample) using an 
Illumina HiSeq 2500 or HiSeq 4000.  
3.4.4 Mutation Calling Criteria 
TAm-Seq sequencing reads were aligned using Burrows-Wheeler Alignment (BWA) (Li 
and Durbin, 2009) and SNVs were detected using proprietary SNV calling software, the 
GENE TARGETING
BRAF p.V600
CTNNB1 p.T41 & p.S45
FGFR3 p.S249, p.K652 & p.y375
HRAS p.G12
KRAS p.G12, p.G13 & p.Q61
NFE2L2 p.G31
PIK3CA p.E545, p.G545 & p.HC1047
TP53 all exons
PROPORTION OF MIBC PATIENTS WITH SNV�
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principles of which were described previously (Forshew et al.). All mutation calling was 
performed blinded to the patient outcome. Patient-specific mutation calls were used to 
determine mutant AFs for any time-point from the 13 patients with detected SNVs, with 
thresholds defined by the highest of mutDNA AF >0.5% (technical threshold, see Results 
Section 3.6.5) or 1/GE copies inputted (sample threshold). Bases that contained a mutant 
call at a frequency below this threshold were not used for further analysis though AF’s 
were retained for interpreting longitudinal mutDNA dynamics. NGS data were analysed 
using the R statistical software package (R Core Team 2015).  
For sWGS analysis, sequence data was analysed using an ‘in-house’ pipeline developed 
by Dr. Christopher Smith (Postdoctoral scientist in the Rosenfeld group), adapted from 
published methods (Heitzer et al.). Briefly, this consisted of removing contaminant adapter 
sequences then aligning paired-end sequence reads to the human reference genome 
(GRCh37) using BWA (version 0.7.13) (Li and Durbin, 2009). SAMtools (version 1.3.1) (Li 
et al., 2009) was then used to convert files to BAM format. PCR and optical duplicates 
were marked using Picard-Tools’ (version 2.2.4) ‘MarkDuplicates’ feature and these were 
excluded from downstream analysis along with reads of low mapping quality and 
supplementary alignments.  
CNA calling was performed in R (R Core Team 2015) using the QDNAseq pipeline 
(Scheinin et al., 2014). Briefly, sequence reads were allocated into equally sized non-
overlapping bins (1Mb and 50kb) throughout the length of the genome. Read counts in 
each bin were corrected to account for sequence GC content and mappability, and bins 
corresponding to previously ‘blacklisted’ (ENCODE) and manually blacklisted regions were 
excluded from downstream analysis. Within the QDNAseq package, bins were segmented 
using the ‘Circular Binary Segmentation’ algorithm (Seshan and Olshen, 2016) and 
significantly ‘amplified’ or ‘lost’ regions were called using CGHcall (van de Wiel et al., 
2007). CNAs were deemed present when a mutation was called in either 1Mb or 50Kb bin 
size to capture both large changes or focal changes in samples with low mutant:wild type 
AF. CNAs were called in peripheral fluids independent of the calls from the corresponding 
TUR sample.  
We compared overall levels of copy number imbalance across the length of the genome in 
our samples by calculating a ‘genome-wide imbalance score’. To generate this value, log2 
adjusted read counts in a given 1Mb bin were compared against the equivalent value in a 
control sample. This control sample, which consisted of pooled sWGS data from 8 buffy-
coat samples, was used for all pairwise comparisons. A linear model was fitted against all 
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autosomal bin values of the test sample vs. the control sample and the squared sum of 
residuals of this fit was calculated. To overcome inherent noise surrounding baseline (i.e. 
copy number neutral) in sWGS data, we only considered the sum of the 5% most extreme 
residual values to represent the ‘genome-wide imbalance score’.  
To indicate whether there was crossover between patients’ samples from collection to the 
data interpretation stage, single nucleotide polymorphism (SNP) unique positions were 
identified from the 1000 genomes phase 3 per chromosome VCF files using Tabix (Li, 
2011) and the amplicon start and end positions listed in Appendix A-3. 
3.5 Statistical Inferences: 
Statistical conclusions were impacted due to the proof of principle nature of the study. 
Where applicable we employed the following statistical analyses: To compare raw AF’s of 
patients who did and did not recur, these two populations were plotted in the form of an 
empirical cumulative distribution function and assessed by applying the Kolmogorov–
Smirnov test. Analyses of correlation between AFs at the 2nd NAC cycle and recurrence 
was performed using the “OIsurv” package in R (Diez, 2013). Survival curves were 
generated using the ‘survfit’ function, which uses the Logrank test to compare differences 
(in the presence of censoring) (Diez, 2013). Exact binomial confidence limits for sensitivity 
and specificity were calculated using the ‘epiR’ package in R (Stevenson, 2016). The SNV 
AFs in different sample types was compared using a Kruskal-Wallis rank sum test after 
testing for normality. sWGS profiles were compared by applying linear-regression 
modelling to the log ratios of two samples and adjusted R2 values were generated using 
the linear model function in R.  
  
3.6 Results 
3.6.1 Patient recruitment for longitudinal analysis of mutDNA kinetics 
Patients attending the Netherlands Cancer Institute (NKI) for cisplatin-based NAC were 
recruited between March 2014 and October 2015. We analysed 282 samples from 17 
patients with MIBC, including tumour tissue samples (16 FFPE TUR and 1 cystectomy; 
TUR tissue from patient 15 was unavailable), 17 white blood cell samples (buffy coat, 
BUF) and 248 body fluid samples (86 plasma, 78 UCP and 84 USN samples), spanning 86 
distinct time-points in total, Figure 3.1.  
 
Figure 3.1: Flow diagram of patient samples used to investigate mutDNA. A. MIBC Samples used for 
mutDNA analysis. 17 patients with MIBC were recruited during the trial window and analysed according to 
the flow chart. *Figure 3.6 analysed samples from time-point 1 to demonstrate that CNA profiles were similar 
to those found in matched TUR samples. ^Figure 3.10 only time-point 2 data was used demonstrate utility as 
an early marker of recurrence. %Tables 3.5-6 analysed data from time-point 1. B. Samples for investigating 
mutDNA kinetics in multiple urinary tract cancer disease settings. Proof of principle analysis was 
conducted to demonstrate the utility of mutDNA kinetics in 3 additional urothelial carcinoma patients.  
TUR samples were requested from referring hospitals whilst peripheral samples were 
collected at the NKI prior to administration of each cycle of NAC (Figure 3.5A). Patients 
were followed up for a median of 742 days (487-952 days) following initiation of NAC and 
588 days (463-851 days) following definitive therapy. Details of the patient demographics, 
tumour characteristics and treatment are outlined in Table 3.2. DNA extraction failed in 2 
samples (1 plasma and 1 USN). DNA concentration was measured by a dPCR assay 
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targeting the RPP30 gene using a 97bp amplicon (Dawson et al.). Excluding the two failed 
samples, we obtained a median of 5,296 amplifiable copies/ml (ranging from 101 to 
937,600 GE copies/ml), with the highest extraction yields from UCP, USN, then plasma 
samples (respective medians in GE copies/ml; 61,610, 5,870 and 3,550, Figure 3.2).  
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Table 3.2: Demographics of 17 MIBC patients: The median age at time of TUR was 59 with the cohort consisting of 12 males (M) and 5 females (F), in keeping 
with the prevalence of BC. The number of TUR, BUF, PLS, UCP and USN samples obtained for each patient are presented. Most patients with MIBC had grade 3 
(G3), locally advanced disease and opted for Radical Cystectomy (RC). Furthermore, 8/17 patients had early recurrence (median 336 days, ranging from 264 to 
507). One patient (*) died shortly after surgery due to surgical complication and was thus excluded from further analysis involving correlations with early recurrence 
outcome. TUR and imaging stage information and final radical cystectomy pathology are provided as per TNM criteria. Definitive Treatments: RC - Radical 
Cystectomy, CR – Chemoradiotherapy, Rad – Radiotherapy, LND – Lymph Node Dissection, ND – Not done. Cystoscopy findings: 0 - no disease present, 1 - 
equivocal findings, 2 - small tumour (<3cm), 3 - large tumour (>3cm), ND - not done. Pathological response categories: pCR- pathological complete response, pPR - 
pathological partial response, pSD - pathological stable disease, pPD - pathological progressive disease. Other*: patient died from post operative complications. 
 
TUR BUF PLS UCP USN
2 57 M 1 1 4 4 4 3 T3N0 3 56 CR PR
7 48 F 1 1 6 5 6 3 T3N0 TP53 0 30 0.000 RC+LND CR T0N0 0.001 0.001
8 76 M 1 1 5 4 5 3 T3N0 TP53 0 44 0.001 RC+LND CR T0N0 0.002 0.002
9 71 F 1 1 5 4 5 3 T3N0 PIK3CA 2 44 0.002 RC+LND SD T3N0 0.003 378 0.001
11 49 F 1 1 5 5 5 3 T2N0M0 KRAS,	TP53 2 36 0.156 RC+LND CR T0 0.039 Other* 0.167
12 66 M 1 1 4 4 4 3 T2N0M0 PIK3CA 2 23 0.038 Rad CR 0.017 269 0.045
13 58 M 1 1 5 5 5 3 T3N0M0 TP53 1 45 0.229 RC+LND SD T2N1 0.018 507 0.060
15 66 F 0 1 6 5 6 3 T3N1 3 49 0.124 RC+LND PD T3N2 0.427 293 0.163
18 56 M 1 1 6 6 6 2 T4N0 2 39 RC+LND SD T3N2 264
19 57 M 1 1 6 5 5 3 T3N0 KRAS,	TP53 1 51 0.005 RC+LND CR T0N0 0.000 0.004
21 64 F 1 1 4 4 4 3 T3N0 2 11 RC+LND CR T0 466
24 66 M 1 1 5 5 5 3 T3N0 1 32 RC+LND PR T0	N1
26 50 M 1 1 6 6 6 3 T3N0 TP53 1 35 0.112 Partial	RC+	Rad SD T3 0.049 472 0.211
27 58 M 1 1 4 3 4 3 T3pN2 TP53 2 81 0.006 RC CR T0 0.006 0.002
29 59 M 1 1 6 6 6 3 T3N0 TP53,	FGFR3,	PIK3CA ND 27 0.003 RC+LND PR T3 0.003 0.002
32 65 M 1 1 5 3 4 3 T3N0 KRAS,	BRAF 1 83 0.489 RC+LND SD T3 0.077 283 0.006
33 70 M 1 1 4 4 4 3 T3N1 TP53,	CTNNB1 0 61 0.002 1.	CR	2.	LND CR N0 0.001 0.002
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Figure 3.2: Amount of DNA (genome equivalent copies/ml) extracted from peripheral samples. UCP 
samples had a statistically higher number of DNA copies/ml of fluid (p<0.0001) as determined by Kruskal 
Wallis testing. There was also a statistically significant difference between extracted DNA copies/ml from 
USN and PLS. The respective medians and ranges in GE copies/ml for UCP, USN and PLS were; 61,610 
(981–937,600), 5,870 (101–235,500) and 3,550 (769-79,230).  
3.6.2 cfDNA yield and mutDNA levels are comparable when extracting with QIAmp 
Circulating Nucleic Acid kit and QIAsymphony (Qiagen) 
During the course of the study, automated DNA extraction from urine samples, with the 
QIAsymphony became available. In brief, the Qiagen QIAsymphony extraction method can 
accommodate up to 96 samples in a single extraction run, though this is done in 4 stages 
of 24 samples. Instead of the silica gel membrane used in the Circulating Nucleic Acid kit, 
the QIAsymphony couples silica extraction with magnetic beads to extract DNA (QIagen, 
2017). The automated nature of sample extraction could allow greater reproducibility, with 
less room for human error together with simplicity when extracting a large number of 
samples. Indeed, using whole blood, Laus et al. have demonstrated that QIAsymphony 
extractions have greater inter-run and intra-run reproducibility when compared with QIAmp 
manual extractions (Laus et al., 2011). When estimating Epstein-Barr Viral loads in the 
blood in paired samples, they found similar viral copies/ml from both extraction methods. 
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To investigate the utility of QIAsymphony urinary DNA extraction, USN samples from 
MIBC patients in the first cohort of analysis underwent manual Circulating nucleic acid kit 
extraction of a 3ml aliquot and TAm-Seq. Nine samples from 3 patients (patient 1, 11 and 
12) were selected based on their high AFs (>1%). A further 3ml USN aliquot of these 
samples was sent for automated QIAsymphony extraction through Qiagen’s commercially 
available sample prep service (c/o Dr Anke Singer, Qiagen Sample prep service, QIAGEN 
GmbH, Hilden Commercial Register Düsseldorf, HRB 45822). Digital PCR using 95bp 
probes was performed in duplicate to quantify cfDNA. Mean dPCR RPP30 counts were 
utilised for conversion to amplifiable GE copies/ml as described in Chapter 2, section 
2.4.2.  
Figure 3.3 shows the amplifiable GE copies/ml for paired aliquots extracted by Circulating 
nucleic acid kit and by QIAsymphony. To analyse concordance, a linear regression model 
was applied using the ‘lm’ function in R (R Core Team 2015). In brief, linear regression 
models can be used to estimate whether there is a relationship between independent 
variables, in this case, the method of DNA extraction. The resulting linear model has a 
slope of 0.778 and a y-intercept of 4059.6 GE copies/ml. The slope indicates that 
QIAsymphony extraction may result in higher DNA yield from paired samples, though the 
intercept indicates a different baseline. Taken in combination the slope predicts that with 
lower cfDNA levels, Circulating Nucleic Acid kits might be preferred, whilst with higher 
cfDNA levels (i.e. >~18,000 GE copies/ml), QIAsymphony extraction may be preferred.  
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Figure 3.3: Scatter plot of total amplifiable copies detected from replicate aliquots extracted by 
QIAsymphony and Circulating Nucleic Acid kits. dPCR demonstrated no significant difference in 
amplifiable copies per ml of USN. The linear model is represented by a grey dotted line (slope = 0.778, 
adjusted R2= 0.5241).  
To assess the strength of any relationship between DNA yield and the extraction methods, 
coefficients of determination were calculated with the ‘lm’ function to illustrate the variance 
between the linear regression model and observed data. The adjusted R2 was 0.5241, 
indicating that just 52% of the data points can be explained by the linear model described 
above. However, the associated p value of 0.0166 rules out a statistically significant 
difference in the extraction efficiencies of the two methods on the resulting DNA yield. 
To investigate whether QIAsymphony DNA extraction had an effect on the mutDNA AF’s, 
TAm-Seq was performed on DNA extracted from the paired QIAsymphony and Circulating 
nucleic acid kit (Qiagen) extractions as previously described by Forshew et al. (Forshew et 
al.) and in Chapter 2, section 2.4.5. The resulting AF’s were plotted in Figure 3.4 and 
colour coded by SNV using R. A linear regression model was applied to determine 
whether there was concordance between the data and resulted in a slope of 0.847 with an 
intercept of 0.002. The slope suggests that higher levels of mutDNA might be obtained 
from the same sample by using QIAsymphony extraction instead of the circulating nucleic 
acid DNA extraction kits. The adjusted R2 value is 0.8942 suggesting that the model can 
explain almost 90% of the data and that variance from the model is low. A p value of 6.358 
x e-12 confirms that there is no effect of extraction method on the AF of a sample. That 
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there is no significant difference between cfDNA yields nor mutDNA AF’s between QIAmp 
Circulating nucleic acid manual extraction and automated QIAsymphony extraction 
corroborates the findings of Laus et al. (Laus et al., 2011) and therefore, QIAsymphony  
was utilised for further cfDNA extractions. 
 
Figure 3.4: Scatter plot of mAFs detected from replicate aliquots extracted by QIAsymphony and 
Circulating Nucleic Acid kits. TAm-Seq was used to estimate the mutDNA load for each sample. The line 
model is represented by a grey dotted line (slope = 0.847, adjusted R2 = 0.8942).  
3.6.3 Detection of DNA alterations in TUR samples from MIBC patients undergoing 
NAC 
For analysis of single nucleotide variant mutations (SNVs), the previously described 
bladder-specific sequencing panel was used. When applied to MIBC, we expect the panel 
to detect SNVs in approximately 72% of cases based on the frequency of SNV mutations 
covered in published data (Table 3.1). TUR sample DNA libraries were submitted for 
125bp paired end NGS using 1 lane of a HiSeq 2500/4000 (Illumina) instrument. The 
HiSeq run resulted in approximately 257.2 million reads. TUR samples had a median 
sequencing depth of 9600X.  
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A total of 22 SNVs were detected across 12 of the 16 patients (75%) Table 3.2 and Figure 
3.5B. The most frequent mutations were detected in TP53 (14 mutations across 10 
patients), followed by KRAS (3 mutations), then PIK3CA (2 mutations). One SNV each 
was also detected in the BRAF, CTNNB1 and FGFR3 genes. These findings agree with 
previous studies annotating the frequency of SNVs in MIBC (Cancer Genome Atlas 
Research, 2014; Forbes et al.) and the predicted mutation rate based on our panel design. 
Though the numbers of SNVs detected in TUR samples varied amongst patients, there 
was no correlation with SNVs in TUR per patient and clinical outcome.  
For CNAs analysis in TUR, the mean number of sequencing reads achieved for each 
sample was 14.2 million. Gross genome wide CNAs were detected in all tumour 
specimens, including for those 5 patients in whom no SNVs were observed (Figure 3.5B). 
Across the 16 TUR samples, we detected focal CDKN2A loss (37.5%), E2F3/SOX4 gain 
(37.5%), PPARG gain (25.0%), YWHAZ gain (18.8%), CREBBP loss (12.5%), MYCL1 
gain (12.5%) and CNAs of other BC genes, as previously shown (Cancer Genome Atlas 
Research, 2014).  
 
  
 
Figure 3.5: Analysis of Longitudinal mutDNA kinetics in MIBC. A. Study design. 17 patients were enrolled at the NKI for mutDNA analysis whilst undergoing 
NAC. TUR was performed at the NKI or at regional institutions. PLS, USN and UCP were taken on one occasion before the initiation of NAC and subsequently on 
each chemotherapy visit, prior to definitive therapy. Examples of longitudinal SNV and CNA data are shown. B. Grid depicting mutDNA detection across all 
patients and time-points. The right y-axis shows patients grouped by recurrence status with recurrence type adjacent; DM - distant metastasis, LR - Local 
recurrence. Individual mutations are listed on the left y axis. The x-axis shows sample-types (top) and time-points (bottom). Each cell of the grid indicates the result 
of mutation analysis. White cells correspond to unavailable samples and light blue cells to samples where analysis did not detect mutDNA. Purple, yellow, red and 
green cells correspond to TUR, PLS, UCP and USN samples (respectively) where mutDNA was detected. No mutations were detected in BUF (Grey). Raw AFs for 
the grid are provided in Table 3.4.  
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Table 3.3: Grid depicting total GE copies inputted per reaction across all patients and time-points. The format of the grid matched that of Figure 3.5.  
  
Pt	ID Reaction	
Type
Recurrance	
status
T0.BUF T0.TUR T1.PLS T2.PLS T3.PLS T4.PLS T5.PLS T6.PLS T1.UCP T2.UCP T3.UCP T4.UCP T5.UCP T6.UCP T1.USN T2.USN T3.USN T4.USN T5.USN T6.USN
2 CNA N 25330 8606 91 513 63940 3030 37500 7473 13340 1372 3030 3030
2 SNV N 7576 7576 90 303 192 256 31950 18660 37450 7576 13350 909 1292 1077
7 CNA N 14000 112700 359 1030 308 13720 8461 3030 3030 3023 3030
7 SNV N 7576 28170 179 303 1585 303 303 154 7576 10960 7576 7703 7576 1028 2277 4249 928 909 1454
8 CNA N 14970 143000 949 3030 0 14250 21960 179 3030 3030
8 SNV N 7576 35710 303 467 438 618 0 7576 3805 7576 10980 90 909 2464 462 909
19 CNA N 15150 513 256 5886 52940 3030 2154
19 SNV N 10080 15150 321 321 1115 1936 1641 167 7576 1489 7576 1237 26460 1705 1782 4769 282 1372
24 CNA N 4788 205 513 10800 0 3030 51
24 SNV N 7333 7576 141 333 949 256 167 192 7576 7576 7576 1124 777 2462 1179 9731 64 64
27 CNA N 7576 974 1333 0 29140 2564 11930
27 SNV N 9939 7576 449 667 641 1295 141 1442 7576 14580 1179 2538 59520 33330
29 CNA N 38640 462 308 11110 0 3030 3030
29 SNV N 10030 38610 192 154 333 474 962 154 7576 7576 7576 7576 1244 662 9051 5513 2064 1205 2808 2141
33 CNA N 45620 513 615 21390 0 1179 1436
33 SNV N 15550 45660 333 333 295 385 256 10700 7576 2306 565 654 3051 1269 782
9 CNA Y 16300 99390 436 333 26150 3030 3030 3030
9 SNV Y 7576 24880 218 269 231 167 282 13070 7576 7576 5797 897 603 654 141 397
12 CNA Y 19150 321200 564 273 6500 3209 3024 5600 3030 3466 9767 1049
12 SNV Y 7576 80000 282 303 303 141 7576 7576 7486 7576 1579 1313 909 909
13 CNA Y 24760 462 462 4545 0 2667 103
13 SNV Y 7879 24750 192 923 1103 359 205 64 2185 7606 1066 2182 2136 1231 7718 962 1128 51
15 CNA Y 154 513 410 462 5779 3030 22410 16450 3030 3267 3030 3764
15 SNV Y 16560 282 205 244 192 282 192 7576 867 11210 28650 8227 4359 16810 7846 5308 25770 18480
18 CNA Y 16650 308 308 0 0 718 615
18 SNV Y 8348 16640 154 282 449 321 423 205 409 621 1333 196 5823 618 244 103 2744 936 418 256
21 CNA Y 7424 256 769 21130 52700 3030 2103
21 SNV Y 10100 7424 167 295 141 385 103 10560 7576 6385 26380 3615 244 231 897
26 CNA Y 73940 205 1282 4545 4545 3030 821
26 SNV Y 9894 74070 103 77 385 372 77 564 2467 1505 7576 7033 7576 6877 2128 141 885 115 1051 513
32 CNA Y 23200 256 974 462 1436 4545 923 154
32 SNV Y 11090 23200 128 218 449 205 218 808 7576 5234 641 22470 1782 51
11 CNA Other 27460 466700 256 394 1182 744 256 3333 13140 3615 5764 4591 3333 3333 3033 3029 5115
11 SNV Other 7576 116700 128 303 303 303 128 13110 7576 7576 7576 7576 872 449 474 909 909
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Table 3.4: Grid depicting mutDNA AFs across all patients and time-points. The format of the grid matched that of Figure 3.5. Where tested, data for CNAs 
were entered manually as 1 or ND depending on whether or not they were called. ND – not detected  
Mut	ID Pt	ID Recurrance	
status
T0.BUF T0.TUR T1.PLS T2.PLS T3.PLS T4.PLS T5.PLS T6.PLS T1.UCP T2.UCP T3.UCP T4.UCP T5.UCP T6.UCP T1.USN T2.USN T3.USN T4.USN T5.USN T6.USN
CNA 2 N ND 1 ND ND ND ND ND ND 1 ND ND ND
CNA 7 N ND 1 ND ND ND ND ND ND ND ND ND
TP53	p.C238F 7 N ND 0.2327 ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
CNA 8 N ND 1 ND ND ND ND ND ND
TP53	Intronic 8 N ND 0.0086 ND ND ND ND ND ND ND ND ND ND ND ND ND ND
TP53	p.R280T 8 N ND 0.7903 ND ND ND ND ND ND ND ND ND ND ND ND ND ND
CNA 19 N 1 ND ND ND ND ND ND
KRAS	p.G12C 19 N ND 0.5853 ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
TP53	p.E204* 19 N ND 0.0204 ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
CNA 24 N 1 ND ND ND ND ND ND
CNA 27 N 1 ND ND ND ND ND ND
HRAS	p.G12C 27 N ND ND ND ND ND ND ND ND ND ND ND ND ND 0.0062
TP53	p.W146* 27 N ND 0.8319 0.0061 ND ND ND ND ND ND ND ND ND ND ND
TP53	p.P89S 27 N ND 0.0162 ND ND ND ND ND ND ND ND ND ND ND ND
CNA 29 N 1 ND ND ND ND ND ND
TP53	p.F270S 29 N ND 0.3324 ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
PIK3CA	p.E54KL 29 N ND 0.3827 ND ND ND 0.0053 ND ND ND ND ND ND ND ND ND ND ND ND ND ND
FGFR3	p.S249C 29 N ND 0.2312 ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
CNA 33 N 1 1 ND 1 ND 1 ND
TP53	p.Q192* 33 N ND ND ND ND ND ND ND ND ND ND ND ND ND 0.0088 ND
CTNNB1	p.S37F 33 N ND 0.0428 ND ND ND ND ND ND ND ND ND ND ND ND ND
CNA 9 Y ND 1 ND ND ND ND
PIK3CA	p.E545K 9 Y ND 0.0072 ND ND ND ND ND ND ND ND ND ND ND ND ND ND
CNA 12 Y ND 1 ND ND 1 1 1 ND ND ND 1 1
TP53	p.E285L 12 Y ND 0.4272 0.0120 ND ND ND 0.0216 0.0450 0.0729 0.0114 0.0375 0.0111 0.0403 0.0172
TP53	p.Q192* 12 Y ND 0.4784 0.0152 ND ND ND 0.0218 0.0435 0.0826 0.0113 0.0376 0.0157 0.0504 0.0124
TP53	p.W53* 12 Y ND ND ND ND ND ND ND 0.0099 0.0355 ND ND ND 0.007 ND
CNA 13 Y 1 1 ND 1 1 1 ND
TP53	p.R158C 13 Y ND 0.6370 0.0071 ND ND ND ND 0.0136 0.0438 0.0241 ND 0.0185 0.2291 0.0596 0.0245 ND 0.0179
TP53	p.S127C 13 Y ND 0.0093 ND ND ND ND ND ND 0.0090 ND ND ND 0.0557 0.0065 ND ND ND
CNA 15 Y 1 ND ND ND 1 1 1 ND 1 1 1 1
TP53	p.R273C 15 Y ND ND ND ND 0.0136 0.0331 0.0831 ND ND 0.0130 0.0113 0.0701 0.0102 0.0122 0.2237 0.3241 0.5570 0.3380
TP53	p.H193A 15 Y ND ND ND ND ND ND ND 0.0160 0.0320 ND ND ND 0.1237 0.1634 0.0201 ND ND ND
TP53	p.Q167P 15 Y ND ND ND ND ND ND ND ND ND ND ND ND 0.0056 ND ND 0.0053 0.0053 ND
TP53	p.A161D 15 Y ND ND ND ND ND ND ND ND ND ND ND ND ND 0.0144 0.0188 0.0178 0.0050 ND
NFE2L2	p.G31A 15 Y ND ND ND ND ND 0.0128 0.0484 ND ND 0.0069 0.0076 0.0428 0.0110 0.0098 0.1684 0.2443 0.3963 0.4272
CNA 18 Y 1 ND 1 1 ND 1 1
CNA 21 Y 1 ND 1 ND ND ND ND
CNA 26 Y 1 ND ND 1 ND 1 ND
TP53	p.V173M 26 Y ND 0.8883 ND ND ND ND ND ND 0.0665 0.2024 0.0318 0.0400 0.0135 0.0159 0.1121 0.2105 0.4843 0.0691 0.0419 0.0487
CNA 32 Y 1 1 ND 1 1 ND
KRAS	p.G12D 32 Y ND 0.2859 ND ND ND 0.0088 ND ND 0.4892 ND 0.3460 ND 0.0071 0.0444
TP53	p.R181H 32 Y ND ND ND ND ND ND ND ND 0.0059 ND ND ND ND ND
BRAF	p.S467L 32 Y ND 0.0542 ND 0.0057 ND ND ND ND 0.2315 ND 0.0546 ND ND 0.0771
CNA 11 Other ND 1 1 ND ND ND ND 1 ND ND ND ND 1 1 ND ND 1
KRAS	p.G12S 11 Other ND 0.2306 0.0407 ND ND 0.0068 ND ND ND ND ND ND ND ND ND 0.0067 ND
TP53	p.G245D 11 Other ND 0.9387 0.1557 ND ND ND ND 0.0459 0.0207 0.0162 ND 0.0309 0.0900 0.1671 0.0284 ND 0.0390
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3.6.4 Comparison of genomic profiles in tumour and pre-NAC peripheral samples  
Pre-NAC samples were collected from patients 1-2 months following their TUR but 
immediately prior to starting NAC. To detect mutDNA in peripheral fluid samples, TAM-Seq 
and sWGS libraries were submitted for 125bp paired end re-sequencing on 3 lanes of a 
Illumina HiSeq 2500. Peripheral samples had a median depth of 7600X for SNV analysis 
and a mean of 13.6 million reads / sample for CNA analysis. Of the 12 patients with SNVs 
detected in TUR, one or more identical SNVs were also detected in 30.8% (4/12) 46.2% 
(5/12) and 46.2% (5/12) of pre-NAC plasma, UCP and USN samples respectively. 
Similarly, CNAs were observed in 25% (4/16), 53.3% (8/15) and 50% (8/16), and of pre-
NAC plasma, UCP and USN samples of all patients with available samples. Figure 3.6 
demonstrates that many of these CNAs occurred in multiple fluid types of some of the 
patients and, that when a mutDNA CNA signal was detectable in peripheral fluids, the 
CNA profile subjectively matched the CNA profile of the corresponding TUR. Linear 
modeling of CNA profiles from each peripheral fluid, in which a CNA was called and the 
matched TUR resulted in a median adjusted R2 of 0.4990 (range 0.0011 – 0.9777) and is 
likely to represent the reduced prominence of CNA profiles in the peripheral samples, 
possibly due to higher levels of germ-line DNA in urine and plasma samples, due to 
successful removal of the bulk of disease by TUR, or due to spatial and temporal tumour 
heterogeneity (discussed below). When combining both methods, mutations (SNVs and 
CNAs) were detected in the first (pre-NAC) time-point in 58.8% (10/17) patients. MutDNA 
was present at the pre-NAC time-point in 35.3% (6/17), 47.1% (8/17) and 52.9% (9/17) of 
plasma, UCP and USN samples respectively.  
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Figure 3.6: sWGS data for TUR and peripheral fluids taken prior to NAC for 17 MIBC patients. Genome 
wide log2 ratio plots depict genomic position (x axis) and log 2 ratio scores using 1Mb bins (y axis). CNAs 
were deemed to be present using CGHcall (van de Wiel et al., 2007) in either 1Mb or 50kb (as described in 
section 3.4.4). All TUR samples (the cystectomy sample for pt15) contained CNAs. CNAs were detected in  
CNAs were detected in 25% (4/16), 53.3% (8/15) and 50% (8/16), and of pre-NAC plasma, UCP and USN 
samples respectively.   
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3.6.5 Presence of mutDNA in pre-NAC peripheral samples has poor correlation to 
outcome. 
To investigate the utility of mutDNA detection as a predictive biomarker for response to 
NAC in patients with MIBC, mutDNA detection in pre-NAC samples was correlated with 
clinical outcome. Presence of mutDNA was defined as its detection in one or more sample 
type(s) at an AF, greater than 1/GE copies inputted per reaction (our input threshold, raw 
data in Table 3.3) and higher than 0.5% (our technical threshold). This technical threshold 
was previously described at 2% for the identification, and 0.14% for the detection of SNVs 
by Forshew et al. in 2012 (Forshew et al., 2012). Whilst, AUC curves (Figure 3.7) show 
that a number of technical thresholds could have been used, we utilised a working 
threshold of 0.5% for our proof of principle study as this ensured 100% specificity, and 
meant that in buffy coat samples AFs at all genomic co-ordinates with non-reference calls 
were below our threshold, Figure 3.8.  
 
Figure 3.7: AUC plots showing the trade off between sensitivity and specificity for mutDNA to predict 
recurrence at various threshold cut-offs.  Prediction of recurrence was assessed using data from samples 
obtained immediately prior to the 2nd cycle of NAC. The ability of mutDNA to predict recurrence is detailed in 
section 3.6.6. Circles represent values obtained when using our threshold of 0.5% AF for mutation calling.  
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Figure 3.8: Buffy coat AFs at TAm-Seq called locations with technical threshold plotted as 0.5%.  
According to these criteria, MutDNA was detected in pre-NAC samples in 6 patients who 
showed complete or partial pathological response and in 4 patients who showed no 
pathological response or progression according to final pathology at radical cystectomy. 5 
patients who responded and 2 patients who did not, showed no evidence of mutDNA at 
this time-point. The sensitivity and specificity of mutDNA detection in pre-NAC samples to 
predict response to chemotherapy was 66.6% and 45.5% respectively, with positive and 
negative predictive values of 40% and 71.4% respectively. Therefore, the detection of 
mutDNA in pre-NAC samples did not correlate with early response to NAC in this sample 
set (Table 3.2 and Table 3.5).  
 Pathological Response to 
NAC 
pCR/pPR pSD/pPD 
mutDNA 
status 
Detected 6 4 
Not Detected 5 2 
 
Table 3.5: Sensitivity and specificity for mutDNA detection to predict response to NAC. Detection of 
mutDNA in pre-NAC samples did not correlate with response to NAC. Response categories: pCR – 
Patholigcal complete response, pPR – Pathological partial response, pSD – Pathological stable disease, 
pPD – Pathological progressive disease. Overall sensitivity and specificity were 54.5% (95% CI: 23% - 83%) 
and 33.3% (95% CI: 4% - 78%) with positive predict value and negative predictive values of 60% and 29% 
respectively. 
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However, the presence of mutDNA pre-NAC seemed to be more in keeping with the 
presence of residual disease as defined by flexible cystoscopy. Indeed, 16/17 patients had 
diagnostic flexible cystoscopy following TUR, before NAC was commenced. On 
cystoscopy, 8/16 patients had obvious residual tumour present, and mutDNA was detected 
in the peripheral samples in 6/8 patients with residual tumour and in 1/3 patients with no 
obvious residual tumour. mutDNA was detected in a further 3/5 patients with equivocal 
cystoscopy findings, Table 3.6. The sensitivity and specificity of mutDNA detection in pre-
NAC samples to predict residual disease detection by flexible cystoscopy was 75% and 
66.6% respectively, with positive predictive value and negative predictive values of 85.7% 
and 50% respectively. 
 Flexible Cystoscopy Findings 
Residual 
tumour 
NAD 
mutDNA 
status 
Detected 6 1 
Not Detected 2 2 
Table 3.6: Sensitivity and specificity for mutDNA detection in pre-NAC samples. Overall sensitivity and 
specificity were 75% (95% CI: 35% - 97%) and 66.6% (95% CI: 9% - 99%) with positive predict value and 
negative predictive values of 85.7% and 50% respectively.  
3.6.6 Presence of mutDNA during NAC is associated with recurrence 
The majority of mutDNA was detected in samples taken from patients who recurred after 
definitive therapy (Figure 3.5B). 8 patients in our cohort recurred, with a median time to 
recurrence of 336 days (maximum 507 days) from initial TUR. One patient (patient 11), 
died due to a post-operative complication of radical cystectomy and was categorised as 
“other” and excluded from further analysis. Patients 8 and 29 developed new primary 
malignant melanoma and lung adenocarcinoma tumours at 882 and 175 days respectively 
during follow up. These patients were censored at the date of new tumour diagnosis to be 
recurrence free for the purposes of our analysis. All other patients were censored at the 
time of analysis. Therefore, a total of 8 patients were recurrence free after a median follow 
up of 781 days after TUR (maximum 1008 days). Overall, 90 SNVs were detected in 219 
mutant-time-point analyses, and 26 CNAs were detected in 54 samples, from the 8 
patients who recurred (Figure 3.5B). However, only 4 SNVs were detected in 193 mutant-
time-point analyses and 4 CNAs were detected in 55 samples tested from the 8 non-
recurring patients. Chi-Squared comparison at each time-point showed a significantly 
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greater mutDNA detection rate in patients that recurred as compared to those that did not 
at time-points 1, 2, 3 and 5, (p= 0.0058 at T1, p= 0.0055 at T2, p= 0.0130 at T3 and p= 
0.0272 at T5 after Bonferroni correction for multiple testing). Also, SNV AFs at each time-
point were significantly higher in patients who recurred compared to those who did not 
(Kolmogorov-Smirnov, p<0.022 at all time-points after Bonferroni correction, see Figure 
3.9).  
 
Figure 3.9: Empirical Cumulative Distribution Function plot of SNV AFs for all samples at each time-
point from patients who recurred (red) and those who did not (black). Each time-point was analysed 
independently. Kolmogorov-Smirnov testing was used to compare SNV AFs between recurrence and non-
recurrence groups, with Bonferroni correction for multiple testing.  
To investigate potential utility of mutDNA analysis for the prediction of recurrence in 
patients with MIBC, we analysed the persistence of mutDNA, in peripheral samples taken 
at an early on-treatment time-point (i.e. just prior to the administration of the 2nd NAC 
cycle). We utilised TAm-Seq to detect mutDNA at this time-point (CNA data for samples 
taken at 2nd NAC cycle was not available). As such 5 patients were precluded from further 
analysis as SNVs were not detected in their tumour nor peripheral samples. Presence of 
mutDNA was defined as its detection in one or more sample type(s) at an AF, greater than 
our input threshold (1/GE copies inputted per reaction, Table 3.3) and higher than our 
technical threshold (0.5% as described in section 3.6.5). According to these criteria, 
mutDNA was present at the 2nd NAC cycle visit in 5 of the 6 patients that recurred, 
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whereas it was not detected in any of the cases that did not recur, 83% sensitivity (95% CI: 
36-100%) and 100% specificity (95% CI: 42-100%), Figure 3.10A and B). All of the 
patients with detected mutDNA at the 2nd NAC cycle had disease recurrence, with a 
median time to recurrence of 293 days (Figure 3.10), whereas patients in whom mutDNA 
was not detected had a low recurrence rate (p=0.006 using log rank test Figure 3.10 
resulting in 100% positive predictive value and 85.7% negative predictive value, Figure 
3.10B).  
For the single patient (patient 9) who recurred despite not having detectable mutDNA at 
this time-point in any peripheral sample, the tumour had a PIK3CA E545K mutation that 
was present at an AF of only 0.7%. It is likely that this mutation represents a minor 
subclone of cells in the tumour and therefore may not be present in recurrent tumour. As a 
biomarker, mutDNA detection in samples taken at cycle 2 of NAC offered a median lead-
time over radiological detection of recurrence of 243 days (range 182-455 days) in our 
data. This association was primarily driven by detection of TP53 SNVs in the urinary 
samples, where 4/5 patients that recurred had mutDNA while only 1/5 patients had a 
BRAF SNV detected in their plasma (Figure 3.10C, raw data in Table 3.4). In a subgroup 
analysis of the 9 patients with TP53 SNVs detected in tumour specimens, all 4 patients 
who had TP53 SNVs detected in their USN sample at the 2nd cycle of NAC recurred, with a 
median time to recurrence of 271 days. The 5 patients who did not have a TP53 SNV 
detected in their USN at the 2nd cycle of NAC did not recur. MutDNA detection in this 
subgroup would have a sensitivity and specificity of 100% and a positive predictive value 
(95% CI: 28-100%) and negative predictive value of 100% (95% CI: 36-100%), Figure 
3.11.  
 
  
 
Figure 3.10: Presence of mutDNA at the 2nd cycle of NAC predicts early recurrence in MIBC. A. Kaplan-Meier curve depicting time to recurrence from 
initial TUR. We compared the rate of recurrence of patients with detectable mutDNA (red line) and undetectable mutDNA (blue line) in peripheral samples taken 
immediately prior to the 2nd cycle of NAC (i.e. 2-3 weeks after the initiation of NAC). MutDNA was detected in 5/6 patients who recurred and in 0/6 recurrence free 
patients. Median time to recurrence in patients with detected mutDNA was 293 days while in patients with undetected mutDNA the recurrence rate was low. 
Numbers at risk for the days from TUR are shown below the x axis. B. Sensitivity and specificity for recurrence prediction. Overall sensitivity and specificity 
were 83.3% and 100% with positive predict value and negative predictive values of 100% and 85.7% respectively. One “other” patient was excluded from recurrence 
analysis due to post-operative death. C. Heatmap comparing SNV maximum AF across all sample types and recurrence states at this time-point. Mutant 
allele fractions (mAFs) are represented by coloured cells ranging from white to scarlet as mAF increases. Patients are grouped by recurrence status, with recurrence 
type below, DM - distant metastasis, LR - Local recurrence. Generally, SNV mAFs are noticeably higher in USN and UCP as compared to PLS. There is a clear 
correlation between SNV mAF in peripheral samples and patient recurrence status. *TUR material was not available for patient 15.  
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Figure 3.11: Kaplan-Meier curve depicting time to recurrence from initial TUR in a subset of 9 
patients who had TP53 SNVs detected in their tumour sample. All 4 patients who had TP53 SNVs 
detected in their USN at the 2nd cycle of NAC (red line) recurred, with a median time of 271 days. The 5 
patients who did not have a TP53 SNV detected in their USN at the 2nd cycle of NAC (blue line) did not recur. 
When applied to MIBC patients with TP53 SNVs detected in tumour specimens, the assay had a sensitivity 
and specificity of 100% (95% CI: 28-100% and 36-100%, respectively) for prediction of early recurrence. 
Numbers at risk shown below the x axis. 
3.6.7 Comparison of peripheral sample types reveals that UCP and USN are 
enriched in mutDNA as compared to plasma 
At 58 time-points all 3 sample-types were drawn simultaneously. Each of the 31 mutations 
was detected in at least one of the peripheral samples in this group. To identify the most 
informative peripheral sample type for mutDNA analysis in MIBC, each SNV detected at a 
single time-point was analysed as an independent variable. SNVs were detected most 
frequently in USN (34.5%, 49/142), UCP (27.5%, 39/142) and lastly plasma (9.9%, 
14/142), Figure 3.12A. CNA analysis was conducted for the first and last time-points, for 
each patient where all three peripheral samples were analysed (35 time-points, patient 32 
had only 1 time-point where all three sample types was drawn). When CNAs were 
detected, they were most frequently found in all three peripheral sample types. More CNAs 
were detected in USN and UCP than plasma but the small numbers precluded statistical 
interpretation Figure 3.12B.  
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Figure 3.12: Venn diagrams demonstrating that more SNVs (A) and CNVs (B) were detected in the 
urine, as compared to the plasma samples for time-points where all three sample types were 
collected. The number of times SNVs or CNVs were detected in peripheral samples per time-point are 
depicted as Venn diagrams. CNAs were only assessed for the first and last time-points for each patient. 52 
out of 56 SNVs and 12 out of 14 CNAs were detected in urinary samples. However for SNVs, 4 
mutations/time-points were detected only in PLS, 2 in UCP and 13 in USN. For CNAs 2 mutations/time-
points were detected only in PLS, 1 in UCP and 3 in USN, confirming that multiple sample analysis can 
improve mutDNA detection in MIBC. 
Figure 3.13 is a box-plot of the raw SNV AF values, grouped by sample type. Mutant AFs 
were analysed for samples where SNVs were detected in one or more sample type(s) at 
that time-point without imposing detection criteria (Forshew et al.). Kruskal-Wallis testing 
demonstrated statistically significant differences in the AFs between sample types (p= 
4.527 x e-12). Post-hoc Dunn-testing revealed significant differences between the AFs of 
UCP and plasma (p=2.12 x e-15) and USN with plasma (p= 3.61 x e-05). Mutant SNV AFs 
were not statistically different between USN and UCP (p=0.6975), Figure 3.13. However, 
no single peripheral sample type captured all of the SNVs that were detected across all the 
samples together, and for each sample type there were SNVs that were unique to it. 
Indeed, 4 of the events (individual SNVs detected in individual time-points) were detected 
only in plasma, 2 only in UCP, and 13 only in USN, Figure 3.12.  
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Figure 3.13: Allele fractions of paired plasma and urinary samples taken from patients with MIBC 
undergoing NAC. 86 time-points had paired sampling of all 3 peripheral sample types. In 22 cases a 
mutation was detected in one sample type, this and its paired sample AFs were plotted above with median 
AFs. The dashed line represents the technical threshold value of 0.5% AF. Kruskal Wallis testing revealed 
significant differences between the AF of urinary samples and the plasma but no difference between USN 
and UCP mAFs.  
3.6.8 Comparison of CNA and SNV detection 
In peripheral samples, though detection rates for SNVs and CNAs were similar, SNVs 
were not always detected in the same samples as CNAs. Therefore, SNVs and CNAs 
were compared for co-occurrence and whether there was a relationship between them. All 
peripheral samples taken from the first and last time-point that had one or more SNVs 
detected were included in the comparison (n=28). Figure 3.14 shows a bar chart of the 
samples ordered by the maximum AF (y-axis) and labelled by sample type (x-axis). 
Samples in which a CNA was detected are coloured red, whilst copy number neutral 
samples are coloured grey. The sensitivity of detection of CNAs using sWGS is considered 
to be 5-10% (Heitzer et al.)2011}, and it is noteworthy that above this threshold (as 
indicated by SNV AF) all samples had detectable CNAs. However, there were examples of 
CNA detection in samples where SNV AFs were low or were absent altogether (Figure 3.5 
and Figure 3.14). This was apparent in all peripheral sample types.  
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Figure 3.14: Waterfall plot depicting the relationship between CNAs and SNV AF.  
This may be due to samples being primarily driven by CNAs and carrying only sub-clonal 
SNVs who’s AF representation in plasma or urine are diminished as compared to tumours, 
or due to a clone having a particularly prominent and focal CNA that was therefore more 
easily detectable. Alternatively, this may be due to the ability of sWGS to interrogate a 
greater breadth of the genome than targeted re-sequencing approaches. This dataset 
demonstrates that sampling multiple body fluids using complementary techniques allows 
for more complete assessment of mutDNA.  
 
3.6.9 Longitudinal analysis of mutDNA in peripheral samples of patients with MIBC 
TAm-Seq was applied to analyse recurrent bladder cancer associated genetic events in 
serial USN, UCP and plasma peripheral samples (taken from NAC initiation through to its 
completion) to assess trends in mutDNA. Peripheral samples were collected longitudinally 
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from each patient over a median of 83 days (46-118 days, median of 15 samples/patient). 
CNA analysis was initially applied to the first and final time-points for all patients across all 
peripheral sample types.  
Figures 3.15-7 show SNV AF kinetics for each patient grouped according to their 
recurrence status. Overall, the SNV AFs trend downwards and are undetectable after the 
initiation of NAC with the exception of the early recurrence group, where SNV AFs persist 
or even increase, most notably in the urinary compartments. Figure 3.18A shows a 
summary of longitudinal SNV AF kinetics for all patients distilled into 3 plots, one for each 
peripheral sample type. There are clear differences in the AF kinetics between peripheral 
sample types. For example, in patient 26, mutDNA levels at time-points 2 and 3 vary 
between UCP, where levels decrease, and USN, where levels increase. Furthermore, 
there are differences in the kinetics between patients. For example, for many patients, 
mutDNA levels fall during NAC with the exception of a few notable cases, e.g. patient 15 
has increasing levels of mutDNA in USN samples.  
Figure 3.18B similarly shows longitudinal mutDNA kinetics in 3 plots, one for each sample 
type. CNA analysis was performed routinely on the first and last time-point for each 
sample (x-axis). The y-axis demonstrates the Genome Wide Imbalance Score calculated 
by modelling the autosomal 1Mb bin read counts in samples against those in a control 
sample, and subsequent summation of the 5% most extreme residual values (i.e. greatest 
difference vs. copy number neutral), as described in the methods section (Section 3.4.4). 
Two predominant trends are observed; firstly, a series of patient samples that have high 
levels (>7) of CNA at their first time-point but much reduced levels at their final time-point. 
Of note, with the exception of patient 33, this series was enriched for patients that recurred 
early. The second trend observed involves ‘genome-wide imbalance scores’ that persist at 
low levels (<7) throughout NAC. Overall, the magnitude of CNA signals was higher in USN 
as compared to UCP, while levels were very low in PLS.  
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Figure 3.15: SNV mutDNA kinetics for each peripheral sample type across the 6 patients who recurred early. Generally all 6 patients had high levels of 
mutDNA (most often) in their urinary samples. Plots are grouped by patients into sets of four (with one plot for each peripheral fluid type and one for TUR and BUF 
samples). Each plot depicts days from TUR on the x-axis and mutDNA AF for SNVs at that time-point on the y axis. Data-points are colour coded according to the 
mutation ID, as per the figure legend. Notably, SNV kinetics of patient 9 were low in all sample types, including TUR indicating that the PIK3CA SNV that we track 
was not a component of the major clone.   
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Figure 3.16: SNV mutDNA kinetics for each peripheral sample type across the 6 patients who were free from early recurrence. Kinetics demonstrate 
generally low levels of mutDNA in all patients regardless of sample type. The format of these figures match the format described in Figure 3.15.  
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Figure 3.17: SNV mutDNA kinetics for each peripheral sample type of patient 11, who died shortly after surgery from surgical complication. The format of 
this figure matches the format described in Figure 3.15.   
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Figure 3.18: Summary of longitudinal dynamics of patient specific SNVs and CNAs. A. Patient specific SNV kinetics across PLS, UCP and USN samples. 
Longitudinal SNV AF kinetics are depicted in 3 plots, one for each peripheral sample type. Each plot depicts time-points on the x-axis. Only the SNV with the highest 
AF at a given time-point is plotted, with line colours corresponding to individual patients. B. Changes in patient specific ‘genome-wide imbalance scores’ 
between first and last time-points, across peripheral sample types. GWISs kinetics are depicted in 3 plots, one for each peripheral sample type. Each plot 
depicts time-points on the x-axis. GWISs were calculated as described in the methods section but, briefly, involved linear modelling of autosomal 1Mb bin read 
counts in samples against those in a control sample, and subsequent summation of the 5% most extreme residual values (i.e. greatest difference vs. copy number 
neutral). UCP and PLS GWIS plots are supplemented by an inset expanding the low imbalance score range.  
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For both SNV and CNA dynamics, the overall trend was a reduction in mutDNA over time 
during NAC (Figure 3.18). However, there were examples of persisting mutDNA, 
particularly in the urinary samples. Furthermore, there were patients who showed variation 
in mutDNA AFs over time. Figure 3.19 shows longitudinal SNV kinetics in a similar format 
to Figure 3.18A. There are clear differences in the AF kinetics between the peripheral 
sample types. Generally levels are low in PLS while AFs rise and fall dynamically in 
urinary specimens. For most patients, mutant allele fractions (mAFs) are low during NAC, 
however, mAFs that were considerably higher than the 0.005 AF detection threshold were 
more found in patients that recurred, see Figure 3.19. These general tends remained true 
when evaluating all SNVs detected in each patient.  
 
Figure 3.19: Maximum mutDNA AF during NAC demonstrates differing kinetics in PLS, UCP and USN. 
The format of these plots is similar to that of Figure 3.18. The 3 plots depict the maximum SNV AF at each 
time-point in PLS, UCP and USN samples for 13 patients with detected SNVs. Patients data points are 
colour coded by recurrence status. 
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3.6.10 Urinary mutDNA demonstrates tumour evolution during therapy 
As opposed to assays targeting mutations detected in matched tumour samples, combined 
use of our disease specific assay and sWGS allowed the detection of de novo mutations. 
To determine additional examples of tumour evolution we performed sWGS analysis of 
samples taken between the first and last time-points in selected patients based on high 
SNV levels or interesting CNA profiles at the first time-point (Figure 3.5B). Indeed, in 5 
patients there was evidence of dynamic tumour evolution during NAC, highlighting the 
strength of studying mutDNA in peripheral fluids as an alternative to traditional biopsy 
approaches (Murtaza et al.; Forshew et al.). All de novo mutations were detected in the 
urinary specimens and were not detected in the initial tumour specimen. There was no 
correlation between the detection of these private mutations and clinical outcome.  
In patient 12, whilst mutDNA levels in plasma fell quickly following the initiation of NAC, 
urinary mutDNA levels remained high and reached a peak at 85 days after TUR. 
Additionally, a new nonsense mutation of TP53 (W53*) was identified in urinary samples at 
this time-point (3.6% in UCP and 0.7% in USN), suggesting the emergence of a new clone 
(Figure 3.20A). Similarly overall CNA levels rose in parallel with SNV AFs and also 
demonstrated the emergence of a new CNA profile (including a novel focal amplification of 
GRIN2A. GRIN2A encodes an ionotropic glutamate receptor that regulates the influx and 
efflux of cations that are important in cellular migration and survival. Amplification of 
GRIN2A has previously been observed in MIBC and has been implicated as a cancer 
oncogene (Morrison et al.; Wei et al., 2011). The short-term persistence of this clone was 
confirmed by sWGS analysis of additional urine samples from this patient (Figure 3.20B). 
Levels of all mutations ultimately fell, though some were detected at the last sample taken 
during NAC. Although a good response to NAC was initially reported for this patient, he 
developed brain metastases approximately 2 months following radical radiotherapy to the 
bladder.  
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Figure 3.20: MutDNA kinetics of patient 12 reveal tumour evolution on therapy. A. Kinetics of SNVs in longitudinally obtained peripheral samples from 
patient 12. Changes in SNV AFs are plotted for PLS, UCP and USN from patient 12. SNVs in TP53 (Q192* and E285L) are at their highest levels (as determined by 
AF) in PLS at time-point 1 but decrease below detection thresholds during NAC. Meanwhile, in UCP and USN, these mutations reach a peak AF at the third time-
point (85 days after TUR). Coincident with this peak is the emergence of a third mutation of TP53 (W53*). This mutation, which was not detected in the original TUR, 
reaches a modest AF of 3.6% in UCP and 0.7% in USN before receding at the final time-point (along with the other two TP53 mutations). Despite its brief 
appearance, this third SNV indicates the emergence of a new clone under the selective pressure of NAC. B. Evidence of changing clonal dynamics during NAC 
through CNA analysis. Coincident with the emergence of TP53 W53*, is the detection of a change in patient 12’s CNA profile. At TUR, the genome-wide CNA 
profile consists of multiple amplifications and losses involving both large chromosomal regions (sometimes whole chromosomes) and focal areas. This is exemplified 
by chromosome 16 (plotted), where 16p contains neighbouring regions showing focal loss (region shown in blue - including the CREBBP gene (20)), and large-scale 
amplification respectively. In peripheral samples, the TUR CNA profile (chromosome 16 and genome-wide) is largely absent. However, focal amplifications of two 
regions on 16p are observed, one of which contains GRIN2A (regions shown in red). The amplitude of these CNAs reached their peak at time-point 3 (in UCP) 
before receding at time-point 4. It is unclear if the focal amplification of GRIN2A is present in USN (low level CNAs) and PLS (time-points missing). Combined, the 
SNV and CNA data point to the emergence of a clone containing a TP53 W53* SNV and a focal amplification of GRIN2A. It is unclear whether this clone has any 
influence on ultimate disease course in this patient who ultimately developed brain metastases after radical radiotherapy. Nonetheless, our data demonstrate the 
potential of mutDNA (in this patient, primarily derived from UCP) in tracking tumour evolution during therapy.  
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In another example, patient 15 had T3N1 disease that recurred 138 days after cystectomy. 
The SNV and CNA profiles observed in her urine specimens suggested tumour evolution 
in response to surgery and/or NAC. Specifically, a clone characterised by a TP53 H193A 
SNV and a focal amplification of YAP1 was dominant at the pre-NAC time point. This 
sample also carried TP53 R273C and NFE2L2 G31A SNVs but they were detectable at 
low AFs (Figure 3.21A and B) and likely represent a minor clone. During NAC, the initially 
dominant (presumably NAC sensitive) TP53 H193A, containing clone receded, whilst the 
minor clone containing TP53 R273C and NFE2L2 G31A SNVs and a focal loss of 
CDKN2A became dominant in all peripheral fluid samples. Radical cystectomy was carried 
out 155 days after TUR and 106 days after the initiation of NAC. We obtained DNA from 
the cystectomy sample and carried out TAm-Seq and sWGS on it. Of note, we found that 
the clone containing CDKN2A loss and TP53 p.R273C and NFE2L2 p.G31A SNVs was 
present at high levels, whilst there was no evidence of the clone containing YAP1 gain and 
the TP53 p.H193A SNV (Figure 3.21A and B). The similarity between peripheral samples 
obtained during NAC and the subsequent cystectomy samples was confirmed by 
modelling the linear relationship between CNA profiles of these samples (Figure 3.21C). 
We also carried out additional sWGS of intermediate time-points for this patient and 
confirmed gradual loss of the pre-NAC CNA profile below our detection threshold. 
Together this data points to ‘on-therapy’ tumour evolution under the selective pressures of 
NAC, as indicated by apparent changes in the dominant clone and its respective AF 
(Figure 3.21D). Whilst most noticeable in USN, this evolution was also evident in matched 
UCP samples, albeit at lower levels. Plasma mutDNA analysis alone would not have 
demonstrated evolution in this case, although it did reveal the emergence of the later clone 
containing CDKN2A loss and TP53 p.R273C and NFE2L2 p.G31A SNVs, Figure 3.22. 
This is possibly due to low mutDNA levels at the early time-points, which may in turn be 
due to spatial differences in the clones resulting in different representation of shed DNA in 
the plasma and urine. 
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Figure 3.21: mutDNA demonstrates on therapy tumour evolution. A. SNV plots for patient 15 
demonstrate tumour evolution. SNV analysis of pre-NAC urinary samples revealed a de novo TP53 
H193A mutation (light blue), whilst TP53 R273C (purple) and NFE2L2 G31A (orange) SNVs were only 
observed at low AFs in USN samples (1% and 1.1% respectively). During NAC, the clone containing TP53 
R273C and NFE2L2 G31A SNVs appears to grow considerably, whilst the TP53 H193A SNV containing 
clone recedes to become undetectable at later time-points. This profile was mirrored by the cystectomy 
sample. B. CNA profiles demonstrate tumour evolution. Marked CNA changes were observed in urine 
sample at pre-NAC (including YAP1 focal amplification). This CNA profile differed from that seen in later 
time-points. At time-point 6, the CNA profile resembles one seen at cystectomy. C. Concordance of 
cystectomy and USN CNA profiles during NAC. We generated a linear model by fitting autosomal 1Mb 
bin read-counts in the cystectomy sample against those in peripheral samples. Initial USN CNA profiles are 
discordant with the cystectomy sample (R2=0.0461). Subsequently a concordant CNA profile emerges 
(R2=0.8760), mirroring the SNV results. D. Longitudinal mutDNA analysis suggests on-therapy tumour 
evolution. We used the changing SNV and CNA profiles to suggest a clonal evolution paradigm in patient 
15. (Images adapted from Servier Medical Art). 
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Figure 3.22: Patient 15 CNA profiles of all three peripheral samples taken pre-NAC (T1), prior to Radical Cystectomy and lymph node dissection (T6) and 
from the radical cystectomy specimen. At T1 a CNA profile consisting of multiple amplifications and losses is obvious in the USN sample. Amongst these is a 
focal gain of YAP1 on chromosome 11 which is also called in the matching UCP sample. At time-point 6, a completely different CNA profile is observed in USN 
(including focal loss of CDKN2A on chromosome 9). The UCP and PLS samples at this point are largely copy number neutral (though may show evidence of low-
level CDKN2A loss). The cystectomy sample contains a similar CNA profile to that of USN T6, with focal CDKN2A loss and amplification of chromosome 1q. The 
dynamics suggested by these profiles match those observed through SNV analysis at the same time-points. Combined, this data points to changing clonal 
dynamics, with the emergence of a new clone following initiation of NAC. Simultaneously, the clone that was dominant at T1 recedes, suggesting that it may be 
sensitive to NAC. Indeed, of all patients considered in this study, patient 15 has the highest SNV AF at the final time-point (Figure 3.18) and examination of their 
clinical notes confirmed that they did not respond to therapy and later recurred. Therefore, mutDNA analysis of peripheral samples (here, in particular USN) can 
guide tracking of tumour evolution and disease course.  
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3.6.11 SNP analysis suggests sample crossover during the experiment is unlikely 
Amongst the ~5Kbps interrogated by the bladder specific panel, there were 90 known SNP 
positions. Following TAM-Seq of the samples, AF’s for each were tabulated with SAMtools 
(Li et al., 2009) and SNP positions were removed if that position was found to be 
uninformative, i.e. if the AF was consistent throughout all of the samples as this SNP 
position in our cohort. Seven SNPs were found to be informative for comparison. Further 
filtering was performed based on the median sequencing depth at all positions. Sample 
coverage was plotted for each sample (see Figure 3.23) and 6 samples with a median 
coverage of <500x were removed from further analysis. The resulting AF data were plotted 
together with median coverage using ‘Heatmap’ function in R in Figure 3.24. 
 
Figure 3.23: Median coverage for all samples included in SNP analysis. The y axis is scaled with natural 
log and the dotted line represents the coverage the threshold of 500x which was used to remove poor quality 
data.  
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Figure 3.24: SNP analysis demonstrating concordance of SNP genotypes for samples taken from the 
same patient. The analysis of 7 SNPs (that were included in our TAm-Seq panel) revealed that most 
patients have unique SNP profiles. Manual clustering of SNP profiles according to patient ID showed that 
SNP profiles from samples from an individual patient match other samples taken from the same patient and 
differ from those taken from other patients.  
Informative SNP analysis revealed unique profiles for the following patient IDs: 2, 7, 8, 9, 
13, 15, 24, 26, 29 and 33. Patients 11 and 12 had an indistinguishable SNP profile from 
each other, as did patients 18, 19, 21, 27 and 32. However, the SNP profile of the later 
group of patients was distinguishable from that of former group of patients. Figure 3.24 
demonstrates that samples collected from the same patient had identical SNP profiles to 
each other, indicating that sample mix up was unlikely. It must be noted that sample mix 
up between patients with an identical SNP profile or between time-points of the same 
patient cannot be ruled out. The likelihood of a sample being mistaken for another patient’s 
pa
tie
nt
m
ed
ian
 co
ve
ra
ge
mean AF
0.8
0.6
0.4
0.2
0
patient
33
32
29
27
26
24
21
19
18
15
13
12
11
9
8
7
2
median
coverage
10000
8000
6000
4000
2000
0
Ch
r1
7:
75
76
84
1 
A>
G
Ch
r1
7:
75
77
64
4 
 C
>G
Ch
r1
7:
75
79
47
2 
G>
C
Ch
r1
7:
75
79
57
9 
 C
>T
Ch
r3
:1
78
91
70
05
 A
>G
Ch
r4
:1
80
78
94
 G
>A
Ch
r1
1:
53
42
42
 A
>G
MUTANT DNA ANALYSIS IN MIBC - Results 
 
118 of 233 
is however unlikely due to the low probability of it being mixed up in exactly the same 
position as another sample with the same SNP profile.  
3.6.12 MutDNA analysis can be valuable in multiple disease settings of urothelial 
cancer 
To explore the applicability of mutDNA detection in other urothelial cancer settings we 
used TAm-Seq with the bladder primer panel and sWGS to analyse mutDNA levels in 3 
additional patients: Patient 1 had Urothelial Cell Carcinoma (UCC) of the distal ureter, 
patient 10 had metastatic UCC of the bladder and patient 30 had UCC of the renal pelvis. 
For patient 1 tumour DNA was extracted from biopsy tissue, for patient 10 DNA was 
extracted from TUR material prior to the diagnosis of metastatic disease, and for patient 30 
DNA extraction was not possible due to the small amount of material obtained from the 
renal pelvis biopsy. All patients were treated with MVAC (methotrexate, vinblastine, 
doxorubicin and cisplatin). In addition, patient 1 had radical nephrouretectomy with lymph 
node dissection (NU + LND), see Table 3.7.  
Table 3.7: Patient demographics for additional patients are shown in a similar format to Table 3.2.  
For patient 1, SNVs in TP53 and KRAS that were identified in tumour DNA, were detected 
at low levels (AFs <5%) in different peripheral samples at different time-points during 
treatment (Figure 3.25A). For patient 10, the CNA profile observed in the tumour (including 
focal loss of CDKN2A and CREBBP) was observed in all peripheral sample types taken 
prior to starting chemotherapy, albeit at lower levels in plasma. MutDNA levels, as inferred 
by the CNA profile, gradually decreased to below the detection threshold of sWGS, first in 
plasma, and then in UCP and USN during treatment (Figure 3.25C). For patient 30 the 
tumour biopsy did not yield sufficient material for DNA extraction. We detected SNVs in 
TP53 and PIK3CA, as well as CNAs (including focal amplifications of MYCL1, E2F3/SOX4 
and PPARG, and focal loss of CDKN2A) in all peripheral samples. SNVs were detected at 
consistently high AFs in the urinary specimens but at moderate levels in the plasma. 
Matching CNA profiles were seen only in the urinary samples, where they persisted 
between the two time-points analysed (Figure 3.25B). These preliminary findings suggest 
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that analysis of mutDNA in body fluids may be useful for disease monitoring in multiple 
urothelial cancer settings.  
  
Figure 3.25: mutDNA kinetics for patients with a broader spectrum of urothelial cancers. The format of these figures match the format described in Figure 
3.15, Figure 3.18 and Figure 3.5B. A. For patient 1 (ureteric UCC), SNV kinetics differ between the urinary component and the plasma, with initially moderate levels 
in the former that decrease during NAC before re-appearing in the later time-points. PLS samples have generally low mutDNA kinetics throughout with low level 
mutDNA detected at 118 days following tumour biopsy B. For patient 30 (renal pelvis UCC), clonal dynamics differed across the 3 sample types, in samples 
collected over the period of 1 week. TP53 p.G279E mutDNA levels in PLS and USN levels declined whilst remaining stable in UCP samples.  However, the clone 
containing the PIK3CA p.E542K mutation increased in the urinary components whilst decreasing in the PLS samples. C. mutDNA kinetics based on a genome wide 
imbalance score (GWIS) in patient 10 (metastatic UBC) demonstrate concordant kinetics in the urinary components, with an initial spike in levels soon after the 
initiation of NAC and a subsequent decrease during NAC. D. Grid depicting mutDNA detection across the 3 additional patients and time-points 
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3.7 Original Contributions to Knowledge 
1. DNA obtained from urine (UCP and USN) had a higher number of SNVs detected 
than plasma and a statistically significantly higher AF. 
2. mutDNA analysis at early time-point during NAC could not predict pathological 
response to NAC but importantly, is associated with recurrence. 
3. Tumour evolution can be demonstrated from urinary mutDNA and we describe the 
first example of monitoring tumour evolution through urinary mutDNA 
This data suggests that mutDNA has promise as a biomarker to predict recurrence in 
MIBC and may be useful in monitoring tumour evolution. 
 

  
CHAPTER 4: ctDNA DETECTION IN LOCALISED PROSTATE 
CANCER 
4.1 Synopsis 
Prostate cancer is the most common cancer in UK men and its incidence is rising. 
Currently, men diagnosed with prostate cancer have repeated Prostate Specific Antigen 
(PSA) measurements to monitor their disease activity. Unfortunately, PSA is non-specific 
and cannot distinguish between indolent and aggressive disease, therefore repeated 
biopsies are often required for active surveillance of prostate cancer, conferring increased 
morbidity. Men with localised prostate cancer often have indolent disease that will not 
affect their lifespan and are over-treated and over-investigated. There is therefore a need 
for a biomarker that can accurately distinguish between indolent and aggressive cancer. 
ctDNA analysis may be a good candidate as samples can be peripherally acquired 
allowing for multiple sampling and may be able to highlight aggressive cancers through 
high ctDNA levels or through changes in mutational signatures. Therefore ctDNA analysis 
could be a useful tool to monitor men with localised prostate cancer.  
I designed and validated a custom prostate cancer gene panel, assessing whole exons or 
hotspots of 15 genes commonly mutated in prostate cancer. From prostatectomy FFPE 
tissue of 19 men with localised prostate cancers the number of SNVs identified by this 
panel was low. However, in a separate group of 19 men who had metastatic prostate 
cancer, 10/19 had TP53 SNVs indicating that certain mutations may predispose to 
aggression. Analysis of TP53 in tissue samples taken at the time of prostatectomy, 
demonstrated the presence of TP53 SNVs identical to those found later in metastatic 
clones in 6/6 men. Furthermore the same TP53 SNVs, were detectable in pre-operative 
plasma samples from 2/3 men. To investigate whether mutations from more than one 
clone were represented in plasma, I developed MRD-Seq. When applied to 2 men with 
multifocal localised prostate cancer, mutations from multiple clones were detectable but 
clonal representation in the plasma was variable and overall levels of ctDNA was low. 
This proof of principle study suggests that aggressive mutations are present and 
detectable in the plasma at the localised stage. Furthermore, that ctDNA analysis may 
allow the non-invasive monitoring of individual clones in multifocal prostate cancer. These 
results warrant further investigation. If corroborated, in the future ctDNA analysis could 
help monitor men on active surveillance and identify aggressive changes at an early stage. 
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4.2 Publications arising from this work 
Work presented in this chapter was described in my first year report and parts were 
published in Nature Communications. Further works described here are being prepared for 
submission to Clinical Biochemistry. The text is therefore excerpted from my first year 
report and related publications except to extend explanations, display updated data and 
provide more in-depth references. 
M.K.H. Hong, G.Macintyre, D.C. Wedge, P. Van Loo, K. Patel, S. Lunke, L. B. 
Alexandrov, C. Sloggett, M. Cmero, F. Marass, D. Tsui, S. Mangiola, A. Lonie, H. 
Naeem, N. Sapre, P. M. Phal, N. Kurganovs, X. Chin, M. Kerger, A. Y. Warren, D. 
Neal, V. Gnanapragasam, N. Rosenfeld, J. S. Pedersen, A. Ryan, I. Haviv, A. J. 
Costello, N. M. Corcoran & C. M. Hovens. Tracking the origins and drivers of 
subclonal metastatic expansion in prostate cancer. Nature Communications. 6605:6. 
http://dx.doi.org/10.1038/ncomms7605 
 
  
4.3 Aims 
My primary objective was to explore whether mutant cfDNA can be an informative 
marker for prostate cancers. I collected samples from patients with localised prostate 
cancer who attended prostate clinics, using previously granted ethical approval 
(MREC:01/4/061, LREC:11/H0311/2 and LREC:03/018) and through international 
collaborations to investigate: 
1. TP53 SNV analysis as a biomarker for aggression: I investigated the ability of 
TP53 detection during localised disease to predict future malignant potential 
using cohorts of men with well documented clinical outcomes and 3-5 year 
follow up. 
2. Whether multi-focal prostate cancer clones can be tracked at the localised 
stage: Through international collaboration, I accessed multi-regional sequencing 
data of men with localised prostate cancer and designed assays to investigate 
whether these mutations can be detected in pre-operative blood samples.  
 
  
4.4 Methods 
4.4.1 Proof of Principle Analysis 
Pilot analysis was retrospectively performed on 12 patient samples collected under the 
Prostate Cancer: Mechanisms of Progression and Treatment study (PrompT), 
MREC/01/4/061. Twelve cases were chosen as the initial panel was intended to detect 
SNVs in ~15% of cases, section 4.4.1.1. All men had previously undergone robotic 
assisted laparoscopic prostatectomy for prostate cancer and were selected due to large 
tumour size. Prostate tumour specimens from FFPE blocks and cores were taken to 
determine tumour grade and stage by Dr Anne Warren (Consultant Histopathologist), as 
previously described (Warren et al.).   
FFPE slides were cut (6µm) and macro-dissection was performed, using 6-8 sections for 
tumours with an area of >1cm2, or 10-12 sections for tumours with a surface area of 
<1cm2. DNA was extracted from FFPE samples using the QIAamp DNA FFPE Tissue Kit 
(Qiagen 56404) using the manufacturers recommended xylene-extraction protocol, with 
the following alterations from the Rosenfeld group Standard Operating Procedure (SOP): 
1) following addition of buffer 180µl of ATL, the sample was incubated for 15 minutes at 
95°C; 2) the sample was allowed to return to room temperature before the addition of 
Proteinase K and continuation of the manufacturers protocol; 3) the elution step was 
adjusted to use only 50µl of buffer AVE and the elution step was repeated with final eluate. 
FFPE extracted DNA was quantified using a florescence-based DNA quantification method 
(Qubit, ThermoFisher). 
Plasma cfDNA was extracted from 1ml of blood plasma using the QIAamp Circulating 
Nucleic Acid kit (55114). Manufacturers’ instructions were followed with the following 
additional steps: 1) a known quantity of ‘spike-in’ Xenopus Tropicalis DNA was added to 
each sample and to a no extraction control sample to estimate yield; 2) following elution of 
DNA, the eluate was re-applied to the QIAamp mini column membrane and incubated for a 
further 3 minutes before final elution, as per the Rosenfeld SOP. 
TAm-Seq was used to interrogate tumour samples for Single Nucleotide Variants (SNVs) 
as described by Forshew et al. (Forshew et al.) and in Section 2.4.5. In brief, up to 50ng of 
DNA was used as input for the TAm-Seq protocol. Each sample was ‘pre-amplified’ using 
a limited number of PCR cycles in a multiplexed reaction (with a pool of primers). ‘Pre-
amplified’ samples were then aliquoted into multiple singleplex PCR reactions using an 
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Access Array (Fluidigm) microfluidic platform, before PCR-based barcoding, pooling and 
Illumina Sequencing (on MiSeq or HiSeq platforms). 
4.4.1.1 Initial Primer Panel 
For initial proof-of-principle studies in localised prostate cancer I used a previously 
published primer panel that targeted genes commonly mutated in several cancer types 
(Forshew et al.). This panel included hotspot mutations in PIK3CA, EGFR, BRAF and 
KRAS and all exons of PTEN and TP53, Appendix A-5. TCGA data suggested that this 
panel could detect SNVs in ~15% of localised prostate cancer cases (Cerami et al., 2012; 
Gao et al., 2013; Cancer Genome Atlas Research, 2015), see Table 4.1. 
 
Table 4.1: Genomic regions interrogated by the initial panel and their mutation frequency in localised 
prostate cancer. Interrogation of the gene set using cBioPortal demonstrates the frequency of SNVs 
reported in previous analyses of localised prostate cancer (Cerami et al.; Gao et al.). The formatting of this 
table is similar to that of Table 3.1. 
4.4.1.2 Prostate Specific Primer Panel 
To allow a more comprehensive analysis, primers were designed to target genomic 
regions of interest in prostate and bladder cancer. Regions of interest were included based 
on the following factors: 
• prevalence of mutation 
• number of primers required to target region 
• ease of targeting region (e.g. GC neutrality, avoiding repetitive regions, etc.) 
Using the COSMIC database (Forbes et al., 2011) and the results of major sequencing 
projects (e.g. Barbieri et al., 2012; Grasso et al., 2012; Guo et al.) I compiled a list of 
mutations and their prevalence in localised prostate cancer. This list was limited to include 
mutations that could be targeted with a manageable number of primer pairs (48-150 total), 
whilst allowing the broadest possible coverage of the patient population. Subsequently, 
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primers were designed to be as close to the ideal specifications as possible, set out in 
Table 2.3. Assays covering several regions of interest had previously been designed by 
other members of the Rosenfeld group and these were utilised with their permission for 
this study. 
Primers were designed using Primer 3 (Untergasser et al., 2012) and an automated 
pipeline developed by Franceso Marass (described in section 2.4.3). Through the above 
methods, a multiplexed prostate specific primer panel was designed targeting hotspot 
SNVs in PIK3CA, HRAS, KRAS, PTEN, AKT1, NRAS, BRAF, EGFR, CTNNB1, IDH1 and 
entire exons of SPOP, FOXA1, TP53, OR5L1 and AR. Table 4.2 lists the genes targeted in 
the multiplexed primer panel and illustrates an expected SNV detection rate of 30% for 
localised prostate cancer (Cerami et al., 2012; Gao et al., 2013; Cancer Genome Atlas 
Research, 2015). In total 150 primers were included in the final prostate specific primer 
panel, including assays from previous designs and those designed specifically for this 
project. Newly designed primer pairs were validated by BLAT searches (Kent et al.), 
insilico PCR (Kent et al.) and experimental validation by PCR with male genomic DNA 
(Promega, PR-G1471), as described in section 2.4.5.  
Primer multiplexing was used on the final primer panel to overcome the limitation imposed 
by the 48 assay input channels in the Access Array microfluidic chip. Multiplexing of 
primers would ideally take into account primer pair annealing temperature, GC content, 
length and genomic location. However, due to the stringent requirements placed upon 
primer pairs during the design stage, primer pairs were considered as equivocal in these 
parameters and multiplexed pools were based primarily on genomic location (e.g. to avoid 
‘nested’ primer pairs).  The final multiplex pattern is shown in Figure 4.1.  
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Figure 4.1: Multiplexed primer pair 96 well template. Primer pairs were multiplexed according to their 
colour code on this template. Care was taken to ensure the primer pairs with the same colour code were 
>5Kb from other primer pairs in the same well. 
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Table 4.2: Genomic regions interrogated by multiplex prostate specific panel in localised prostate 
cancer. Analysis of the gene set by cBioPortal demonstrates the expected frequency of SNVs, based on the 
results of previous studies (Cerami et al.; Gao et al.). This table is formatted according to Table 3.1. 
4.4.2 Exploring the utility of ctDNA analysis in aggressive Prostate Cancer 
To explore whether ctDNA analysis be an informative biomarker in men with aggressive 
disease, in particular those who later go on to develop metastatic prostate cancer, I 
interrogated longitudinal samples collected at early and late disease stages. Following 
informed consent and ethical approval from the Royal Melbourne Hospital (Austrialia) 
Human Ethics committee, samples were collected from 19 patients with overt metastatic 
prostate cancer in collaboration with Mr. Mathew Hong and Dr. Chris Hovens. These 
samples from patients who went on to develop metastasis were compared to 19 patients 
with localised disease, which were collected at Addenbrooke’s Hospital, see Section 4.4.1. 
DNA was extracted from fresh frozen tissue and FFPE tissue using the QIAamp DNeasy 
Blood & Tissue Kit (69504) and QIAamp DNA FFPE Tissue kit (Qiagen 56404) according 
to the manufacturer’s protocols (with modifications as outlined in the Rosenfeld Group 
SOPs). DNA from 1ml of plasma and 200µl of whole-blood samples were extracted using 
QIAamp circulating nucleic acid and QIAmp mini blood kits (Qiagen), respectively. To 
interrogate entire exonic regions of TP53 alone, a specific amplicon panel was created 
from primers previously designed by Dr Tim Forshew. Details are listed in Appendix A-6. 
Samples from all 38 patients were analysed by performing tagged-amplicon deep 
sequencing (TAm-Seq). Sequencing libraries were prepared as previously described 
(Forshew et al., 2012). Libraries were quantified using KAPA qPCR library quantification 
kits, and sequenced on the Illumina MiSeq platform using 150bp paired-end sequencing 
protocol over two lanes. Sequencing reads were demultiplexed according to sample-
specific barcodes and aligned to the reference genome (hg19) using BWA (0.7.5a) (Li and 
ctDNA DETECTION IN LOCALISED PROSTATE CANCER - Methods 
 
131 of 233 
Durbin, 2009). Mutations were called and quantified as previously described (Forshew et 
al., 2012). 
4.4.3 Accounting for prostate heterogeneity in localised disease 
To assess the representation of intratumoural heterogeneity in ctDNA, I secured 
collaboration with the International Cancer Genome Consortium (ICGC) to identify men 
whose prostatectomy specimens had undergone multi-region whole-genome sequencing 
(Cooper et al., 2015). Only 2 of these men (case 7 and case 8) had pre-operative plasma 
blood draws. Plasma samples and multi-region whole-genome sequencing data to a 
median depth of 50x were acquired for these 2 men. DNA from the plasma samples were 
extracted using the Circulating Nucleic acid kit (QIAamp 55114) and quantified with dPCR 
as described in section 2.4.2. 
Through collaboration with the ICGC Working Group details of mutations from each region 
of the tumours (SNVs and re-arrangements) and remaining tumour DNA were obtained. 
Figure 4.2 details the spatial relationships and Gleason grading of the regions analysed by 
whole-genome sequencing by the ICGC group. 
 
Figure 4.2: Prostate samples sent for genome wide sequencing as part of ICGC prostate cancer 
project.  “ERG rearrangements determined by FISH. Case 7 had localised multifocal prostate cancer 
containing two separate foci (T1/T2/ T4/T5 and T3). Case 8 was also multifocal, with nodules T1/T2 and T3). 
Yellow, un-rearranged normal ERG gene; red, ERG gene split but both 3′ and 5′ ends retained; green, ERG 
gene rearranged but only its 3′ end retained (Del)” (Cooper et al., 2015)). The differing ERG rearrangement 
status of the clones, suggest that regions may have unique mutational landscapes. (Figure and caption 
modified from Cooper et al., 2015) 
Patient- and clone-specific primers were designed to target cfDNA. Targets were selected 
based on their high AF in tumour samples and differences between inferred clones, 
including exonic, intronic, intergenic, mitochondrial SNVs and re-arrangement breakpoints. 
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average read depth of 10,000. Substitutions were present in an esti-
mated ~48% and ~42% of cells in morphologically normal samples 
from case 6 and case 7, respectively (Supplementary Fig. 3b), dem-
onstrating clonal expansions of cells within morphologically normal 
prostate tissue, in agreement with studies using mitochondrially 
encoded enzyme cytochrome c oxidase as a marker8.
Aiming to understand the subclonal architecture and phylogeny of 
the tumors, we initially constructed phylogenetic trees on the basis 
of copy numbers (Supplementary Figs. 4 and 5 and Supplementary 
Data Set 1) and substitution data. We adapted our previously devel-
oped Bayesian Dirichlet process to identify clusters of substitutions in 
n dimensions9, where n was the number of samples from a given case, 
such that shared and distinct subclones could be identified between 
related samples (Fig. 2 and Supplementary Fig. 6). To further explore 
the fine details and confirm the main features of the phylogeny tree 
and clonal structure, we sequenced a selection of substitutions from 
each potential relationship between samples to an average read depth 
of 10,000 in independent DNA sequencing analyses, which verified 
279 mutations across all samples. This provided us with our final 
integrated phylogenetic trees (Fig. 2a–c) and final list of somatic point 
mutations (Supplementary Data Set 2). The structure of these trees 
was also supported by verified insertions, deletions and breakpoints 
(Supplementary Data Sets 3 and 4). The single cancer mass from case 6 
contained three independent cancer clones represented by samples 
6_T2, 6_T3 and 6_T4 (Fig. 2a), with a single verified substitution 
linking 6_T1/6_T2 and 6_T3. Case 7 contained at least three inde-
pendent cancer lineages: one (7_T3) representing the smaller can-
cer nodule, and two (7_T1/7_T2 and 7_T4/7_T5) present in the 
larger cancer mass (Fig. 2b). Ten mutations were common to the 
morphologically normal prostate sample and to cancer samples 7_T1 
and 7_T2, and three mutations joined 7_T4/7_T5 to the separate 
multifocal lesion 7_T3. These observations show that case 7 contained 
at least two clones of cells that existed before the formation of the 
distinct cancer lineages. Case 8 contained two cancer lineages repre-
sented by 8_T1/8_T2 and 8_T3 (Fig. 2c), with 43 substitutions shared 
between the three tumor samples 8_T1, 8_T2 and 8_T3, 8 of which 
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Figure 1 Prostate samples chosen for genome- 
wide sequencing. (a) ERG rearrangements  
determined by FISH. Case 7 was a multifocal  
cancer containing two separate foci (T1/T2/ 
T4/T5 and T3). Case 8 was also designated  
as a multifocal cancer (with nodules T1/T2  
and T3). Yellow, unrearranged normal ERG  
gene; red, ERG gene split but both 3? and  
5? ends retained; green, ERG gene rearranged  
but only its 3? end retained (Del). (b,c) Three- 
color FISH used to distinguish different ERG- 
locus translocation breakpoints in case 7.  
(b) Position of the three FISH probes:  
probe 1 (blue: 1, BAC RP11-164E1, and 1a,  
BACs RP11-95G19, RP11-720N21 and  
CTD-2511E13) was labeled in Aqua (Kreatech  
415 Platinum Bright), probe 2 (red; fosmid  
G248P80319F5, 37 kb) was labeled with  
Cy3 and probe 3 (green: 3, fosmid  
G248P86592E2, 38.5 kb; and  
4, BACs RP11-372O17, RP11-115E14 and  
RP11-729O4) was labeled with fluorescein  
isothiocyanate. Ex, exon; Chr, chromosome.  
The purple arrows represent the positions of  
ERG breakpoints detected in these experiments. 
For the precise positions of ERG breakpoints  
G and H, see Table 2. (c) Left, tumor areas  
with ERG locus breaks G and H are indicated in light and dark green, respectively. Break J was found in an adjacent prostate section not shown in  
this figure. Right, representations of the ERG FISH patterns. Original FISH images are show in Supplementary Figure 1. “Split” denotes that 5? and  
3? ERG signals were separated but retained in the cell.
Table 1 Mutations and clonal expansions in morphologically normal tissue
Sample Description Gene
Protein  
description Type Reads (%)
Total number  
of reads
MA predicted  
functional impact
ANNOVAR  
significant algorithms
0006#N Chr9:g.131115799G>A SLC27A4 p.V435I Missense 13.79 58 Low 1
0006#N Chr14:g.20389481C>T OR4K5 p.T239M Missense 13.25 83 High 4
0006#N Chr15:g.33873844G>T RYR3 p.A525S Missense 33.33 48 Medium
0006#N Chr4:g.88766379C>G MEPE p.S120* Nonsense 20.83 24 NA 2
0007#N Chr5:g.150885254A>T FAT2 p.S4308T Missense 23.4 47 Low 5
0007#N Chr7:g.150934857G>T CHPF2 p.R470L Missense 17.24 58 Medium 5
0007#N Chr8:g.24192995G>A ADAM28 p.D470N Missense 17.78 45 Neutral 2
0007#N Chr12:g.24989522G>T BCAT1 p.L276M Missense 26.47 34 Medium
Point mutations present in exons with an indication of functional significance. Missense and nonsense mutations detected and visually confirmed in adjacent morphologically  
normal tissue were tested for functional impact using MutationAssessor.org27 (MA) and wANNOVAR28 services. OR4K5 was excluded as a candidate because of the potential to  
overcall mutations in genes encoding very large proteins29. As none of the mutations had a high MA value, we considered that epigenetic changes might be a more likely driver of 
clonal expansion. NA, not applicable.
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Primers were validated in singleplex PCR reactions, adhering closely to TAm-Seq 
conditions. PCR products were screened for the expected product on 2% agarose e-Gels 
(Life technologies). 
DNA was extracted from 1ml of pre-prostatectomy plasma, using the QIAamp Circulating 
Nucleic Acid kit (Qiagen). TAm-Seq was applied to the remaining DNA (extracted from 
each region for case 7 and 8 by the ICGC working group) and plasma DNA with the 
patient specific primers, as described previously (section 2.4.5., (Forshew et al.)).  
 
  
4.5 Results 
4.5.1 Few mutations are detectable in localised prostate cancer using a standard 
gene panel 
For a proof of principle analysis, DNA was extracted from FFPE slides for 12 
prostatectomy specimens. All 12 men had locally advanced prostate cancer and had no 
evidence of recurrence, Figure 4.3 and Table 4.3. 
 
Figure 4.3: Flow diagram of patient material used to investigate ctDNA in localised prostate cancer. 
A. Samples used for proof of principle ctDNA analysis in localised prostate cancer. Samples from 12 
and 11 men with localised prostate cancer were used to investigate the feasibility of ctDNA detection using a 
generic and prostate specific primer panel. Through collaboration with Melbourne University Hospital, 
samples from 19 men with metastatic prostate cancer were screened for exonic TP53 SNVs and compared 
to a cohort of 19 men with localised disease. The reported prevalence of TP53 mutations was 7% (Forbes et 
al.) and therefore, >14 men were required for this analysis. Men with localised disease were selected due to 
quantity of remaining DNA following proof of principle analysis. B. Samples used to assess TP53 SNVs in 
tissue samples. C. Sample flow to investigate prostate heterogeneity in localised disease  
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Table 4.3: Clinical characteristics of samples used in the proof-of-principle cohort. *Clinical details for 
case KP1 were unavailable. 
Table 4.4 shows the concentration of DNA extracted from the FFPE slides. Fifty 
nanograms of extracted DNA used as input for the TAm-Seq protocol. MiSeq 150bp paired 
end sequencing resulted in 8.5 million reads of which 7 million aligned to the reference 
genome. In total 3 SNVs were found in 2/12 of men, all of which were exonic and non-
synonymous (see Table 4.5). These results demonstrate the technical feasibility of TAm-
Seq to detect SNVs in tissue DNA from men with locally advanced prostate cancer. The 
low detection rate is likely due to the intra-and inter-tumour heterogeneity of localised 
prostate cancer, and hence an extended primer panel would be required to increase the 
number of men in which mutations are detected. 
  
ID	 Diagnosis	PSA	
Treatment	
option	 Stage		 Gleason	
Last	PSA	
value	
KP1*	
	 	 	 	 	KP2	 6.3	 RRP	 pT2c	 7	 0.05	
KP3	 9.5	 RRP	+	LN	 pT3a	 7	 <0.1	
KP4	 6.3	 RRP	 pT2c	 6	 <0.1	
KP5	 8	 RRP	 pT2c	 7	 0.02	
KP6	 4.1	 RRP	 pT2c	 7	 0.01	
KP7	 10.3	 RRP	 pT3a	 7	 0.02	
KP8	 8.8	 RRP	 pT3a	 7	 0.02	
KP9	 8.7	 RRP	 pT3a	 7	 0.02	
KP10	 7	 RRP	 pT3a	 7	 0.02	
KP11	 6.8	 RRP	 pT2c	 7	 0.11	
KP12	 9.6	 RRP	 pT2c	 9	 0.02	
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Sample DNA concentration (ng/µl) 
KP1 11.6 
KP2 31 
KP3 20.2 
KP4 36.1 
KP5 23.3 
KP6 10.2 
KP7 141 
KP8 38.5 
KP9 91.9 
KP10 59.9 
KP11 40.9 
KP12 33.2 
Table 4.4: Qubit fluorometer DNA quantification of DNA extracted from FFPE embedded tissue for the 
pilot prostate TAm-Seq analysis. 
 
Sample ID AF Mutation (hg19) Effect 
KP6 0.0545 chr10:89720683_C>G PTEN, p.F278L 
KP6 0.031 chr7:55259530_G>A EGFR, p.G863D 
KP9 0.139 chr7:55259452_A>C EGFR, p.D837A 
Table 4.5: Single Nucleotide variants in two samples from patients with localised prostate cancer. 
 
4.5.2 Using multiple targets to improve detection in localised prostate cancer 
To improve the yield of mutations detected by TAm-Seq in localised prostate cancer, I 
developed an expanded prostate panel.  
4.5.2.1 Prostate Specific Panel validation 
Primer specificity was determined by PCR using control DNA extracted from the white 
blood cells of healthy male volunteers (MCDNA). PCR conditions were similar to that 
which would occur in TAm-Seq. PCR conditions were designed to match the cycling 
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conditions used in TAm-Seq. Primer specificity was assessed by checking that PCR 
products were of the expected length.  
 
Figure 4.4: Agarose eGel (Invitrogen) image following PCR amplification of 65 newly designed 
primers for the prostate cancer panel. The red arrows show amplicons that have failed QC and the green 
arrows highlight examples where DNA size bands are within the expected range for the PCR products. 
Figure 4.4 shows an image of an eGel following PCR amplification of 65 new prostate 
primer pairs including targets for FOXA1, SPOP, OR5L1, AR, AKT1, HRAS & IDH1. Some 
amplicons failed or produced non-specific products, and where possible were redesigned. 
Figure 4.5 shows 3 primer pairs that successfully amplified target loci following redesign. 
Of the 64 new primer pairs that were designed, 5 regions failed QC despite redesigning. 
These 5 loci represented infrequently mutated regions of SPOP and FOXA1 and were a 
small fraction of the SNVs detected in localised prostate cancers. Therefore, the remaining 
59 new primer pairs were used to generate a final 149 loci prostate cancer panel that was 
used for further analysis. The final primer panel is detailed in Appendix A-7.  
 
Figure 4.5: Agarose eGel (Invitrogen) image analysis following PCR amplification of duplicate results 
of 3 re-designed primer pairs with positive (lane 1-6) and negative (lane 10) controls.  
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4.5.3 Localised prostate tumour tissue contains few mutations detected by 
prostate specific TAm-Seq 
The prostate specific primer panel was used to perform TAm-Seq on FFPE tissue samples 
from 11 men with locally advance prostate cancer with no evidence of recurrence on latest 
PSA analysis, with median follow up of 54 months, see Table 4.6.  
Patient	ID	 Diagnosis	PSA	
treatment	
option	 Stage		 Gleason	
Last	PSA	
value	
Follow	up	
period	
(months)	
Matched	5	 2.86	 RRP	 pT2C	 6	 0.1	 67	
Matched	6	 11.6	 RRP	 pT3a	 7	 0.1	 51	
Matched	11	 5.3	 RRP	 pT2C	 6	 0.1	 61	
Matched	3	 4.6	 RRP	 pT3a	 7	 0.1	 40	
Matched	4	 6.9	 RRP	 pT2c	 6	 0.1	 63	
Matched	1	 9.6	 RRP	 T2c	 7	 0.1	 56	
Matched	2	 89	 RRP	 T3b	 9	 0.1	 4	
Matched	10	 11	 RRP	 T2a	 7	 0.1	 42	
Matched	9	 7.5	 RRP	 T3a	 7	 0.1	 41	
Matched	8	 8.3	 RRP	 T2c	 7	 0.1	 9	
Matched	7	 8.5	 RRP	 T3a	 6	 0.1	 59	
Table 4.6: Clinical details of 11 men with localised prostate cancer subjected to TAm-Seq analysis 
using the prostate specific primer panel. 
Five patients had areas of normal prostate tissue, marked by an academic uropathologist 
(Dr. Anne Warren), on the same slide as the tumour. These “benign” areas were macro 
dissected and DNA extracted for use as matched normal controls, see Table 4.7. DNA 
extraction from FFPE prostatectomy samples yielded a median eluate concentration of 
31.4 ng/µL (ranging 6.8 ng/µL - 247 ng/µL) as measured using DNA specific fluorescent 
dye (Qubit, Thermofisher), see Table 4.7. 
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Sample 
name 
Concentration 
ng/µL 
Matched_1 29.8 
Matched_2 28.9 
Matched_3 81 
Matched_4 65.3 
Matched_4N 26.3 
Matched_5 32.9 
Matched_5N 4.91 
Matched_6 247 
Matched_6N 24.4 
Matched_7 25.8 
Matched_8 6.83 
Matched_9 61 
Matched_9N 18.6 
Matched_10 14.3 
Matched_10N 49.2 
Matched_11 21.3 
Table 4.7: Qubit fluorometer DNA quantification of DNA extracted from prostate FFPE embedded 
tissue of 11 men and matched normal tissue (where applicable).  
Pooled TAm-Seq libraries were re-sequenced on an Illumina HiSeq 2000 using 125bp 
paired end chemistry and resulted in 74.6 million aligned reads. Despite this the median 
coverage was only 333x and 35.5% (53/149) of primers had a median coverage of 100x or 
less. These poor coverage primers targeted regions in AR, FOXA1, SPOP, PTEN and 
TP53, see Figure 4.6. Subsequently, only 1 SNV was detected in patient 11 from an 
intergenic region of AR (Table 4.8). 
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Figure 4.6: Median amplicon coverage for TAm-Seq using the prostate primer panel. Bars represent 
the median coverage (y axis) for each amplicon in the panel (x-axis). The dotted line represents the overall 
median coverage (333x). 
 
Patient ID AF Mutation (hg19) Effect 
Matched 7	 0.1644	 Chr23:66765798_C>T	 AR	intergenic	
Table 4.8: Single Nucleotide variant detected in one patient with Tam-Seq using the extended 
prostate panel. 
The AR intergenic SNV was not previously catalogued by the COSMIC database (Forbes 
et al.). Due to the intergenic nature is of uncertain tumourigenic effect. The low detection 
rate of SNVs in this experiment is likely to be multi-factorial. Firstly regions with low 
coverage will have reduced detection rates for SNVs at low AF in those regions. Secondly, 
the broad mutational spectrum of prostate cancer, with a long tail of infrequently mutated 
genes (Barbieri et al.), and a low mutation rate of 0.9/Mb (Berger et al., 2011) may result in 
poor detection rate despite attempting to cover almost 22Kb of the genome. Furthermore, 
the utility of a clinical ctDNA test would be further obfuscated by prostate tumour 
heterogeneity and I subsequently explored this hypothesis. However, capture based 
sequencing will allow the interrogation of increased genomic regions and urinary or semen 
cfDNA may concentrate prostate specific cfDNA. As the cost of sequencing continues to 
drop (Hayden, 2014) high coverage capture sequencing of cfDNA from plasma, urine 
and/or semen may improve the utility of cfDNA analysis in localised prostate cancer. 
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4.5.4 Clones that dominate in metastatic castrate resistant prostate cancer are 
present at a localised stage 
To evaluate whether ctDNA could be an informative biomarker of aggressive cancer, on 
samples were collected from 19 patients with metastatic disease and 19 with localised 
disease. The collection comprised of 91 samples, including 48 metastatic tissue, /blood/ 
and plasma samples taken at or after the time of clinical relapse and 43 primary tissue, 
/blood and /plasma samples taken at or before the time of prostatectomy. 
Local samples were chosen from the pilot cohorts described above and were included 
base on the quantity of DNA remaining. Samples from metastatic patients yielded a mean 
of 26.0 ng/µL, 98.0 ng/µL, 3647.3 ng/µL and 6.4 ng/µL, for FFPE tissue, fresh frozen 
tissue, whole-blood and plasma, see Table 4.9. 
 
Sample ID on 
tube 
Sample 
Type 
DNA 
ng/µl 
Patient 002 
002_blood whole-blood 18.8 
002_plasma plasma 6.35 
002_tissue01 tissue 66 
002_tissue02 tissue 59.6 
002_tissue03 FFPE tissue 0.652 
002_tissue04 FFPE tissue 1.01 
Patient 014 
014_blood01 whole-blood 30.8 
014_plasma plasma 10.37 
014_tissue01 tissue 48.7 
014_tissue02 FFPE tissue 63.6 
014_tissue03 FFPE tissue 49 
014_tissue04 tissue 49 
Patient 067 
067_blood01 whole-blood 4922.5 
067_blood02 whole-blood 20 
067_tissue01 tissue 37.6 
067_tissue02 tissue 70 
Patient 068 
068_blood whole-blood 4922.5 
068_Tissue02 tissue 62.4 
068_Tissue03 tissue 91 
068_Tissue04 tissue 29 
068_Tissue05 tissue 32.8 
Patient 094 
094_blood whole-blood 4922.5 
094_tissue tissue 97.8 
Patient 130 
130_blood whole-blood 4922.5 
130_tissue tissue 106 
Patient 152 
152_blood whole-blood 4922.5 
152_tissue tissue 97 
Patient 177 
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177_blood whole-blood 4922.5 
177_blood02 whole-blood 30.8 
177_tissue01 tissue 78.6 
177_tissue02 tissue 1.94 
177_tissue03 tissue 49 
177_tissue04 tissue 41 
177_tissue05 tissue 27.8 
Patient 188 
188_plasma plasma 4.65 
188_tissue tissue 86.4 
Patient 197 
197_blood whole-blood 4922.5 
197_tissue tissue 65 
Patient 252 
252_blood01 whole-blood 4922.5 
252_blood02 whole-blood 4922.5 
252_Tissue tissue 96.6 
Patient 298 
298_tissue01 tissue 65.8 
Patient 299 
299_blood01 whole-blood 4922.5 
299_plasma plasma 7.4 
299_tissue01 tissue 91.8 
299_tissue04 FFPE tissue 15.8 
299blood_02 whole-blood 84.8 
299tissue_02 tissue 66.2 
299tissue_03 tissue 95.4 
Patient 486 
486_blood whole-blood 4922.5 
486_plasma plasma 6.35 
486_tissue01 tissue 604 
486_tissue02 tissue 102 
Patient 498 
498_blood01 whole-blood 4922.5 
498_blood02 whole-blood 19.9 
498_plasma plasma 3.17 
498_tissue02 tissue 66.6 
498_tissue03 tissue 54 
498_tissue04 tissue 1.59 
Patient 513 
513_blood whole-blood 4922.5 
513_tissue01 tissue 302 
513_tissue02 tissue 66 
Patient 650 
650_blood whole-blood 4922.5 
650_tissue01 tissue 236 
650_tissue02 tissue 49 
Patient 752 
752_blood whole-blood 4922.5 
752_tissue tissue 3.54 
Patient 854 
854_blood whole-blood 4922.5 
854_tissue tissue 130 
Patient 932 
932_plasma whole-blood 4922.5 
932_tissue01 tissue 400 
932_tissue02 tissue 96.2 
Table 4.9: DNA yield of samples obtained from men with metastatic prostate cancer. Tissue = fresh 
frozen tissue. 
TAm-Seq was initially performed on DNA extracted from each sample and was sequenced 
to an average depth of 7,848x permitting detection of low-frequency TP53 mutations. The 
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results (summarised in Figure 4.7, Figure 4.8 and Appendix A-8) show that 10 out of 19 
metastatic patients had detectable TP53 mutations, compared with one out of the 19 
patients with localisedlocalized disease. High depth targeted sequencing showed that 
TP53 mutations were detectable in primary tumours from men who went on to develop 
metastatic disease, in six of the 10 metastatic patients with mutant TP53 for which a 
matching primary sample was available (Figure 4.7b). Furthermore, in most of these 
cases, we were able to detect these mutations in the blood or plasma.  
 
Figure 4.7: TP53 mutations identified via TAm-Seq. (a) Pie charts representing the number of patients 
with detected TP53 mutations across the metastatic and localised cohorts. (b) A schematic indicating the 
presence of TP53 mutations and their allele frequency for all patients in the metastatic cohort that had 
matched primary and metastatic samples.  
Patient 299
PB
Patient 498
P
P = Primary tissue
B = Benign tissue
M = Metastatic tissue
= Plasma
= Whole-blood
P
B
M
M MM
= High mutant allele fraction (>30%)
= Low mutant allele fraction (<5%)
= Not Detected
p.P152L
p.T125M
p.R174W
p.F134L
p.C135Y
Collected at Prostatectomy Collected at time of metastasis
* Collected after Radiotherapy
b
FFPE Fresh
Sacrum Surg. bed Sacrum* 
a
Localised Cohort
Metastatic Cohort
WT 
TP53
n=9
Mut
TP53
n=10
Shoulder
Patient 001
Patient 002
Patient 513
Patient 486
Pelvis Penis
p.R273C
p.N239T
BrainBrain
p.V272L
p.P359S
Mut
TP53
n=1
WT 
TP53
n=18
Fresh Fresh Fresh Fresh
Ischium
Lymph node
ctDNA DETECTION IN LOCALISED PROSTATE CANCER - Results 
 
143 of 233 
 
Figure 4.8: TP53 mutations identified via TAm-seq.  (a) A schematic indicating the location of each of the 
identified TP53 mutations within the protein. Mis-sense mutations are shown in green and frame-shift in red. 
b) The detection results for the application of targeted amplicon sequencing of TP53 across 72 samples. 
Only patients with a TP53 mutation are listed (n=10), the remaining nine patients who were negative for 
TP53 mutations are not shown.  
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This enrichment of TP53 mutations in the metastasis samples, which appear at low 
frequency in primary samples, strongly suggests that the acquisition of TP53 mutations in 
the prostate cancer setting enhances the metastatic potential of tumour subclones. Further 
supporting this observation is the additional TP53 mutations found in patients 299 and 
498. In both patients, a TP53 mutation was detected at high frequency in the metastases, 
and this mutation was detected at low frequency in the primary. However, a second TP53 
mutation was detected at low frequency in the primary tumour, which was not found at 
high frequency in the metastasis. If these low frequency, secondary TP53 mutations in the 
primary tumour confer metastatic potential, then the clones containing this mutation should 
be more likely to be detected in the blood/plasma of these patients, as was observed.  The 
functional consequences of these secondary TP53 mutations, as well as the cellular 
contexts in which they occurred, should also be taken into account when assessing the 
likely metastatic potential of these clones. To achieve this, future studies using single-cell 
sequencing and phenotypic validation will be required.  
4.5.5 TP53 SNVs in tissue samples are unlikely to accurately predict biochemical 
recurrence 
The relatively high incidence of TP53 mutations in metastatic samples has previously been 
described (Robinson et al., 2015; Grasso et al., 2012; Barbieri et al., 2012). The data 
described above (Section 4.5.4) suggests that these potentially malignant clones can be 
detected directly from primary tumour tissue taken at the time of prostatectomy. To explore 
the potential utility of sequencing TP53 in tumour tissue to predict aggressive disease, I 
investigated the prevalence of TP53 mutations in a cohort of 16 men with Gleason 7 
localised prostate cancer. Eight men developed biochemical recurrence within 5 years 
whilst 8 did not. Clinical characteristics are provided in Table 4.10.  
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Table 4.10: Clinical characteristics of men with localised prostate cancer used to determine the 
prognostic utility of TP53 mutation analysis. Sixteen men were identified retrospectively from the 
PROmpT study, with 8 men remaining recurrence free for 4 years post surgery (range: 0-7 years). The other 
8 men developed biochemical recurrence within 4 years (range: 0-8 years), 2 of these men remain in 
biochemical remission following adjuvant therapy at the census date. RALP – Robotic Assisted Laparoscopic 
Surgery. 
FFPE cores were generated from the dominant tumour foci and from adjacent benign 
regions of prostatectomy specimens and DNA was extracted with DNA-FFPE-Tissue 
(QIAmp, 56404), with paraffin removal performed by the heptane methods as described in 
the manufacturers instructions in 50µL of eluate. A mean concentration of 92.3 ng/µL of 
DNA was extracted from the samples (Table 4.11). 
  
Pt ID Age at diagnosis
PSA at 
diagnosis
Gleason 
Grade Treatment 
Treatment 
date
Pathological 
Grade LN Last PSA
Last PSA 
date
Biochemical 
recurrence
RELP_1 69 5.4 3+4=7 RALP 25/11/10 pT2c 0/5 <0.02 01/12/15 N
RELP_2 58 4.2 4+3=7 RALP 01/05/13 pT2c 0 <0.02 04/08/16 N
RELP_3 71 12.2 4+3=7 RALP 01/12/11 pT2a x <0.05 19/08/16 N
RELP_4 60 13.72 3+4=7 RALP 13/06/12 pT2c 0/1 <0.1	 01/11/16 N
RELP_5 61 0 3+4=7 RALP 01/09/12 pT2c 0/10 <0.02 13/12/16 N
RELP_6 65 3.53 3+4=7 RALP 29/11/12 pT2c x <0.1	 24/10/16 N
RELP_7 55 1.8 3+4=7 RALP 10/04/13 pT2a x <0.02 10/02/14 N
RELP_8 66 14.58 3+3=7 RALP 23/07/13 pT2c <0.02 07/06/16 N
RELP_9 58 4.3 3+4=7 RALP 21/04/08 pT2a 0 0.18 26/09/16 Y
RELP_10 60 5.8 3+4=7 RALP 12/11/08 pT3a x <0.1 31/01/11 Y
RELP_11 63 7.7 4+3=7 RALP 07/01/09 T1c N0 2.2 25/10/16 Y
RELP_12 52 8.4 3+4=7 RALP 07/05/09 pT2c N0 0.31 28/10/14 Y
RELP_13 66 11.7 3+4=7 RALP 26/04/10 pT3a pN1 0.43 15/10/10 Y
RELP_14 58 4.85 3+4=7 RALP 09/09/10 pT2c pN0 0.98 11/11/15 Y
RELP_15 65 6.2 4+3=7 RALP 11/02/12 pT3a pN0 0.26 13/12/16 Y
RELP_16 66 5.07 3+4=7 RALP 10/10/12 pT2c pN0 <0.02 05/09/16 Y
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Sample ID Tissue Type 
DNA 
concentration 
(ng/µL) 
1_B BENIGN 60 
2_B BENIGN 142 
3_B BENIGN 128 
4_B BENIGN 135 
5_B BENIGN 95.4 
6_B BENIGN 51 
7_B BENIGN 73.4 
8_B BENIGN 114 
9_B BENIGN 91.6 
10_B BENIGN 130 
11_B BENIGN 26 
12_B BENIGN 70.8 
13_B BENIGN 226 
14_B BENIGN 62 
15_B BENIGN 161 
16_B BENIGN 88.8 
1_T TUMOUR 49.6 
2_T TUMOUR 90.6 
3_T TUMOUR 101 
4_T TUMOUR 122 
5_T TUMOUR 148 
6_T TUMOUR 8.96 
7_T TUMOUR 64.4 
8_T TUMOUR 123 
9_T TUMOUR 109 
10_T TUMOUR 28.8 
11_T TUMOUR 57.8 
12_T TUMOUR 73.4 
13_T TUMOUR 146 
14_T TUMOUR 26 
15_T TUMOUR 79.4 
16_T TUMOUR 71.2 
Table 4.11: DNA yield from FFPE prostatectomy slides in 16 men treated for Gleason 7 localised 
prostate cancer. 
Fifty nanograms of DNA samples were used as input for the TAm-Seq workflow using the 
TP53 primer panel, as described in section 4.4.2 and detailed in Appendix A-6. Libraries 
were pooled and quantified before sequencing on a MiSeq (Illumina) with 150bp paired-
end chemistry. Figure 4.9 shows the median coverage for all amplicons with a median 
depth of over 10,000x from the 27 million reads. 
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Figure 4.9: Median coverage for amplicons in the TP53 panel, showing each amplicon (x axis) vs. the 
median depth of sequencing coverage (y axis) for all samples. Dotted line represents overall median 
coverage. 
SNVs in TP53 were detected in 3 patients, 2/8 patients with TP53 SNVs did not have 
biochemical recurrence whilst only 1/8 men with TP53 SNVs did go on to develop 
biochemical recurrence, see Table 4.12. Although the cohort of patients in this exploratory 
study was small, it seems that TP53 analysis of individual prostatectomy specimens would 
not prove clinically useful due to the low sensitivity and specificity to predict biochemical 
recurrence. This may be due to the relatively short follow-up for this cohort and that the 
cohort was followed up for biochemical recurrence, which may not correlate to prostate 
cancer specific mortality (Freedland et al., 2005; Pound et al., 1999). However, only the 
dominant clone of the prostatectomy sample was analysed for TP53 status in this study 
and, as prostate cancer is a heterogeneous cancer, the results of TP53 analysis are 
affected if the clinically significant clone is not included in the analysed sample. Therefore, 
the use of biopsy material for TP53 analysis would be problematic due to the well-
documented concerns that standard needle biopsy sampling may miss a significant clone 
in prostate cancer (Eichler et al.; Patel and Tsui). For these reasons, the development of a 
tissue based approach for TP53 analysis was not investigated further. However, ctDNA 
has been shown to represent multiple clones in metastatic cancer (Murtaza et al., 2013). 
Therefore, TP53 analysis of ctDNA could overcome the problems of prostate 
heterogeneity and is worthy of further investigation in a well-annotated cohort.  
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Patient	Id	 Mutation	(hg19)	 Effect	 AF	
13	 Chr17:7573983_C>T	 TP53	p.L309L	 0.2	
7	 Chr17:7578419_C>A	 TP53	p.E132X	 0.001	
2	 Chr17:7579472_G>A	 TP53	p.P33L	 0.001	
Table 4.12: TP53 SNVs detected in prostatectomy samples in men with Gleason 7 prostate cancer. 
 
4.5.6 Investigating prostate heterogeneity in localised disease 
To investigate the ability of ctDNA to overcome prostate heterogeneity in patients with 
localised prostate cancer, patient and clone specific primers were designed and evaluated. 
Figure 4.10 depicts a 2% agarose e-Gels (Life technologies) of amplicon products 
following singleplex PCR with primer pairs designed to target clones identified from case 7. 
The majority of primer pairs produced a single PCR product in the expected size range. 
However, over both panels, 6 primer pairs did not produce a single band. As e-Gel 
analysis of PCR product may have a reduced sensitivity over re-sequencing and since the 
number of failed primers was low, the entire primer panel was used for further analysis. 
 
Figure 4.10: Image of e-Gel PCR product analysis for primers designed to target case 7 clones. Most 
primer pairs produced a single PCR product of the expected size (green arrow). Primer pairs targeting 
breakpoints did not produce any product due to the normal DNA template used in the reaction (yellow 
arrow). Six primers that were expected to produce a specific product did not (e.g. red arrow), although 2/6, 
had double product bands (both for case 8, data not shown). 
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A total of 77 and 41 primers were included for the analyses of case 7 and 8 respectively. 
Final primer panels are detailed in appendices A-9 and A-10. The 77 primers for Case 7 
were multiplexed in to 48 wells, such that each well contained 1-3 primer pairs, see Figure 
4.11. Whole Genome Amplification (WGA) (REPLI-G, Qiagen) was applied to 10ng DNA 
extracted from clonal regions and amplified DNA quantities listed in Table 4.13. TAm-Seq 
was performed using case 7 and 8 primer panels with WGA DNA template. PCR products 
were harvested, barcoded, pooled and quantified as previously described (Forshew et al., 
2012). Libraries for case 7 and case 8 were pooled and submitted for 125bp paired-end 
sequencing on an Illumina MiSeq.  
CRUK ID 
Input 
DNA 
(ng) 
Output 
DNA in 
ng/50µL 
Case  7_ N 10 107 
Case  7_ T1 10 103 
Case  7_ T2 10 29.3 
Case  7_ T4 10 65.5 
Case  7_ T3 10 105 
Case  7_ T5 10 122 
Case  8_ T3 10 259 
Case  8_ T1 10 72 
Case  8_ T2 10 26.8 
Case  8_ N 10 44.1 
MCDNA 10 54 
NTC 0 5.1 
Table 4.13: Table of DNA amounts from multiregional patients with prostate cancer  before and after 
whole genome amplification (REPLI-G, Qiagen). N - adjacent normal tissue, T - clonal regions (as 
depicted in Figure 4.2). MCDNA – Male genomic DNA (Promega, PR-G1471), NTC – No Template Control. 
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Figure 4.11: Multiplex planning for Case 7 primer pairs. Primer pairs were multiplexed into 48 wells 
according to their colour code. The multiplexing plan was designed by a bioinformatic pipeline developed by 
Dr. James Morris (Senior Bioinformatics Analyst, Rosenfeld group), which accounted for the amplicon GC 
content, annealing temperature, and proximity of primers as detailed in section 4.4.1.2. 
Sequencing resulted in 3.48 and 3.81 million reads aligning to the human genome from 
case 7 and case 8 barcoded samples. The median read depth was 790 and 1700 for case 
7 and 8 respectively, analysis of reads aligning to each amplicon revealed that some 
amplicons had no coverage. Indeed, no primer pairs targeting re-arrangement breakpoints 
produced a PCR product that aligned to the expected region, neither did a further 2 and 3 
primer pairs from case 7 and 8 respectively, see Figure 4.12. Seventy and 37 primer pairs 
successfully targeted regions of interest for case 7 and 8 respectively. There was no 
association between primer pair position and failure rate. 
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Figure 4.12: Median coverage (y axis) per amplicon (x axis) for Case 7 (a) and Case 8 (b).  
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None of the structural variant primers produced the expected product and to investigate 
whether this was caused by allelic drop out during whole genome amplification I performed 
singleplex PCR with fusion primers with unamplified DNA from the relevant tumour foci. 
Fusion PCR products were run on a DNA1000 bioanalyser chip (Agilent). Three primer 
pairs produced a specific product in the expected range, whilst one primer pair had a 
product in the expected range of primer dimer and the remaining primer pair generated 
non-specific products. The bam files from the WGA DNA experiment were interrogated for 
sequences covering the breakpoints using samtools (Li et al., 2009) however, no fusion 
sequences were detected. The lack of fusion PCR product may be due to the combination 
of a single multiplexed PCR reaction followed by multiple singleplex PCR reactions during 
TAm-Seq. It is possible that primer pairs targeting DNA re-arrangements have far fewer 
template DNA molecules during the initial multiplexed PCR than the other primer pairs, 
which amplify wild type and ctDNA alike. Subsequently, little re-arranged DNA would be 
amplified resulting in reduced chance of pairing with re-arrangement primer pairs in the 
microfluidic singleplex PCR chamber. Fusion amplicons may work in direct singleplex PCR 
reactions, but due to the need for a separate reaction, template DNA was spared for 
multiplex TAm-Seq and so re-arrangement primer pairs were not included for further 
analysis. 
4.5.6.1 Heterogeneity in localised prostate cancer is not well represented in 
plasma ctDNA using standard TAm-Seq  
Levels of ctDNA in localised prostate cancer were assessed using the patient specific 
primers detailed in section 4.4.3. These primers targeted mutations that were 
heterogeneously represented in the spatially separated tumour foci (Figure 4.1). TAm-Seq 
of both plasma and tumour tissue samples from case 7 and 8 were performed and libraries 
were pooled, cleaned and quantified, before being submitted with libraries from other 
projects and sequencing with 125bp paired end chemistry using a HiSeq 2500 (Illumina). 
Overall, 24.2 million reads aligned to the human genome for case 7 and case 8 samples 
combined. The median amplicon coverage was 5,700 and 11,000 for case 7 and 8 
respectively with many primers failing to amplify the expected target loci, see Figure 4.13. 
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Figure 4.13: Median coverage (y axis) per amplicon (x axis) with overall median coverage in dotted 
black for primer pairs targeting case 7 (a) and case 8(b), indicating that sequencing coverage was not 
even across the amplicons. 
Despite poor coverage in 30/70 and in 22/45 primer pairs for cases 7 and 8 respectively, 
available data was analysed for tumour AF concordance between TAm-Seq analysis, and 
WGS AF (supplied by the ICGC). Figure 4.14 demonstrates a good correlation between 
the two methods for the mutations tested (r2 = 0.8-9.4). There were however, occasions 
when mutations were detected by one library preparation method only. Importantly, 
comparison of library preparation method with these results will be confounded by the 
failure of many primer pairs. When considering only primer pairs yielding sufficient depth, 
Figure 4.15a illustrates that 19 SNVs were detected by WGS that were not detected in 
TAm-Seq, and 9 SNVs were detected in TAm-Seq that were not present in WGS (for a 
specific sample), across all clones from case 7. These results suggest that while there is 
an overall good agreement between TAm-Seq and WGS library preparation methods, 
each method may have specific advantaged to detect individual mutations. 
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Figure 4.14: Concordance of AFs between TAm-Seq and WGS determined AFs for Case 7 (a) and 
Case 8 (b). Mutations identified in separate tumour foci are colour coded and linear modelling, using 
Wilkinson-Rogers model in R (R Core Team 2015), has been applied to assess correlation (dotted black 
line). Adjusted r2 values demonstrate good agreement between the data types by the linear model for case 7 
and 8 (0.8029 and 0.9369). 
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Figure 4.15: Heatmap depicting AFs for each genomic location (y axis) in libraries prepared from 
spatially separate tumour foci and from plasma (x axis) in case 7 (a) and case 8(b) 
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Table 4.14 shows the concentration of DNA extracted from the pre-prostatectomy plasma 
samples of case 7 and 8. Analysis of plasma AFs in detection mode (Forshew et al., 2012) 
suggested ctDNA presence at low AFs but this was obfuscated by background noise (also 
present in some healthy control plasma samples, see Figure 4.15a). The inability to 
confidently detect ctDNA may be due to several reasons including; the loss of 
approximately half of all intended primer pairs or that levels of ctDNA are very low or 
absent in men with curable localised prostate cancer (both men were cured following 
surgery with no evidence of recurrence with >5 years of follow up).  
 
Table 4.14: Amplifiable GE copies in cfDNA extracted from plasma of men with heterogenous 
localised prostate cancer. PPC – Healthy Plasma Control, NEC_Plasma – No Extraction Control. 
4.5.7 Development of a Multiplexed Replicate Dilution Sequencing approach (MRD-
Seq) 
To further investigate the levels of ctDNA in localised prostate cancer a sensitive ctDNA 
detection process was developed to detect known mutations at low levels in cfDNA of 
bodily fluids. Despite improvements in the analytical sensitivity of methods, with the ability 
to detect mAFs as low as 0.01% reported (Vogelstein and Kinzler, 1999; Milbury et al., 
2014; Kinde et al., 2011), the amount of available material remains a limiting factor for 
analysis of low levels of ctDNA. Methods that aim to detect a single mutation will have 
poor sensitivity to detect ctDNA at levels lower than one molecule per sample on average, 
even if they have excellent analytical accuracy (Bettegowda et al.).  
One way to increase the number of mutant molecules sampled is to increase the amount 
of material collected, for example using large volumes of plasma by plasmaphoeresis 
(Marleau et al., 2012). However these methods are under developed and would be 
challenging to implement in clinical practice. An alternative approach would be to increase 
the number of sampled mutant molecules, by analysis of multiple mutations in parallel 
(Newman et al., 2014; Newman et al., 2016). Methods that have been optimised for 
exquisite sensitivity (e.g. dPCR) have a limited capacity for multiplexing and generally 
Sample	ID
Extraction	
Sample	
Volume	(ml)
elution	
Volume	(ul)
Enrichment	
Ratio
CNA	dPCR	
Loading	
Volume	(ul)
Est.	ROX	
Targets
Est.	FAM	
Targets
Yield	Est.
Amplifiable	
Copies/ml
Avearge	
Amplifiable	
copies	/ml
	Amplifiable	
copies	/	ul	of	
eluate
Case	7 1 50 1 1.5 34 183 74.5% 2340.6 2306 117
Case	7 1 50 1 1.5 33 212 86.4% 2271.7
Case	8 1 50 1 1.5 60 203 82.7% 4130.4 4130 209
Case	8 1 50 1 1.5 60 186 75.8% 4130.4
PPC 1 50 1 1.5 46 137 55.8% 3166.7 3408 173
PPC 1 50 1 1.5 53 161 65.6% 3648.6
NEC_Plasma 0.44 50 1.5 0 251 102.2% 0 0 0
NEC_Plasma 0.44 50 1.5 0 240 97.8% 0
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require samples to be distributed into a series of parallel reactions to achieve analysis of 
multiple targets (where rare molecules may not end up in the correct reaction) (Milbury et 
al., 2014; QIagen, 2016). On the other hand, methods that enable parallel analysis of 
multiple regions such as using next-generation sequencing have a limited sensitivity for 
each individual mutation, as illustrated by Forshew et al. (Forshew et al.). To overcome 
these limitations, we developed a method for genomics analysis of multiple regions whilst 
retaining sensitivity for detection of individual mutant molecules, using multiplex replicate 
dilution sequencing, or MRD-Seq.  
MRD-Seq distributes a DNA sample into multiple replicate reactions, where each reaction 
contains a small number of initial template molecules. This number of template molecules 
per reaction (Nw), is determined based on the performance metrics of the sequencing 
process. The detection of a single mutant molecule in Nw wild-type molecules will generate 
a sequencing signal that is clearly discernible above the background AF for non-reference 
reads in that sequencing process. For example, if the sequencing process has a 
background AF of 0.5%, Nw can be chosen to be 40 molecules. Therefore, one mutant 
molecule in a pool of 40 molecules would create a sequencing signal with a mAF of 
~2.5%, significantly higher than the background. Furthermore, each reaction can be 
multiplexed using primers that target mutations in multiple regions of the genome. The 
dilution process creates a “noise buffer” to limits false positive signals even if a large 
number of targets, Nt, is analysed and even if the multiplexed PCR amplification creates a 
high level of background sequencing noise. Each diluted replicate reaction can be 
separately barcoded, and a large number of replicates (Nr) sequenced. By sequencing a 
large number of multiple replicate dilution reactions, each including Nw molecules, all 
available template molecules can be analysed (Nm=NrxNw). The process can analyse a 
large number of targets in each reaction, so that the total number of molecules sampled for 
the presence of mutations by the process, Ns=NrxNwxNt, is much larger than the amount of 
template molecules for each mutation Nm, whilst reducing false positives. This approach 
would theoretically allow for sensitive detection of low levels of mutant DNA. With Nw=40, 
Nr=100, Nt=50, MRD-Seq could allow sensitivity down to a few mutant copies per 200,000 
template molecules, even if the initial input included only 4,000 copies of the genome.  
4.5.7.1 MRD-Seq optimisation with high fidelity enzymes 
To improve background noise cause by polymerase errors during PCR reactions, Kapa HiFi HotStart 
(Kapa BIosystems KR0369), Accuzyme (Bioline BIO-21051), Phusion Hot Start II High-Fidelity 
(Thermofisher F549L) and Q5 Hot start (NEB M0493S) DNA polymerase enzymes were selected for 
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further testing based on error rates, hot-start and exonuclease activity from commercially available 
high fidelity enzymes, see  
Table 4.15. 
Enzyme 
Kapa 
HiFi 
Q5 Hot 
start 
Phusion 
Hot 
Start II 
Accu-
zyme 
Qiagen 
Hot 
Start 
Pfu 
Plati
num 
Roche KOD 
Reported 
error rate vs 
Taq  
100 >100 50 47 10 8 6 4 4 
Hot start Y Y Y Y Y Y Y Y Y 
Exonuclease Y Y Y Y Y N N N N 
 
Table 4.15: Comparison of high fidelity enzyme error rates, hot start and exonuclease activity. 
Enzyme information was obtained from publications (McInerney et al., 2014) and product technical 
datasheets literature. 
Enzymes were subjected to the MRD-Seq workflow using healthy plasma template cfDNA 
(Sera labs) and the patient specific primer panels described above for case 7 and case 8 
(Section 4.5.6.1). Each enzyme underwent PCR cycling using manufacturers 
recommended PCR reagents without additional DMSO or Magnesium Chloride. PCR 
cycling temperatures were agreed with respective technical support departments and 
using cycling timings matching TAm-Seq, including a long annealing time see Table 4.16. 
PCR products were analysed using DNA1000 chips on a Bioanalyser (Agilent).  
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Enzyme Temperature (ºC) Time 
No. of 
cycles 
Kapa Hi-fi 
95 5 mins 1 
98 20 secs 
20 60-72 4 mins 
Q5 
98 30 secs 1 
98 
4 mins 20 58-72 
Phusion 
98 30 secs 1 
98 10 secs 
20 60-72 4 mins 
Accuzyme 
97 3 mins 1 
97 15 secs 
20 55-68 4 mins 
 
Table 4.16: PCR cycling conditions used for assessing high-fidelity enzymes. 
 
Expected amplicon sizes were calculated based on the target sequence start and end 
locations with the addition of the primer pair tags that allow subsequent sample barcoding, 
see Figure 4.16.  
 
 
Figure 4.16: Density plot of expected amplicon sizes with additional amplicon tags for the case 7 
primer panel. 
Bioanalyzer traces of PCR products were produced to compare against the expected 
amplicon size range, see Figure 4.17. No trace followed the ideal size distribution, i.e. with 
a dominant peak at ~135 bases. Of note, following standard TAm-Seq pre-amplification, 
with samples taken from the experiments described in section 4.4.3, and using the Roche 
Polymerase, the Bioanalyzer trace had little or no product at the expected range (Figure 
4.17). One possibility for the absence of products in the expected size range is that the 
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PCR reaction has failed, but this is unlikely as the Roche enzyme pre-amplification 
material yielded on-target sequencing data after the subsequent access array and 
barcoding steps. More likely is that during the multiplexed PCR reaction, an abundance of 
primer dimers are created along with some specific products. Indeed, the length of 2 
primers with tags would be ~90bp (as observed in most traces in Figure 4.16). During the 
subsequent singleplex PCR reaction, the intended product is amplified more efficiently, 
yielding predominantly the specific product and little primer dimer. Therefore, I proceeded 
to select optimum pre-amplification temperatures for each high fidelity enzyme based on 
the representation of peaks at ~150bp and reduced peak at the expected primer dimer 
peak (as indicated in Figure 4.16). A final list of temperatures and enzyme combinations 
input into the access array are listed in Table 4.17. 
 
 
Accuzyme_68.0°C Accuzyme_67.0°C Accuzyme_65.4°C
Accuzyme_62.9°C Accuzyme_59.9°C Accuzyme_57.5°C
Accuzyme_55.9°C Accuzyme_55.0°C Roche NTC
Roche NTC Roche PPC Roche PPC
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Figure 4.17: DNA1000 Bioanalyser traces showing size distribution of PCR products created with 
high-fidelity enzymes using case 7 primer panel and template DNA extracted from healthy plasma. 
Temperatures used for PCR cycling are recorded adjacent to the enzyme name. Expected size range is 
indicated in a trace (green arrow). 
Kappa_72.0°C Kappa_71.1°C Kappa_69.6°C
Kappa_67.2°C Kappa_64.5°C Kappa_62.4°C
Kappa_60.9°C Kappa_60.0°C Q5_72.0°C
Q5_71.0°C Q5_69.2°C Q5_66.4°C
Q5_63.3°C Q5_60.7°C Q5_59.0°C
Q5_58.0°C Phusion_72.0°C Phusion_71.7°C
Phusion_69.6°C Phusion_67.2°C Phusion_64.5°C
Phusion_62.4°C Phusion_60.9°C Phusion_60.0°C
°
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  1 2 3 4 5 6 
A Kapa_63.3ºC Kapa_63.3ºC Kapa_63.3ºC Kapa_63.3ºC Kapa_63.3ºC NTC 
B Kapa_63.3ºC Kapa_63.3ºC Kapa_63.3ºC Kapa_63.3ºC Kapa_63.3ºC NTC 
C Q5_59ºC Q5_59ºC Q5_59ºC NTC Q5_59ºC Q5_59ºC 
D Q5_59ºC Q5_59ºC Q5_59ºC NTC Q5_59ºC Q5_59ºC 
E Phusion_64.5ºC NTC Phusion_64.5ºC Phusion_64.5ºC Phusion_64.5ºC Phusion_64.5ºC 
F Phusion_64.5ºC NTC Phusion_64.5ºC Phusion_64.5ºC Phusion_64.5ºC Phusion_64.5ºC 
G Accuzyme_67ºC Accuzyme_67ºC Accuzyme_67ºC Accuzyme_67ºC Accuzyme_67ºC Accuzyme_67ºC 
H Accuzyme_67ºC Accuzyme_67ºC Accuzyme_67ºC Accuzyme_67ºC Accuzyme_67ºC Accuzyme_67ºC 
Table 4.17: List of temperatures and high-fidelity enzymes input into microfluidic multiple singleplex 
PCR.  
4.5.7.1.1 Optimising PCR reactions for MRD-Seq 
When starting with low numbers of molecules in MRD-Seq (e.g. 40 copies) each true 
variant would have a high AF (e.g. >2.5%) and so high depth sequencing may not be 
required.  In addition the AccessArray singleplex step adds cost to the MRD-Seq process. 
To evaluate whether singleplex PCR was necessary for MRD-Seq, multiplexed PCR 
products listed in Table 4.17 were split into two groups. The first group were subjected to 
ExoSap cleaning and immediate barcoding, whilst samples in the second group were split 
to perform multiple singleplex PCR reactions using the Access Array chip (Fluidigm). 
Singleplex PCR thermocycling was carried out as per manufacturers recommendations. 
Samples from both groups were then barcoded as previously described (Forshew et al., 
2012). DNA libraries were purified, pooled and submitted for sequencing with 125bp paired 
end chemistry on the MiSeq platform (Illumina). Overall, 22 million reads were generated, 
however primer dimer accounted for the majority of reads, with aligned reads amounting to 
only 1.06 million, see Figure 4.18.  
 
Figure 4.18: MiSeq reads resulting from investigation of high-fidelity enzymes. 
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Although raw read counts were broadly the same amongst the samples, reads aligning to 
the human reference genome (hg19) were not evenly distributed (Figure 4.19a). Samples 
undergoing secondary PCR with the Access Array produced aligned reads whilst the 
group of samples that omitted this step did not produce aligned reads (Figure 4.19 and 
Figure 4.20). Figure 4.19b shows that samples processed using the Q5 and Phusion 
enzymes accounted for the majority of aligned reads. Kolmogorov–Smirnov testing 
between Q5 and Phusion enzymes, revealed that Q5 samples had significantly better 
coverage (p<2.2 xe-16), see Figure 4.20.  
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Figure 4.19: Distribution of reads allocated to samples. a. Proportion of raw reads, filtered reads and 
reads aligning for each sample. b. The median and interquartile ranges for coverage of aligned reads per 
sample. 
b
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Figure 4.20: ECDF plots of each group of samples undergoing PCR with a specified each enzyme 
type (coloured). Empirical cumulative distribution function graphs depict the coverage (x axis) and the 
proportion of observations less than or equal to this value (y axis). Therefore ECDF plots can depict 
differences between the distributions data sets. One-sided Kolmogorov–Smirnov test demonstrated a 
significant difference between Q5 and Phusion enzyme coverage, confirming that Q5 samples had improved 
coverage (p<2.2 xe-16).  
For the target genomic locations all non-reference read counts were compared to 
determine the background noise attributable to the Q5 and Phusion enzymes. Figure 4.21 
shows the background noise profile for Q5 and Phusion enzymes in MRD-Seq replicates 
using 40 copies of healthy volunteer plasma DNA per reaction. This demonstrated a 
reduced background noise profile for Q5 over the Phusion enzyme, with fewer bases 
having an AF of 0.5% or more. Kolmogorov–Smirnov testing confirmed a statistically 
significant difference between distributions (p=5.24 xe-19). Therefore, the higher-fidelity Q5 
enzyme utilising a second round of parallel singleplex PCR reactions was chosen for 
further optimisation. 
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Figure 4.21: Barchart showing the frequency of bases (y axis) having a non-reference AF (x axis) for 
MRD-Seq using healthy volunteer plasma. Data generated using the Q5 and Phusion enzymes are 
shown. 
4.5.7.1.2 Optimisation of PCR cycling conditions for high-fidelity enzyme 
To improve the yield of the desired products, PCR cycling conditions were optimised within 
the MRD-Seq workflow. The effect of magnesium concentration, enzyme concentration 
and annealing time on multiplexed PCR were explored. PCR annealing allows primers to 
attach to matched DNA template. During a multiplexed PCR, additional time given to this 
process can improve coverage but conversely can also increase the amount of non-
specific product created e.g. primer dimer. Therefore, we tested 1-minute versus 4-minute 
pre-amplification annealing times. Katrin Heider (PhD student in Rosenfeld lab) had 
previously conducted experiments to improve the limit of detection for TAm-Seq using the 
Q5 polymerase enzyme. She showed that inputting 5 times the recommended Q5 enzyme 
concentration had significantly improved the yield of PCR product and therefore, we tested 
1x and 5 x recommended enzyme concentration. Magnesium cation is required for DNA 
polymerase to function and its concentration can alter the efficiency of the enzyme. Higher 
concentrations will improve efficiency but lower the specificity of the enzyme (Markoulatos 
et al., 2002; Bustin, 2010). Higher annealing and extension temperatures increase PCR 
product specificity but lower yield (Biassoni and Raso, 2014). Therefore we tested a 
annealing and extension temperature range from 58ºC to 70ºC. 
The addition of DMSO has been shown to reduce nonspecific annealing and lowers the 
temperature of primer-template hybridization (Bustin, 2010). Therefore, it can be 
particularly useful in standardising the annealing temperature of multiplexed reactions 
especially when some primers are GC rich. However, the manufacturer recommends that 
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DMSO is not be required and provide a Q5 High GC Enhancer which can be used if PCR 
fails. Furthermore, primers were selected based on predicted annealing temperature and 
GC content. Therefore, the addition of DMSO was not tested. 
 
DNA extracted from healthy volunteer plasma and case 7 patient-specific primer pairs 
were used. Samples were arranged in a 96 well plate before carrying out multiplexed PCR, 
using all case 7 primer pairs and the Q5 polymerase. Samples were subsequently 
transferred for parallel singleplex PCR using the Access Array (Fluidigm), barcoding, 
pooling and sequencing with 125bp paired end chemistry on the MiSeq platform (Illumina). 
31.8 million reads were produced with only 0.83 million aligning to the reference human 
genome (hg19), see Figure 4.22. Again, the distribution of raw reads was broadly even 
amongst the samples, with a few samples accounting for the majority of aligned reads 
(resulting in a median depth of 25 across all conditions).  
 
Figure 4.22: Distribution of reads for the PCR condition optimisation experiment. a. Boxplot of reads 
assigned to each sample, split by read class (raw, filtered, aligned). b. Pie chart of read allocations by read 
class across all conditions tested.  
Figure 4.23 shows that a 2.5mM magnesium buffer concentration, recommended 
polymerase concentrations and an increased annealing time of 4 minutes, identical to the 
annealing time used in TAm-Seq (Forshew et al., 2012), yields significantly higher target 
coverage (median depth of 77.5 for 2.5mM vs. 38 for 4.5mM magnesium buffer 
concentration, 14 for 1 minute vs. 148 for a 4 minute annealing time and 12 for 1x vs. 9 for 
5x enzyme concentrations). Figure 4.24 demonstrates that a 2.5mM magnesium 
concentration and 1 minute annealing time had reduced background noise. There was no 
statistical difference between the error rate when varying the polymerase concentration.  
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Figure 4.23: ECDF plots of sequencing target depth for varying annealing time (a), polymerase 
concentration (b), magnesium concentration (c) and PCR annealing and extension temperatures (d). 
Kolmagov-Smirnoff 2 sample testing was used to identify statistically significant differences in the 
distributions (inset p-values). 
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Figure 4.24: Box plots comparing the background noise distributions from experiments comparing 
different Magnesium concentrations (a), annealing times (b), the polymerase enzyme concentrations 
(c) and PCR annealing and extension temperatures (d). Kolmagov-Smirnoff testing was used to 
determine statistically significant distributions (noted as inset p-values). 
Figure 4.23 and Figure 4.24 show that a magnesium concentration of 2.5mM increased 
depth and background noise level. The 4-minute annealing and extension time was 
maintained from the Tam-Seq protocol because results demonstrated that it improved 
DNA yield significantly (Figure 4.23) whilst having only a small, but statistically significant 
increase in background noise (Figure 4.24). Initial impressions, led to the use of 5x 
enzymes in the MRD-Seq workflow however, in-depth analysis reveals a small but 
significant improvement in DNA yield with standard polymerase concentrations (Figure 
4.23).  
Figure 4.23 shows that for optimal sequencing depth, a temperature of 60.7ºC should be 
used for Q5 PCR annealing and extension steps, with higher and lower deviations in 
annealing and extension temperature resulting in lower yields (Kruskal-Wallis p= 0.0033, 
p= 5.50xe-7 and p= 3.930e-06 for 58ºC versus 60.7ºC, 58ºC versus 66.4ºC and 60.7ºC 
versus 66.4ºC, after Bonferroni correction for multiple testing). However, Figure 4.24 
demonstrates that higher annealing temperatures (66.4ºC) has a reduced background 
noise. To balance these factors, a compromised annealing and extension temperature of 
63ºC was selected.  
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4.5.7.1.3 Removal of primer dimer to improve proportion of aligned reads for MRD-
Seq 
The Rosenfeld group use a custom bioinformatics pipeline developed by Dr Francesco 
Marass and Dr James Morris to filter out primer-dimer reads (PEDRO). In brief, the 
pipeline filters primer-dimer sequences by removing reads where paired-end read 1 does 
not match the known primer pair of paired-end read 2. For data generated in section 
4.5.6.1 with the case 7 primer panel using the standard TAm-Seq method, 9.9% and 
35.7% of reads were filtered by PEDRO (1.89/19.1 million) and were aligned (6.82/19.1 
million) respectively. During the optimisation of PCR conditions and reagents for MRD-
Seq, 54.1% reads were filtered by PEDRO (17.2/31.8 million), whilst only 2.6% of reads 
were aligned (0.83/31.8 million). 
Much of the ‘off-target’ reads were therefore attributable to short primer dimer artefacts.  
To investigate the effects of size selection to improve the proportion of on-target reads I 
performed DNA library size-selection using the Pippin Prep system (Sage). Pippin Prep 
uses an electrical gradient to separate DNA fragments along a gel matrix prior to eluting 
the selected size range in solution (Sage Science, 2017). I used the Pippin Prep system to 
remove PCR products in the primer-dimer size range from MRD-Seq libraries by selecting 
for DNA size fragments of between 105 – 200bp following pre-amplification or between 
175 – 270bp following barcoding.  
Libraries were generated using template DNA from healthy volunteer plasma and the 
optimised MRD-Seq workflow conditions (Section 4.5.7.1). Libraries were subjected either 
to size selection following pre-amplification (followed by Access Array parallel singleplex 
PCR, barcoding and pooling) or size selection after barcoding and pooling. Libraries were 
purified and submitted for sequencing using 125bp paired end chemistry with MiSeq 
(Illumina). 
Figure 4.25a shows that 42.9% of reads were aligned following some form of size 
selection. Figure 4.25b shows that samples having size selection immediately following 
pre-amplification have a reduced proportion of reads removed by PEDRO and have a 
higher proportion of reads aligning to the human reference genome. 
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Figure 4.25: Distribution of reads following library size selection. a. Pie chart of read allocations by 
class. b. Barplot showing the percentage (y axis) of reads that were lost, removed by PEDRO, clipped and 
aligned for each sample, grouped by the point at which size selection was applied (x axis). 
Library size selection after barcoding and pooling does increase aligned reads and would 
have streamlined the MRD-Seq workflow. However size selection immediately after the 
pre-amplification step increased the proportion of aligned reads dramatically and was 
therefore incorporated into the MRD-Seq workflow. Of interest, the results imply that the 
multiplexed pre-amplification step creates the majority of primer-dimers and hence size 
selection after this stage improves the proportion of reads aligning to the reference human 
genome. 
4.5.7.2 Characterisation of MRD-Seq detection limit 
To characterise the detection limit of MRD-Seq I performed a dilution series using tumour 
DNA diluted with wild type DNA (Promega, PR-G1471). Case 7 tumour region 2 DNA 
(Figure 4.2) was selected due to the presence of a high number of SNVs (14) at high AFs, 
7 at ~20% AF and 7 at ~10% AF, see Figure 4.14. Bioanalyser traces showed that the 
DNA samples from tumour region 2 and Male genomic DNA (MCDNA) had similar size 
profiles, and dPCR was used to accurately quantify DNA stock concentrations, as 
described previously (see section 2.4.2). Table 4.18 demonstrates the dilution factors 
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assessed, dilution factors were calculated based on high AF (7 SNVs at ~20%). MRD-Seq 
was performed on samples according to the optimised protocol described above.  
Concentration	
ID	
Expected	
AF	for	14	
mutations	
in	region	T2	
No	of	
reactions	
(Nr)	
No	of	GE	
copies	/	
reaction	
(Nw)	
No	of	
Targets	(Nt)	
No	of	
molecules	
sampled	
(Ns)	
A	 0.156	 4	 40	 14	 2240	
B	 0.078	 12	 40	 14	 6720	
C	 0.0078	 111	 40	 14	 62160	
D	 0.0039	 176	 40	 14	 98560	
E	 0.0020	 264	 40	 14	 147840	
MC	 0	 96	 40	 14	 53760	
Table 4.18: Number of reactions (Nr) per dilution factor used to determine the detection limit of MRD-
Seq. Expected AFs were calculated by averaging the AF reported by WGS for the 14 mutations in case 7 
region 2. MC- Male genomic DNA. 
Overall, 663 reactions were performed. Samples were barcoded, cleaned and submitted 
for sequencing with 125bp paired-end chemistry over 2 lanes of HiSeq 2500 (Illumina). 
This resulted in 523.19 million reads, of which 37.6% aligned. The median depth for target 
loci was 90x. The expected AF for a true mutation in a single MRD-reaction was defined 
as 1/genomic input Nw, using 40-copies as input resulted in a threshold of 2.5%. Replicates 
were deemed to collect one mutant molecule for every 2.5% AF recorded, e.g. 10% AF 
indicating the presence of 4 mutant molecules. Figure 4.26 depicts the AF at every mutant 
position tested across multiple replicates. There is a clear trend for AFs to reduce with 
increasing dilution factor. Table 4.19 demonstrates the overall AF estimate for each 
dilution. ECDF plots were generated (Figure 4.27) and Kolmogorov–Smirnov testing used 
to identify statistically significant differences between each dilution series and control DNA 
(p<0.0001 for all pairs). 
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Figure 4.26: Heatmap demonstrating the number of molecules detected during characterisation of 
MRD-Seq sensitivity. Replicates are grouped by dilution factor (x axis). Mutant position locations are 
recorded on y axis. AFs for Dilution A shown to the left of the y axis. 
 
Concentration	
ID	
Expected	
AF	for	14	
mutations	
in	region	T2	
No	of	
mutant	
detected	
(Nm)	
No	of	
molecules	
sampled	
(Ns)	
Overall	AF	
estimate	using	
MRD-Seq	
A	 0.156	 203	 2240	 0.0906	
B	 0.078	 426	 6720	 0.0634	
C	 0.0078	 2280	 62160	 0.0367	
D	 0.0039	 153	 98560	 0.0016	
E	 0.0020	 135	 147840	 0.0009	
MC	 0	 13	 53760	 0.0002	
Table 4.19: Characterisation of the MRD-Seq detection limit. Expected AFs were calculated as described 
in Table 4.18. Overall AF estimates using MRD-Seq for each dilution were calculated by dividing the number 
of mutant molecules detected by the number of molecules assessed (Nm/Ns). 
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Figure 4.27: ECDF plot demonstrating cumulative AF distribution for each dilution to determine the 
limit of detection for MRD-seq. AFs are depicted on the x axis, with the proportion of samples with AFs  
less than that value are depicted on the y axis. Samples/dilution factors are grouped by colour code (see 
legend) and one-sided Kolmogorov–Smirnov test p-values are inset adjacent to the sample IDs (see legend). 
Statistically significant differences were demonstrated for each dilution factor and the healthy control DNA 
(MCDNA) distribution. 
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4.5.7.3 Utilising MRD-Seq to detect ctDNA AFs in heterogeneous localised 
prostate cancer 
To demonstrate the effectiveness of this process, I applied MRD-Seq to quantify ctDNA 
levels in the plasma of two men with multifocal localised prostate cancer (man 7 and 8), 
where 4-6 regions of prostatectomy samples underwent whole genome re-sequencing, as 
described previously (Cooper et al., 2015), see section 4.4.3. One of these regions 
included an area of adjacent, histo-pathologically normal area for each man. From WGS 
data I selected 88 and 78 mutations for man 7 and 8 respectively to represent the 
intratumour heterogeneity of each man’s tumour. Of these 69 and 45 assays were 
designed for man 7 and man 8 (number of targets, Nt) on the basis of high mAF in the 
tumour. Pre-operative plasma from man 7 and 8 had 2300 and 4130 amplifiable GE 
copies/ml of DNA respectively (total cfDNA). Replicate dilutions were performed from 
approximately 1000 GE copies such that the number of template molecules per reaction 
(Nw) is 38 and 39 for man 7 and man 8, respectively. 
Detection thresholds (Dt) were calculated by defining a ratio of one mutant copy over the 
total GE input for each reaction (see Table 4.20) to give an expected lower limit of ~2.5% 
AF for both men. Healthy volunteer plasma (HVP, Seralabs) was used to define the 
background error rate for the target mutations. DNA was extracted from HVP using 
QIAsymphony (QIagen) and quantified with dPCR. HVP cfDNA replicates were made such 
that 40 copies were aliquotted into each reaction (Nw=40) in the MRD-Seq process and 
were analysed in parallel to the MRD-Seq plasma samples. Illumina sequencing was 
performed on pooled libraries (MiSeq for controls and HiSeq for plasma).   
Figure 4.28 shows that median coverage for each amplicon was variable amongst sample 
types and in particular, demonstrates poor coverage for the majority of amplicons from the 
pre-operative plasma DNA. 
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Figure 4.28: Median amplicon coverage for MRD-Seq from healthy volunteer plasma (HVP) samples 
with man 7 assays (a), pre-operative plasma from man 7(c), HVP samples and man 8 assays (b) and 
pre-operative plasma from man 8(d). Bars represent the median coverage (y axis) for each amplicon in the 
panel (x-axis). The dotted line represents the median coverage across all amplicons for a given sample (a= 
260, b= 626, c= 10, d= 11). Inset figures within Figure 4.28b and d represent the coverage with a limited y-
axis. 
 
Figure 4.29 shows the distribution of plasma AFs for each man compared with HVP and 
demonstrates that there is no statistically significant difference between the two 
distributions for either man. However, the analysis may be confounded by the reportedly 
lower error rate of HiSeq (used for the patient samples) compared to MiSeq (used for 
HVP) sequencing (Quail et al., 2012). Indeed, while KS testing demonstrated no significant 
difference between the AF distributions, the AFs for control samples, sequenced on a 
MiSeq platform, appear to be higher than plasma AFs.  A more specific assessment of 
signal in this experiment may therefore be to count events above the expected detection 
threshold (Dt). 
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Figure 4.29: ECDF plot showing the distribution of AFs in the plasma (red) and HVP (black) replicates 
of man 7 (a) and man 8 (b). HVP – healthy volunteer plasma. One-sided Kolmagov-Smirnoff testing did not 
demonstrate statistically significant difference in the distributions of neither man (noted as inset p-values). 
 
Pt ID dPCR GE 
Copies /µL 
of Eluate 
GE 
Copies / 
reaction 
Replicates 
Used 
Nucleotides 
Sampled 
(Ns) 
Mutant 
Molecules 
Identified 
Estimated 
AF 
7 46.1 40 24 818 8 0.009 
HVP (for man 
7 assays) 
89.7 40 14 614 0 0 
8 82.6 40 24 484 2 0.004 
HVP (for man 
8 assays) 
89.7 40 14 395 0 0 
Table 4.20: Input amounts GE copies, assays targeted, number of replicates, mutant molecules and 
sensitivity estimates for each patient. HVP – Healthy Volunteer Plasma. 
 
Sequencing reads were filtered for depth resulting in 818 and 484 molecules sampled (Ns) 
for pre-operative plasma and 614 and 195 molecules sampled for HVP samples for man 7 
and 8 respectively, Table 4.20. Heatmaps were created to assess the AF for every depth-
filtered amplicon, highlighting the AFs that crossed the MRD-Seq detection threshold 
(Figure 4.30). Of note, there were no healthy control plasma molecules with a mutant AF 
above Dt (0 false positives). However, 8 and 2 mutant molecules above Dt plasma were 
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demonstrated in man 7, and 8 respectively (Table 4.21) and were present in more than 
one read and on both the positive and negative strand. 
Case Mutation Gene Effect Clonal origin 
Mutant Reads 
(AF%) 
7 chr3:100497179 G>A ABI3BP	 p.R717* T2 (6.25) 
7 chr7:104449653 C>A LHFPL3	 Intronic N+T1+T2 (14.29) 
7 chrM:1968 G>A   T1 (5.26) 
7 chr8:24192995 G>A ADAM28	 p.D470N N (5.00) 
7 chr11:41199322 A>G 	 Intergenic T2 (10.53) 
7 chrM:5175 C>T 	 Intergenic T1 (2.54) 
7 chr6:74612812 G>T 	 Intergenic T3+T4+T5 (3.70) 
7 chr3:87172207 C>A 	 Intergenic T1+T2 (3.13) 
8 chr16:55853491 G>A CES1	 p.R288* T1+T2 (5.88) 
8 chr14:21321862 T>C 	 Intergenic T3 (3.85) 
Table 4.21: MRD-Seq results showing mutation position, gene, effect, clonal origin and AFs for 
mutant molecules above Dt. 
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Figure 4.30: Heatmaps showing the distribution of mutations detected in MRD-Seq experiments. The 
x-axes denotes the replicate reactions, whilst the y-axes shows the genomic targets (mutations). AFs for 
each sample:location are colour coded according to patient specific detection thresholds illustrated in the 
legend. Healthy volunteer re-sequencing results are display on the left of the heatmap for comparison. 
Figure 4.30a and Figure 4.30b show the results for man 7 and 8. The MRD-Seq replicates detected signal 
from 8 molecules with AF>2.5% for man 7 (a) and 2 molecules with AF>2.5% from man 8 (b).  
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To assess the distribution of signals for each mutation independently, the AFs for all 
replicates were plotted on barplots. Figure 4.31 shows examples of AFs at specific 
genomic locations. These plots demonstrate that at many positions, MRD-Seq replicates 
did not detect a mutant molecule (i.e. all AFs were below Dt; Figure 4.31a and b). 
However, for a subset of target positions the AF of an MRD-Seq replicate was clearly 
above Dt. Figure 4.31c and d show examples of replicates with an AF significantly above 
the AF in other replicates / healthy controls at the same location. Although for each 
mutation position only one MRD-Seq replicate crosses the Dt limit, the detection of 
mutations in patient samples and their absence on HVP controls suggest the presence of 
mutant ctDNA molecules in these early stage prostate cancer plasma samples. 
 
Figure 4.31: Waterfall plot showing the ordered Allele Fractions (y axis) for patient (red) and healthy 
control (black) plasma replicates (x-axis) at four example genomic locations. a and c shows AFs for 
man 7 and b and d shows data for man 8. Dt is represented by a dotted line. 
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Despite the uneven sequence coverage in these pilot experiments, MRD-Seq analysis 
suggests the presence of 8 mutant molecules out of the 818 molecules tested in man 7 
and 2 mutant molecules out of 484 for man 8, demonstrating AFs of approximately 1 in 
150 molecules or 0.7% in localised prostate cancer (see Table 4.20 and Figure 4.30). Of 
potential clinical importance, the mutations detected in plasma ctDNA were enriched for 
specific regions in the prostate of these men. Specifically, plasma from man 7 contained, 2 
mutant molecules emanating from region T1, 2 from region T2 and 1 from region N (but 
none from regions T3, T4 or T5). Three further mutant molecules represent shared 
mutations from regions T1/T2, regions N/T1/T2, and regions T3/T4/T5 respectively.  
Therefore, 7/8 mutations detected in ctDNA are derived from one half of the predicted 
genomic phylogeny (i.e. regions T1/T2/N and not regions T3/T4/T5), suggesting a bias for 
ctDNA release from tumour clones in these regions. Plasma from man 8 contained clones 
emanating from region T3 and a shared mutation from regions T1 and T2. (Figure 4.2 and 
Figure 4.30). This proof-of-principle study suggests that ctDNA analysis of plasma may 
demonstrate the complexity of heterogeneous localised prostate cancer but requires 
further investigation. If corroborated in larger cohorts, ctDNA analysis could be used to 
monitor tumour clones for the appearance of aggressive mutations (e.g. TP53) and alert 
clinicians to the presence of significant disease at an early stage. 
  
4.6 Original Contributions to Knowledge 
1. We confirmed that TP53 SNVs are more prevalent in metastatic prostate cancer. Of 
potential clinical significance, we found that these SNVs could be detected in 
historical samples taken at the time of prostatectomy. 
2. We developed MRD-Seq to demonstrate private mutations in ctDNA from multifocal 
prostate cancer in 2 cases.  
This data suggests that ctDNA can detect private mutations from multiple clone and 
therefore may be able to detect the emergence of potentially aggressive mutations e.g. 
TP53. 
 
  
CHAPTER 5: DISCUSSION  
5.1 Urinary DNA extraction 
Since the conception of the project, other groups have detected mutDNA in urine. In 2016, 
Togneri et al. compared the analytical sensitivity of mutant detection using Oncoscan 
(Affymetrix) and DNA extracted from urine cell pellets and urine supernatant at diagnosis 
from patients with bladder cancer (Togneri et al., 2016). They utilised the Urine DNA 
Isolation Slurry kit (Norgen) to extract DNA from an average of 18ml of urine. 
Unfortunately, urinary cfDNA yield or quantification data was not provided. However, that 
there was adequate DNA material for the 12ng input into the Oncoscan infers that DNA 
yields were adequate, lending support to results that column based extraction methods are 
suitable for urinary mutDNA analysis. Also in 2016, Birkenkamp-Demtröder et al. reported 
the use of the QIAsymphony Circulating NA kit (Qiagen, Hilden, Germany), to extract 
cfDNA from approximatley 3ml of 101 urine supernatants, ranging from 0.8ml – 4.5ml 
(Birkenkamp-Demtroder et al., 2016). Reported purification efficiencies ranged from 1.3% - 
100% with a pooled mean of approximatley 51.8% (calculated accross reported means for 
each group of patients) and copies/ml ranged from 0 – 654,872, with a pooled mean of 
21,579 copies/ml. Birkenkamp-Demtröder et al.’s reported mean is almost identical to the 
mean we report (22,810 GE copies/ml). 
In our group of 7 volunteers, of the four DNA extraction methods tested, SnoMag (which 
has since ceased production) was the only kit to have statistically significantly reduced 
cfDNA yields. However the small number of volunteers and that one commercial DNA 
extraction kit producer has potentially changed their extraction kits will impact statistical 
analysis. Furthermore, that urinary cfDNA can be collected in large volumes could negate 
the need for excellent yield of extraction and make other features of extraction, e.g. size of 
cfDNA extracted or reliability more important. Comparisons of urinary cfDNA size between 
the four extraction methods used could have been assessed by sWGS. However, on 
balance, it was felt that the Qiagen circulating nucleic acid kit would be the most suitable 
for further experimentation due to the Rosenfeld laboratory’s significant experience with 
using Qiagen circulating nucleic acid kits for plasma DNA extraction, the higher mean yield 
of DNA when testing this kit with urine and the lack of statistical evidence supporting the 
use of another kit. 
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Since the testing of urinary cfDNA extraction, several other companies have released 
commercially available kits with specific urinary cfDNA extraction protocols. For example, 
NEXTprep-MagTM Urine cfDNA Isolation Kit (Bio Scientific) have released a magnetic bead 
based cfDNA extraction method capable of DNA extraction from 1 – 50ml of urine. 
MagMAXTM Cell‐Free DNA Isolation Kit (ThermoFisher Scientific) have also released a 
magnetic bead based method capable of extracting cfDNA from 1 – 10 ml or urine 
supernatant. Sigma-Aldrich offer the column based GenEluteTM Urine Cell-Free DNA 
Purification Mini Kit, isolating cfDNA from 250µL-2mL of urine supernatant. Furthermore, 
several groups report using plasma DNA extraction kits to extract urinary DNA, for 
example, Tsui et al. report using Wizard PLUS kit (Promega) to investigate foetal and 
maternal urinary DNA. These and other urinary cfDNA extraction methods have not been 
investigated as part of this project, though could form part of future work if deemed 
appropriate. 
5.1.1 Urinary processing protocols 
Our data suggest that timely urine processing, i.e. within 1 hour, with centrifugation and 
the addition of EDTA urine improves cfDNA yield. When considering centrifugation of 
urine. for non-urological cancers, this would seem vital to reduce contamination of wild-
type DNA from shed urothelial cells however, no comparisons have been published. 
Though no comparison was reported, Togneri et al. and Birkenkamp-Demtröder et al. 
describe the use of urinary centrifugation with 2000rpm and 3000g respectively for 10 
minutes for urine processing in their analysis (Togneri et al.; Birkenkamp-Demtroder et al.). 
However, for urological cancers, particularly BC, one might consider un-centrifuged or 
whole urine analysis. Indeed, whole urine may allow investigation of private UCP and USN 
mutants in one sample type with reduced processing requirements (potentially allowing 
sample processing in peripheral hospitals) and would be worthy of further analysis. The 
addition of EDTA was not strongly supported by the results of our analysis. Furthermore, 
neither Togneri nor Birkenkamp-Demtröder et al. report using EDTA in urine for mutDNA 
analysis. However, for urinary cfDNA analysis several reports utilise EDTA (Tsui et al., 
2012) and EDTA has been shown to improve DNA stabilisation in plasma over other 
stabilisers (Bronkhorst et al., 2015) or no stabiliser (Barra et al., 2015). 
Many studies use a sample processing time of 1-4hours for the analysis of ctDNA in 
plasma. Our data corroborates that there is a significant difference in DNA yields when 
samples are left unprocessed for longer periods of time. These findings suggest that 
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obtaining samples from peripheral sites would be problematic not least due to the 
requirement for high-speed centrifuge. However, Cell-Free DNA BCTs (Blood collection 
tubes, Streck) have been shown to improve DNA yield in plasma stored at room 
temperature for several days (Norton et al., 2013) and outperform the addition of EDTA 
over this time period for the detection of ctDNA (Parpart-Li et al., 2017; Sherwood et al., 
2016). Streck also promote the Cell-Free DNA Urine Preserve tube for the preservation of 
25-100ml of urine for up to 7 days at room temperature and have recently launched an 
additive for urine (Streck, 2017). To date, there are no independent comparisons between 
Streck tube urine preservation methods and EDTA addition for the analysis of urinary 
mutDNA yield and would be of great importance to allow wider study participation. 
5.1.2 Urinary DNA size 
My findings suggest that longer fragments were not abundant in urinary cfDNA, particularly 
in whole urine, where I expected to see a greater proportion of cellular DNA released 
during lysis stage of DNA extraction, were initially surprising. A potential reason for this 
may have been that 360bp amplicon would be expected to give a lower count than 97bp 
fragments (or shorter) due to the preferential amplification of shorter fragments and that 
primers targeting a 97bp apmlicon are more likely to find primer landing and take off sites 
on a DNA fragment than primers producing a longer as the longer DNA region has more 
chance of being fragmented within the target amplicon. A potential control for this could 
have been to use size specific controls with un-fragmented DNA. However, during the 
course of studies, several key publications corroborated our initial results. In 2012, Tsui et 
al. described the size profile of urinary cfDNA extracted from spun urine (Tsui et al., 2012). 
Of note, Tsui et al. demonstrated a 29bp peak in adult cfDNA, using WGS. Potential 
biases may occur at every step of cfDNA analysis. Briefly, shorter fragments may be 
preferentially extracted over fragments several hundreds of bps in length, when using 
column based extraction kits. Secondly library preparation methods may preferentially 
amplify shorter DNA fragments. Lastly, the NGS chemistry used by Tsui et al. and to 
generate these results, select for shorter fragments.  
By using sWGS data of USN samples from our MIBC study, plots of DNA fragments size 
versus frequency were created, similar to those of Tsui et al. (Tsui et al., 2012). Figure 5.1 
shows urinary cfDNA size distribution for a healthy volunteer who contributed urine to the 
urine optimisation study, see section 2.4.1. The distribution of fragment sizes appears to 
match that of maternal urine described by Tsui et al. (Tsui et al., 2012).  
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Figure 5.1: DNA fragment size distribution for healthy urine. Fragment sizes (x axis) are compared to 
their frequency (y axis). 
When considering urinary cfDNA sizes from samples with detectable CNAs, a noticeable 
shift towards shorter size distributions is observed, see Figure 5.2. Indeed, the distribution 
peak shifts from 144bp in healthy and CNN urinary cfDNA samples to 100bp for mutDNA 
samples. 
 
Figure 5.2: Fragment size distribution showing the differing sizes of urinary cfDNA with detectable 
CNAs, urinary cfDNA without detectable CNAs and from healthy volunteers.  
Of interest is our finding that mutDNA is more often found in shorter fragments of urinary 
cfDNA. This extends previous work by Jiang et al. who found that CNAs were 
preferentially found in shorter plasma cfDNA fragments in 90 patients with hepatocellular 
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carcinoma, (Jiang et al., 2015). Together, these results may help improve the 
understanding mutDNA generation and may help design more efficient mutDNA analysis 
methods (Mouliere and Rosenfeld, 2015). 
5.1.3 Detection of mutDNA for urine processing study 
The inability to detect mutDNA in the urine processing arm of the study is unfortunate and 
is likely to be multifactorial. Firstly only samples from 2 patients were obtained limiting the 
ability of our panel to detect mutations. Secondly, the panel used only detects mutations in 
72% of cancers (Table 3.1) and a more broad panel design may have been able to detect 
SNVs in these samples. Specifically, the inability to target TERT will have affected the 
ability to detect SNVs in more cases. Indeed, TERT has been shown to harbour promoter 
region SNVs in 66% of patients with bladder cancer  (Cancer Genome Atlas Research, 
2014; Forbes et al.). These promoter SNVs occur within a highly repetitive region of the 
human genome. As cfDNA is likely to be short (~166bp), short amplicons would need to be 
designed to target TERT mutations and would therefore fall within the repetitive region, 
losing specificity. Indeed, where non-invasive TERT detection has been reported, it has 
been in more intact DNA e.g. urine cell pellet (Kinde et al., 2013b; Fedriga et al., 2001; 
Allory et al., 2014; Ward et al., 2016), allowing targeting with longer amplicons than would 
be suitable for cfDNA detection. As all other primers worked and >70% of SNVs would be 
captured by the existing panel no further attempts at targeting TERT were made. Lastly, 
the TUR samples for these patients were unavailable. Analysis of the TUR samples may 
have allowed identification of SNVs that could then have been tracked in detection mode 
or alternatively, exome sequencing of the tumour could have been performed and assay 
design to patient specific mutations. 
5.2 MutDNA in MIBC 
MutDNA analysis has been shown to have translational potential in many solid cancers 
(Bettegowda et al., 2014). MutDNA has been studied in plasma but little data has been 
presented on the analysis of mutDNA in urine. In our cohort of MIBC patients we confirm 
the presence of SNVs and CNAs previously reported in BC (Cancer Genome Atlas 
Research; Forbes et al.). We confirm that mutations found in TUR samples are detectable 
in both the plasma and urine of BC patients. Our data, based upon the analysis of 86 time-
points, demonstrate that mutDNA is detected more frequently and at higher levels in urine 
(both USN and UCP) and agrees with previous work (Birkenkamp-Demtroder et al.). 
DISCUSSION - MutDNA in MIBC 
 
188 of 233 
Importantly however, in some cases mutDNA was only detected in one individual sample 
type (including plasma). These private mutations could represent local anatomy or biology. 
For example, one could speculate that mutations private to plasma represent tumour 
clones situated deeper in muscle and/or closer to the vasculature. This analysis may be 
important as such clones could have different clinical outcomes. In this study, the 
observation of such plasma-specific mutations did not associate with response to NAC or 
early recurrence, though the number of patients was small. Nonetheless, our data 
indicates an advantage in assessing both urine (UCP & USN) and plasma for the 
comprehensive analysis of mutDNA in MIBC. Additionally, the observation that urinary AFs 
were higher than plasma AFs, suggests that the presence of mutDNA in urinary samples is 
due to direct tumour shedding. Beyond BC, this study confirms the role of sampling 
peripheral fluids in close proximity to diseased organs in order to improve the sensitivity of 
the detection of mutDNA (Wang et al.; Patel and Tsui).  
Of potential clinical significance, we found that detection of mutDNA at the second cycle of 
NAC (2-3 weeks after initiation of therapy, depending on the specific regimen) using our 
methods was predictive of early disease recurrence, with a sensitivity of 83% and 
specificity of 100%. We acknowledge that we have studied a small number of cases and 
with a relatively short follow-up period (possibly resulting in recurrence events being 
missed). However, it is noteworthy that MIBC often recurs within 2 years (Zehnder et al.) 
and our recurrence rates are comparable with published data (Witjes et al.). Our proof of 
principle study therefore encourages further large-scale investigation. In our series, the 
single false negative case was likely due to the narrow focus of our bladder-specific panel, 
since we only detected a PIK3CA mutation in the TUR sample at low AF, which likely 
represents a minor sub-clone (similar to those described in patients 12 and 15). Analysis 
of additional targets, through the use of an expanded panel for targeted sequencing or by 
capture-based strategies (as has been used in other cancer types (Murtaza et al.; 
Newman et al.)), may have identified alternative cancer pathway mutations in this patient. 
Whilst we attempted to overcome this by interrogating the wider cancer genome through 
CNA profiling (Cancer Genome Atlas Research), we note that CNA analysis is limited to 
detecting mutDNA at ~5% mutant:wild type AF ratio (Heitzer et al.). Alternatively, by 
applying only TP53 detection to the USN of the 9 patients who had TP53 mutations in their 
TUR, a focussed TP53 urinary assay would have detected all 4 patients that recurred 
(Figure 3.11).  
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If confirmed by larger studies, mutDNA detection in pre-NAC samples and in samples 
taken before the 2nd NAC cycle may be used to stratify patients into 3 groups (Figure 5.3). 
Firstly, those that are negative at both time-points may have a low (or no) burden of 
disease. Secondly, those that have a positive pre-NAC sample but negative samples at 
the 2nd NAC cycle are benefiting from their NAC and subsequent definitive therapy. The 
final group of patients has detectable mutDNA at both time-points and often progresses. 
Patients in this group are not benefiting from NAC and should be considered for expedited 
definitive therapy or alternative systemic therapy (e.g. targeted therapy or immune 
checkpoint inhibition). The specific mutations arising (or persisting) during therapy may 
inform further therapeutic strategy. Analysis of the presence of mutDNA in samples from 
later time-points was also informative but, would be less clinically useful. An early decision 
on continuation of NAC would prevent administration of multiple cycles of toxic therapy 
that is not benefiting the patient (Figure 3.5B).  
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Figure 5.3: MutDNA analysis may help stratify patients with MIBC in the future. Based on our data, we 
have generated a model by which a patient’s outcome can be predicted by mutDNA status before and during 
NAC. Specifically, mutDNA status may be used to stratify patients into 3 groups. Firstly, patients with 
undetectable mutDNA pre-NAC and during NAC, have a low (or no) burden of disease (green). Secondly, 
patients with detected mutDNA pre-NAC but with negative samples at the 2nd NAC cycle are likely to benefit 
from their NAC and subsequent definitive therapy (yellow). Finally, patients with mutDNA detected before 
and during NAC are unlikely to benefit from continued NAC and often progress (red). These patients should 
be considered for expedited definitive treatment or alternative treatments (e.g. targeted therapy or immune 
checkpoint inhibition).  
These results represent the first description of tumour evolution through de novo mutation 
detection in urinary specimens. We hypothesise that the changes in the mutational profiles 
observed in these patients represent tumour evolution under the selective forces of 
surgery and NAC. This is exemplified by patient 15. It is likely that multiple clones were 
present initially, with analysis of initial urinary samples highlighting a dominant somatic 
profile consisting of TP53 H193A and YAP1 gain. Initiation of NAC allowed for the 
apparent emergence of a distinct (presumably NAC resistant) tumour clone, containing, 
TP53 R273C, NFE2L2 G31A and CDKN2A loss. Meanwhile the clone containing TP53 
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H193A and YAP1 gain mutations appears to respond well to NAC and recedes. Our data 
emphasises the presence of multiple concomitant tumour clones and, the importance of 
monitoring mutDNA with an unbiased sequencing panel (e.g. one targeting all of TP53), 
rather than relying solely on the detection of known mutations from matched tumour 
samples. In addition, though we cannot rule out the effects of tumour heterogeneity in 
biasing our radical cystectomy sample analysis, the equivalent longitudinal data from 
peripheral fluid samples suggests that a combined body fluid sampling method is capable 
of overcoming the effects of spatially distinct clones. Overall, the data demonstrates the 
strength and potential of mutDNA profiling for non-invasive monitoring of clonal dynamics 
throughout therapy.  
This proof of principle study has several weaknesses. Patient numbers were relatively 
small and thus firm clinical conclusions cannot be made. However, by studying several 
biological samples per patient at various time-points during NAC, the results establish a 
comprehensive overview of mutDNA in BC and generate specific hypotheses that can now 
be tested in prospective, sufficiently-powered, clinical studies. In addition, although the 
presence of mutDNA at the second cycle of NAC was associated with clinical outcome, we 
found instances where patients with favorable outcome had mutDNA detected in samples 
at later time-points. At this point, it is unclear whether these findings are clinically 
meaningful. However, it is clear that patients with a favorable outcome tend to lose 
detectable presence of mutDNA (Figure 3.5B). Finally, the detection methods chosen have 
limitations in panel size, sequence depth and sensitivity. These could be supplemented 
with the inclusion of other genomic regions of interest, e.g. ERBB2, ERCC2 or other DNA 
damage pathway genes, mutations in which have been shown to predict responsiveness 
to NAC (Van Allen et al., 2014; Groenendijk et al., 2016; Yap et al., 2014). However, the 
current panel design represents a reasonable trade-off in comparison with methods like 
digital PCR (high coverage but few mutations analysed) and capture-based NGS assays 
(large gene panels but coverage limited by sequencing costs).  
Together with previous work, this study demonstrates the utility of urinary mutDNA 
analysis across the full spectrum of bladder cancer. Using multiple sample sources and 
complementary genetic techniques we have provided a more rigorous analysis of 
mutDNA. Furthermore, despite the small numbers of patients, this prospective study 
highlights the important role that mutDNA analysis can have in predicting aggressive 
disease in MIBC and could offer an opportunity for patients to consider expedited definitive 
therapy or alternative regimens.  
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5.3 ctDNA in Localised Prostate cancer 
Our attempts to use a targeted panel to detect mutations in localised prostate cancer were 
unsuccessful. This is likely due to several factors. Firstly, the low mutation rate of prostate 
cancer, reportedly <0.9 mutations /Mb (Berger et al., 2011) in localised disease and even 
as low as 2 mutations /Mb in heavily treated CRPC (Grasso et al., 2012) suggests that 
there will be few mutations to track. Secondly, though mutations may be present, there are 
few recurrent mutations (Grasso et al., 2012; Barbieri and Tomlins, 2014) making it difficult 
to design prostate cancer specific panels. Lastly, the multi-focality of prostate cancer 
(Cooper et al., 2015), will mean that identifying clones at a localised disease stage to track 
using personalised panels will also be problematic. These factors are likely to result in 
prostate cancers being one of the most challenging solid cancers to monitor at the 
localised stage. 
However, despite the multi-focality of localised prostate cancer, Lui et al. have 
demonstrated that most metastatic prostate cancers have a monoclonal origin through 
SNP and copy number analysis (Liu et al., 2009). More recently, others have confirmed 
this through exome sequencing of CRPC and matched localised prostate cancer samples 
(Grasso et al., 2012; Carreira et al., 2014). If the potentially malignant clone can be 
detected at an early stage, ctDNA analysis may help identify men with poor prognoses. 
There remain three important challenges to overcome before such an approach could be 
viable. Firstly, whether recurrent mutations are present in CRPC. Secondly, whether 
clones containing these mutations are present in plasma at localised prostate cancer 
stage. Thirdly, whether individual clones are detectable in amongst multifocal and 
heterogeneous localised prostate cancer (Andreoiu and Cheng, 2010; Cooper et al., 
2015).  
5.3.1 TP53 as a marker of aggressive disease 
Several studies suggest that CRPC may have recurrent mutations and in particular may 
harbour TP53 SNVs. Indeed, out of 50 CRPC cases investigated by Grasso et al., 21 
cases had TP53 SNVs (including 1 case with a 2 base deletion) (Grasso et al., 2012), 
whilst Beltran et al. found TP53 mutations in 40% of cases (Beltran et al., 2013). In our 
study of 19 metastatic samples from men with CRPC, 11 TP53 SNVs were detected, 
confirming the association of TP53 with CRPC. Furthermore, in all men who had 
prostatectomy samples available for analysis (n=6), the same TP53 SNV present in the 
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dominant malignant clone was found. Though the numbers studied are small, these results 
lend weight to the hypothesis that lethal CRPC may have monoclonal origin (Grasso et al., 
2012; Liu et al., 2009) and confirms Haffner et al.’s observation that the dominant clone 
during malignancy can be traced back to a clone present at the localised prostate cancer 
stage (Haffner et al., 2013).  
In addition, historical pre-operative plasma samples in 3 men were subjected to amplicon 
sequencing to identify the same TP53 SNVs that would dominate future malignant clones, 
in 2/3 of the men’s samples. These results build on Carreira et al.’s findings that 3/16 of 
men TP53 SNVs, detectable in pre-castration resistant disease persist at the CRPC stage, 
though the pre-castration stage is likely metastatic due to the high AFs, (Carreira et al., 
2014). Our proof of principle finding is an important contribution to knowledge and has 
significant clinical implications. Though the numbers are small, the findings suggest that 
acquisition of TP53 SNVs may confer metastatic potential and that this aggressive change 
can be detected in plasma at the localised stage of disease. If corroborated in larger 
studies, ctDNA analysis could help identify potentially aggressive prostate cancers or help 
monitor prostate cancer during active surveillance, through timely detection of aggressive 
changes. These results warrant further large-scale trial in longitudinal studies. 
5.3.2 Accounting for prostate heterogeneity 
When considering the clinical application of a ctDNA test, the multi-focality and 
heterogeneity of prostate cancer will impact on the ability to track aggressive clones in 
localised disease. Indeed, Figure 4.15 demonstrates that current standards of amplicon 
sequencing alone will not allow the identification of ctDNA from clonally heterogeneous 
primary prostate tumours. MRD-Seq was developed and used to demonstrate the 
presence of mutations in plasma samples taken at the localised stage, representing 
discrete tumour regions from multifocal disease. 
Dilution experiments demonstrate the analytical sensitivity of MRD-Seq to detect AFs 
down to 0.09% (the limit of sensitivity) and suggests a background error rate of 0.02% AF 
(MCDNA), see Table 4.19. Figure 4.27 suggests that the actual limit of sensitivity for MRD-
Seq could be improved with further dilutions, thus pushing the actual limit of sensitivity 
closer to the background error rate. Thus the ability of MRD-Seq to assess multiple 
amplicons is likely to be between 1 mutant in 1,100 – 5,000 mutant:wild-type copies. This 
improves on the previously reported analytical sensitivity of Tam-Seq in detection mode of 
1 in 700 mutant:wild-type molecules (Forshew et al., 2012) and would be similar to 
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standard dPCR techniques (Vogelstein and Kinzler, 1999). MRD-Seq is however, likely to 
be less sensitive than more advanced dPCR techniques, e.g. droplet dPCR, with a 
reported sensitivity of detecting 1 in 13,000 mutant:wild-types (Milbury et al., 2014), 
although such sensitivities can rarely be achieved in the analysis of cfDNA where starting 
material is frequently limited to ~103 copies/ml plasma.  
MRD-Seq does however, have the added benefit of tracking multiple mutations, reducing 
the risk of missing disease recurrence through clonal evolution when applied to 
longitudinal sample collections. Developing the idea of tracking multiple mutations, 
Newman et al. described Capp-Seq, which leverages thousands of mutations, to obtain a 
reported analytical sensitivity to detect 1 in 5000 mutant:wild-type molecules (Newman et 
al., 2014). Further computational refinements have improved the sensitivity to detect 1 in 
25,000 mutant:wild-type molecules (Newman et al., 2016) outperforming MRD-Seq for 
analytical sensitivity by ~5 fold when input material is not a limiting factor.  
However, Capp-Seq is likely to be more costly than MRD-Seq as it relies on DNA capture 
technology. With the majority of the cost per sample due to the expense of capture baits 
and the need for deep sequencing of large regions of the genome. Conversely, the current 
cost of MRD-Seq for assessing a single plasma sample using 50 replicates is 
approximately £650, though this excludes the costs of exome sequencing / WGS of the 
tumour, and purchasing the primer panel, both of which are one off costs. Furthermore, it 
is likely that the cost of MRD-Seq can be significantly reduced through optimisation. In 
particular, investigating the barcoding of individual replicates during pre-amplification to 
enable pooling the replicates prior to library size selection, could significantly lower the 
cost. This may be achieved by using molecular barcodes (Peng et al., 2015) for each 
replicate, though the cost of primers may increase, or by optimising PCR conditions to omit 
the microfluidic singleplex PCR step. These improvements could conceivably bring the 
cost of MRD-Seq down to £300-400 per sample and within the reach of current recurrence 
detection tests, for example, a single flexible cystoscopy attendance costs ~£430, whilst a 
CT scan costs ~£150 (Monitor, 2016). Therefore, MRD-Seq may be a cost effective 
method to longitudinally screen plasma samples for minimal residual disease or 
recurrence. This is likely to be useful in cancer types where the detection of minimal 
residual disease is an area of need e.g. breast cancer, cervical cancer, glioma, etc., 
though for prostate cancer, PSA detection is a suitable, cheaper alternative.  
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The limited coverage obtained from the pre-operative plasma samples, limits the ability to 
draw firm conclusions about whether clonal heterogeneity can be monitored in localised 
prostate cancer. This aspect could not be further evaluated due to the lack of sample 
material. That the pre-operative plasma DNA alone suffered from poor coverage, whilst 
tumour dilutions and healthy plasma control coverage was as expected, suggest the 
possibility of technical issues with the pre-operative plasma samples. Possible 
explanations include poor initial processing (low yields or contaminant carry over), and the 
age of plasma samples (collected in December 2012). Indeed, Sozzi et al. applied 
quantitative PCR of hTERT to paired lung cancer plasma samples to show that the 
quantity of DNA isolated decreases by approximately 30% per year despite storage at -
80°C (Sozzi et al., 2005). If this holds true for the prostate plasma samples, after 5 years 
of storage the quantity of cfDNA may be ~16.8% of the material originally collected. 
In addition, the ECDF distribution of AFs for pre-operative plasma and HVP samples were 
not statistically significantly different. This could be due to the use of different sequencing 
platforms, the lower number of HVP samples used and the differing coverage achieved by 
MRD-Seq on plasma and HVP samples (as every base will have a unique non-reference 
error profile). In addition, the global signal may be dominated by technical noise and using 
the detection threshold (1 / number of copies per replicate) leverages the potential benefits 
of MRD-Seq. Analysis of pre-operative plasma DNA using this detection threshold 
approach suggests the presence of private mutations from clonally distinct regions of 
prostate cancer in plasma DNA. In our proof-of-principle study, some clones were better 
represented in the plasma DNA e.g. (regions T1 and T2 for man 7), whilst others were less 
well represented e.g. (region T5 from man 7). The reasons for this are at present poorly 
understood but could include features of the clones in these regions; proximity to tumour 
vasculature, size, grading and cell turnover rate. These factors together with the clinical 
relevance of differing clonal representation in the plasma need further investigation. 
These proof-of-principle experiments demonstrate that ctDNA analysis of pre-operative 
plasma samples may allow the detection of potentially aggressive TP53 SNVs and may 
demonstrate the heterogeneity of localised prostate cancer. Taken together ctDNA 
analysis may allow the detection potentially aggressive mutational changes in a clone at 
an early stage and warrants further investigation. Further work is needed to optimise the 
MRD-Seq approach and to test these preliminary findings in larger patient cohorts, where 
detecting minimal residual disease is an unmet clinical need.  
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5.4 Future Work 
Work presented in this thesis represent important contribution to knowledge and some 
aspects have the potential for translation into clinical practice and warrant further 
investigation. For bladder cancer, the urinary processing for the detection of mutDNA 
could be further refined. This could take the form of increasing the number of commercially 
available kits being assessed and increasing the number of samples used or introducing 
more nuanced processing steps e.g., comparing 0mM, 5mM and 10mM concentrations of 
EDTA addition. More importantly however, would be an assessment of whether urine 
processing and DNA extraction is optimised for mutDNA detection. Specifically this should 
involve a rigorous assessment of whether mutDNA is more prominent in whole urine 
samples, or urine supernatant. In MIBC initial results seem encouraging that mutDNA 
analysis may detect early treatment failure, so that further adjuvant therapies may be 
used. In the first instance, these results would need corroboration in larger cohorts of 
patients ideally across multiple institutions.  
In prostate cancer, though we (Hong et al., 2015) and others (Kumar et al., 2011; Beltran 
et al., 2013) have identified some potentially aggressive drivers, a complete understanding 
of events and their timings remain elusive and requires further investigation through multi-
spatial genome/exome wide sequencing of targeted populations of men and functional 
studies. The finding that potentially malignant clones are detectable in the plasma of men 
at the stage of localised disease warrants validation in large-scale studies, especially 
considering the scope of potential benefit. Furthermore, our findings demonstrate that the 
analysis of cfDNA, based on the MRD-Seq principles of tracking multiple targets and using 
diluted replicates, may be sensitive enough to monitor ctDNA in localised prostate cancer. 
If corroborated in larger cohorts, these methods can be adapted to assay potentially 
aggressive markers of prostate cancer. Indeed, the refinement of ultra-sensitive ctDNA 
detection techniques and the known markers of aggression are required before 
implementation of a ctDNA test for aggressive prostate cancer can be considered. 
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APPENDICES 
A-1 Amplifiable GE copies/ml of urine in cfDNA extracted from 
urine supernatant samples taken from healthy volunteers 
 
Sample	ID Volunteer	ID
Sample	Spun	
(Y/N)
DNA	Extraction	
Kit
Extraction	
Sample	
Volume	(ml)
Elution	
Volume	(ul)
Enrichment	
Ratio
NA	dPCR	
Loading	
Volume	(ul)
Est.	ROX	
Targets
Est.	FAM	
Targets
Yield	Est.
Amplifiable	
Copies/ml
Avearge	
Amplifiable	
copies	/ml
	Amplifiable	
copies	/	ul	of	
eluate
SNA A Y Norgen 4 50 1 1.5 182 168 0.554 3297.1 3890.4 311.2
SNA A Y Norgen 4 50 1 1 165 165 0.587 4483.7
SNB B Y Norgen 4 50 1 1.5 26 233 0.769 471.0 738.2 59.1
SNB B Y Norgen 4 50 1 1 37 338 1.203 1005.4
SNC C Y Norgen 4 50 1 1 31 242 0.861 842.4 656.7 52.5
SNC C Y Norgen 4 50 1 1.5 26 268 0.884 471.0
SNP P Y Norgen 1 50 1 1 40 261 0.929 4347.8 2934.8 58.7
SNP P Y Norgen 1 50 1 1.5 21 170 0.561 1521.7
SQA A Y Qiagen 4 50 1 1 200 296 1.053 5434.8 3890.4 311.2
SQA A Y Qiagen 4 50 1 1.5 192 278 0.917 3478.3
SQA A Y Qiagen 4 50 1 1.5 179 332 1.287 3242.8
SQA A Y Qiagen 4 50 1 1.5 188 346 1.341 3405.8
SQB B Y Qiagen 4 50 1 1.5 21 205 0.677 380.4 570.7 45.7
SQB B Y Qiagen 4 50 1 1 28 240 0.854 760.9
SQC C Y Qiagen 4 50 1 1 44 316 1.125 1195.7 933.0 74.6
SQC C Y Qiagen 4 50 1 1.5 37 296 0.977 670.3
SQP P Y Qiagen 1 50 1 1.5 102 299 1.191 7391.3 3768.1 75.4
SQP P Y Qiagen 1 50 1 1.5 2 9 0.036 144.9
SSnA A Y SnoMag 1 50 1 1.5 49 268 0.884 3550.7 3351.4 67.0
SSnA A Y SnoMag 1 50 1 1 29 171 0.609 3152.2
SSnB B Y SnoMag 1 50 1 1 38 219 0.779 4130.4 2391.3 47.8
SSnB B Y SnoMag 1 50 1 1.5 9 243 0.802 652.2
SSnC C Y SnoMag 1 50 1 1.5 4 157 0.518 289.9 634.1 12.7
SSnC C Y SnoMag 1 50 1 1 9 192 0.683 978.3
SSnP P Y SnoMag 1 50 1 1 9 201 0.715 978.3 1394.9 27.9
SSnP P Y SnoMag 1 50 1 1.5 25 140 0.462 1811.6
NB B N Norgen 4 50 1 1.5 296 0 0.000 5362.3 5615.9 449.3
NB B N Norgen 4 50 1 1 307 0 0.000 5869.6
NC C N Norgen 4 50 1 1.5 64 0 0.000 1159.4 1544.4 123.6
NC C N Norgen 4 50 1 1 71 0 0.000 1929.3
QB B N Qiagen 4 50 1 1.5 368 253 1.008 6666.7 8494.1 679.5
QB B N Qiagen 4 50 1 1 429 297 1.669 11657.6
QB B N Qiagen 4 50 1 1.5 463 319 1.236 8387.7
QB B N Qiagen 4 50 1 1.5 401 280 1.085 7264.5
QC C N Qiagen 4 50 1 1 103 270 1.076 1865.9 2237.3 179.0
QC C N Qiagen 4 50 1 1.5 96 277 1.556 2608.7
SnB B N SnoMag 1 50 1 1.5 49 215 0.857 3550.7 2155.8 43.1
SnB B N SnoMag 4 50 1 1 28 139 0.781 760.9
SnC C N SnoMag 1 50 1 1.5 10 80 0.319 724.6 403.1 8.1
SnC C N SnoMag 4 50 1 1 3 44 0.247 81.5
NE E N Norgen 4 50 1 1.5 316 151 0.619 5724.6 2343.0 187.4
NE E N Norgen 4 50 1 1.5 375 217 0.882 6793.5
NE E N Norgen 4 50 1 1.5 19 231 0.935 344.2
NE E N Norgen 4 50 1 1.5 15 253 1.024 271.7
NE E N Norgen 4 50 1 1.5 19 242 0.980 344.2
NE E N Norgen 4 50 1 1.5 32 217 0.879 579.7
SNE E Y Norgen 4 50 1 1.5 233 134 0.549 4221.0 5788.0 463.0
SNE E Y Norgen 4 50 1 1.5 406 255 1.016 7355.1
NF F N Norgen 4 50 1 1.5 445 163 0.668 8061.6 10221.9 817.8
NF F N Norgen 4 50 1 1.5 675 244 0.992 12228.3
NF F N Norgen 4 50 1 1.5 562 191 0.740 10181.2
NF F N Norgen 4 50 1 1.5 575 199 0.771 10416.7
NP P N Norgen 1 50 1 1.5 5 89 0.365 362.3 561.6 11.2
NP P N Norgen 1 50 1 1.5 17 143 0.570 1231.9
NP P N Norgen 1 50 1 1.5 6 0 0.000 434.8
NP P N Norgen 1 50 1 1 2 0 0.000 217.4
QE E N Qiagen 4 50 1 1.5 56 154 0.631 1014.5 878.6 70.3
QE E N Qiagen 4 50 1 1.5 41 236 0.959 742.8
QE E Y Qiagen 4 50 1 1.5 278 155 0.635 5036.2 8491.8 679.3
QE E Y Qiagen 4 50 1 1.5 577 285 1.135 10452.9
QE E Y Qiagen 4 50 1 1.5 522 267 1.035 9456.5
QE E Y Qiagen 4 50 1 1.5 498 225 0.872 9021.7
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DNA was extracted from the samples using 4 commercially available kits and dPCR was conducted as 
previously described in section 2.4.2 to target RPP30. Average amplifiable copies were calculated from 
replicate samples. Initially, multiple replicates were tested before reducing the replicates to 2 per sample. 
 
 
Sample	ID Volunteer	ID
Sample	Spun	
(Y/N)
DNA	Extraction	
Kit
Extraction	
Sample	
Volume	(ml)
Elution	
Volume	(ul)
Enrichment	
Ratio
NA	dPCR	
Loading	
Volume	(ul)
Est.	ROX	
Targets
Est.	FAM	
Targets
Yield	Est.
Amplifiable	
Copies/ml
Avearge	
Amplifiable	
copies	/ml
	Amplifiable	
copies	/	ul	of	
eluate
QF F N Qiagen 4 50 1 1.5 672 111 0.455 12173.9 13931.2 1114.5
QF F N Qiagen 4 50 1 1.5 866 420 1.707 15688.4
QP P N Qiagen 1 50 1 1.5 61 341 1.398 4420.3 2253.6 45.1
QP P N Qiagen 1 50 1 1.5 57 251 1.020 1032.6
QP P N Qiagen 1 50 1 1.5 31 300 1.195 2246.4
QP P N Qiagen 1 50 1 1 26 287 1.612 2826.1
QP P N Qiagen 1 50 1 1.5 41 124 0.620 742.8
SnP P N SnoMag 1 50 1 1.5 7 87 0.347 507.2 416.7 8.3
SnP P N SnoMag 1 50 1 1 3 88 0.494 326.1
NeoE E N NeoGeneStar 5 50 1 1.5 200 138 0.566 2898.6 3333.3 333.3
NeoE E N NeoGeneStar 5 50 1 1.5 260 150 0.610 3768.1
SNeoE E Y NeoGeneStar 5 50 1 1.5 632 176 0.715 9159.4 8717.4 871.7
SNeoE E Y NeoGeneStar 5 50 1 1.5 571 212 0.845 8275.4
NeoF F N NeoGeneStar 5 50 1 1.5 824 104 0.426 11942.0 13731.9 1373.2
NeoF F N NeoGeneStar 5 50 1 1.5 1071 203 0.825 15521.7
NeoP P N NeoGeneStar 1 50 1 1.5 1 2 0.008 72.5 36.2 0.7
NeoP P N NeoGeneStar 1 50 1 1.5 0 1 0.004 0.0
SNF F Y Norgen 4 50 1 1.5 1059 185 0.737 19184.8 22056.2 1764.5
SNF F Y Norgen 4 50 1 1.5 1376 235 0.955 24927.5
SQF F Y Qiagen 4 50 4 1.5 586 73 1.000 10615.9 10534.4 842.8
SQF F Y Qiagen 4 50 4 1.5 577 95 1.301 10452.9
SNeoF F Y NeoGeneStar 5 50 4 1.5 748 38 0.521 10840.6 10398.6 1039.9
SNeoF F Y NeoGeneStar 5 50 4 1.5 687 54 0.740 9956.5
NG1 G1 N Norgen 4 50 1 1.5 976 211 0.977 17681.2 22537.6 1803.0
NG1 G1 N Norgen 4 50 1 1.5 927 160 0.741 16793.5
NG1 G1 N Norgen 4 50 1 1.5 878 160 0.741 15905.8
NG1 G1 N Norgen 4 50 4 1.8 116 29743.6
NG1 G1 N Norgen 4 50 4 1.8 127 32564.1
QG1 G1 N Qiagen 4 50 4 1.5 976 25 0.32051282 70724.6 68731.9 5498.6
QG1 G1 N Qiagen 4 50 4 1.5 921 36 0.46153846 66739.1
NG2 G2 N Norgen 4 50 4 1.5 651 78 1 47173.9 37759.2 3020.7
NG2 G2 N Norgen 4 50 4 1.5 577 52 0.66666667 41811.6
NG2 G2 N Norgen 4 50 4 1.8 120 30769.2
NG2 G2 N Norgen 4 50 4 1.8 122 31282.1
NG3 G3 N Norgen 4 50 4 1.5 601 76 0.97435897 43550.7 41123.2 3289.9
NG3 G3 N Norgen 4 50 4 1.5 534 60 0.76923077 38695.7
NG4 G4 N Norgen 4 50 4 1.5 663 64 0.82051282 48043.5 49275.4 3942.0
NG4 G4 N Norgen 4 50 4 1.5 697 61 0.78205128 50507.2
QG2 G2 N Qiagen 4 50 4 1.5 904 41 0.52564103 65507.2 66956.5 5356.5
QG2 G2 N Qiagen 4 50 4 1.5 944 42 0.53846154 68405.8
QG3 G3 N Qiagen 4 50 4 1.5 921 43 0.55128205 66739.1 56396.3 4511.7
QG3 G3 N Qiagen 4 50 4 1.5 851 23 0.29487179 61666.7
QG3 G3 N Qiagen 4 50 4 1.8 188 48205.1
QG3 G3 N Qiagen 4 50 4 1.8 191 48974.4
QG3 G4 N Qiagen 4 50 4 1.5 1157 46 1 83840.6 87137.7 6971.0
QG3 G4 N Qiagen 4 50 4 1.5 1248 45 0.97826087 90434.8
SNG1 G1 Y Norgen 4 50 4 1.5 363 80 1.73913043 26304.3 26123.2 2089.9
SNG1 G1 Y Norgen 4 50 4 1.5 358 71 1.54347826 25942.0
SQG1 G1 Y Qiagen 4 50 4 1.5 614 39 0.84782609 44492.8 43550.7 3484.1
SQG1 G1 Y Qiagen 4 50 4 1.5 588 37 0.80434783 42608.7
  
A-2 Amplifiable GE copies per ml of urine in cfDNA extracted from 
urine supernatant samples taken from healthy volunteers 
 
  
Sample	ID Volunteer	ID
Sample	
Processing	Time	
(hrs)
Sample	Spun	
(Y/N)
EDTA	(Y/N)
Extraction	
Sample	
Volume	(ml)
Elution	
Volume	(ul)
Enrichment	
Ratio
NA	dPCR	
Loading	
Volume	(ul)
Est.	ROX	
Targets
Est.	FAM	
Targets
Yield	Est.
Amplifiable	
Copies/ml
Avearge	
Amplifiable	
copies	/ml
A1 A 1 Y Y 3.8 75 1 1.8 43 126 140.0% 4352 3391
A1 A 1 Y Y 3.8 75 1 1.8 24 158 175.6% 2429
A10 A 48 N Y 3.8 75 1 1.8 915 45 50.0% 92611 91144
A10 A 48 N Y 3.8 75 1 1.8 886 49 54.4% 89676
A11 A 48 Y N 3.8 75 1 1.8 11 122 135.6% 1113 1063
A11 A 48 Y N 3.8 75 1 1.8 10 132 146.7% 1012
A2 A 1 N Y 3.8 75 1 1.8 2195 56 62.2% 222166 228846
A2 A 1 N Y 3.8 75 1 1.8 2327 51 56.7% 235526
A3 A 1 Y N 3.8 75 1 1.8 4 131 145.6% 405 253
A3 A 1 Y N 3.8 75 1 1.8 1 136 151.1% 101
A4 A 1 N N 3.8 75 1 1.8 2327 52 57.8% 235526 235526
A4 A 1 N N 3.8 75 1 1.8 2327 50 55.6% 235526
A5 A 6 Y Y 3.8 75 1 1.8 0 167 185.6% 0 51
A5 A 6 Y Y 3.8 75 1 1.8 1 166 184.4% 101
A6 A 6 N Y 3.8 75 1 1.8 2327 45 50.0% 235526 235526
A6 A 6 N Y 3.8 75 1 1.8 2327 59 65.6% 235526
A7 A 6 Y N 3.8 75 1 1.8 29 164 182.2% 2935 2530
A7 A 6 Y N 3.8 75 1 1.8 21 192 213.3% 2126
A8 A 6 N N 3.8 75 1 1.8 2327 59 65.6% 235526 235526
A8 A 6 N N 3.8 75 1 1.8 2327 69 76.7% 235526
A9 A 48 Y Y 3.8 75 1 1.8 16 81 90.0% 1619 1569
A9 A 48 Y Y 3.8 75 1 1.8 15 81 90.0% 1518
B1 B 1 Y Y 3.8 75 1 1.8 1 181 635.1% 101 101
B1 B 1 Y Y 3.8 75 1 1.8 1 160 561.4% 101
B10 B 48 N Y 3.8 75 1 1.8 4 38 118.8% 405 304
B10 B 48 N Y 3.8 75 1 1.8 2 52 162.5% 202
B11 B 48 Y N 3.8 75 1 1.8 1 77 240.6% 101 51
B11 B 48 Y N 3.8 75 1 1.8 0 72 225.0% 0
B12 B 48 N N 3.8 75 1 1.8 0 50 156.3% 0 101
B12 B 48 N N 3.8 75 1 1.8 2 57 178.1% 202
B2 B 1 N Y 3.8 75 1 1.8 7 158 175.6% 709 1164
B2 B 1 N Y 3.8 75 1 1.8 16 134 148.9% 1619
B3 B 1 Y N 3.8 75 1 1.8 1 151 167.8% 101 152
B3 B 1 Y N 3.8 75 1 1.8 2 161 178.9% 202
B4 B 1 N N 3.8 75 1 1.8 13 153 170.0% 1316 962
B4 B 1 N N 3.8 75 1 1.8 6 161 178.9% 607
B5 B 6 Y Y 3.8 75 1 1.8 16 161 503.1% 1619 1974
B5 B 6 Y Y 3.8 75 1 1.8 23 162 506.3% 2328
B6 B 6 N Y 3.8 75 1 1.8 16 127 396.9% 1619 1721
B6 B 6 N Y 3.8 75 1 1.8 18 127 396.9% 1822
B7 B 6 Y N 3.8 75 1 1.8 3 127 396.9% 304 253
B7 B 6 Y N 3.8 75 1 1.8 2 155 484.4% 202
B8 B 6 N N 3.8 75 1 1.8 31 169 528.1% 3138 3087
B8 B 6 N N 3.8 75 1 1.8 30 123 384.4% 3036
B9 B 48 Y Y 3.8 75 1 1.8 0 54 168.8% 0 51
B9 B 48 Y Y 3.8 75 1 1.8 1 79 246.9% 101
C1 C 1 Y Y 3.8 75 1 1.8 3 164 575.4% 304 304
C1 C 1 Y Y 3.8 75 1 1.8 3 168 589.5% 304
C10 C 48 N Y 3.8 75 1 1.8 1 100 312.5% 101 202
C10 C 48 N Y 3.8 75 1 1.8 3 92 287.5% 304
C11 C 48 Y N 3.8 75 1 1.8 0 119 371.9% 0 152
C11 C 48 Y N 3.8 75 1 1.8 3 128 400.0% 304
C12 C 48 N N 3.8 75 1 1.8 3 108 189.5% 304 202
C12 C 48 N N 3.8 75 1 1.8 1 85 149.1% 101
C2 C 1 N Y 3.8 75 1 1.8 14 122 214.0% 1417 1468
C2 C 1 N Y 3.8 75 1 1.8 15 147 257.9% 1518
C3 C 1 Y N 3.8 75 1 1.8 20 150 468.8% 2024 2277
C3 C 1 Y N 3.8 75 1 1.8 25 128 400.0% 2530
C4 C 1 N N 3.8 75 1 1.8 11 138 431.3% 1113 962
C4 C 1 N N 3.8 75 1 1.8 8 140 437.5% 810
C5 C 6 Y Y 3.8 75 1 1.8 2 140 437.5% 202 253
C5 C 6 Y Y 3.8 75 1 1.8 3 126 393.8% 304
C6 C 6 N Y 3.8 75 1 1.8 6 150 468.8% 607 1215
C6 C 6 N Y 3.8 75 1 1.8 18 139 434.4% 1822
C7 C 6 Y N 3.8 75 1 1.8 2 129 403.1% 202 304
C7 C 6 Y N 3.8 75 1 1.8 4 136 425.0% 405
C8 C 6 N N 3.8 75 1 1.8 2 136 425.0% 202 354
C8 C 6 N N 3.8 75 1 1.8 5 131 409.4% 506
C9 C 48 Y Y 3.8 75 1 1.8 3 129 403.1% 304 152
C9 C 48 Y Y 3.8 75 1 1.8 0 162 506.3% 0
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DNA was extracted from the samples using Qiagen Circulating Nucleic acid commercially available kit. 
dPCR was conducted as previously described in section 2.4.2 to target RPP30. Average amplifiable copies 
were calculated from replicate samples. Of note, the yield is particularly high, however, this is likely to be due 
to reduced amount of Xenopus Tropicalis DNA being added to the 8 no-extraction controls that were used as 
comparisons. The median estimated targets detected for the no-extraction samples was only 32 (range 21-
59) during this analysis or 164 GE copies / µL of eluate. 
Sample	ID Volunteer	ID
Sample	
Processing	Time	
(hrs)
Sample	Spun	
(Y/N)
EDTA	(Y/N)
Extraction	
Sample	
Volume	(ml)
Elution	
Volume	(ul)
Enrichment	
Ratio
NA	dPCR	
Loading	
Volume	(ul)
Est.	ROX	
Targets
Est.	FAM	
Targets
Yield	Est.
Amplifiable	
Copies/ml
Avearge	
Amplifiable	
copies	/ml
D1 D 1 Y Y 3.8 75 1 1.8 8 155 543.9% 810 810
D1 D 1 Y Y 3.8 75 1 1.8 8 142 498.2% 810
D10 D 48 N Y 3.8 75 1 1.8 44 169 187.8% 4453 3998
D10 D 48 N Y 3.8 75 1 1.8 35 139 154.4% 3543
D11 D 48 Y N 3.8 75 1 1.8 0 162 180.0% 0 0
D11 D 48 Y N 3.8 75 1 1.8 0 139 154.4% 0
D12 D 48 N N 3.8 75 1 1.8 4 68 75.6% 405 354
D12 D 48 N N 3.8 75 1 1.8 3 69 76.7% 304
D2 D 1 N Y 3.8 75 1 1.8 44 201 705.3% 4453 5010
D2 D 1 N Y 3.8 75 1 1.8 55 155 543.9% 5567
D3 D 1 Y N 3.8 75 1 1.8 6 187 656.1% 607 405
D3 D 1 Y N 3.8 75 1 1.8 2 158 554.4% 202
D4 D 1 N N 3.8 75 1 1.8 49 185 649.1% 4960 5162
D4 D 1 N N 3.8 75 1 1.8 53 145 508.8% 5364
D5 D 6 Y Y 3.8 75 1 1.8 5 172 603.5% 506 506
D5 D 6 Y Y 3.8 75 1 1.8 5 157 550.9% 506
D6 D 6 N Y 3.8 75 1 1.8 42 181 635.1% 4251 4251
D6 D 6 N Y 3.8 75 1 1.8 42 151 529.8% 4251
D7 D 6 Y N 3.8 75 1 1.8 0 162 568.4% 0 51
D7 D 6 Y N 3.8 75 1 1.8 1 145 508.8% 101
D8 D 6 N N 3.8 75 1 1.8 30 138 431.3% 3036 3138
D8 D 6 N N 3.8 75 1 1.8 32 113 353.1% 3239
D9 D 48 Y Y 3.8 75 1 1.8 8 149 465.6% 810 709
D9 D 48 Y Y 3.8 75 1 1.8 6 169 528.1% 607
E1 E 1 Y Y 3.8 75 1 1.8 2 132 463.2% 202 101
E1 E 1 Y Y 3.8 75 1 1.8 0 147 515.8% 0
E10 E 48 N Y 3.8 75 1 1.8 65 201 223.3% 6579 6123
E10 E 48 N Y 3.8 75 1 1.8 56 209 232.2% 5668
E11 E 48 Y N 3.8 75 1 1.8 0 162 180.0% 0 0
E11 E 48 Y N 3.8 75 1 1.8 0 181 201.1% 0
E12 E 48 N N 3.8 75 1 1.8 14 147 163.3% 1417 1215
E12 E 48 N N 3.8 75 1 1.8 10 151 167.8% 1012
E2 E 1 N Y 3.8 75 1 1.8 174 194 680.7% 17611 18674
E2 E 1 N Y 3.8 75 1 1.8 195 151 529.8% 19737
E3 E 1 Y N 3.8 75 1 1.8 0 162 568.4% 0 0
E3 E 1 Y N 3.8 75 1 1.8 0 172 603.5% 0
E4 E 1 N N 3.8 75 1 1.8 33 169 593.0% 3340 2935
E4 E 1 N N 3.8 75 1 1.8 25 183 642.1% 2530
E5 E 6 Y Y 3.8 75 1 1.8 3 178 624.6% 304 202
E5 E 6 Y Y 3.8 75 1 1.8 1 158 554.4% 101
E6 E 6 N Y 3.8 75 1 1.8 57 145 508.8% 5769 5769
E6 E 6 N Y 3.8 75 1 1.8 57 185 649.1% 5769
E7 E 6 Y N 3.8 75 1 1.8 0 172 603.5% 0 0
E7 E 6 Y N 3.8 75 1 1.8 0 174 610.5% 0
E8 E 6 N N 3.8 75 1 1.8 37 136 238.6% 3745 3543
E8 E 6 N N 3.8 75 1 1.8 33 125 219.3% 3340
E9 E 48 Y Y 3.8 75 1 1.8 0 135 421.9% 0 0
E9 E 48 Y Y 3.8 75 1 1.8 0 136 425.0% 0
F1 F 1 Y Y 3.8 75 1 1.8 65 160 177.8% 6579 7186
F1 F 1 Y Y 3.8 75 1 1.8 77 140 155.6% 7794
F10 F 48 N Y 3.8 75 1 1.8 2 2 2.2% 202 202
F10 F 48 N Y 3.8 75 1 1.8 2 2 2.2% 202
F11 F 48 Y N 3.8 75 1 1.8 2 136 151.1% 202 152
F11 F 48 Y N 3.8 75 1 1.8 1 133 147.8% 101
F12 F 48 N N 3.8 75 1 1.8 26 127 445.6% 2632 2530
F12 F 48 N N 3.8 75 1 1.8 24 158 554.4% 2429
F2 F 1 N Y 3.8 75 1 1.8 220 160 561.4% 22267 23836
F2 F 1 N Y 3.8 75 1 1.8 251 151 529.8% 25405
F3 F 1 Y N 3.8 75 1 1.8 18 197 691.2% 1822 1721
F3 F 1 Y N 3.8 75 1 1.8 16 177 621.1% 1619
F4 F 1 N N 3.8 75 1 1.8 167 169 593.0% 16903 17358
F4 F 1 N N 3.8 75 1 1.8 176 176 617.5% 17814
F5 F 6 Y Y 3.8 75 1 1.8 76 181 635.1% 7692 8350
F5 F 6 Y Y 3.8 75 1 1.8 89 176 617.5% 9008
F6 F 6 N Y 3.8 75 1 1.8 251 167 586.0% 25405 24545
F6 F 6 N Y 3.8 75 1 1.8 234 151 529.8% 23684
F7 F 6 Y N 3.8 75 1 1.8 21 178 624.6% 2126 1619
F7 F 6 Y N 3.8 75 1 1.8 11 181 635.1% 1113
F8 F 6 N N 3.8 75 1 1.8 69 142 443.8% 6984 6883
F8 F 6 N N 3.8 75 1 1.8 67 153 478.1% 6781
F9 F 48 Y Y 3.8 75 1 1.8 61 123 384.4% 6174 6630
F9 F 48 Y Y 3.8 75 1 1.8 70 120 375.0% 7085
G1 G 1 Y Y 3.8 75 1 1.8 303 120 210.5% 30668 32540
G1 G 1 Y Y 3.8 75 1 1.8 340 103 180.7% 34413
G2 G 1 N Y 3.8 75 1 1.8 158 135 236.8% 15992 16447
G2 G 1 N Y 3.8 75 1 1.8 167 126 221.1% 16903
  
A-3 Pilot Bladder Primer Panel 
 
Primer	Name	 Forward	Sequence	 Reverse	Sequence	 chr	 Amplicon	
Start	
Amplicon	
ENd	
TP53_D0008_001	 GTGGGGAACAAGAAGTGGAGA	 CTCCCTGCTTCTGTCTCCTAC	 17	 7572903	 7573031	
TP53_D0008_002	 AGGAAGGGGCTGAGGTCA	 GCGCTTCGAGATGTTCCGA	 17	 7573904	 7574019	
TP53_D0008_003	 TTGAGTTCCAAGGCCTCATTCA	 GTACTGTGTATATACTTACTTCTCCCCC	 17	 7573975	 7574077	
TP53_D0008_004	 AAACGGCATTTTGAGTGTTAGAC	 ACAACACCAGCTCCTCTCC	 17	 7576789	 7576917	
TP53_D0008_005	 CATCCAGTGGTTTCTTCTTTGG	 TTCACTTTTATCACCTTTCCTTGCC	 17	 7576873	 7576961	
TP53_D0008_006	 CGCTTCTTGTCCTGCTTGC	 TGTGCCTGTCCTGGGAGA	 17	 7576996	 7577115	
TP53_D0008_007	 ATTCTCTTCCTCTGTGCGCC	 TTGCTTCTCTTTTCCTATCCTGAGT	 17	 7577074	 7577182	
TP53_D0008_008	 GGTCAGAGGCAAGCAGAGG	 CCTCACCATCATCACACTGGAA	 17	 7577434	 7577528	
TP53_D0008_009	 CAAGTGGCTCCTGACCTGG	 CTAGGTTGGCTCTGACTGTACC	 17	 7577484	 7577612	
TP53_D0008_010	 ACTGTTACACATGTAGTTGTAGTGGA	 CTTGCCACAGGTCTCCCC	 17	 7577561	 7577667	
TP53_D0008_011	 GGCCACTGACAACCACCC	 TCGACATAGTGTGGTGGTGC	 17	 7578120	 7578213	
TP53_D0008_012	 AGACCTCAGGCGGCTCA	 CCTCAGCATCTTATCCGAGTGG	 17	 7578173	 7578278	
TP53_D0008_013	 ATCCAAATACTCCACACGCAAATTT	 CCTCTGATTCCTCACTGATTGCT	 17	 7578228	 7578317	
TP53_D0008_014	 TGTCGTCTCTCCAGCCCC	 GGCCATCTACAAGCAGTCACA	 17	 7578343	 7578450	
TP53_D0008_015	 GCCTCACAACCTCCGTCAT	 AACTGGCCAAGACCTGCC	 17	 7578407	 7578523	
TP53_D0008_016	 GGAATCAACCCACAGCTGC	 AACTCTGTCTCCTTCCTCTTCCTA	 17	 7578483	 7578581	
TP53_D0008_017	 TGGAAGCCAGCCCCTCA	 GTCATCTTCTGTCCCTTCCCAG	 17	 7579284	 7579408	
TP53_D0008_018	 CCGTAGCTGCCCTGGTAG	 AGCTCCTACACCGGCG	 17	 7579364	 7579453	
TP53_D0008_019	 TGACAGGGGCCAGGAG	 CAATGGTTCACTGAAGACCCA	 17	 7579405	 7579533	
TP53_D0008_020	 GCATTCTGGGAGCTTCATCTG	 TGACTGCTCTTTTCACCCATCT	 17	 7579488	 7579616	
TP53_D0008_021	 CCCAGCCCAACCCTTGTC	 GAAGCGAAAATTCCATGGGACTG	 17	 7579677	 7579766	
TP53_D0008_022	 GCCCTTCCAATGGATCCACT	 CTTCCGGGTCACTGCCAT	 17	 7579816	 7579928	
TP53_D0008_023	 CTAGGATCTGACTGCGGCTC	 TGGAAGTGTCTCATGCTGGATC	 17	 7579887	 7579981	
BRAF_D0008_001	 ACTGTTCAAACTGATGGGACCC	 ACTTACTACACCTCAGATATATTTCTTCATGA	 7	 140453098	 140453209	
BRAF_D0009_001	 TCACCTATTTTTACTGTGAGGTCTTCA	 TCTTCATAATGCTTGCTCTGATAGGA	 7	 140453154	 140453259	
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BRAF_D0009_002	 CACATTACATACTTACCATGCCACTTT	 GGACTCGAGTGATGATTGGGAG	 7	 140481360	 140481476	
PIK3CA_D0012_002	 CTCAAGAAGCAGAAAGGGAAGAATTT	 TCTTTTCTTCACGGTTGCCTACT	 3	 178916834	 178916947	
PIK3CA_D0012_001	 CTTCGGCTTTTTCAACCCTTTTTAAAA	 AATATTTTAGAAAGGGACAACAGTTAAGCT	 3	 178916887	 178917036	
PIK3CA_D0012_003	 CATTTCCACAGCTACACCATATATGAAT	 ATTTGACTTTACCTTATCAATGTCTCGAAT	 3	 178921448	 178921589	
PIK3CA_D0012_004	 CCCATTATTATAGAGATGATTGTTGAATTTTCC	 AACAAGTTTATATTTCCCCATGCCAAT	 3	 178927868	 178928011	
PIK3CA_D0008_001	 AGGGAAAATGACAAAGAACAGC	 TTTTAGCACTTACCTGTGacTCCA	 3	 178936028	 178936135	
PIK3CA_D0012_005	 GATGCTTGGCTCTGGAATGC	 TTGTCCAGCCACCATGATGT	 3	 178951957	 178952102	
PIK3CA_D0008_002	 CAAGAGGCTTTGGAGTATTTCATGAA	 ATGCATGCTGTTTAATTGTGTGGA	 3	 178952042	 178952144	
KRAS_D0034_001	 CAGTCCTCATGTACTGGTCCC	 TACAGGAAGCAAGTAGTAATTGATGGA	 12	 25380235	 25380340	
KRAS_D0034_002	 GATTCTGAATTAGCTGTATCGTCAAGG	 GGCCTGCTGAAAATGACTGAATATAA	 12	 25398240	 25398330	
KRAS_D0036_002	 CTTGCTAAGTCCTGAGCCTGTT	 TTAAGGACTCTGAAGATGTACCTATGG	 12	 25378594	 25378690	
KRAS_D0036_003	 TCTGTATTTATTTCAGTGTTACTTACCTGTC	 TGATTTGCCTTCTAGAACAGTAGACA	 12	 25378522	 25378644	
FGFR_EX_6	 GCCCCTGAGCGTCATCT	 TGCGTCACTGTACACCTTGC	 4	 1803535	 1803668	
FGFR_EX_8	 GAGCTGGTGGAGGCTGAC	 GAGCCCAGGCCTTTCTTG	 4	 1806067	 1806207	
FGFR_EX_13	 CGAGGACAACGTGATGAAGA	 GGCGTCCTACTGGCATGA	 4	 1807821	 1807953	
NFE2L2_D0048_003	 TTCTGACTGGATGTGCTGGG	 CAAAAGGAGCAAGAGAAAGCCTTT	 2	 178098760	 178098858	
NFE2L2_D0048_001	 GTCAAATACTTCTCGACTTACTCCAA	 GCATAATGTGAATTAATTTATGTGGTATCTGTC	 2	 178098931	 178099080	
NFE2L2_D0048_002	 GGAGTTGTTCTTGTCTTTCCTTTTCA	 GATTGACATACTTTGGAGGCAAGATATAG	 2	 178098858	 178098988	
CTNNB1_D0008_001	 AGCGGCTGTTAGTCACTGG	 GTATCCACATCCTCTTCCTCAGG	 3	 41266060	 41266179	
CTNNB1_SUPP	 CCACTACCACAGCTCCTTCT	 CTCAAAACTGCATTCTGACTTTCA	 3	 41266119	 41266296	
HRAS_D0036_001	 CCCCGGTGCGCATGTA	 AGCAGGTGGTCATTGATGGG	 11	 533830	 533931	
HRAS_D0043_003	 TGCTGGCACCTGGACG	 TAAGCTGGTGGTGGTGGGCG	 11	 534180	 534311	
  
A-4 Amplifiable GE copies in cfDNA extracted from urine 
supernatant samples taken from patients with metastatic 
bladder cancer 
 
 
Sample	ID
Extraction	
Sample	
Volume	(ml)
elution	
Volume	(ul)
Enrichment	
Ratio
NA	dPCR	
Loading	
Volume	(ul)
Est.	ROX	
Targets
Est.	FAM	
Targets
Yield	Est.
Amplifiable	
Copies/ml
Avearge	
Amplifiable	
copies	/ml
	Amplifiable	
copies	/	ul	of	
eluate
K1 3.8 75 1 1.8 467 104 82.9% 47267 47166 2390
K1 3.8 75 1 1.8 465 95 75.7% 47065
K2 3.8 75 1 1.8 1701 37 29.5% 172166 168219 8523
K2 3.8 75 1 1.8 1623 39 31.1% 164271
K3 3.8 75 1 1.8 305 116 92.4% 30870 31883 1615
K3 3.8 75 1 1.8 325 95 75.7% 32895
K4 3.8 75 1 1.8 2327 46 36.7% 235526 231579 11733
K4 3.8 75 1 1.8 2249 56 44.6% 227632
K5 3.8 75 1 1.8 617 77 61.4% 62449 60577 3069
K5 3.8 75 1 1.8 580 83 66.1% 58704
K6 3.8 75 1 1.8 1320 47 37.5% 133603 136842 6933
K6 3.8 75 1 1.8 1384 52 41.4% 140081
K7 3.8 75 1 1.8 339 112 89.2% 34312 33907 1718
K7 3.8 75 1 1.8 331 114 90.8% 33502
K8 3.8 75 1 1.8 1808 46 36.7% 182996 180972 9169
K8 3.8 75 1 1.8 1768 59 47.0% 178947
K9 3.8 75 1 1.8 1036 75 59.8% 104858 103138 5226
K9 3.8 75 1 1.8 1002 77 61.4% 101417
K10 3.8 75 1 1.8 831 40 31.9% 84109 81123 4110
K10 3.8 75 1 1.8 772 45 35.9% 78138
K11 3.8 75 1 1.8 106 78 62.2% 10729 11387 577
K11 3.8 75 1 1.8 119 82 65.3% 12045
K12 3.8 75 1 1.8 1188 29 23.1% 120243 121457 6154
K12 3.8 75 1 1.8 1212 41 32.7% 122672
L1 3.8 75 1 1.8 111 132 105.2% 11235 11032 559
L1 3.8 75 1 1.8 107 134 106.8% 10830
L2 3.8 75 1 1.8 2327 52 41.4% 235526 235526 11933
L2 3.8 75 1 1.8 2327 52 41.4% 235526
L3 3.8 75 1 1.8 76 144 114.7% 7692 7844 397
L3 3.8 75 1 1.8 79 136 108.4% 7996
L4 3.8 75 1 1.8 1599 35 27.9% 161842 158350 8023
L4 3.8 75 1 1.8 1530 33 26.3% 154858
L5 3.8 75 1 1.8 113 140 111.6% 11437 11184 567
L5 3.8 75 1 1.8 108 144 114.7% 10931
L6 3.8 75 1 1.8 2327 50 39.8% 235526 235526 11933
L6 3.8 75 1 1.8 2327 47 37.5% 235526
L7 3.8 75 1 1.8 78 128 102.0% 7895 9413 477
L7 3.8 75 1 1.8 108 128 102.0% 10931
L8 3.8 75 1 1.8 1665 30 23.9% 168522 168117 8518
L8 3.8 75 1 1.8 1657 23 18.3% 167713
L9 3.8 75 1 1.8 40 144 114.7% 4049 4150 210
L9 3.8 75 1 1.8 42 139 110.8% 4251
L10 3.8 75 1 1.8 2053 28 22.3% 207794 210830 10682
L10 3.8 75 1 1.8 2113 21 16.7% 213866
L11 3.8 75 1 1.8 119 126 100.4% 12045 12500 633
L11 3.8 75 1 1.8 128 116 92.4% 12955
L12 3.8 75 1 1.8 861 11 8.8% 87146 88563 4487
L12 3.8 75 1 1.8 889 18 14.3% 89980
NEC_USN 0.69 75 1 1.8 0 126 100.4% 0 0 0
NEC_USN 0.69 75 1 1.8 0 125 99.6% 0
PUC 3.8 75 1 1.8 41 97 77.3% 4150 3796 192
PUC 3.8 75 1 1.8 34 125 99.6% 3441
  
A-5 Proof of Principle Primer Panel 
Primer	Name	 Forward	Sequence	 Reverse	Sequence	 chr	 Amplicon	
Start	
Amplicon	
ENd	
EGFR_E00001601336_1	 GCGTCTTCACCTGGAAGGG	 CCGGACATAGTCCAGGAGG	 7	 55248902	 55249111	
EGFR_E00001601336_2	 GCGTGGACAACCCCCAC	 GGCTCCTTATCTCCCCTCC	 7	 55249005	 55249213	
EGFR_E00001631695_1	 GTGTCACTCGTAATTAGGTCCA	 GGCCTCAGTACAAACTCATTAGC	 7	 55260366	 55260575	
EGFR_E00001681524_1	 GGATGCAGAGCTTCTTCCCA	 TTCTCTTCCGCACCCAG	 7	 55259352	 55259542	
EGFR_E00001681524_2	 GGTCTTCTCTGTTTCAGGGCAT	 GCTGACCTAAAGCCACCTCC	 7	 55259395	 55259591	
EGFR_E00001773562_1	 TACCCTCCATGAGGCACAC	 GGAGAgCTGTAAATTCTGGCTT	 7	 55269336	 55269516	
EGFR_E00001779947_1	 TGTTCATTCATGATCCCACTGC	 CCACCAGTCACTCACACTTG	 7	 55266362	 55266571	
EGFR_E00001779947_2	 TCCCTGCCAGCGAGAT	 AGGGATGCAAAGGCCTCA	 7	 55266461	 55266641	
EGFR_E00001790701_1	 GCCTTCTTTAAGCAATGCCATCTTTAT	 CAATGGAAGCaCAGACTGCAA	 7	 55267932	 55268134	
EGFR_E00001801208_1	 CCCCTGCTCCTATAGCCAA	 ATGAGGTACTCGTCGGCATC	 7	 55268806	 55268987	
EGFR_E00001801208_2	 ACTTCTACCGTGCCCTGA	 GTTCAAATGAGTAGACACAGCTT	 7	 55268921	 55269101	
EGFR_Exon19	 TCACAATTGCCAGTTAACGTCT	 CCACACAGCAAAGCAGAAAC	 7	 55242373	 55242537	
PTEN_E00001156315_1m	 GCAACAGATAACTCAGATTGCCTT	 GTTTCCTCTGGTCCTGGTATGA	 10	 89720457	 89720706	
PTEN_E00001156315_5	 AGGACAAAATGTTTCACTTTTGGGTAA	 ACTAGATATTCCTTGTCATTATCTGCAC	 10	 89720649	 89720799	
PTEN_E00001156315_7	 CCTCAGAAAAAgTAGAAAATGGAAGTC	 ACAAGTCAaCAACCCCCACA	 10	 89720706	 89720915	
PTEN_E00001156321_1	 TGACAGTTTGACAGTTAAAGGCAT	 CACACACAGGTAACGGCTGA	 10	 89717547	 89717726	
PTEN_E00001156321_2	 TGTGGTCTGCCAGCTAAAGG	 TCTCCCAATGAAAGTAAAGTACAAACC	 10	 89717620	 89717802	
PTEN_E00001156321_4m	 TCCACAAACAGAACAAGATGCT	 GGCCTTTTCCTTCAAACAGGATT	 10	 89717748	 89717956	
PTEN_E00001156327_1	 TCTTAAATGGCTACGACCCAG	 TCCAGATGATTCTTTAACAGGTAGC	 10	 89711775	 89711942	
PTEN_E00001156327_4	 CAGTCAGAGGCGCTATGTGT	 TCTAGATATGGTTAAGAAAACTGTTCCA	 10	 89711889	 89712077	
PTEN_E00001156330_1	 ttCTTATTCTGAGGTTATCTTTTTACCAC	 TCATTACACCAGTTCGTCCCT	 10	 89692739	 89692919	
PTEN_E00001156330_3	 TGACCAATGGCTAAGTGAAGATGA	 TCCAGGAAGAGGAAAGGAAAAACA	 10	 89692840	 89693048	
PTEN_E00001156337_4	 TATATCACTTTTAAACTTTTCTTTTAGTTGTGC	 CTCGATAATCTGGATGACTCATTATTGTT	 10	 89690776	 89690940	
PTEN_E00001156344_1	 AATCTGTCTTTTGGTTTTTCTTGATAGT	 AATAGTTGTTTTAGAAGATATTTGCAAGC	 10	 89685172	 89685367	
PTEN_E00001156351_1	 TGCTGCATATTTCAGATATTTCTTTCCTTA	 ATGAAAACACAACATGAATATAAACATCAAT	 10	 89653738	 89653927	
PTEN_E00001456541_1	 AGATGAGTcATATTTGTGGGTTTTCA	 TCTGGATCAGAGTCAGTGGT	 10	 89724997	 89725180	
PTEN_E00001456541_2	 GTAGAGGAGCCGTCAAATCCA	 TTCATGGTGTTTTATCCCTCTTGA	 10	 89725068	 89725264	
PTEN_E00001456562_1	 GCAGCTTCTGCCATCTCTCT	 TCCGTCTACTCCCACGTTCT	 10	 89624175	 89624372	
TP53_00001404886_13	 tctgTATCAGGCAAAGTCATAGAA	 GCCTCAAAGACAATGGCTCC	 17	 7576584	 7576734	
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TP53_E00001255919_1	 GAGAAAGCCCCCCTACTGC	 AGCATCTTATCCGAGTGGAAGG	 17	 7578091	 7578274	
TP53_E00001255919_3	 TCCAAATACTCCACACGCAAA	 gCTGCCCCCACCATGAG	 17	 7578229	 7578406	
TP53_E00001255919_5	 AGCTGCTCACCATCGCTA	 CCAACTGgCCAAGACCT	 17	 7578361	 7578525	
TP53_E00001255919_6	 TGTGCTGTGACTGCTTGTAG	 TGCCCTGACTTTCAACTCTGT	 17	 7578425	 7578594	
TP53_E00001596491_1	 TTTCGCTTCCCACAGGTCTC	 CAGCCAGACTGCCTTCCG	 17	 7579758	 7579940	
TP53_E00001612188_1	 ATACGGCCAGGCATTGAAGT	 CCTCCTGGCCCCTGTC	 17	 7579260	 7579421	
TP53_E00001612188_2	 GGAAACCGTAGCTGCCCTG	 AAGACCCAGGTCCAGATGAA	 17	 7579359	 7579520	
TP53_E00001665758_1	 GGGGTCAGaGGCAAGCAG	 CTTGGGCCTGTGTTATCTCC	 17	 7577432	 7577631	
TP53_E00001728015_1	 GGAATCCTATGGCTTTCCAACC	 CCCCCTCCTCTGTTGCTG	 17	 7573859	 7574054	
TP53_E00001757276_1	 GACCCAAAACCCAAAATGGC	 TCCCTGCTTCTGTCTCCTAC	 17	 7572850	 7573030	
TP53_E00001789298_1	 AGAAAACGGCATTTTGAGTGT	 AAGGGTGCAGTTATGCCTCA	 17	 7576786	 7576983	
TP53_E00001789298_2	 CTGGTGtTGTTGGGCAGT	 ATCTCCgCAAGAAAGGGGAG	 17	 7576908	 7577075	
TP53_E00001789298_3	 TGTCCTGCTTGCTTACCTCG	 GCCTCTTGCTTCTCTTTTCCT	 17	 7577003	 7577187	
KRAS_AA_HS	 GCCTGCTGAAAATGACTGAA	 AGAATGGTCCTGCACCAGTAA	 12	 25398163	 25398329	
BRAF_AA_HS	 TCATAATGCTTGCTCTGATAGGA	 CTGATGGGACCCACTCCAT	 7	 140453108	 140453256	
EXP0116_TP53_E4	 CAGCCTCTGGcATTCTGG	 cctggtcctctgaCTGCTCT	 17	 7579479	 7579626	
EXP0116_TP53_E3	 TCAAATCATCCATTGCTTGG	 ccatgggactgactttctgc	 17	 7579557	 7579754	
PIK3CA_Ex10_gap	 cAGAGGGGAAAAATaTGACAAA	 AACAGAGAATCTCCATTTTAGCAC	 3	 178935943	 178936150	
PIK3CA_Exn21_gap	 TGAGCAAGAGGCTTTGGAGT	 GGTCTTTGCCTGCTGAGAGT	 3	 178952038	 178952227	
 
 
  
A-6 TP53 Primer Panel 
Primer	name	 Forward	sequence	 Reverse	sequence	 Chromosome	 amp	start	 amp	end	
TP53_D0008_001F	 GTGGGGAACAAGAAGTGGAGA	 CTCCCTGCTTCTGTCTCCTAC	 17	 7572903	 7573031	
TP53_D0008_002F	 AGGAAGGGGCTGAGGTCA	 GCGCTTCGAGATGTTCCGA	 17	 7573904	 7574019	
TP53_D0008_003F	 TTGAGTTCCAAGGCCTCATTCA	 GTACTGTGTATATACTTACTTCTCCCCC	 17	 7573975	 7574077	
TP53_D0008_004F	 AAACGGCATTTTGAGTGTTAGAC	 ACAACACCAGCTCCTCTCC	 17	 7576789	 7576917	
TP53_D0008_005F	 CATCCAGTGGTTTCTTCTTTGG	 TTCACTTTTATCACCTTTCCTTGCC	 17	 7576873	 7576961	
TP53_D0008_006F	 CGCTTCTTGTCCTGCTTGC	 TGTGCCTGTCCTGGGAGA	 17	 7576996	 7577115	
TP53_D0008_007F	 ATTCTCTTCCTCTGTGCGCC	 TTGCTTCTCTTTTCCTATCCTGAGT	 17	 7577074	 7577182	
TP53_D0008_008F	 GGTCAGAGGCAAGCAGAGG	 CCTCACCATCATCACACTGGAA	 17	 7577434	 7577528	
TP53_D0008_009F	 CAAGTGGCTCCTGACCTGG	 CTAGGTTGGCTCTGACTGTACC	 17	 7577484	 7577612	
TP53_D0008_010F	 ACTGTTACACATGTAGTTGTAGTGGA	 CTTGCCACAGGTCTCCCC	 17	 7577561	 7577667	
TP53_D0008_011F	 GGCCACTGACAACCACCC	 TCGACATAGTGTGGTGGTGC	 17	 7578120	 7578213	
TP53_D0008_012F	 AGACCTCAGGCGGCTCA	 CCTCAGCATCTTATCCGAGTGG	 17	 7578173	 7578278	
TP53_D0008_013F	 ATCCAAATACTCCACACGCAAATTT	 CCTCTGATTCCTCACTGATTGCT	 17	 7578228	 7578317	
TP53_D0008_014F	 TGTCGTCTCTCCAGCCCC	 GGCCATCTACAAGCAGTCACA	 17	 7578343	 7578450	
TP53_D0008_015F	 GCCTCACAACCTCCGTCAT	 AACTGGCCAAGACCTGCC	 17	 7578407	 7578523	
TP53_D0008_016F	 GGAATCAACCCACAGCTGC	 AACTCTGTCTCCTTCCTCTTCCTA	 17	 7578483	 7578581	
TP53_D0008_017F	 TGGAAGCCAGCCCCTCA	 GTCATCTTCTGTCCCTTCCCAG	 17	 7579284	 7579408	
TP53_D0008_018F	 CCGTAGCTGCCCTGGTAG	 AGCTCCTACACCGGCG	 17	 7579364	 7579453	
TP53_D0008_019F	 TGACAGGGGCCAGGAG	 CAATGGTTCACTGAAGACCCA	 17	 7579405	 7579533	
TP53_D0008_020F	 GCATTCTGGGAGCTTCATCTG	 TGACTGCTCTTTTCACCCATCT	 17	 7579488	 7579616	
TP53_D0008_021F	 CCCAGCCCAACCCTTGTC	 GAAGCGAAAATTCCATGGGACTG	 17	 7579677	 7579766	
TP53_D0008_022F	 GCCCTTCCAATGGATCCACT	 CTTCCGGGTCACTGCCAT	 17	 7579816	 7579928	
TP53_D0008_023F	 CTAGGATCTGACTGCGGCTC	 TGGAAGTGTCTCATGCTGGATC	 17	 7579887	 7579981	
 
  
A-7 Prostate Specific Primer Panel 
Primer	name	 Forward	sequence	 Reverse	sequence	 Chr	 Amplicon	
start	
Amplicon	
end	
BRAF_D0008_001	 ACTGTTCAAACTGATGGGACCC	 ACTTACTACACCTCAGATATATTTCTTCATGA	 7	 140453098	 140453209	
BRAF_D0009_001	 TCACCTATTTTTACTGTGAGGTCTTCA	 TCTTCATAATGCTTGCTCTGATAGGA	 7	 140453154	 140453259	
BRAF_D0009_002	 CACATTACATACTTACCATGCCACTTT	 GGACTCGAGTGATGATTGGGAG	 7	 140481360	 140481476	
EGFR_D0008_001	 TCTTCGGGGAGCAGCG	 GAGACACGCCCTTACCTTT	 7	 55086955	 55087073	
EGFR_D0008_002	 GGTGGCTGGTTATGTCCTCA	 GCATCATAGTTAGATAAGACTGCTAAGG	 7	 55211009	 55211137	
EGFR_D0008_003	 AGCGTGTCCTCTCTCCTCC	 CGGGGTTCACATCCATCTGG	 7	 55221681	 55221800	
EGFR_D0008_004	 CATGCTCTACAACCCCACCA	 GATGCCTGACCAGTTAGAGGG	 7	 55221757	 55221885	
EGFR_D0008_005	 GCTATGCAAATACAATAAACTGGAAA	 GGTGACTTACTGCAGCTGTTTT	 7	 55227942	 55228041	
EGFR_D0008_006	 TGCCCACTACATTGACGGC	 CTGCGTACTTCCAGACCAGG	 7	 55232996	 55233084	
EGFR_D0008_007	 ATCGGCCTCTTCATGCGA	 GCCCTTGTTCCTGTCGGG	 7	 55240746	 55240874	
EGFR_D0008_008	 GTCTCTGTGTTCTTGTCCCCC	 GCCCAGCACTTTGATCTTTTTGAA	 7	 55241589	 55241709	
EGFR_D0008_009	 TCTCTTGAGGATCTTGAAGGAAAC	 GGGACCTTACCTTATACACCGT	 7	 55241658	 55241746	
EGFR_D0008_010	 GTTAACGTCTTCCTTCTCTCTCTGT	 AGATGTTGCTTCTCTTAATTCCTTGATAG	 7	 55242385	 55242486	
EGFR_D0008_011	 CCAGAAGGTGAGAAAGTTAAAATTCCC	 CCACACAGCAAAGCAGAAACT	 7	 55242427	 55242537	
EGFR_D0008_012	 CCCTCCTTCTGGCCACCA	 GCACACGTGGGGGTTGT	 7	 55248931	 55249027	
EGFR_D0008_013	 GCCTACGTGATGGCCAGC	 CCAGGAGGCAGCCGAA	 7	 55248989	 55249100	
EGFR_D0008_014	 AGCTCATCACGCAGCTCAT	 ATCTCCCTTCCCTGATTACCTTTG	 7	 55249062	 55249190	
EGFR_D0008_015	 GCTCAACTGGTGTGTGCAG	 GCTATCCCAGGAGCGCAG	 7	 55249144	 55249249	
EGFR_D0008_016	 ACAGCAGGGTCTTCTCTGTTTC	 CTTGACATGCTGCGGTGTTTT	 7	 55259388	 55259498	
EGFR_D0008_017	 GGCAGCCAGGAACGTACT	 TCCTTACTTTGCCTCCTTCTGC	 7	 55259456	 55259574	
EGFR_D0008_018	 CTGGGTGCGGAAGAGAAAGAATA	 GCTAGTGGGAAGGCAGCC	 7	 55259526	 55259635	
KRAS_D0008_001	 CAGATCTGTATTTATTTCAGTGTTACTTACCT	 CAGGCTCAGGACTTAGCAAGAA	 12	 25378518	 25378613	
KRAS_D0009_001	 TTCTTGCTAAGTCCTGAGCCTG	 TTAAGGACTCTGAAGATGTACCTATGG	 12	 25378592	 25378690	
KRAS_D0008_002	 ACACAAAGAAAGCCCTCCCC	 AGGAAGCAAGTAGTAATTGATGGAGA	 12	 25380216	 25380337	
KRAS_D0009_002	 TATTGTTGGATCATATTCGTCCACAAAA	 CTTGTGGTAGTTGGAGCTGGT	 12	 25398211	 25398303	
KRAS_D0008_003	 GAATTAGCTGTATCGTCAAGGCAC	 ATTATAAGGCCTGCTGAAAATGACTG	 12	 25398246	 25398337	
NRAS_D0012_001	 AGAAAATAATGCTCCTAGTACCTGTAGAG	 GGATACAGCTGGACAAGAAGAGT	 1	 115256400	 115256543	
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NRAS_D0008_001	 GTATTGGTCTCTCATGGCACTGT	 TACCCTCCACACCCCCAG	 1	 115256498	 115256617	
NRAS_D0008_002	 AAGTGGTTCTGGATTAGCTGGATT	 TTCCAACAGGTTCTTGCTGGT	 1	 115258699	 115258807	
PIK3CA_D0012_002	 CTCAAGAAGCAGAAAGGGAAGAATTT	 TCTTTTCTTCACGGTTGCCTACT	 3	 178916834	 178916947	
PIK3CA_D0012_001	 CTTCGGCTTTTTCAACCCTTTTTAAAA	 AATATTTTAGAAAGGGACAACAGTTAAGCT	 3	 178916887	 178917036	
PIK3CA_D0012_003	 CATTTCCACAGCTACACCATATATGAAT	 ATTTGACTTTACCTTATCAATGTCTCGAAT	 3	 178921448	 178921589	
PIK3CA_D0012_004	 CCCATTATTATAGAGATGATTGTTGAATTTTCC	 AACAAGTTTATATTTCCCCATGCCAAT	 3	 178927868	 178928011	
PIK3CA_D0008_001	 AGGGAAAATGACAAAGAACAGC	 TTTTAGCACTTACCTGTGacTCCA	 3	 178936028	 178936135	
PIK3CA_D0012_005	 GATGCTTGGCTCTGGAATGC	 TTGTCCAGCCACCATGATGT	 3	 178951957	 178952102	
PIK3CA_D0008_002	 CAAGAGGCTTTGGAGTATTTCATGAA	 ATGCATGCTGTTTAATTGTGTGGA	 3	 178952042	 178952144	
TP53_D0008_001	 GTGGGGAACAAGAAGTGGAGA	 CTCCCTGCTTCTGTCTCCTAC	 17	 7572903	 7573031	
TP53_D0008_002	 AGGAAGGGGCTGAGGTCA	 GCGCTTCGAGATGTTCCGA	 17	 7573904	 7574019	
TP53_D0008_003	 TTGAGTTCCAAGGCCTCATTCA	 GTACTGTGTATATACTTACTTCTCCCCC	 17	 7573975	 7574077	
TP53_D0008_004	 AAACGGCATTTTGAGTGTTAGAC	 ACAACACCAGCTCCTCTCC	 17	 7576789	 7576917	
TP53_D0008_005	 CATCCAGTGGTTTCTTCTTTGG	 TTCACTTTTATCACCTTTCCTTGCC	 17	 7576873	 7576961	
TP53_D0008_006	 CGCTTCTTGTCCTGCTTGC	 TGTGCCTGTCCTGGGAGA	 17	 7576996	 7577115	
TP53_D0008_007	 ATTCTCTTCCTCTGTGCGCC	 TTGCTTCTCTTTTCCTATCCTGAGT	 17	 7577074	 7577182	
TP53_D0008_008	 GGTCAGAGGCAAGCAGAGG	 CCTCACCATCATCACACTGGAA	 17	 7577434	 7577528	
TP53_D0008_009	 CAAGTGGCTCCTGACCTGG	 CTAGGTTGGCTCTGACTGTACC	 17	 7577484	 7577612	
TP53_D0008_010	 ACTGTTACACATGTAGTTGTAGTGGA	 CTTGCCACAGGTCTCCCC	 17	 7577561	 7577667	
TP53_D0008_011	 GGCCACTGACAACCACCC	 TCGACATAGTGTGGTGGTGC	 17	 7578120	 7578213	
TP53_D0008_012	 AGACCTCAGGCGGCTCA	 CCTCAGCATCTTATCCGAGTGG	 17	 7578173	 7578278	
TP53_D0008_013	 ATCCAAATACTCCACACGCAAATTT	 CCTCTGATTCCTCACTGATTGCT	 17	 7578228	 7578317	
TP53_D0008_014	 TGTCGTCTCTCCAGCCCC	 GGCCATCTACAAGCAGTCACA	 17	 7578343	 7578450	
TP53_D0008_015	 GCCTCACAACCTCCGTCAT	 AACTGGCCAAGACCTGCC	 17	 7578407	 7578523	
TP53_D0008_016	 GGAATCAACCCACAGCTGC	 AACTCTGTCTCCTTCCTCTTCCTA	 17	 7578483	 7578581	
TP53_D0008_017	 TGGAAGCCAGCCCCTCA	 GTCATCTTCTGTCCCTTCCCAG	 17	 7579284	 7579408	
TP53_D0008_018	 CCGTAGCTGCCCTGGTAG	 AGCTCCTACACCGGCG	 17	 7579364	 7579453	
TP53_D0008_019	 TGACAGGGGCCAGGAG	 CAATGGTTCACTGAAGACCCA	 17	 7579405	 7579533	
TP53_D0008_020	 GCATTCTGGGAGCTTCATCTG	 TGACTGCTCTTTTCACCCATCT	 17	 7579488	 7579616	
TP53_D0008_021	 CCCAGCCCAACCCTTGTC	 GAAGCGAAAATTCCATGGGACTG	 17	 7579677	 7579766	
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TP53_D0008_022	 GCCCTTCCAATGGATCCACT	 CTTCCGGGTCACTGCCAT	 17	 7579816	 7579928	
TP53_D0008_023	 CTAGGATCTGACTGCGGCTC	 TGGAAGTGTCTCATGCTGGATC	 17	 7579887	 7579981	
CTNNB1_D0008_001	 AGCGGCTGTTAGTCACTGG	 GTATCCACATCCTCTTCCTCAGG	 3	 41266060	 41266179	
FOXA1_D0006_001	 ACGGTTTGGTTTGTGTGGTTTT	 AGCCCCATCGAGCCCT	 14	 38060479	 38060647	
FOXA1_D0006_002	 TAGTACGCCGGCTCCAGG	 ACTCCTTCAACCACCCGT	 14	 38060610	 38060808	
FOXA1_D0006_003	 AGGAGGACATGAGGTTGTTGATG	 GCGCCTCGGAGTTGAAGA	 14	 38060764	 38060955	
FOXA1_D0006_004	 GCGCAGTTGAGGAGGCT	 TGGCGCCTCTAACCCCA	 14	 38060917	 38061095	
FOXA1_D0006_005	 ATGGAGGGGCGAGTCG	 TCCGGCAACATGTTCGAGAA	 14	 38061059	 38061241	
FOXA1_D0006_006	 GCTTCTGGCGGCGCAA	 GCAGAACCAGCAGCGC	 14	 38061196	 38061365	
FOXA1_D0006_007	 GAGTGGCGGATGGAGTTCT	 TACCCGCACGCCAAGC	 14	 38061327	 38061493	
FOXA1_D0006_008	 TGATGAGCGAGATGTACGAGTAG	 AGGCGGCCTCCATGAATG	 14	 38061451	 38061630	
FOXA1_D0006_009	 ACGGGTTCATGGCGGC	 CAGTAGCCGGCATGCC	 14	 38061580	 38061747	
FOXA1_D0006_010	 TGCTGTTCATGGCGCCC	 TGAACTCCATGAACACCTACAT	 14	 38061703	 38061867	
FOXA1_D0006_011	 CGCTCGTAGTCATGGTGTTCA	 CCTCCAGTGCCCACCA	 14	 38061820	 38061978	
FOXA1_D0006_012	 TGCCTGCCTTGCCTGG	 TGGTTGTATTGGGCAGGGTG	 14	 38064012	 38064205	
SPOP_D0006_001	 ACGGAGTCTTACAACAAGCAGG	 AACCCATTTCTCCACATTTCTCCT	 17	 47677715	 47677910	
SPOP_D0006_002	 CTACTTGCCTGCTTTACCCACTA	 GCAGAAATTCTCATCCTGGCC	 17	 47679133	 47679300	
SPOP_D0006_003	 TTCAACTGATCTGCACTGTGGA	 AGAACTATTGCTGCTCTGATGACA	 17	 47679254	 47679413	
SPOP_D0006_004	 TTTACCCACAATGCAACATAGAATCC	 TCATTTACACGGGGAAGGCTC	 17	 47684521	 47684679	
SPOP_D0006_005	 AAATCATCAGCCATTTTGTCGAGG	 TTTAGTTTAGGGATTTTGTTCTGTTGGAA	 17	 47684631	 47684793	
SPOP_D0006_006	 ATGAATCTGCAGCTAAAGTGGGA	 CCTTATCTGCTTGTTTCTCTTTGACTT	 17	 47685157	 47685323	
SPOP_D0006_007	 CCTTATTTCACCAAAACTATAAAATTCCTCATG	 AAGGTTCCTGAGTGCCGG	 17	 47688596	 47688762	
SPOP_D0006_008	 CCACAGTCCTCCTAACTCATCTG	 ACAGCAGTTAGGTAAAAGTCGTCT	 17	 47688718	 47688905	
SPOP_D0006_009	 GCTAGTCTCAGCAGAATACAAGGA	 TCCCCACCCCAGAGAGTC	 17	 47696314	 47696482	
SPOP_D0006_010	 GCCTTGCACAAACCTATATGCC	 CAAGGGAGAAGAAACCAAAGCTATG	 17	 47696439	 47696621	
SPOP_D0006_011	 AACCAGATCAAAGCCACAACTTG	 ACCTGTTACTGGTCAGCTGTC	 17	 47696513	 47696688	
SPOP_D0006_012	 TGAATTTTGCCCGAACTTCACTC	 CAGTTCTATCAAAATGGATGCTTTTGAC	 17	 47696641	 47696803	
SPOP_D0006_013	 CAGTGTCCCATAAAACCAAACAAAAC	 TCCTACATGTGGACCATCAATAACTTT	 17	 47699236	 47699411	
SPOP_D0006_014	 CCCATTTCCTCCCGGCAAA	 ATGCAGAGGGAGGGAGGG	 17	 47699362	 47699527	
SPOP_D0006_015	 AGATGCAAGATTCACAGGCTGA	 GGTGAAGAGGGAACAGAAATCTTTG	 17	 47700059	 47700238	
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OR5L1_D0006_001	 GGAGACATGGGCAAGGAAAAC	 GACCTGAATCAGTGCAATCATG	 11	 55578937	 55579095	
OR5L1_D0006_002	 TGGAGTCACGTTGTTAGCCAA	 CACCATGCACCCTAGGAAG	 11	 55579047	 55579239	
OR5L1_D0006_003	 TTAACAAGGACAAAGCCATCTCC	 CAGCTCCACACGCACCT	 11	 55579199	 55579374	
OR5L1_D0006_004	 TTGCTATACACAGTCACCATGTCT	 CACAGTGATATCAGAGCAAGCAAG	 11	 55579330	 55579524	
OR5L1_D0006_005	 TCTGTGATCTACCTCCTGTCTT	 TGGGAAGCACAGGTGGAG	 11	 55579475	 55579673	
OR5L1_D0006_006	 CAGAGGGCAGGCACAAAG	 AGTTCAGCATAGGAATCACGACT	 11	 55579634	 55579801	
OR5L1_D0006_007	 AAAGTGGCCACCGTGTTCT	 CCAACACTGTGCCTCTCCC	 11	 55579756	 55579953	
AR_D0006_001	 AGTAGGTGGAAGATTCAGCCAAG	 CAAACTGGCGCCGGGA	 X	 66764959	 66765150	
AR_D0006_002	 GTGATCCAGAACCCGGGC	 CATCCTCACCCTGCTGCTG	 X	 66765085	 66765271	
AR_D0006_003	 GCAAGAGACTAGCCCCAGG	 CAGGCTCTGGGACGCA	 X	 66765225	 66765394	
AR_D0006_004	 AGTGCCACCCCGAGAGA	 GTGCTGGCCTCGCTCA	 X	 66765359	 66765557	
AR_D0006_005	 TGCTCCGCTGACCTTAAAGAC	 GCGTTGTCAGAAATGGTCGA	 X	 66765517	 66765695	
AR_D0006_006	 CTCCAAGGACAATTACTTAGGGGG	 CAAAAGTGGGGCGTACATGC	 X	 66765648	 66765807	
AR_D0006_007	 AGGGGAACAGCTTCGGGG	 CCTTCTAGCCCTTTGGTGTAAC	 X	 66765765	 66765953	
AR_D0006_008	 ACTGCTGAGTATTCCCCTTTCAAG	 GTCGCGACTCTGGTACG	 X	 66765904	 66766077	
AR_D0006_009	 GAGCACTGGACGAGGCA	 GTCCCCATAGCGGCACTG	 X	 66766040	 66766218	
AR_D0006_010	 TGGACTACGGCAGCGC	 CCATACAACTGGCCTTCTTCG	 X	 66766166	 66766331	
AR_D0006_011	 CATCCTGGCACACTCTCTTCA	 TCGCTTTCCTGGCCCG	 X	 66766286	 66766475	
AR_D0006_012	 TACACTCGGCCCCCTCAG	 AGGCGACATTTCTGGAAGGAA	 X	 66766435	 66766633	
AR_D0006_013	 ACCTGAGACTTCACTTGCCTATTT	 CCATAGTGACACCCAGAAGCTT	 X	 66863027	 66863199	
AR_D0006_014	 AGACCTGCCTGATCTGTGGA	 GTTAGTGTCTCTCTCTGGAAGGTAAA	 X	 66863154	 66863315	
AR_D0006_015	 ACTCATTATCAGGTCTATCAACTCTTGTAT	 AGAGGAAGGAGGAGGAAGAGAAA	 X	 66905810	 66906005	
AR_D0006_016	 AAAAGGTAGTTGCATTGTGTGTTTTT	 GCTTCTGGGTTGTCTCCTCA	 X	 66931176	 66931336	
AR_D0006_017	 TTCCAGCACCACCAGCC	 CAAGGCTGCAAAGGAGTCG	 X	 66931296	 66931461	
AR_D0006_018	 GCTGGACACGACAACAACC	 TCCATAGGAGCGTTCACTAAATATGAT	 X	 66931420	 66931595	
AR_D0006_019	 CAGACTGACCACTGCCTCTG	 GCGAAGTAGAGCATCCTGGA	 X	 66937285	 66937443	
AR_D0006_020	 TGGCGATCCTTCACCAATGT	 GCTAAGCTTCACTGTCACCCC	 X	 66937400	 66937558	
AR_D0006_021	 TTCCTCTGTGTATCTCCTTCCC	 ATTCCCTGCACTTCTAGGCAC	 X	 66941651	 66941830	
AR_D0006_022	 GTCAGAAAACTTGGTGCTTTGTCTA	 CATGCAATGATACGATCGAGTTCC	 X	 66942590	 66942753	
AR_D0006_023	 TTCTTTGATGAACTTCGAATGAACTACA	 GCTCTATCAGGCTGTTCTCCC	 X	 66942698	 66942876	
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AR_D0006_024	 ACAAAAGGCTGAAAGACCAAAAATCA	 AAGTCCACGCTCACCATGT	 X	 66943428	 66943595	
AR_D0006_025	 AGTTCACTTTTGACCTGCTAATCA	 TGGGGTGGGGAAATAGGGT	 X	 66943547	 66943712	
AKT1_D0006_001	 TGTAGCCAATGAAGGTGCCAT	 GCACATCTGTCCTGGCACA	 14	 105246485	 105246649	
OR5L1_D0007_008	 TTTTTAAGTTTCTTTTCCTCCAATC	 CATCTGATAGTCCAAGGAGAATG	 11	 55578901	 55579000	
HRAS_D0008_001	 TGCGCATGTACTGGTCCC	 CCGGAAGCAGGTGGTCATT	 11	 533836	 533936	
HRAS_D0008_002	 GGATGGTCAGCGCACTCTT	 AGGTGGGGCAGGAGAC	 11	 534259	 534377	
IDH1_D0008_001	 GCCAACATGACTTACTTGATCCC	 GGTGGCACGGTCTTCAGAG	 2	 209113078	 209113197	
SPOP_D0020_001	 TGGTTTCTTCTCCCTTGGCATT	 CCAAAGGGTTAGATGAAGAAAGCAA	 17	 47696605	 47696730	
SPOP_D0020_002	 CCAGTAACAGGTAAAGTGACAGGTA	 GTTCTATCAAAATGGATGCTTTTGACATT	 17	 47696677	 47696801	
SPOP_D0020_003	 ATTCTTCCTCACCATTTCAGTTTATCATT	 TCCTACATGTGGACCATCAATAACTTT	 17	 47699296	 47699411	
SPOP_D0020_004	 CCCATTTCCTCCCGGCAAA	 CCACTTCCTATTTAATTGCTTCCTGTT	 17	 47699362	 47699469	
SPOP_D0020_005	 AGATGCAAGATTCACAGGCTGA	 TCCAAGTCCTCCACCTCCG	 17	 47700059	 47700161	
SPOP_D0020_006	 CGGGGCCACTCGACATTT	 CTGACTTTGGAAATCTCGTTTAACCT	 17	 47700121	 47700209	
FOXA1_D0020_007	 CTCATGCACGGGTTCATGG	 CATGGGTACGGCGCTGAG	 14	 38061573	 38061680	
FOXA1_D0020_008	 CATTCATGGAGGCCGCC	 GGGCGCCATGAACAGCA	 14	 38061613	 38061719	
FOXA1_D0020_009	 GTACCCATGGCCGTCACG	 CATGTCCTATGCCAACCCG	 14	 38061672	 38061794	
PTEN_E00001156315_1m	 GCAACAGATAACTCAGATTGCCTT	 GTTTCCTCTGGTCCTGGTATGA	 10	 89720457	 89720706	
PTEN_E00001156315_5	 AGGACAAAATGTTTCACTTTTGGGTAA	 ACTAGATATTCCTTGTCATTATCTGCAC	 10	 89720649	 89720799	
PTEN_E00001156315_7	 CCTCAGAAAAAgTAGAAAATGGAAGTC	 ACAAGTCAaCAACCCCCACA	 10	 89720706	 89720915	
PTEN_E00001156321_1	 TGACAGTTTGACAGTTAAAGGCAT	 CACACACAGGTAACGGCTGA	 10	 89717547	 89717726	
PTEN_E00001156321_2	 TGTGGTCTGCCAGCTAAAGG	 TCTCCCAATGAAAGTAAAGTACAAACC	 10	 89717620	 89717802	
PTEN_E00001156321_4m	 TCCACAAACAGAACAAGATGCT	 GGCCTTTTCCTTCAAACAGGATT	 10	 89717748	 89717956	
PTEN_E00001156327_1	 TCTTAAATGGCTACGACCCAG	 TCCAGATGATTCTTTAACAGGTAGC	 10	 89711775	 89711942	
PTEN_E00001156327_4	 CAGTCAGAGGCGCTATGTGT	 TCTAGATATGGTTAAGAAAACTGTTCCA	 10	 89711889	 89712077	
PTEN_E00001156330_1	 ttCTTATTCTGAGGTTATCTTTTTACCAC	 TCATTACACCAGTTCGTCCCT	 10	 89692739	 89692919	
PTEN_E00001156330_3	 TGACCAATGGCTAAGTGAAGATGA	 TCCAGGAAGAGGAAAGGAAAAACA	 10	 89692840	 89693048	
PTEN_E00001156337_4	 TATATCACTTTTAAACTTTTCTTTTAGTTGTGC	 CTCGATAATCTGGATGACTCATTATTGTT	 10	 89690776	 89690940	
PTEN_E00001156344_1	 AATCTGTCTTTTGGTTTTTCTTGATAGT	 AATAGTTGTTTTAGAAGATATTTGCAAGC	 10	 89685172	 89685367	
PTEN_E00001156351_1	 TGCTGCATATTTCAGATATTTCTTTCCTTA	 ATGAAAACACAACATGAATATAAACATCAAT	 10	 89653738	 89653927	
PTEN_E00001456541_1	 AGATGAGTcATATTTGTGGGTTTTCA	 TCTGGATCAGAGTCAGTGGT	 10	 89724997	 89725180	
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PTEN_E00001456541_2	 GTAGAGGAGCCGTCAAATCCA	 TTCATGGTGTTTTATCCCTCTTGA	 10	 89725068	 89725264	
PTEN_E00001456562_1	 GCAGCTTCTGCCATCTCTCT	 TCCGTCTACTCCCACGTTCT	 10	 89624175	 89624372	
 
  
A-8 Summary of TP53 mutant allele fractions determined using 
TAm-seq 
Sample	 Chr	 Position	 Reference	 Mutation	 AF	(weighted	average)	
002_blood	 17	 7577565	 T	 G	 0.04%	
002_plasma	 17	 7577565	 T	 G	 1.54%	
002_tissue01	 17	 7577565	 T	 G	 76.09%	
002_tissue02	 17	 7577565	 T	 G	 0.97%	
002_tissue03	 17	 7577565	 T	 G	 45.29%	
002_tissue04	 17	 7577565	 T	 G	 0.00%	
014_blood01	 17	 7579422	 G	 A	 0.26%	
014_blood01	 17	 7579421	 G	 A	 0.46%	
014_blood01	 17	 7577121	 G	 A	 0.25%	
014_plasma	 17	 7579422	 G	 A	 0.36%	
014_plasma	 17	 7579421	 G	 A	 0.64%	
014_plasma	 17	 7577121	 G	 A	 30.00%	
014_tissue01	 17	 7579422	 G	 A	 0.20%	
014_tissue01	 17	 7579421	 G	 A	 0.16%	
014_tissue01	 17	 7577121	 G	 A	 37.65%	
014_tissue02	 17	 7579422	 G	 A	 0.78%	
014_tissue02	 17	 7577121	 G	 A	 48.09%	
014_tissue02	 17	 7579421	 G	 A	 1.02%	
014_tissue03	 17	 7579422	 G	 A	 1.36%	
014_tissue03	 17	 7577121	 G	 A	 1.66%	
014_tissue03	 17	 7579421	 G	 A	 1.20%	
014_tissue04	 17	 7577121	 G	 A	 35.45%	
014_tissue04	 17	 7579421	 G	 A	 0.18%	
014_tissue04	 17	 7579422	 G	 A	 0.20%	
068_blood	 17	 7577139	 G	 A	 0.18%	
068_bloodrep_2	 17	 7577139	 G	 A	 0.19%	
068_Tissue02	 17	 7577139	 G	 A	 32.98%	
068_Tissue03	 17	 7577139	 G	 A	 0.17%	
068_Tissue04	 17	 7577139	 G	 A	 0.19%	
068_Tissue05	 17	 7577139	 G	 A	 0.65%	
094_blood	 17	 7577085	 C	 T	 0.00%	
094_bloodrep_2	 17	 7577085	 C	 T	 0.15%	
094_tissue	 17	 7577085	 C	 T	 33.02%	
130_blood	 17	 7577121	 G	 A	 0.24%	
130_bloodrep_2	 17	 7577121	 G	 A	 0.24%	
130_tissue	 17	 7577121	 G	 A	 60.96%	
299_blood01	 17	 7579313	 G	 A	 0.19%	
299_blood01	 17	 7578475	 G	 A	 0.30%	
299_blood01rep_2	 17	 7578475	 G	 A	 0.36%	
299_blood01rep_2	 17	 7579313	 G	 A	 0.20%	
299_plasma	 17	 7579313	 G	 A	 0.16%	
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299_plasma	 17	 7578475	 G	 A	 0.12%	
299_tissue01	 17	 7579313	 G	 A	 0.20%	
299_tissue01	 17	 7578475	 G	 A	 0.22%	
299_tissue04	 17	 7579313	 G	 A	 0.43%	
299_tissue04	 17	 7578475	 G	 A	 0.38%	
299blood_02	 17	 7578475	 G	 A	 0.25%	
299blood_02	 17	 7579313	 G	 A	 0.28%	
299tissue_02	 17	 7579313	 G	 A	 0.23%	
299tissue_02	 17	 7578475	 G	 A	 0.32%	
299tissue_03	 17	 7578475	 G	 A	 66.49%	
299tissue_03	 17	 7579313	 G	 A	 3.53%	
486_blood	 17	 7577124	 C	 G	 0.00%	
486_bloodrep_2	 17	 7577124	 C	 G	 0.01%	
486_plasma	 17	 7577124	 C	 G	 0.26%	
486_tissue01	 17	 7577124	 C	 G	 0.35%	
486_tissue02	 17	 7577124	 C	 G	 58.72%	
498_blood01	 17	 7578528	 A	 T	 0.31%	
498_blood01	 17	 7578526	 C	 T	 0.34%	
498_blood01	 17	 7578410	 T	 A	 0.07%	
498_blood01rep_2	 17	 7578526	 C	 T	 0.29%	
498_blood01rep_2	 17	 7578410	 T	 A	 0.10%	
498_blood01rep_2	 17	 7578528	 A	 T	 0.41%	
498_blood02	 17	 7578526	 C	 T	 0.57%	
498_blood02	 17	 7578528	 A	 T	 0.54%	
498_blood02	 17	 7578410	 T	 A	 0.29%	
498_plasma	 17	 7578528	 A	 T	 0.06%	
498_plasma	 17	 7578526	 C	 T	 0.19%	
498_plasma	 17	 7578410	 T	 A	 0.13%	
498_tissue01	 17	 7578528	 A	 T	 0.05%	
498_tissue01	 17	 7578410	 T	 A	 0.89%	
498_tissue01	 17	 7578526	 C	 T	 0.31%	
498_tissue02	 17	 7578526	 C	 T	 24.81%	
498_tissue02	 17	 7578410	 T	 A	 0.02%	
498_tissue02	 17	 7578528	 A	 T	 60.45%	
498_tissue03	 17	 7578410	 T	 A	 0.06%	
498_tissue03	 17	 7578528	 A	 T	 65.35%	
498_tissue03	 17	 7578526	 C	 T	 27.91%	
498_tissue04	 17	 7578410	 T	 A	 0.08%	
498_tissue04	 17	 7578526	 C	 T	 0.58%	
498_tissue04	 17	 7578528	 A	 T	 0.70%	
513_blood	 17	 7573952	 G	 A	 0.18%	
513_bloodrep_2	 17	 7573952	 G	 A	 0.17%	
513_tissue01	 17	 7573952	 G	 A	 1.70%	
513_tissue02	 17	 7573952	 G	 A	 0.14%	
CamP_FFPE_11	 17	 7579422	 G	 A	 6.65%	
 
  
A-9 Multifocal Prostate Cancer Case 7 Primer Panel. 
Primer	name	 Fwd	sequence	 Rev	sequence	 Chromosome	 amp	start	 amp	end	
Exon_ABI3BP_7_T2F	 GTACATGACTAACGTACCTGCACTT	 CTTGCCACCCAGACCTACAC	 3	 100497111	 100497204	
Exon_ADAM28_7_NF	 TTTTGTTTTTCTACAGTTTAAAAAGGCTGG	 AGATTTACCATTACACATTTCAGGCAG	 8	 24192943	 24193033	
Exon_ATF1_7_N+7_T1+7_T2F	 GTATGTGACAAAAGATACCATAAAGAAAC	 CCTTCTGTTAGGTCTCTTATTTACAG	 12	 51211428	 51211575	
Exon_AUTS2_7_T1+7_T2F	 gtgatccacccacctTCTTTT	 TGTACAACATCTCAGTGTCCAC	 7	 70186522	 70186621	
Exon_BCAT1_7_NF	 TGTCACTCCTGGAAGAATGATGC	 TGTAGTGAAAGTTTGAAAATGTCCCAA	 12	 24989478	 24989571	
Exon_C1RL_X_F	 ctaaactttcagtaaatacctgccttgg	 ttctccgtgtaactcaattttgcc	 12	 23274587	 23274677	
Exon_CEP112_7_NF	 GGTCTTCTGAAGCTGGAGATGAA	 CACGTGAGAAGACCGAATCCTC	 17	 63640501	 63640591	
Exon_CHPF2_7_NF	 CCTGCTGTTGGAATGTGTGAC	 GATTTCCACCCGGCTCAGT	 7	 150934789	 150934879	
Exon_CLEC12A_7_T1F	 ggaggattgggttgtgagtgaa	 tttcgtgacaaactttcttctccaaa	 12	 10159148	 10159239	
Exon_CXorf38_7_T1F	 cttttggctatagtgaatggagc	 aaGaaacaattaaacagttaccacatgac	 X	 40503305	 40503440	
Exon_DEPDC1B_7_T1+7_T2F	 ttggtgctgcagacatttactaa	 ctttctttccctgtattatggtggac	 5	 59957684	 59957790	
Exon_DLC1_7_T1F	 AGGTAATCAGGTATGTACAGCCACTA	 ACTCTCACTACTATAGCAAAGTCTTATAGAAAT	 8	 13334861	 13334970	
Exon_FAT2_7_NF	 GTCAGAGCCCTCATAGTTGGG	 CAAGGGGGTGGGTATGCG	 5	 150885171	 150885291	
Exon_GGNBP1_7_NF	 gtctcaactttgctattcctttgctat	 agatgcacaggaaagcttaca	 6	 33554891	 33555017	
Exon_GSDMD_7_T3F	 AACTGGAGCTTTTGGACAGAGAG	 GCTCACCGCCTCCTCCAA	 8	 144644204	 144644307	
Exon_KIT_7_T1+7_T2F	 GAGATCCTGGATGAAACGAATGAGAA	 GTTTGTTGGTGCACGTGTATTTG	 4	 55561815	 55561911	
Exon_LHFPL3_7_N+7_T1+7_T2F	 cgtgcccagccGGATCTT	 AGATCTATAAACTTCTGAATAGCTCCAGG	 7	 104449630	 104449728	
Exon_MIPOL1_7_T3F	 ACCCTTAGTACATATGAAGAAGCTTTAAAA	 GTTGCAGTTGAGTAGCCAGTTC	 14	 37969165	 37969258	
Exon_PARP3_7_T3F	 TATGAGGACTACAACTGCACCC	 AGCAGGTGAAGAAGCGGTT	 3	 51978108	 51978213	
Exon_POTEA_7_T3F	 tcacctctcactgcatcctct	 gtacaaagaaattagctgggcat	 8	 43210586	 43210698	
Exon_RFTN1_7_T5F	 CACTATGCCCCTCCTCTGTG	 TCTCCCTGGGTCGTTCATTAAA	 3	 16408330	 16408436	
Exon_SF3B1_7_T1+7_T2F	 CATAAAGGCTTTAACACAGAATCAAAAGAT	 GTTTTGTAGGTCTTGTGGATGAGC	 2	 198266737	 198266863	
Exon_SH3RF2_7_T3F	 GGTGTCCTCGTCCTCCAGA	 TGTTGTGATGGAAAACTGCCC	 5	 145393384	 145393474	
Exon_STAB1_7_T3F	 GGTGAGCAGCGACCATGAG	 CATCAGGCTCCCAGTGCAG	 3	 52553312	 52553403	
fusion_7_T1-7_T2_FWD	 TAACTGTGGCCTCCACAACA	 TCTGGTCTGAACGTTGCACT	 21	 39872107	 42861556	
fusion_7_T2_FWD	 GTTTCCCAAGGCCACATAAG	 TGATCCTCCAGTCTTGAAACA	 21	 39831176	 42875664	
fusion_7_T3_FWD	 TGCTTCCAGTTTAGGAGTTCA	 AGTGCTCTGTGAAGCCCTGT	 21	 39861534	 42865380	
fusion_7_T4_FWD	 CATTGGATCCATAGCCTGGT	 TTGTCATGAAGGAACTCCTGTTT	 21	 39835710	 42867198	
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fusion_7_T4-7_T5_FWD	 GTATAACACATTTGGATGTTTTGC	 CCTATCATTACTCGATGCTGTTG	 21	 39868687	 42870094	
Inter_7_N_R30F	 ATCAGAGCAGGTTTGCAGGA	 TCATTGAGAGCTCCCCTTTT	 5	 110209013	 110209100	
Inter_7_N_R32F	 CCTTCCATACTGCCCTAGCA	 GGATGTACGGAAACATCTGGA	 X	 141602686	 141602775	
Inter_7_N+7_T1+7_T2_R33F	 AAGTTGGAACAATCTGGAGGT	 TCTGGAAGTGGAATTTCTAAGTCA	 6	 45861989	 45862078	
Inter_7_N+7_T1+7_T2_R34F	 GAGGCTGGCAATTTCAAGAG	 CCATGTTATGCCTTCTGCAA	 8	 29553417	 29553487	
Inter_7_T1_R35F	 GAATGACCTGGTAGAGCTTGG	 GCAAAAGTTTAGGAACCTCTGG	 12	 41275171	 41275280	
Inter_7_T1_R36F	 CCCTACCCGGTGTAGTGCTT	 TGCTGCTTTCATTCTTCCAA	 3	 117270159	 117270260	
Inter_7_T1_R37F	 TGTCAAAATCAGGTGTTGTAAAGC	 AGCGAGAACCTGTCTCCAAA	 5	 166259124	 166259235	
Inter_7_T1+7_T2_R38F	 TGACCGATGTTGGTTCTTGT	 TGGTTTTGCCTTCATTTTACG	 13	 54324236	 54324325	
Inter_7_T1+7_T2_R39F	 TGCTCTTCCATAATGGTGTCA	 TCAGCATGGAAAAACTAGAATGA	 4	 116523668	 116523758	
Inter_7_T1+7_T2_R41F	 TCTGGCAGAGACGTCTGAAA	 CCAAATTACCAGTATTTACTTCAGAAAG	 5	 18258995	 18259149	
Inter_7_T1+7_T2_R42F	 GACTAAAGGTTTGGTGTGAGGA	 ACTCAGGCCCTGCTGTTCT	 10	 109614775	 109614867	
Inter_7_T1+7_T2_R43F	 TGGAATGATGAGAATGAAGCA	 TGGGTCTGTGGTATTCCATTT	 3	 87172178	 87172266	
Inter_7_T1+7_T2_R44F	 GTGCAGCAGAGAAAATCCAA	 TTACTGCCCACTCCACACTG	 13	 80622031	 80622120	
Inter_7_T1+7_T2+7_T3+7_T4+7_T5_R45F	 TCCCAAGTAGCTGGGACTACA	 CTGGCCAACATGGTGAAAC	 1	 5130934	 5130934	
Inter_7_T2_R40F	 TCCCAAAGACTGAAAATTAGGA	 CCAGATGTTTGACCTTGAGAAA	 5	 130131369	 130131467	
Inter_7_T2_R46F	 TCCCTGTGGAATGTTTGTGA	 TGCTTGCAAAGGAATTACACC	 6	 97811929	 97812021	
Inter_7_T2_R47F	 GCACAACAGTAATGACTTCCATTT	 GGGCGATGTGATTGCCTAT	 11	 41199267	 41199359	
Inter_7_T2_R48F	 CCTACACCAGCTAAAGAGGTCA	 TGCTCCATAAAGGAGGAGAAA	 4	 78936913	 78937005	
Inter_7_T2_R49F	 CATCTAGTTATTTCTAATCACTTGGTAGC	 TGGCCACCTAAATTCTAGAGC	 1	 79871422	 79871541	
Inter_7_T2_R50F	 CAAAACAAACAAACAAAAAGCAC	 CTGTGTCAAGATTCATGGAAGG	 14	 26540930	 26541010	
Inter_7_T3_R51F	 GAGAAAATCAATTAAACCAAAAGCTG	 GATTTTGATAATTCGTGTCTTTCTGT	 9	 25277874	 25277983	
Inter_7_T3_R52F	 AATTCATTCCCAGAGGCAAA	 GGATTCAAAAGGGCCTCAGT	 6	 135025448	 135025534	
Inter_7_T3+7_T4_R53F	 AGAAGCACCCAGCAAGATGT	 TGGAGTTCAGTGAGGTGTGAA	 16	 9513898	 9513986	
Inter_7_T3+7_T4_R54F	 AGGTAGCCAGTCAGACGTGA	 TCAACTGACTTTCCTGGTTGG	 11	 920454	 920529	
Inter_7_T3+7_T4_R55F	 AGGCTCTCTCCAAGAAGAAACA	 CAGGGAACAAGGGAAAACAA	 7	 109273264	 109273350	
Inter_7_T3+7_T4+7_T5_R56F	 GGAAATGCGCAGAAAGAAAA	 TTCATGTGCCATTACCACAA	 15	 98904543	 98904655	
Inter_7_T3+7_T4+7_T5_R57F	 GCCTTGGCGTCCACTCT	 GCTGGCTCTGAACTTGCTCT	 6	 74612755	 74612848	
Inter_7_T4_R58F	 CGGTGGCTCACACCTGTAAT	 TCAGGCTCGTCTCAAACTCC	 3	 182725221	 182725221	
Inter_7_T5_R59F	 TGCCATTACAAAACGATTACAAA	 TTCCTTCTCCTCCCAAATGA	 10	 36173021	 36173114	
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Inter_7_T5_R60F	 GAGGACAACATACACTCCACCA	 ACACAGCTGCAGCAAATGAT	 7	 9063467	 9063541	
Inter_7_T5_R61F	 TGGTCTTGGGTAAGATCTGGA	 GAAACTCCACTTGCTTGAGAGAA	 5	 28556789	 28556880	
Mitochon_7_10_F	 TCTCACTTCAACCTCCCTCAC	 GGTTTCGATGATGTGGTCTTT	 M	 13438	 13531	
Mitochon_7_11_F	 CATCCCTACGCATCCTTTACA	 TGAAGATTAGTCCGCCGTAGT	 M	 7822	 7941	
Mitochon_7_12_F	 ACTACGGCGGACTAATCTTCA	 ACTCGATTGTCAACGTCAAGG	 M	 7921	 8011	
Mitochon_7_13_F	 CCCACAGGTCCTAAACTACCA	 GTTCGCTTTGACTGGTGAAGT	 M	 2772	 2883	
Mitochon_7_14_F	 GCCTTCTCCTCACTCTCTCAA	 TGCTAAGATTTTGCGTAGCTG	 M	 4925	 5010	
Mitochon_7_15_F	 ACCGAACGAAAAATTCTAGGC	 GAAGAGTTTTATGGCGTCAGC	 M	 3374	 3475	
Mitochon_7_16_F	 AGCCAATATTGTGCCTATTGC	 AGGCCATATGTGTTGGAGATT	 M	 10635	 10730	
Mitochon_7_17_F	 TCCCCCATTATTCCTAGAACC	 TATTATACGAATGGGGGCTTC	 M	 7955	 8045	
Mitochon_7_18_F	 GCCGCAGTACTGATCATTCTAT	 TTAGTCATTGTTGGGTGGTGA	 M	 8582	 8675	
Mitochon_7_19_F	 ATTTAGCTGACTCGCCACACT	 CCACCTACGGTGAAAAGAAAG	 M	 6864	 6959	
Mitochon_7_20_F	 AGCAGGAACAGGTTGAACAGT	 ATGGCCCCTAAGATAGAGGAG	 M	 6267	 6389	
Mitochon_7_21_F	 CAGCACCACGACCCTACTACT	 AGGAGGGTGGATGGAATTAAG	 M	 5139	 5216	
Mitochon_7_22_F	 AAAATTCTCCGTGCCACCTAT	 CGGGAAGGGTATAACCAACAT	 M	 4367	 4465	
Mitochon_7_23_F	 GCTCTCCATGCATTTGGTATT	 GATACTGCGACATAGGGTGCT	 M	 38	 128	
Mitochon_7_24_F	 CCAACCTCCTACTCCTCATTG	 GGGCCTTTGCGTAGTTGTAT	 M	 3318	 3417	
Mitochon_7_25_F	 CCGGCGTAAAGAGTGTTTTAG	 AATCCCAGTTTGGGTCTTAGC	 M	 933	 1079	
Mitochon_7_26_F	 AAAAGAGCACACCCGTCTATG	 CTTGGACAACCAGCTATCACC	 M	 1937	 2030	
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A-10 Multifocal Prostate Cancer Case 8 Primer Panel. 
Primer	name	 Fwd	sequence	 Rev	sequence	 Chromosome	 amp	start	 amp	end	
Exon_AASDH_8_T1F	 TATCCCTGTAGTCCCTGATGTATGTA	 AAATAAAAAGCATAAGTTCTGAGCATGTC	 4	 57244370	 57244485	
Exon_ATM_8_T1+8_T2F	 GAAAATTCTTCTTGCCATATGTGAGC	 CTCCTAAGCCACTTTTTATATCTTTCAGTAAT	 11	 108160340	 108160467	
Exon_CDK12_8_T3F	 gttgggaatacaggcgcat	 aggctgaggtgggtggat	 17	 37662598	 37662725	
Exon_CEACAM1_8_T1+8_T2F	 GCTGAAGTTGGTTGTGTGGG	 AACTGATCATTATTTGTGCTTTTCAGATG	 19	 43013316	 43013406	
Exon_CES1_8_T1+8_T2F	 AGTTTACAGGGTTTGGGCTACG	 CCACCACCTCTGCTGTCATG	 16	 55853409	 55853523	
Exon_GMDS_8_T2F	 GCCATGTGTTTGCTGCTGT	 TGTGATTTTCCAAGTGATTTCTCTT	 6	 2087092	 2087198	
Exon_PCNXL2_8_NF	 tctgacttacaatggttcaacttatg	 acagctgggcaaaatcatcaaatac	 1	 233367941	 233368088	
Exon_RGS7_8_T1+8_T2F	 CTAGTGAGTTACAACCAATAAGTATTAAGA	 ACTCAAACAGACTTTTCTCACTTTTCTAAT	 1	 241492530	 241492640	
Exon_SDC2_8_N+8_T1+8_T2+8_T3F	 CTCTTTTCAGTAGGACAGTACAAAACAG	 gcacatagtaaacaggcagtatatcag	 8	 97563548	 97563638	
Exon_SDK1_8_T1+8_T2F	 ttgggggaaggagggagtg	 atcatccatcttcagcacatct	 7	 3686577	 3686658	
Exon_SREBF1_8_T1+8_T2F	 TCGCAGAGCACAGTCCTG	 CACCTGGACCTGGCTTGTA	 17	 17719841	 17719960	
Exon_ZMYM4_8_T1F	 CCATTTGCTCTTGGTTATTTCTTCAGT	 CCAATGACATTATGCCAGTAATAGAGG	 1	 35830502	 35830595	
Inter_8_N+8_T1+8_T2+8_T3_R62F	 CATTGGGAGTTGGGATTTCA	 GATGACTCACCGTATCCCAGA	 3	 151360274	 151360374	
Inter_8_N+8_T1+8_T2+8_T3_R63F	 TCGTATAGTTCATAGAAAATCTGAGCA	 CTGGGCGACAGAGAGAGACT	 10	 20754877	 20754962	
Inter_8_N+8_T1+8_T2+8_T3_R64F	 GCGCCACATTTATCCTTCTC	 CTTCAGGTTTGTTCACGTTGAG	 5	 29895550	 29895638	
Inter_8_T1_R65F	 GATTGGATAAAGTTGGGGTCAA	 CATTCTGGATAAGACAAGAAGCTG	 9	 30013330	 30013417	
Inter_8_T1_R66F	 GGGGCACGTGTTACTGATTT	 CCTGTTCCACGAAATCCTCT	 1	 235254174	 235254240	
Inter_8_T1_R67F	 GGAGTCCATAAGGAAGTCAGGA	 GGTCATGTGGCCTTCTTCTG	 8	 41015446	 41015532	
Inter_8_T1+8_T2_R68F	 TGTTCAGTTTCTTCTGTAGGGATTC	 TCCACAACTGGATTGGAGAA	 12	 80160118	 80160223	
Inter_8_T1+8_T2_R69F	 TCTGTGATCTCACATTCTCTTTCA	 CTGGTACATACAAGGCCCTCA	 9	 25298709	 25298790	
Inter_8_T1+8_T2_R70F	 TGTTTGGAATGATTATCTCTCTGA	 CAGAGGTCATAAATGTAGTAAGAAACAA	 5	 120673859	 120673948	
Inter_8_T1+8_T2_R71F	 TGATGGGTTTTCTGAGGTTCA	 AATGACTGCCTTTCCCCTTT	 15	 98499694	 98499789	
Inter_8_T1+8_T2+8_T3_R73F	 GGAGGGATGTCAGCAAGATG	 CATCCATGGGTAGTTACCAAAA	 6	 82708900	 82708985	
Inter_8_T1+8_T2+8_T3_R74F	 GGGAAGCAACAGATGGAAAC	 TGTGTTTTCTTTCTTGACAACTCAG	 11	 106003670	 106003797	
Inter_8_T1+8_T2+8_T3_R75F	 TCTCATTGTGGTTTTGATTTGC	 ATACCTTACATGCGGCCAAG	 9	 103685135	 103685218	
Inter_8_T1+8_T2+8_T3_R76F	 CGATATTGACAGATGTCCCTTTT	 CCTCCCACCTAACCTTCTCC	 2	 199067660	 199067749	
Inter_8_T1+8_T2+8_T3_R77F	 ATGCATCAAAGCTGCCTTTC	 TTCCAACGAAAGGTCGTAGC	 4	 126695839	 126695909	
Inter_8_T2_R78F	 CCAGCCATGTGAAACTGTGA	 CATGCTGCTATGAAGAACTACCA	 3	 190200667	 190200747	
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Inter_8_T2_R79F	 TGTGGAATAGTTGCATGAAAAA	 TGCTGAGATTACAGGCGTGA	 7	 84528423	 84528423	
Inter_8_T2_R80F	 AACTGGGACCATAGGCATGT	 CCCTGGCAATGTAGCAAGA	 1	 120884815	 120884902	
Inter_8_T2_R82F	 GCAGGAACAAAAGGAAGGAA	 AGTCCAAGGTCAAACAGAGCA	 X	 145838513	 145838594	
Inter_8_T2_R83F	 TCACACCTGTAATCCCAGCA	 TATATTGCCAGGGCTGGTCT	 16	 18331328	 18331328	
Inter_8_T3_R84F	 TTCTGCTTCATTCACACCTTT	 TCTCTCCCTCACAACATCCA	 X	 65262099	 65262173	
Inter_8_T3_R85F	 TGCAGGTCTGTCCTTGTTTG	 AATATGGGATAGGGCGAGGT	 14	 21321829	 21321899	
Inter_8_T3_R86F	 TTCTTTCCCTTGGCCTCTAA	 CCATGAAAGTTGCAGGAGGT	 8	 34811291	 34811391	
Inter_8_T3_R87F	 CCCTAGGAATCTGCCACTGA	 TCAAGTTTAGAGATTGGGAAAGAAA	 13	 38952938	 38953026	
Inter_8_T3_R88F	 ATGTCTCCCAGCCTGGACT	 CCCTCTTCCTGCTCTTCAGAC	 2	 45859175	 45859262	
Inter_8_T3_R89F	 TCTGCAAGTCTCAGTTCCTTCA	 GAACTTAGACAAAGGGATAAATTTGAG	 X	 126134012	 126134098	
fusion_8_T1-8_T2_FWD	 GCCATTTTAATCACCCCCTAA	 TTCCCGATGGATGTTTGAGT	 21	 39831486	 42870455	
Mitochon_8_27_F	 CATCCCTACGCATCCTTTACA	 TGAAGATTAGTCCGCCGTAGT	 M	 7822	 7941	
Exon_C1RL_X_F	 ctaaactttcagtaaatacctgccttgg	 ttctccgtgtaactcaattttgcc	 12	 23274587	 23274677	
 
 
